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ABSTRACT 
A major debate has raged over the existence and 
causes of a phenomenon known as "drug lag". 
Protagonists in the debate have argued that the· U.S.A. 
is typically late to receive new pharmaceutical pro-
ducts because of the very lengthy delays imposed by 
F.D.A. regulations before new products can be launched 
on the U.S. market. Supporters of the. F.D.A. have 
denied the U.S.A. suffers from a drug lag while pro-
posing alternative explanations for its existence. 
In this thesis attempt is made to resolve the 
debate by investigating the pattern of inter-country 
diffusion of pharmaceutical products. Hypotheses are 
postulated and tested in an attempt to provide answers 
to four fundamental questions posed about inter-country 
diffusion. These questions are: 
·1. What factors determine the speed of diffusion of 
pharmaceutical products? 
2. What factors determine the extent of diffusion of 
pharmaceutical products? 
3. What factors determine when pharmaceutical products 
are launched in each country? 
4. What factors determine how many pharmaceutical 
products are launched in each country? 
A survey of the relevant literature on diffusion of 
innovations reveals that profit-related variables are 
iii. 
consistently useful explanators of diffusion patterns. 
The tenor of the hypotheses postulated for testing in 
this thesis is that firms in this industry strive to 
launch products in a manner designed to maximize 
their contributions to profits. The diffusion patterns 
between 18 countries, of 190 products first launched 
on to the world's markets between 1956 and 1976 are 
examined to test the hypotheses and thus provide 
answers to the four questions listed above. Statistical 
analysis is undertaken to test the hypotheses. 
There appears to be relatively little evidence to 
support many of the hypotheses tested about speed and 
extent of diffusion. However there is considerable 
evidence that the speed of diffusion of products, after 
their first launch, has increased steadily throughout the 
period studied. Deeper investigation suggests the 
typical time between discovery of products useful 
properties, and their typical times of availability on the 
worlds markets may have remained almost constant through-
out the twentyone year period studied. Pharmaceutical 
companies may have acted to compensate for increasingly 
lengthy delays before products are first launched, by more 
rapid subsequent launch of products. 
The number of products which are launched in a 
country and the magnitude of the delay before they are 
launched in each country appear to be relatively 
predictable. Both of these parameters appear to be 
iv. 
strongly influenced by countries levels of development. 
Countries with high health expenditures per capita, 
appear to receive more produc~s, more rapidly, than do 
lower expenditure countries. 
Interest ultimately focuses on the question of 
drug lags and the affects of regulations. Drug lags 
are shown to exist for the U.S.A., Japan and some 
other countries. When the period studied is divided 
into two sub-periods relatively strong correlations 
are shown to exist between ratings of regulatory tight-
ness in markets; and changes in the numbers of products 
diffusing to markets and; changes ~n mean times before 
products are launched in markets. Regulations do 
appear to exert considerable influence on the patterns of 
inter-country diffusion of pharmaceuticals in the latter 
part of the period studied. 
v. 
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C H A P T E R 0 
INTRODUCTION 
This is a study of the inter-country diffusion of 
pharmaceutical products. A sample of 190 pharmaceutical 
products, first launched onto the world's markets between 
1956 and 1976, is selected to provide representative data 
on the patterns of diffusion of pharmaceutical products to 
eighteen countries. No other comprehensive study of dif-
fusion of pharmaceutical products is known to have been 
attempted before, which may prompt the question why should 
anyone want to study the inter-country diffusion of phar-
maceutical. products? There are Hillaryesque answers, but 
these have never been satisfactory either in response to 
questions about alpine pursuits, or as here in response to 
a query about reasons for studying a topic. Some enduring 
motivating force is necessary to maintain the sustained 
effort required both to scale peaks and to research some 
esoteric subject. 
The catalysing stimulus for this study was the 
debate about the existence and causes of a "drug-lag" in 
the U.S.A. Briefly, this debate is about the time of 
availability of new pharmaceutical products in the U.S.A. 
Protagonists in the debate have attempted to establish 
that compared to some other countries new drugs were 
becoming available in the U.S.A. later than they were in 
other countries, and that the reasons for these delays in 
time of availability of new products were the US. Food and 
2. 
Drug Administration regulations controlling the intro-
duction of new products. A scan of the literature on 
this topic revealed that no systematic attempt had been 
made to determine what are the factors which control the 
time of availability of pharmaceutical products in a 
country. Further thought suggested that time of avail-
ability of pharmaceutical products was but one facet of 
the processes of inter-country diffusion of pharmaceut-
ical products. Instead of focussing attention narrowly 
on one topic such as "causes of drug lags", a ~ore 
comprehensive study of diffusion was chosen for research. 
Four fundamental puzzles about the inter-country 
diffusion of pharmaceutical product~ are addressed in this 
thesis. 
1) What factors determine the speeds of diffusion of 
pharmaceutical products 
2) What factors determine the extent of diffusion of 
pharmaceutical. products. 
3) What factors determine when pharmaceutical products 
are launched in each country. 
4) What factors determine how many pharmaceutical products 
are lauched in each country. 
This thesis is an attempt to provide answers to these 
four questions. 
Three assumptions underly the analysis in this 
thesis, and should be explicitly stated at this point. 
3. 
First it is assumed that the international pharmaceutical 
industry performs extremely valuable services by invent-
ing, producing, and supplying pharmaceutical products for 
the world's markets. This is not a universally held view, 
as the discussion in subsequent chapters makes clear. 
Neither is it an unqualified endorsement of all activities 
by the world's pharmaceutical firms. It would be very 
surprising if all the complaints made about the actions of 
multin~tional pharmaceutical firms turned out to be 
groundless. But rather than label these firms good or 
bad, it seems sensible to avo.id use of thought-preventing 
labels and to examine instead the usefulness of their 
actions. The judgment, which may permeate this thesis, 
is that multinational pharmaceutical firms, on balance, 
perform very useful functions which assist in increasing 
global welfare. 
The second assumption, which has a major impact 
on the form of the analysis is that firms in this indus-
try are believed to be guided in their actions by desire 
to earn profits. In particular,firms are assumed to 
strive to market new products in ways which maximise 
profits. This theme dominates the form of the hypotheses 
postulated about inter-country diffusion of pharmaceuticals. 
Thus the tests of the hypotheses are to a considerable 
extent tests of the "pursuit-of-profits" assumption. 
Hypotheses predicated on alternative assumptions may 
be of very different form to those tested in this thesis. 
4. 
Only test will establish whether alternative hypotheses 
are more successful than those employed here. 
The assumption of a strong profit orientation in 
this industry does not seem too controversial. Apologists 
for the industry might argue that the industry is very 
competitive and that firms are compelled to strive to 
maximise profits to ensure that they survive. Critics 
of the industry might point to tendencies by firms to : 
overprice products; indulge in transfer pricing; spend 
large amounts on advertising and marketing; concentrate 
their efforts on "non-essential" large selling products; 
and so forth. All of these activities can be shown to 
be consistent with a goal of achieving profits. Pursuit 
of profit is believed to be a driving force for this 
industry. 
A third assumption woven into the analysis is that 
time of availability of pharmaceutical products is of some 
importance. Concern about time of availabtlity of pharm-
aceutical products is in fact the raison d'etre for this 
study. A classic article in the study of the economics 
of the pharmaceutical industry is that of Peltzman, An 
1 . fC t. '1 · l Eva uat1on o onsumer Pro ect1on Leg1s at1on. Perhaps 
the central conclusion to be drawn from Peltzman's study 
is that societies which introduce regulations controlling 
1. Peltzman, S. An Evaluation of Consumer Protection Legis-
lation; The 1962 Drug Amendments. Journal of Political 
Economy, 81,5 1049-1091, 1973. 
5. 
the time at which products can be marketed should be 
aware that delaying the introduction of new products is 
likely to impose costs on society because theraputic 
benefits are postponed. When Peltzman compared the 
benefits achieved by the consumer protection legislation 
reduction in amounts of toxicity caused by new drugs - with 
the costs imposed by the legislation, he concluded that 
·the costs far outweighed the benefits. The magnitude of 
the costs imposed because of the delay in time availability 
of new products were argued to be quite awesome. 
A belief which is -implicit in this thesis is that, 
ceteris paribus, earlier times of availability of new pro-
ducts are preferable to later times. Only in one minor 
section of this thesis is the validity of the abov,2 assumpt-
ion important to the conclusions drawn. The conclusions 
drawn about the value of the existing patterns of diffus-
ion to developing countries are heavily dependent on the 
assumption that delays in introduction of new products 
are undesirable. This assumption is germane to the 
remainder of the analysis, but the results of the empir-
ical tests conducted in chapters five to eight are not 
crucially dependent on the validity of the assumption. 
To be explicit; the answers to the four puzzles about 
inter-country diffusion of pharmaceuticals will not 
alter if the assumption is proved to be ill-founded, but 
the motivation to seek answers to those puzzles will be 
much reduced if it does not matter when products first 
6. 
become available in each country. 
Chapter four of this thesis is devoted to a dis-
cursive analysis of the likely behaviour of firms in this 
industry, and the formulation of hypotheses about inter-
country diffusion of pharmaceuticals. The approach is 
Popperian in style. Hypotheses are explicitly stated, 
and tested to allow conclusionsto be deduced and new 
hypothesis to be formulated. While this approach is 
believed to be the most fruitful method ·of conducting 
research there are some associated problems. Particularly 
there are the problems of what is a test of a hypothesis, 
and when should a hypothesis be re,jected? Hypotheses 
can only be rejected if they have been subjected to a com-
prehensive test. The inadequacy of the data available 
to test some of the hypotheses postulated in this thesis, 
is such that no decision can be made about the status of 
the relevant hypotheses. It is fair to ask whether 
attempts to test some hypotheses should be made given 
the absence of suitable data. The judgment made in this 
thesis is that tests of hypotheses, using proxies for the 
desired data, are preferable to no tests at all. 
Varying amounts of support are found for the profit-
maximisation based hypotheses, but perhaps the most inter-
esting feature of the results obtained in this thesis is 
the way in which relationships between dependent and 
independent variables appear to disintegrate in the latter 
7. 
part of the period studied, Thus while the core of these 
hypotheses is profit maximising behaviour, it is difficult 
to ignore the influence on inter-country diffusion of 
factors unrelated to profit maximisation. The controversy 
which sparked interest in this topic, the impact of regu-
lations controlling the marketing of new products, appears 
ultimately to have correctly focussed on one of the major 
influences on inter-country diffusion of pharmaceuticals. 
Hopefully this study makes some useful contribution to the 
debate about the impact of regulations as well as examin-
ing the importance of market forces on inter-country 
diffusion. 
The thesis falls readily into two sections. In the 
first, the characteristics of the pharmaceutical industry 
are outlined, the literature on diffusion both of non-
pharmaceuticals and pharmaceuticals are examined, and 
hypotheses are formulated for subsequent test. These 
hypotheses are subject to test in Chapters five to eight. 
Some brief concluding comments in Chapter nine complete 
the thesis. 
C H A P T E R 1 
INNOVATION, COMPETITION, &~D DIFFUSION 
(0) INTRODUCTION 
The pharmaceutical industry is science based and 
depends for its growth and vlgour on the development and 
launch of new and superior products. Forty years of 
intense research effort have produced over one thousand 
new pharmaceutical products which have been marketed 
worldwide providing new methods of treatment for a very 
wide range of human ailments. The industry does not 
conform to a textbook model of price competition by way 
of cost reduction, rather competition typically occurs 
by the process of developing improved products which dis-
place the existing products from their market positions. 
( 1) EVOLUTION 
The modern pharmaceutical industry is a mid-twentieth 
century phenomenon, and differs markedly from its fore-
-
runners. Drugs-have, of course, been used for centuries, 
and some advances were made long ago, e.g. opium was 
discovered circa 4,000 B.C., mercury in 1495, quinine in 
1647 and morphine in 1803~ The pharmaceutical industry 
can trace its lineage back to the alchemists, herbalists 
and spice merchants of the middle ages, and to the healers 
1. James, Barrie G. The Future of the Multinational 
Pharmaceutical Industry to 1990. London, Associated 
Business Programmes, 1977,P. 1. 
9. 
and medicine men of even earlier ages. The apothecaries 
of the sixteenth and seventeenth centuries became the 
major suppliers of drugs in that age and ..• "several 
multinational drug companies can trace their origin to 
2 
apothecaries opened in the seventeenth century" notably 
E. Merck and Sons and Merck Sharp and Dohme. Several 
~ 
pharmaceutical firms began life as dye-stuff and organic 
chemical manufacturers and later turned to the production 
of pharmaceuticals: Ciba, Geigy, and Hoffman La Roche 
are examples. 
Until 1909 only three synthetic drugs were known, 
aspirin, phenacetin, and barbitone, all developed in 
3 Germany. But between 1909 and 1935 three major dis-
coveries were made which were to revolutionise the 
pharmaceutical industry. These were Ehrlich's discovery 
of arsphenamine - a treatment for syphillis, Domagk's 
demonstration of the anti-microbial qualities of pront-
osil - the first sulphonamide, and Fleming's isolation of 
the first antibiotic - penicillin. These discoveries 
were of crucial importance because they demonstrated that 
it was possible to develop products which had specific 
actions in the body and yet did not kill the patient. 
Thus the advent of chemotherapy. 
Competition up until that time in the industry 
2. James, Barrie G. The Future ... P. 3, 
3. Cooper, M.H. Prices and Profit in the Pharmaceutical 
Industry, Oxford, Pergamon Press, 1966, P. 4. 
differed sharply from that which was to follow. 
In the 1920's some six drugs either singly 
or in combination, accounted for over 60 per 
cent of the prescriptions written. Most of 
the pharmaceutical companies produced the 
entire range of therape~tic substances and 
supplied them to the Chemist to make up into 
final form. Competition between them was 
10. 
based upon the completeness of their cata-
logues and their brands reputation for purity 
and dependability. Many of the products of the 
1880's survived until the Second World War. 
The Eli Lilly catalogue for 1943 for example 
still listed Fluid Extract of Dandelion. 4 
But following the first successes in the research lab-
oratories enormous changes were to occur in the industry. 
Succeeding the first three inventions of the century have 
been hundreds of similar successes in research labor-
atories, typically the research laboratories of pharm-
aceutical companies. An important feature of these 
research successes has been the skill of the pharmaceutical 
industry in improving on the original breakthrough in 
demonstrating theraputic effectiveness, to produce products 
which can be used for human therapy. This latter activity 
is an often overlboked aspect of the pharmaceutical 
industrY's efforts. Society tends to remember the dramatic 
breakthroughs e.g. Fleming's "discovery" of penicillin, 
.but forgets the equally valuable efforts of later workers 
in establishing how penicillin works, how to supply it in 
a stable consistent form, and how to produce it in com-
4. Cooper, M.H. Substitute Competition and the Internat-
ional Pharmaceutical Industry, Australian Journal of 
Pharmaceutical Sciences 6, 113-118, 1977, P. 113. 
11. 
mercial quantities at an acceptable price. 
Given these research successes and the push given 
by the advent of World War II, the industry became a 
dynamic high technology one where large profits were 
earned on the relatively small amounts of capital invested. 
The industry has been characterised by its prolific output 
of new pharmacologic substances reaching a peak of approx-
imately 100 new entities a year in the 1960's. 5 These 
successes tended at first to build on existing products 
to produce a string of related products, e.g. chlortetra-
cycline, oxytetracycline, tetracycline, - but increasingly 
distinct new products have been produced influencing a 
wide variety of physiological functions. 
Today the range of entities is so broad that no 
company attempts to supply more than a small proportion of 
the total range. Product lives tend to be quite short, 
or dominance of a therapeutic submarket by one product 
is short lived. Thus submarkets are almost ~nvariably 
dominated by products less than twenty years old. As is 
typical for a high technology industry, research and 
development, patenting and marketing are conspicuous 
activities of member firms. 
5. Reis-Arndt, E. Neue Pharmazeutische Wirkstoffe 
1961-1973, Die Pharmazeutische Industrie, 37 
233-240, 1975, P. 234. 
12. 
(2} THE MODERN INTERNATIONAL INDUSTRY 
Pharmaceutical production:is a two stage process. 
Stage one is the production of the active therape::utic 
substances, stage two involves formulating and finishing 
these substances for sale as consumer products. Pro-
duction of the active ingredients is a complex process 
usually requiring highly specialised capital and labour. 
Seven countries dominate the western world production 
·of these basic ingredients, and pharmaceutical production 
in total, as Table 1.1 demonstrates. 
Formulating and finishing involves much simpler 
processes and a large proportion of all countries can and 
do take part in these final steps in the production process. 
World trade in pharmaceuticals is also dominated by a few 
countries, primarily the leading western world producers, 
as Table 1.2 illustrates. All other western countries 
have substantial pharmaceutical balance of trade deficits. 
They depend heavily on the few leading suppliers for a 
large proportion of their pharmaceuticals. 
Pharmaceutical sales are also concentrated in a 
relatively few major markets. As Table 1.3 below shows 
the thirteen largest markets in 1975 accounted for 75 
per cent of total world sales. Per capita figures vary 
widely between countries and also undoubtedly between 
regions within countries. Urban areas such as Rio de 
Janiero have very westernised consumption 
13. 
TABLE 1.1 
World Pharmaceutical Production 1970 
Estimated Per Cent of 
Production Total 
Country u.s. $ m. Production 
U.S.A. 6.153.8 31.5 
Japan 2,840.7 14.6 
West Germany 1,732.1 8.9 
France 1.126.4 5.8 
U.K. 1.148.4 5.9 
Italy 873.6 4.5 
Switzerland 453.3 2.3 
Seven Largest 14,328.3 73.5 
Rest of World 5,177.2 26.5 
-
Total World 19,595.5 100.0 
Source James, Barrie, G. The Future ... , Table 2.6. 
TABLE 1. 2 
World Trade in Pharmaceuticals 1974.U.S. $m 
Balance 
Country Exports Imports of Trade 
West Germany 1,035.0 432.7 603.2 
U.S.A. 805.9 213.6 592.3 
Switzerland 749.1 159.4 589.7 
U.K. 706.4 216.0 490.4 
France 502.1 309.2 192.9 
Netherlands 266.9 202.3 64.7 
Denmark 123.9 92.5 314 -· 
Italy 335.3 309.5 25.8 
Japan 137.1 455.8 -318.6 
Spain 48.8 174.8 -126.0 
Belgium/ 282.8 330.0 - 47.1 
Luxemburg 
- 66.8 
Sweden 86.9 153.8 
Source Pharmaceutical Manufacturers Association 
Factbook 1976, Washington, 1976 Table 36. 
14. 
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patterns 6 while some rural areas in Brazil are likely to 
~ave nil pharmaceutical sales. 
As might be expected expenditure on pharmaceuticals 
R and D is concentrated in the same few countries which 
dominate production and trade. Not surprisingly these 
same countries have been the major sources of new pharma-
7 ceutical products. For the non-innovating countries 
access to the very large number of pate.nted products 
discovered in the last twenty years is by way of ...... . 
"importing,pa,ying royalties on the know how or by allow-
ing the establishment of foreign subsidiaries". 8 
The importance of R and D and its products to the 
pharmaceutical industry can be gauged from the tables 
below showing rates of expenditure on R and D and 
marketing .. 
6. White, K.L. International Comparisons of Medical Care, 
Scientific American, 233, 2, 17-23, 1975. 
7. Table 3.1 below provides data on souces of invention. 
8. Cooper, M.H. Substitute Competition ... P. 113. 
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Source Parker, J.E.S., The Economics of Innovation, 
London, Longman, 1974, P. 51. 
-
Approximately 1,000 distinct new pharmaceutical products 
have been launched onto the world markets in the last 
thirty years. 9 Products less than ten years old are 
thought to dominate pharmaceutical markets. One U.S. 
study showed that the 200 most heavily prescribed drugs 
10 in the U.S. had an average age of 9.8 years. 
9. Pharmaceutical Manufacturers Assn. Factbook '76, 
Washington, Pharmaceutical Manufacturers Assn, 1976, 
pp. 18-20. 
10. James, Barrie, G. The Future ..... P. 24. 
18. 
Clearly the pharmaceutical industry is research 
intensive, and this research effort has produced large 
numbers of new products to be launched on the worlds 
markets. 
TABLE 1. 5 
SALES PROMOTION COSTS AS A PERCENTAGE OF SALES 
BY SIZE OF COMPANY (1969) 
Sales of Prescription No. of Average Percentage of 
Medicine in U.K. $m Companies Sales spent on Sales 
Promotion 
8 4 9.6 
5 - 8 4 10.0 
3 - 5 9 12.1 
2 - 3 9 16.9 
1 - 2 6 23.2 
0.5 - 1 14 24.3 
0 - 0.5 52 40.0 
Source Monopolies Commission Report, Chlordiazepoxide and 
Diazepam, April 1973, P. 40. Quoted in Slatter, 
S.St. P. Competition and Marketing Strategies 
in the Pharmaceutical Industry, London,Croom 
Helm, 1977, P. 37. 
(3) INNOVATION AND COMPETITION 
Two accusations which have been made against the 
pharmaceutical industry are those of the low significance 
of many ·innovations, and the apparent lack of competition 
in the industry. Critics of the industry claim that 
the industry does not invest large amounts of money in 
research to produce new superior products, rather it 
directs most of its efforts towards modification of 
existing products resulting in a proliferation of sim-
ilar products. These products are differentiated from 
one another at high expense by extensive marketing 
campaigns. Consumers and society are therefore the 
losers because they get few genuinely new therapies, have 
to bear cOntinually high development and marketing costs 
which are spread over all products thus greatly increasing 
their prices. So goes one popular version of the phar-
. 1 . d t . t' 't' 11 maceut1ca 1n us r1es ac 1v1 1es. 
A second popular belief about the pharmaceutical 
industry is that there is no competition in the industry, 
that it is dominated by a few monopolistic firms who can 
set whatever prices they wish for their products. The 
industry is represented as a cosy club whose members 
individually and collectively act to dominate and con-
trol world prices, the supply of products, and access 
12 to technology. These popular beliefs are simplistic 
for reasons discussed below. 
11. For descriptions of the industry of this type see 
Lall, S. Major Issues in the Transfer of Technology 
to Developing Countries. New York, UNCTAD TD/B/C 
6/4. 1975. Ledogar, R.J. Hungry for Profits : US 
Food and Drug Multinationals in Latin America. New 
York, IDOC North America Inc. 1975. Handousa, H.A. 
The Pharmaceutical Industry in Egypt. Unpublished 
dissertation, University of London, 1974. 
12. See Lall, S. Major Issues .... , Ledogar, R.J. 
Hungry for Profits, Handousa, H.A., The Pharmaceut-
ical Industry ... 
20. 
Technological progress is frequently viewed as a 
series of quantum leaps which revolutionise a particular 
product or ilindustry. The tendency is to regard scientific 
breakthroughs such as the invention of the telephone, the 
discovery of penicillin, the production of hybrid corn as 
the typical form of scientific progress. By those stand-
ards anything less is mere fiddling which does little to 
advance human welfare, occurs because imitation is simple, 
and leads to significant profits for the firms involved. 
For the adherents of this school of thought "molecular 
manipulation" by the pharmaceutical industry is a waste-
ful process contributing little to the advance of pharm-
acological technology. There is, of course, another view 
of the process of technological change. This regards the 
dramatic breakthroughs as rare events, aberrations from 
the normal development of technology. 
Those familiar with the process underlying innov-
ation in all types of industry will know that pro-
gress is usually achieved by a gradual and painstaking 
accumulation of minor changes. This process is 
known as technology building on technology and 
refers to a situation where innovations arise out 
of a~process of a cumulative synthesis of past 
knowledge. Particular innovations tend to be 
modest and come from and tend to be based on the 
technology that has preceded them. This does 
not imply that the rate of advance will be slow. 
When aggregated these minor improvements may 
well represent a brisk rate of technological 
change. For most industries this process of 13 cumulative synthesis is accepted as normal. 
13. Parker, J.E.S. Regulating Pharmaceutical Innovation, 
Washington, American Enterprise Institute, 1977, 
P. 169 . . ,
21. 
If cumulative synthesis is the normal means of progress 
why should the pharmaceutical industry be attacked in 
vitriolic terms when it produces series of products which 
differ in chemical form, bio-availability, delivery system, 
toxicity? The record of the multinational pharmaceutical 
industry is one of success in introducing variants on 
existing products and thus both meeting new needs and 
adding further increments to pharmacologic knowledge. 
Spectacular breakthroughs are rare (or as frequent) in 
pharmacology as in most other industries. Those which 
do occur for example in the beta-blockers,in tranquilli-
zers, in synthetic penicillins - are invariably succeeded 
and superseded by similar but superior products. The 
observer who sees the modest change embodieq in each new 
drug launched on the market and concludes that this 
represents negli~ible technological gain at a substantial 
R and D cost, fails to recognise the cumulative gain that 
these successive developments bring. ModQfying the action 
of a product, or discovery of a new indication for it, 
may not conform to a layman's view of innovation. But 
these changes do represent technological gains. 
Further, the fact that there are in many theraputic 
sub-markets a number of approximately similar products, 
means that there is the basis for competition. As 
suggested above there is claimed to be a lack of competit-
ion in the pharmaceutical industry. That this view 
receives much of a hearing may be due to the success of 
22. 
economists in instilling in us the idea that competition 
means price competition. This may be the mode of compet-
ition in markets where product form changes little, but 
there are argued to be several other means of competition 
for a lively industry such as pharmaceuticals. Primarily, 
competition occurs through the introduction of new products 
which have different pharmacological characteristics to 
existing products. The introduction of a series of 
beta-blockers say, ensures first that the original beta-
blocker - Propranolol - will have to share that sub-market 
with the new products, and second if the new products 
prove to be more useful in some respect than the pioneer 
then they will erode its market share and eventually 
displace it from its market leadership position. Cooper 
comments:-
A significant advance, backed by the threshold 
level of promotion and at a price usually within 
the range of dosage costs already established 
within the market typically make rapid and large 
inroads into existing market shares, displacing 
inferior substitutes until such time as a rival 
repeats the process. In the static sense, the 
industry competes within a series of oligopolistic 
sub-markets, but viewed over time, competition 
can be seen to be fierce. 14 
The evidence does support this view; product lives and 
particularly product leadership tend to be short. For 
example, only three of the products in the 1965 New 
Zealand top twenty sellers list were still in the 1975 
14. Cooper, M.H. Substitute Competition ... P. 114. 
23. 
top twenty sellers list. 15 Slatter, in a study of the 
U~K. pharmaceutical market found that .o. "the extent of 
product competition [was] indicated by the fact that mar-
ket leadership changed in twenty out of the top thirty 
therar:eutic class~s between 1964 and 197 3". 16 
It should not be assumed that all new pharmac-
eutical products launched contain significant new pharm-
acological entities, .and that these all succeed in 
achieving market dominance as a matter of course. 
Replication of existing products does occur after patent 
protection expires, and almost immediately where patents 
are not recognised. Success, in terms of per cent of 
market share gained, eludes many products. Reekie 
concludes that ... "a substantial minority of inn6vations 
. 17 
perform very poorly o 11 He found that 57 products 
out of a total sample of 125 launched in the U.K. during 
1962-73 failed to achieve a cumulative market share of 
5 per cent after two years. Similarly Slatter found 
that-of 407 new products launched in the U.K. between 
1964 and 1973, 65 per cent failed to achieve a market 
'11 18 share of 5 per cent as Table 1.6 l ustrates. 
15. Cooper, M.H. Substitute Competition Government Regu-
lation and the International Pharmaceutical Industry, 
University of Otago, Economics Discussion Paper No. 7701. 
l6o Slatter, S.St. P. Competition and Marketing Strategies 
in the Pharmaceutical Industry, London, Croom Helm, 
1977, P. 51. 
17. ~eekie, WoDo Pricing New Pharmaceutical Products, 
London, Croom Helm, 1977 Po 2lo 
l8o Slatter, So St.P. Competition and Marketing Strategies 
o o. o Po 67. 
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TABLE 1. 6 
MARKET SHARES ACHIEVED BY NEW PRODUCTS 
Market Share Achieved No. of Products Per Cent 
15% 49 12 
10.0 - 14.9% 22 5 
5.0 - 9.9% 70 17 
1.0 - 4.9% 164 40 
1. 0% 102 25 
TOTAL 407 100 
Source : Slatter, S. pt;i_ P., Comp~tition and Marketing 
Strategies ... Table 3.16 
The process of competition by introduction of new 
products which compete with existing products for market 
shares can be termed innovation competition and appears 
to be a characteristic feature of pharmaceutical markets. 
There is a growing body of evidence which suggests that 
this innovation competition is frequently accompanied 
19 by orthodox price competition. Cooper argues: 
In fact the [pharmaceutical] industry's compet-
itive structure varies from others only to a 
degree. Most industries compete on a mixture 
of price, quality, promotion, goodwill and 
service. Within the [pharmaceutical] industry, 
the relative importance of each of these will 
vary with the particular drug under consideration 
ranging from a non patented and unbranded 
'standard', which as closely resembles the con-
ditions of perfect competition as any other 
one can think of, to a major theraputic advance 
19. Reekie, W.D. Pricing New ..... , Slatter, S.St. P. 
Competition and Marketing Strategies 
25 . 
. h 1 b . 20 w1t no c ose su st1tutes. 
Competition does exist in the pharmaceutical indus-
try. The introduction of new products is a crucially im-
portant means of competition, as well as being a major 
source of growth for the whole industry. 
(4) PHARMACEUTICALS AND PRODUCT LIFE CYCLES 
It is obligatory for writers on diffusion of 
innovation to mention product life cycles. The term 
refers to the typical behaviour of products of having 
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20. Cooper, M.H. Substitute Competition ... P. 114. 
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The fact that products are "born'', "grow", reach "maturity" 
and frequently eventually have declining sales is of 
interest but of little use unless it provides some insight 
into the processes of innovation, diffusion, marketing 
strategies or whatever. Fitting pharmaceutical products 
to this type of model reveals that they are archetypal 
innovations. Slatter for example reports that "success-
ful" pharmaceuticals in the U.K. have a short growth period, 
followed by a maturity phase and ultimately a long period 
of declining sales " This is the classical form of the 
product cycle." 21 For pharmaceutical products, as might 
be expected in light of the discussi~n in Section 3 above, 
the time to reach sales maximum is quite short. Slatters' 
study of 119 products introduced in the U.K. between 1965 
and 1967, " ... indicated that 46 per cent of all new pro-
duct introductions achieved their maximum market penetrat-
22 ion within three years of their date of introduction", 
and two thirds of them within five years of their date of 
introduction. I£ the pattern is similar for pharmaceut-
ical products in other countries then their proprietors 
will have clear evidence of their relative merits, as 
assessed by the market, in a quite short time period. This 
will be particularly so for the more successful products. 
For firms contemplating market launch of new products 
21. Slatter, s.st. P. Competition and Marketing Strategies 
. . . . . P. 65. 
22. Slatter, S.St. P. Competition and Marketing Strategies . . . . . P. 67. 
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in foreign markets, evidence on which to base these 
decisionswill soon be forthcoming from sales performance 
on the pioneer market. It seems plausible to argue that 
diffusion rates between countries will be influenced by 
the performance of products within the markets of original 
launch. But the importance of this as a predictor of 
inter-country diffusion speed is a matter of conjecture. 
·(S) DIFFUSION SPEEDS AND WELFARE 
This too has been a topic of conjecture and debate. 
The pharmaceutical industry has been subjected to close 
scrutiny following the Thalidomide disaster of the early 
1960's, particularly in the U.S.A. where caution about 
new pharmaceuticals has approach~d phobia levels, despite 
the fact that Thalidomide was not released onto the U.S.A. 
market. In the aftermath of the Thalidomide debacle 
there has been a marked slowdown in the rate at which new 
drugs proceed through the American Food and Drug Admin-
istration (F.D.A.) pre-marketing trial and evaluation pro-
cedures. As a consequence new pharmaceutical products 
are argued to have been slower to diffuse onto the Amer-
ican market than they might otherwise have been. (See 
Chapter 3 below.) There have been suggestions that 
similar slowdowns in diffusion rates, due to increasingly 
stringent regulatory requirements, have occured in other 
28. 
t 
. 23 coun r1es. These events and the furore surrounding 
them have prompted both denials by the F.D.A. that they 
are responsibl~, for the slowdown in the supply of. new 
drugs to the U.S.A., and acceptance of credit for pre-
venting new drugs being marketed which would potentially 
24 
have been harmful to some people. 
The interesting question for our puLpose is, 
what is the correct rate of tradeoff between speed of 
introduction of pharmaceutical innovati~ns, and changes 
in the level of risk associated with the use of these 
pharmaceutical innovations? 
Points which can be made unequivocally are : 
(a) The use of pharmaceutical products invariably 
involves some risks because pharmaceutical pro-
dubts by definition, alter process, or processes 
within the body. 
23. For example see, Parker J.E.S. Regulating Pharma-
ceutical Innovation,P. 164. Australian Pharmaceutical 
Manufacturers Association, The Extension of Patent 
Term on Substances of Medicinal Purposes. An un-
published submission to the Minister of Productivity 
1978. 
24. See Kennedy, D. A Calm Look at Drug Lag. Journal 
of American Medical Association, 239, 5, 1978, and 
Wardell W.M. A Close Inspection of the Calm Look, 
Journal of American Medical Association, 239, 19, 
1978. 
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(b) Information about the effects pharmaceuticals 
will have, is a typical economic good. It is 
scarce, more of it is wanted, and scarce 
resources have to be foregone to obtain it. 
(c) There is uncertainty about the size of the 
benefits and costs associated with changes in 
introduction speeds and levels of knowledge. 
Does a slowdown in the rate of approval of new 
drugs for marketing imply a cost to society? It is an 
easy matter to argue that if a country delays the launch-
ing time for new pharmaceutical products then this will 
imply a foregoing of potential therapeutic benefits if 
the product would have provided therapies of a sort not 
already provided, and/or if it provided therapies in a 
most cost-effective manner. So far as partial equilib-
rium analysis goes this argument appears incontrovert-
ible. The difficulty, of course, lies in determining 
how great these foregone benefits are. One very bold 
attempt to establish the magnitude of the costs has been 
d b lt f h S. • t • 25126 rna e y Pe zman or t e U .. Sl uatlon. · 
25. Peltzman, S. An Evaluation of Consumer Protection 
Legislation: The 1962 Drug Amendments. Journal of 
Political Economy, 81, 5, 1973, and Peltzman, S. 
Regulation of Pharmaceutical Innovation. The 1962 
Amendments. Washington, American Enterprise Institute 
1974. 
26. But see also McGuire, I. Nelson R., and Spavins T., 
"An Evaluation of Consumer Protection Legislation: 
The 1962 Drug Amendments": A Comment. Journal of 
30. 
Peltzman estimates the costs imposed by the mortal-
ities and morbidity caused by various diseases and calcu-
lates the reduction in these costs that would be achieved 
by the introduction of drugs which reduced the mortality 
and morbidity rates. He then asks how much higher are 
these costs than need be if the launch dates had been 
delayed for some reason such as increases in evaluative 
trials prior to marketing. By varying the reductions in 
mortality. and morbidity rates and the length of the delays 
in marketing, a range of values for these costs/benefits 
foregone is produced. Using the same-basis for calcul-
ations as was used to produce the range of "benefits 
foregone" values, (i.e. evaluating lives on the basis of 
discounted future earnings, and evaluating morbidity 
costs on the basis of treatment costs, hospital costs and 
missed earnings), an estimate of the costs can be made. 
Finally the magnitude of the two estimates can be com-
pared to gauge whether increases in pre-marketing eval-
uation - and hence delays in introduction - are likely to 
have a favourable payoff in terms of prevention of 
adverse reactions to the drugs. 
Politcial Economy, 83,3,1975, pp. 655-662, and 
Peltzman, S. "An Evaluation of Consumer Protection 
Legislation: The 1962 Drug Amendments": A Reply, 
Journal of Political Economy, 83,3,1975, pp. 663-668. 
31. 
What are the magnitudes calculated? A two year 
delay in the introduction of poliomy~li.tis vaccine in the 
U.S.A. would have imposed a cost of about $150 million. 27 
This may seem quite a large sum but compared to the costs 
associated with two year delays in the introduction of 
tranquillizers and tuberculosis therapies of $2.1 billion 
d $2 0 b '11' . 1 . . . . 1 28 an . 1 1on respectlve y, 1t lS m1n1scu e. 
The magnitude of the payoff by way of reductions in adverse 
reactions is two orders of magnitude smaller for a drug 
such as chloramphenicol, i.e. a present value of the 
deaths avoided of $22.3 million. 29 (Chloramphenicol 
was introduced in the U.S.A. in 1949, and was subsequently 
discovered to be the cause of deaths in some users). 
The benefits achieved through averting a Thalid-





What are Peltzman's conclusions? 
It would ... require the prevention of more than 
one chloramphenicol incident annually to affect 
the direct cost in lives lost because of a two 
year delay of a once in a decade innovation like 
the T.B. drug. A similar comparison between 
something like the tranquillizers and chloramph-
enicol cannot be this direct, since a tradeoff · 
Peltzman s. Re~ulation of Pharmaceutical Innovation 
. . . . . P. 68. 
Peltzman s. Regulation of Pharmaceutical Innovation 
. . . . . P. 60, 65. 
Peltzman s. Regulation of Pharmaceutical Innovation 
. . . . . P . 54 . 
32. 
between lives and disabilities is involved. 
However, the more-than-fifty fold differences 
between the cost of a ·two year delay in intro-
ducing something like tranquillizers and the 
total cost of excess chloramphenicol deaths 
indicates how great the pessimism about safety 
of unregulated drugs or the nonmeasurable value 
of life must be for the prospective benefits 
of the amendments to affect their costs. 
These conclusions hold even when we consider the 
potential costs of a Thalidomide tragedy in 
its most virulent form and on the most extreme 
interpretation of its costs - that malformation 
is the equivalent of death .... Moreover, it 
should be remembered that these do not nearly 
exhaust the major innovation of the pre 1962 
period, while it would be difficult to expect 
anything like a Thalidomide tragedy more than 
once in a decade ... When one considers pros·-
pe.ctive payoff for innovation in the treatment 
of something like heart disease or cancer, the 
potential cost of del~y bec6mes awsome. 30 
On the basis of benefits foregone due to slower introduct-
ion speeds compared to benefits achieved through avoidance 
of adverse reactions there appeared to be a case in the 
U.S.A. for increasing the speeds of approval of new drugs 
for marketing. The case is further.strengthened when it 
is considered that there are other substantial costs of 
delay. 
(a) The slowdown in rate of approval for marketing 
of new drugs means that there will be fewer new 
drugs in each sub-market affected. This implies 
less competition for the existing products and 
thus higher prices than would otherwise have been 
paid. 
30. Peltzman, S. Regulation of Pharmaceutical Innovation 
. . . . . PP. 7 2-7 3. 
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If this occurs then the results of caution on 
drug approvals may well be higher prices to 
consumers. 
(b) Regulations aimed to slow the rate of intro-
duction of new drugs and so prevent potentially 
dangerous drugs reaching the market may have 
contradictory results in that they force doctors 
to prescribe existing products which, in some 
instances themselves, have dangerous side effects. 
The new safer drugs have been kept from the 
market by the cautious regulations, and this at 
least partially affects any advantage gained by 
reducing the amount of toxQcity due to new drugs. 
A comparative study of the U.S. and British 
regulatory systems for pharmaceuticals by William 
Wardell, to determine whether Britain had gained 
or lost in therapeu·tic terms by adopting a more 
permissive policy concluded: 
..• considering the size of the total burden 
of drug to~icity the portion due to new drugs 
was extremely small, and would in any case be 
at least partially offset by the adverse 
effects of older alternative drugs had the 
latter been used instead. Conversely, Britain 
experienced clearly discernible gains by intro-
ducing useful new drugs, either sooner than the 
United States or exclusively. On balance 
Britain appears to have gained in comparison 
from its more permissive policy toward the 
marketing of new drugs coupled with a more 31 rigorous program of postmarketing surveillance. 
31. Wardell, W .M. Therapeutic Implications of the Drug Lag 
Clinical Pharmacology and Theraputics, 15, 1, 1974. 
p. 73. 
34. 
It does seem therefore that reducing the 
number of new drugs available may force the use 
of older less-safe drugs in some instances. 
(c) A result of the U.S. drug regulations has been to 
greatly increase the cost of developing new 
drugs. Because the U.S. ~egulations require proof 
of efficacy and safety and because of the very 
lengthy delays in obtaining F.D.A. approvals to 
begin both clinical trials and marketing, crossing 
the regulatory hurdles imposes enormous costs on 
the developing companies. This, it is argued 
(see Chapter 3 below), has lead to a reduction 
in the innovation activities of drug companies in 
the U.S.A., and thus further costs are imposed on 
consumers 1 by way of fewer products to choose 
from, and by higher prices as the drug companies 
seek to recover their much higher costs. 
Of these three additional types of costs imposed 
because of cautious regulations, (a) and (b) seem likely 
to occur in any country which imposes similar regulations. 
The third cost (c), seems likely to occur only in large 
markets such as the U.S., or where a large number of coun-
tries enact similar legislation compelling innovating com-
panies to meet much more stringent requirements before 
marketing approval is granted. 
35. 
The weight of evidence does suggest that the U.S. 
has erred on the side of caution over pharmaceutical 
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regulations. In attempting to avoid some very visible 
costs - deaths and malformations due to toxicity - it has 
incurred some other very much larger costs - primarily 
the foregoing of benefits associated with the use of new 
superior products. Thus there appears to be a steep 
tradeoff between diffusion speed and risk reduction. 
The choice made by the U.S. appears to produce an unfav-
curable result. Pre-marketing evaluation has not proved 
particularly useful in reducing risk. The U.S. attempt 
to establish all the information about a product, before 
it is launched, has slowed the rate of diffusion of new 
products to that market. Faster diffusion appears to 
bring consider~ble benefits, and ceteris paribus, this 
suggests an improvement in national welfare. 
(6) INTERNATIONAL DIFFUSION AND THE TRANSFER OF 
TECHNOLOGY 
The international transfer of technology is 
a popular topic, and there have been numerous articles 
about the "problems" associated with the transfer of 
32. See Peltzman, S. Regulation of Pharmaceutical 
Innovation ... 
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pharmaceutical technology. As Wortzel points out 
36. 
" .•. a reading of this literature ..•.•. suggests that 
it is in vogue either to discuss the subject without 
defining it, or - equally likely - to adopt whatever 
definition best seems to serve the researchers' purposes 
34 
in conducting the study at hand.". If technology 
transfer is the process by which a package of" •.. skills, 
knowledge and procedures for making, using and doing 
useful things getsJfrom one person to another, or from 
35 
one place to another", then the international diffusion 
of pharmace~tical products seems to fit that description. 
This study is primarily concerned with establishing: 
(a) the factors which determine the speed and extent 
33. See for example the following works. Lall, s. Major 
Issues ... Ledogar, R.J. Hungry for Profits .. , Lall, 
S. and Streeten, P. Foreign Investment, Transnationals 
and Developing Countries, London, MacMillan, 1977. 
Bertero, C.O. Drugs and Dependency in Brazil. New York, 
Cornell University, 1972. O'Brien,.P. Trademarks the 
International Pharmaceutical Industry and the Develop-
ing Countries, The Hague, Institute of Social Sciences 
Occasional Paper, .No~ 63, 1977. 
Vaitsos, C.V. Intercountry Income Distribution and 
Transnational Enterprises, Oxford, Clarendon Press, 
1974 .. Handousa, H.A. The Pharmaceutical Industry .... 
UNCTAD Secretariat, Case Studies in Transfer of 
Technology : Pharmaceutical Policies in Sri Lanka 
UNCTAD, TD/B/C.6/21, 1977 (The Bibile Report). 
34. Wortzel, L.H. Technology Transfer in the Pharmaceut-
ical Industry, New York, UNITAR, Research Report, 
No. 14, 1971, P. 2. 
35. Wortzel, L.H. Technology Transfer •.... P. 2. 
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of diffusion of pharmaceutical products, and 
(b) the factors which determine diffusion times to 
each country. 
As such it is not directly concerned with the major 
issues raised by writers such as Lall, Vaitsos, Ledogar, 
Handousa, et. al., but it seems pertinent to make some 
brief comments about the role of diffusion in transferring 
pharmaceutical technology to the worlds markets. 
As has been argued ·in Section 5 apove, rapid 
diffusion of pharmaceutical innovation appears to contribute 
sizeable benefits. These benefits seem likely to be 
gained from the diffusion of new products to all markets, 
including those in developing countries. The case for 
restricting the rate of diffusion of new products, on 
safety grounds again appears to be a weak one. Placing 
impediments in the path of innovative drug companies such 
as the requirement that they generate clinical data in 
each coun.try they wish to market the product, appears to 
be a foolish policy, unless the country is the first in 
which the product has been marketed. It will normally 
be the case for countries other than the very innovative 
ones· that overseas clinical trial results will be avail-
able at the time approval to market is sought. Adopting a 
policy of basing decisions about marketing approvals on 
existing information is likely to result in faster rates 
of diffusion with its concomitant benefits. Insisting on 
the generation of new evidence within each country may be 
38. 
a luxury most countries can ill-afford, and certainly 
ill-need. 
For countries concerned about drug toxicity, post 
marketing surveillance appeals as being a much preferable 
alternative to time consuming evaluative trials. 
What does particularly concern the developing 
countries is that they are subjected to a continual flow 
of new products .from foreign based multinational companies 
and continually have to pay higher prices for pharmaceut-
icals than they would prefer, because they are asked to 
meet the necessary R and D and marketing loading. ~heir 
preference they claim, is for a smaller range of drugs 
to choose from whose prices are lower because they do not 
have such a high R and D and marketing cost loading. 
Acceptance of this belief has lead W.H.O. to publish a 
list of "essential" drugs which it recommends developing 
countries should base their pharmaceutical selections 
36 on. A similar type of list has been drawn up by an 
37 Indian Parliamentary Committee in the Hathi Report. 
The developing countries claim that the multi-
national drug companies operate in developing countries 
so that they can exploit the returns from marketing" ... a 
36. W.H.O. The Selection of Essential Drugs, Geneva, World 
Health Organisation, T~chnical Report Series No. 615,1977. 
37. The Committee on Drugs and Pharmaceutical Industry, 
Report of the Committee on Drugs and Pharmaceutical 
Industry, Ministry of Petroleum and Chemicals,Government 
of India, 1975, Chairman : Shri Jaisukhlal Hathi. 
(The Hathi Report), 
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sophist~cated high differentiated, and heavily promoted, 
constantly changing and well packaged range of 
d . . " 38 comma 1t1es·. Their concern is that the drug companies 
concentrate on rapid introduction of non-essential drugs 
such as tranquillizers and do little to produce and 
introduce products which are of particular use in meeting 
the L.D.C. needs. 
Clearly this is a major topic in itself. Determin-
ation·of the socially optimal rate at which to produce 
new pharmaceutical products is likely to be achieved only 
by a major research effort. The question of relevance 
here is, do the present channels of diffusion for new 
pharmaceuticals serve the developing countries well? 
An attempt to answer this question will be made in later 
chapters. But it seems sensible to point out that the 
arguments regarding restrictions on,the rate of diffusion 
lis~ed above will have relevance for all countries 
including developing ones. Diffusion is the process by 
which riew superior products are brought to the world's 
markets. To restrict this process may be to miss out 
on substantial consumer benefits. 
(7) CONCLUDING COMMENTS 
This chapter has discussed in brief outline, the 
developments of the modern pharmaceutical industry, the 
38. Cilingiroglu A. Transfer of Technology for Pharmaceu-
tical Chemicals, Paris O.E.C.D. 1975, P. 71. 
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importance of innovation both as a source of improved 
products and as a means of competition, and the case for 
rapid diffusion of new products. Before embarking on 
the study of international diffusion processes a survey 
of the existing studies and theories of diffusion is 
carried out in the following two chapters. 
C H A P T E R 2 
DIFFUSION LITERATURE; A SELECTIVE OVERVIEW 
(0) INTRODUCTION 
There is an enormous volume of literature on the 
diffusion of innovation. Rogers and Shoemaker in their 
1971 book Communication of Innovations, 1 list 6811 
documents of innovation diffusion research held by 
Michigan State University. The sheer volume of literature 
and the number.of disciplines and approaches they span 
compels the reviewer to be sel_ective and confine his 
attention to a few areas of the literature. 
A major premise of this study is that the diffusion 
processes studied are significantly influenced by economic 
factors. The analysis is therefore "economic" analysis, 
and hence the literature reviewed is selected either bee-
ause it employs economic analysis or because it shares 
similar perspective and methodologies to the present 
research. 
The purpose of this chapter is: to make some 
observations about research in general; and to survey 
the various types of similar and analogous research on 
other than pharmaceutical diffusion. 2 
1. Rogers, E.M. and Shoemaker, F.L. Communication of Innov-
ations. 2nd Ed. New York, The Free Press, 1971. 
2. Pharmaceuticals diffusion research literature is sur-
veyed in Chapter 3 below. 
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(1) OBSERVATIONS ON DIFFUSION RESEARCH 
Diffusion has been the subject of research for over 
fifty years by researchers in many different fields, where 
most have been _unaware until quite recently of the research 
on diffu~ion by people in fields other than th.eir own. 
An early example of diffusion research was that of Chapin 3 
who in 1928 published a book containing the results of his 
investigations into the spread of certain new ideas of 
public administration among Amer~can cities. But the 
important catalysing study was that of Ryan and Gross 
(1943) 4 , two rural sociologists who investigated the dif-
fusion of hybrid corn within two Iowa (U.S.A.)communities. 
Ryan. and Gross have been succeeded by hundreds of rural 
sociologists and varying numbers of geographers, medical 
sociologists, educationalists, psychologists, anthropolog-
ists, marketers, economists and numerous others all intent 
on further illuminating the diffusion process. Some 
comments on their research output from the vantage point 
of the present research are appropriate. Five. points 
are discussed in turn below. 
(a) A very large proportion of all the research on 
diffusion has been directed at the process and timing of 
adoption of an innovation within a population. Adoption 
3. Chapin, F.S. Cultural Change. New York,Century, 1928. 
4. Ryan B. and Gross N.C. The Diffusion of Hybrid Corn in 
two Iowa Communities. Rural Sociology, 8, 15-24, 1943. 
43 .• 
here means the first use of innovations by members of 
populations. Such research is concerned for example 
with the relative innovativeness of members of a population, 
or the earliness of first hearing of an innovation among 
members of the population, and what effects these factors 
have on individuals rates and timing of adoption of 
innovations. Rogers and Shoemaker classify over 4,000 
documents of diffusion research as being of these forms. 5 
Clearly establishing what are the factors which influence 
the timing and rate of adoption of innovations are import-
apt questions which have to be answered to enable explan-
ation of the process of diffusion of an innovation. But 
replication of effort on the scale which has occurred 
seems likely to have resulted in diminishing returns. 
The increment to the sum of knowledge about diffusion must 
have been very small from very many of the 4,000 plus 
studies mentioned above. Such concentration of effort 
also lends itself to criticisms of myopia on the part of 
these researchers, for the "adoption step" is only one 
part of the diffusion process and being able to explain 
how and why "adoption" occurs with greater and greater 
accuracy does not mean that the total process of diffusion 
has been adequately explained. Global views of diffusion 
will surely reveal that the diffusion of an innovation is 
influenced by many other factors besides the innovativeness 
5. Rogers E.M. and Shoemaker, F.L. Communication of Innov-
ations PP. 72-73. 
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of individuals in a population and how early they learn 
about the innovation. For example, when and how the 
innovatiion is supplied to an area or population may have 
a major influence on the timing of adoption by individuals 
within the population. 
(b) An observation related to (a) above is the rarity 
of studies in which the innovation and the systems of 
supply of the innovations are made the independent 
variable. Rogers and Shoemaker comment; 
When one peruses the diffusion research 
literature, he is impressed with how much 
effort has been expended in studying "people" 
differences in innovativeness (that is, in 
determining the characteristics of the 
different adop~er categories) and how little 
effort has been devoted to analysing "innovation" 
differences (that is, in investigating how the 
properties of the innovation effect its rate 
of adoption). 6 
This comment is less applicable to studies of 
diffusion by economists because in the relatively few 
studies which have been completed by them, the perceived 
features of the innovations have been central to the 
7 explanations of the pattern and'timing of diffusion. 
6. Rogers, E.M. and Shoemaker, F.L. Communication of 
Innovations, P. 135. 
7. See for example; Griliches, z. Hybrid Corn; An Explor-
ation in the Economics of Technological Change, 
Econometrica, 25,501-522,1957. Mansfield, E. Technical 
Change and the Rate of Innovation, Econometrica, 29, 
741-766, 1969~ Nabseth, L. The Diffusion of Innovations 
in Swedish Industry, in Williams, B.R. ed. Science and 
Technology in Economic Growth, London, MacMillan, 1973. 
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Economists have also been the authors of some of the very 
few studies examining "supply" side influence on diffusion8 . 
But for diffusion studies in general the comment is valid. 
Rogers and Shoemaker claim that only 1.2 per cent of the 
diffusion research studies listed in the Michigan State 
University files, make the attributes of innovations th~ 
independent variable. 
(c) A factor which may partially explain why (a) and 
(b) above occur, is the concentration on particular types 
of innovation in the majority of diffusion studies~ There 
aprears to have been marked biases by diffusion research-
ers in favour of two types of innovatiions: 
1. those which represent major -discrete improvements 
over existing techniques or products 
2. those which tend to have "public good" 
h t . t. '10 c arac er1s J.:cs. 
The att~activeness of the former group to researchers 
8. Griliches, Z. Hybrid Corn; An Exploration .. , and Grab-
owski, H.G., Regulation and the International Diffusion 
of Pharmaceuticals. Unpublished paper presented at AEI 
Conference, the International Supply of Medicines, Wash-
ington,D.C. 15/9/1978. Both examine the process of supply 
of innovations. 
9. Rogers,E.M. and Shoemaker, F.L. Communication of 
Innovations. PP. 73-73. 
10. The term "public good characteristic", is used to mean 
having properties of being freely and equally available 
to all persons in the relevant population; if more is 
demanded by one individual this does not reduce the 
amount available to others. 
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is obviousi they are identifiable where minor innovations 
may not be so easily traced. Because they are signif-
icant improvements there tends to be much better records 
of their diffusion, and respondents can recall their 
introductioR much more readily. As argued in Chapter 1 
above, such innovations are not typical of technological 
change, and therefore it cari be asked whether rather dif-
ferent types of research may be needed to analyse the 
diffusion of more usual changes in technology. 
The attraction of ·the "public good" type of innov-
ation is also clear. It allows researchers to concentrate 
on a reduced number of variables which may explain diffe-
rences in patterns of diffusion. Knowledge, particularly 
knowledge not embodied in some capital good is freely 
and equally available to all, thus removing a supply side 
constraint upon diffusion. Diffusion researchers have 
in many cases stressed how access to, and knowledge of the 
innovation has not been a significant factor explaining 
h d . f d . f f . ll Th t e spee , pattern or extent o ~ uslon. e con-
elusions of these researchers may have been different if 
for example, the innovations had been patent protected. 
11. Researchers who have made this point include: Ray 
G.F. The Diffusion of New Technology, National Inst-
itute Economic Review, 48, 40-83, May 1969. Maddala, 
G.S. and Knight, P.T. The International Diffusion of 
Technical Change. Economic Journal. 77, 531-558, 
1967. In these studies of diffusion, access to the 
innovations was considered not to be constrained 
by patent protection or other forms of proprietor-
ship of the innovations. 
4.7. 
In several cases, research has been concerned with 
innovations which have been selected because they were 
freely available to all members of a population. 
12 
Given 
these biases, the one where the case for adoption is 
compelling, the other where the "supply" of the innovation 
is almost universal, concentration on the adoption step 
and on the characteristic of the adopters is understandable. 
The "supply" side of the process has been neutralised, and 
hence is impotent in explaining diffusion. Thus the bias 
in favour of "demand" side explanations of diffusion. 
Clearly not all innovations are equally and freely 
available to all. Proprietary ownership of knowledge does 
occur. Patents and licence agreements cover many innovat-
ions. It would therefore be expected that the actions and 
intentions of owners of such innovations will exert major 
influences on the diffusion of such innovations. For 
innovations which are typically rathe.r small improvement 
on existing technology, the marketing strategies that the 
-
innovators choose .may again be a principal determinant 
of the pace and extent of diffusion. Intuitively it 
would seem likely that both of these influences will be 
present in a knowledge based industry such as pharmaceut-
icals, where innovations are usually patented and progress 
is normally an incremental process. In such an industry 
12. Examples of such studies are; Mansfield, Technical 
Change ... , and Fliegel, F.C. and Kivlin, J.E. Farmer~ 
Perceptions of Farm Practice Attitudes. Rural Sociology 
31, 197-206, 1966. 
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studying the characteristics of the adopters of innovations 
may be less useful th~n "supply" side studies in explaining 
diffusion. 
(.d) There are few comparative international studies 
or eve~ inter-region studies. There are studies in 
several disciplines which compare rates of diffusion of 
an innovation within different countries, 13 but studies 
examining when innovations first reach several countries 
or regions are extremely rare. 
Comparison appears to be an underutilised tool 
in diffusion research. This is surprising for innovations 
appear to lend themselves to physical science type compar-
ative trials to shed light on why innovations differ in 
their diffusion patterns. It would appear to be a 
straight forward matter to divide a group of innovations 
on the basis of say number of markets diffused to within 
X years of first launch and then to compare groups to 
determine what causes the differences in diffusion patterns. 
14 
But such studies are again rare. 
13. Ray, G.F. The Diffusion of .. , and Maddala, G.S. and 
Knight, P.T. The International Diffusion of ... are 
two examples of studies which examine rates of dif-
fusion within selected countries. 
14. Freeman, C. A Study of Success and Failure in 
Industrial Innovation. In Williams, B.R. (ed.), Science 
and Technology in Economic Growth, London, MacMillan, 
1973, does employ comparative techniques in a study 
of fifty-eight attempted innovations in the chemicals 
and scientific instruments industry. The focus of 
attention in the study is success and failure in in-
novation. Diffusion is considered as a final step 
in the innovation process.·. 
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(e) Classification of the myriad types of diffusion 
research can be carried out in several ways. Rogers and 
Shoemaker for example classify diffusion research by the 
choice of dependent and independent variable used~lS It 
seems useful for the purpose of this study to represent dif-
fusion research on three dimensions and to then classify 
each item on the basis of its positions on this represent-
at ion. The first dimension is on a "demand-supply" basis, 
i.e. there are diffusion studies which concentrate on the 
demand side of the diffusion process just as there are 
studies which concentrate on the supply side influences 
on diffusion. In some rare cases both sets of factors 
are considered in the one study; in such cases the cons-
tituent parts will be discussed in the relevant sections. 
Monotype studies will naturally fall into either demand, 
or less frequently supply side sections. 
A second dimension on whichr: diffusion research 
can be· placed is on a spatial-temporal continuum. 
Temporal diffusion· studies attempt to anaryse and rep~esent 
diffusion as a process occurring through time. Such 
research tends to ask when diffusion occurred (particularly 
when adoption occurred) and what were the factors influen-
cing the timing of the diffusion process. Spatial dif-
fusion researchers on the other hand study the flow of 
diffusion of an innovation through geographic locations. 
15. Rogers E.M. and Shoemaker F.L. Communication of 
Innovations, PP. 72-73. 
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Their concern is to explain why an innovation spreads 
geographically as it does, and what factors influence 
this. 
Third it seems useful to divide diffusion research 
into intra, and inter country or region studies. Intra-
region studies examine the diffusion of innovations 
within regions, whereas inter-region studies examine the 
diffusion of innovations between regions or countries. 
The present research examines the diffusion of pharmaceut-
ical innovations between various countries and is therefore 
an inter-country study. 
A diagramatic illustration of the three dimensional 
division of the diffusion literature may be represented 
as below, 
Using such a three way division the diffusion 
literature relevant to this study is surveyed in this 
overview. The intention is to select studies that will 
provide useful insights into methodologies employed, and 
because their results are judged to be broadly represent~ 
ative for the hypotheses tested. The raison d'etre for 
such a selective overview is: to illustrate what has been 
achieved so far in diffusion research; what the typical 
results of the research are; and thus to indicate what 
reasonable aspirations for the present study might be, and 








Representation of Three Dimensional Division of Diffusion Literature 
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'Because the distinction between "demand'' and 
"supply" studies is believed to be the most important 
one, the other two divisions are subsumed under this major 
division. The literature is therefore split into 
diffusion demand literature and diffusion supply literature. 
(2) DIFFUSION DEMAND LITERATURE 
(a) Intra-Region Studies. 
The temporal diffusion studies of direct relevance 
have been conducted by economists and rural sociologists. 
The economists 16 have concentrated their efforts on 
identifying the observed temporal differences in diffusion, 
and hence attempted to analyse and in some cases model 
these diffusion patterns. 
Griliches studied the diffusion of hybrid corn in 
the U.S.A., attempted to determine what the factors were 
which influenced diffusion speed and modelled the dif-
fusion of this innovation. H~ established, as others had 
before him, that the graph of the cumulative proportion 
of persons adopting an innovation over time typically 
has an S or logistic shape. Diffusion took place over 
a considerable period of time. It took bwenty-five 
years from date of first introduction of hybrid corn 
anywhere in the U.S.A., until 80 per cent of all corn 
16. For example, Griliches, Z. Hybrid Corn~ An Explorat-
ion ... Mansefield, E. Technical Change ... , Nabseth, 
L. The Diffusion of Innovations in Swedish Industry. 
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17 acreage was planted with hybrid corn seed in some states. 
When Griliches conducted tests to see which factors were 
most strongly correlated with high rates of acceptance of 
hybrid corn he found that farmers .•. "behaved in a 
fashion consistent with the idea of profit maximisation"~ 8 
Griliches found a strong positive relationship between 
profitability of the innovation and rate of acceptance of 
the innovation. 
Mansefield conducted a series of investigations 
into diffusion of industrial innovations. In an early 
study19 he drew on data from twelve innovations in the bit-
uminous coal; iron and steel, brewing and railroad 
industries. He used this data to test a model which 
can be summarised as below. 20 
(1) That the greater the number of firms in an industry 
adopting an innovation the greater is the probability 
that a non-user will adopt. 
(2) That the_expected profitability of an innovation 
is directly related to the probability of adoption. 
(3) That the probability of adoption is smaller for 
innovations of equal profitability, where a large 
17. Griliches, Z. Hybrid Co~n and the Economics of Innovat-
ion, Science, 132, 275~280, 1960, P. 276. 
18. Griliches, z. Hybrid Corn and the Economics ... P. 275. 
19. Mansefield, E. Technical Change .... 
20. Mansefield, E. Industrial Research ~nd Technological 
Innovation, New York, Norton, 1968, P. 137. 
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investment is involved. 
(4) That the probability of adoption for innovations 
requiring the same investment and offering equal 
profitability will vary from industry to industry. 
(
M .. ( ) ) , ~ t . 
1\l.J.(t) =f. N '1T .. ,s, .... ' l . . lJ l.J 
lJ . 
Where :\ij (t) = proportion of firms not using the 
innovation at time t, that introduce it by time 
t+l; 
Nij = the total of firms for the j th innovation 
in the i th industry (j = 1, 2, 3, i = 1, 2, 3, 4,); 
Mij(t) =the number of firms having introduced this 
innovation at time t; 
1T.. =the profitability of installing this innov-
lJ 
ation relative to that of other investments; 
Sij = the investment required to install this innov-
ation as a p§rcentage of the average total assets of 
these firms.; 
Mansefield found that rates of diffusion varied widely but 
that for his safuple of important new techniques it generally 
took more than ten years :r:'or ·all of the major American firms in 
21 these industries to begin using these techniques. Using 
the model he can ''explain 1' practically all of the variations 
in the rates of diffusion. He concluded; 
21. Mansefield, E. Industrial Research ...•. 
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It is clear ... that the rate of diffusion of an 
innovation depends on the average profitability 
of the innovation, the variation among firms in 
the profitability of the innovation,· the size of 
the investment required to introduce the innov-
ation, the number of firms in the industry, 
their average size, the inequality in their sizes 
and the amount that they spend on Research and 
Development. 22 
Mansefield conducted similar.investigations into intra-
firmdiffusion, (the diffusion of innovations within 
individual firms), and found from the study of the 
dieselization of American railroad companies that; 
two thirds of the variation in the rate of 
intra-firm dieselization among the.rail-
roads can be explained by the following 
factors: profit expectation of the invest-
ment in diesel locomotives, the date when 
a firm begins to dieselize, size of the 
firm, the age distribution of its steam 
locomotives, and a ·firm's initial liquidity. 23 
As in his earlier study it appeared that the most import-
ant variable affecting the diffusion rate was expected 
profitability of the investment. 
This finding suggests that there exists an 
important economic analogue to the classic 
psychological law relating reaction time 
to the intensity of the stimulus. The profit-
ability of investment apparently acts as a 
stimulus, the ~ntensity of which seems to 
govern quite closely a firm's speed of response. 
In terms of the diffusion process, it governs 
both how rapidly a firm begins using an innov-
ation and how rapidly it substitutes it for 
22. Mansefield, E. Technical Change 
23. Mansefield, E. The Economics of Technolb~i~al Ch~nge, 
New York, Norton, 1968, P. 125. 
24 
older methods. 
Diffusion researchers in other countries have 
56. 
found similar results. Nabseth studied the diffusion of 
25 process innovations in Sweden, and tested four hypotheses. 
(1) The earlier information about a new process is 
received and the greater the ability of the decision 
making unit to evaluate the information, the sooner 
the process will be introduced in the company or 
plant. 
(2) The more profitable it is for a company or plant to 
use the technique the earlier it will be introduced. 
(3) The larger the ratio between net income and -invest-
ment expenditure the easier it has been to finance 
investment in new techniques and the earlier such 
techniques should have been introduced. 
(4) Differences in attitudes towards new processes may 
affect the rate of diffusion of new techniques~ 
-
Obtaining data to catch accurately the effects 
Nabs~th lists proved to be a difficult task, but the cor-
relation results are interesting. The proxy variables 
for profitability, and attitudes towards new technologies 
and processes both seem to be very closely associated 
with time of introduction of innovations. The coincidence 
24. Mansefield, E. Industrial Research ..•. 
25. Nabseth, L.The Diffusion of Innovation in Swedish 
Industry. PP. 263-266. 
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between earliness of knowing about the innovation and 
earliness of first introduction was also as hypothesised. 
The financial variable performed badly in this study. 
Diffusion was a slow process in Sweden, some innovations 
taking twenty-five years to reach their maximum levels 
of adoption. 
This survey of diffusion literature has so far 
examined economists studies of diffusion, and'their 
·attempts to find the factors which are correlated with the 
speed and timing of diffusion. As sociologists have 
pointed out these investigations do not explain how dif-
fusion occurs and place little emphasis upon behavioural 
. bl f . fl . d. ff . 26 . ff . var1a es as actors 1n uenc1ng 1 us1on. Dl us1on 
requires communications and learning by individuals so 
studying the human factors involved in diffusion is 
likely to provide some useful insights. 
Rural sociologists have attempted to isolate the 
sociological determinants of diffusion patterns, their 
contributions have been to develop a standardised basis 
for classifying adopter categories, and to establish the 
importance of the "interaction effect" in diffusion. 
The early study by Ryan and Gross for example explained 
26. See Brandner, L. and Straus, M.A. Congruence versus 
Profitability in the Diffusion of Hybrid Sorghum. 
Rural SociolOgy, 24, 381-383, 1959 for the ~irst of 
a series of articles in which this topic was debated. 
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variations in timing of adoption of hybrid corn by reference 
to a list of socioeconomic characteristics of the adopters. 
Adopt~rs of inno~ations have been classified into five groups 
based on their time of first use of an innovation. In the 
standard nomenclature developed by rural sociolagists the 
five groups are; innovators, early adopters, early majority, 
27 late majority, and laggards. In terms of their speed of 
reaction innovators are the fastest to adopt innovations and 
laggards uhe slowest. A diagramatic representation of the 
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27. Rogers, E.M. and Shoemaker, F.L. Communication of 
Innovations, PP. 180-182. 
28. From Rogers, E.M. and Shoemaker F.L. Communication of 
Innovations, P. 182. 
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Rural sociologists such as Rogers have suggested 
that the members of each group can be determined by 
considering the age, education, income, occupation, social 
status and social contacts of individuals and these 
classifications can then be used to explain differences 
in rates of adoption. Innovators in farming, it has 
been suggested, can be profiled as follows: 
They are venturesome, young, high in social 
status, wealthy, cosmopolitan and in close 
contact with the scientific community. In 
contrast, laggards tend to be tradition-
oriented, older, semi-isolated and low 
in social status and income. 2 9 
Clearly in situations where diffusion can be characterised 
as a process of communication, behavioural characteristics 
of the adopters are likely to exert considerable influence 
on the process. To argue that the characteristics of the 
innovation alone determines rates of diffusion is implaus-
ible. The "interaction effect", the process whereby 
population members who have adopted an innovation influe-
nee those who have not yet adopted, seems to be a key 
part of the diffusion of innovations. The importance and 
role of interaction effects and profitability in explaining 
diffusion have been the subject of a protracted debate 
29. Rogers, E.M. Diffusion of Innovations, New York, 
Free Press, 1962. 
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between Rogers, Griliches and others. 30 The conclusion 
to be drawn from this debate is that economic forces may 
well be important explanations of variations in the rate 
of diffusion of innovations but they cannot account for 
all of the variations in diffusion rates. Economic 
forces certainly do not explain how the diffusion process 
occurs. Thus Griliches conceded after considerable 
debate that: 
" .• true it [the model] did not explain it 
[the process of diffusfon] . It just assumed 
that this is the sensible way in which any 
adjustment, ado~tion of spread of information 
process works.3 
What contribution to knowledge have these intra-region 
temporal studies of diffusion made? It has been established 
that the characteristics of both the innovations and the 
potential adopters determine the way in which innovations 
spread through a region. The cumulative adoption of 
innovations when graphed against time has been repeatedly 
shown to exhibit an-S or logistic shape, although the 
reasons why this ·occurs have not. be demonstrated by 
30. The participants in this debate included; Griliches 
Z. Congruence versus Profitability: A Ealse Dichotomy, 
Rural Sociology, 25, 354-356, 1960. Havens, A.E. and 
Rogers, F.M. Adoption of Hybrid Corn: Profitability 
and the Interaction Effect. Rural Sociology, 26, 
409-414, 1961. Griliches, z. Profitability versus 
Interaction : Another False Dichotomy. Rural Sociology, 
27,327-330, 1962. Havens A.E. a·nd Rogers E.M. ReJoinder 
to Griliches Another False Dichotomy. Rural Sociology, 
27,330-332, 1962. Babcock, J.M. Adoption of Hybrid Corn 
A Comment, Rural Sociology, 27, 332-338, 1962. 
31. Griliches, Z. Profitability versus Interaction 
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these researchers. Rural sociologists have established 
that the interaction effect, which is the process whereby 
individuals are influenced to adopt an innovation by 
individuals who have already adopted, is of major import-
ance in explaining how innovations diffuse. Economists 
have established that there are consistently strong link-
ages between the expected profitability from adoption of 
innovations and the rate of adoption of innovations. The 
attraction of potential profits appears to explain why 
firms adop·t innovations. 
Spatial diffusion studies are associated with 
Hagerstrand, a Swedish social geographer ... "who has 
constructed a variety of simulation models in which infer-
mation flows between potential adopters about an innovation 
32 were a key element in the diffusion process". Hagerstrand 
observed that there was considerable stability in the 
patterns of spatial diffusion of innovations, and on the 
basis of these observations and his empirical studies he 
formulated a principle termed the "neighbourhood effect". 
This states that ... "the probability of a new adoption 
is highest in the vicinity of an earlier one and decreases 
33 with increasing dist.ance." 
32. Lindner, R.K. and Pardey,P.G. The Micro Prncesses of 
Adoption - a Model. Unpublished paper presented at 
Australian and N.Z. Association for the Advancement of 
Science Conference, Auckland, January 1979. 
33. Hagerstrand, T. Quantitive techniques for anlaysis of 
the spread of information and technology. In, Anderson 
C.A. and Bowman,M.J. eds. Education and Economic Develop-
ment, London, Frank Cass, 1966, PP. 261-262. 
Further he observed that there appeared to be a system of 
hierarchial centres from which innovations spatially 
diffused in accordance with the neighbourhood effect. 
This model phd the conclusions drawn from it show 
considerable similarities with the temporal diffusion 
studies, particularly in the emphasis that they place on 
the information transfer process. Indeed Hagerstrand 
postulates that ... " the "telling" between people who meet 
and talk informaily is the most.important part of the 
(diffusion process)." 34 Thus the "neighbourhood effect" 
reflects the impact of physical distance on communication 
between persons within a given locality. Useful insight 
into the patterns of diffusion have been gained from 
use of this model, but it appears to provide a rather 
crude and partial representation of diffusion. Note that 
it excludes the possibility of non-interpersonal flows 
concerning the innovation, assumes that an innovation is 
adopted as soon as it is heard of, and concentrates 
attention on the "demand'' ·forces in the diffusion process. 
Finally as Hudson has pointed out, this spatial diffusion 
model is unable to explain the cause of the logistic shaped 
34. Hagerstrand, T. Quantitive Techniques .... P. 263. 
f 1 t . d t. 35 curve o cumu a 1ve a op 1on. 
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Some of the deficienc-
ies of this model have been overcome by subsequent modif-
ications but other defects which Hudson draws attention 
to appear congenital. This model shares with the temporal 
diffusion models surveyed above the defect of a myopic 
vision of diffusion. They ignore the role of suppliers 
of innovations in making innovations available at varying 
times. To adequately explain the whole diffusion process 
this facet of diffusion needs to be included in diffusion 
models. 
(b) Inter-Region Studies~ 
Such studies are relatively few in number and even 
fewer have been completed by economists. The contribu-
ution of these studies to understanding of international 
diffusion is slight, because they are little different 
from intra-country studies. Their primary role is to 
discover how several innovations diffuse within a number 
of countries. Two studies will serve to illustrate the 
methodologies used and the principal results. Ray studied 
the diffusion of ten industrial processes in nine 
industries across six countries, Austria, France, Germany 
35. Hudson, J.C. Diffusion in a central place system, 
Geogra,phical Analysis 1,45-49,1969. Hudson has hypoth-
esised and tested a, model of diffusion in which innov-
ations diffuse through a hierarchy of "central places'' 
before spreading to outlying subsidia,ry areas. The· 
model incorporates both neighbourhood effects and· 
central place hierarchies ~o provide an explanat~on for 
the frequently observed S shaped curve of cumulative 
frequency of adopters of an innovation. 
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Italy, Sweden, and the U.K. 36 He reports when the 
innovations first reached the various countries as a 
matter of background information. From this data lag 
times of first introduction of the techniques in each 
country have been calculated, revealing that average lag 
times typically fall between four and ten years, but 
there are also instances of processes taking several 
decades to diffuse to some countries. Tunnel kilns for 
example were introduced in the U.K. in 1902, but were not 
introduced in Sweden until 1948 and even later in the other 
four survey countries. One technique, the use of 
Gibberellic acid in brewing was prohibited in West Germany 
and Italy. A summary of the diffusion of the ten techn-
iques is given in Table 2.1. below. 
A noticeable feature of this summary data is the 
leisurely pace of diffusion within the countries following 
the first introduction of the innovation. Penetration rates 
have generally been quite low. For five of the processes, 
the g~aphing of times to reach X per cent of an industries 
output against lag times in introduction, suggests a ... 
"fairly marked negative relationship between the speed of 
diffusion and the time-lag of introduction: countries 
which are pioneers tend to have slower speeds of dif-
fusion." 37 
36. Ray, G.F. The Diffusion of 












Diffusion of Ten Innovations 
OXY cc SP 
( 19 .• ) 
"' 52 52 66 
56 60 65 
57 54 65 
64 58 65 
56 63 63 
70 60 64 
Number of years after pioneer 
Austria 0 0 3 
France 4 8 2 
Germany 5 2 2 
Italy 12 6 2 
Sweden 4 11 0 
U.K. 8 8 .1 
Years to produce indicated Per Cent 20 1 10 
percentage of output by 
process 
' I 
Austria 2 10 1 
France 12 .. 2 
Germany 8 9 2 
Italy 2 7 .. 
Sweden 9 3 2 
U.K. 5 6 3 
NC SL FG TK SCM ATL GA 
63 61 57 
57 53/54 66 49 60 47 66 
62 54 66 59 53 54 
60 60 65 51 62 50 
58 57 49 50 55 59 
55 58 58 02 50 47 59 
8 7 9 
2 0 8 1 10 0 7 
7 1 8 11 3 7 
5 6 7 3 12 3 
3 3 0 0 8 0 
0 4 0 0 0 0 0 
2 10 30 50 
.. 4 
. . 12 . . . . 
6 2 1 
3 10 15 
9 8 2 3 
6 . . 10 4 
Cont .... 
Cont. 
OXY cc SP NC SL FG TK SCM ATL GA 
IV. Diffusion (per cent) by 
68 indicated yeara ( 19 .• ) 67 66 68 66 68 66 66 66 68 
Austria 67 1.2 35 (5.0) 58 
France 17 0.6 (25) 0.81 ( 8. 5) 7 31 68 
Germany 32 2.4 15 0.35 9.5 6 48 66 81 
Italy 27 2.0 4 0.36 3.0 6 45 48 39 
Sweden 33 2.2 52 2.4 59 80 97 48 
U.K. 28 1.6 24 0.88 8.0 25 12 36 52 70 
(a) Except for machine tools (number per thousand tools, including aircraft industry) propor-
tions are based on respondents' total output for SL, TK, SCM, and ATL; otherwise on 
national output. Figures in brackets are estimates. 
Abbreviations Used: 
OXY = basic oxygen process in steelmaking 
CC = continuous casing of steel 
SP = special paper presses 
NC = numerically controlled machine tools 
SL = shuttleless looms in cotton weaving 












tunnel kilns in brickmaking 
new steel cutting methods in shipbuilding 
automatic transfer lines for car engines 
Gibberellic Acid in brewing/malting 
67.. 
Ray suggests that this result may be due to the 
fact that the pioneer faces all sorts of teething troubles, 
which are likely to be partly and gradually solved by the 
time others adopt the innovation. He suggests that ... "it 
is therefore not necessarily desirabl~ to be the first to 
introduce a new technique." 38 The conclusions of the 
study relate primarily to the spread of the innovations 
within each country, viz: 
no evidence that any country tends to 
lead the others in introducing new techniques ... 
the three most important and ·general influences 
on the diffusion of the techniques are probably 
the advantage of the new process in terms of 
overall profitability, the attitude of management 
to the adoption of new tecbniques, and the access 
to capital, though other considerations proved 
weighty in individual cases. 39 
These comments appear to relate primarily to the actions 
of the adopters of these innovations. Some sporadic 
comments about supply factors do occur in the discussion 
of the individual diffusion processes. Legal restrictions 
and licensing requirements are thought to have been delay-
ing influences on the diffusion of the Gribberellic acid 
and float glass processes respectively. Fragmentary 
evidence is presented suggesting that for two of the pro-
cesses there is a correlation between the size of the 
industry or home market and the year of first introduction 
f h h 
. 40 o t e tee n1que. 
38. Ray, G.F. The Diffusion of p. 83. 
39. Ray, G.F. The Diffusion of PP. 81,....83. 
40. Ray, G.F. The Diffusion of PP. 4 9, 7 3. 
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There also appears to be a negative correlation between 
average size of the companies in the countries involved 
and time of first introduction. While this is far from 
conclusive evidence it does suggest that for industrial-
ists ... "the bigger their easily accessible home market 
the keener may be the competition forcing them into 
cost saving new ventures." 41 
Ray's approach is an eclectic one; he presents 
evidence on a variety of influences on the diffusion 
patterns for these industrial processes. This does 
provide .a reasonably comprehensive view of the diffusion 
process. There are some deficiencies however : the 
study is primarily concerned with understanding diffusion 
within a series of countries. No formal models of the 
diffusion process are tested for across-country data. 
The results are valuable but impressionistic and do little 
to answer the question of why some countries obtain innov-
ations earlier than do others. 
Maddala and Knight trace the diffusion of one very 
capital requiring technique, the Linz-Donawitz steel 
making process. This Austrian innovation provides major 
savings in both capital and production costs for steel-
making and is of considerable interest because of its 
westward diffusion across the Atlantic. Contrary to 
popular belief this study demonstrates that even a 
41. Ray, G.F. The Diffusion of ..... P. 49. 
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patented industrial process innovation can diffuse 
quite rapidly from the originating country. Despite the 
rigidities caused by the presence of existi:ng steelmaking 
capital, the process was first introduced in Canada only 
five years after first introduction in Austria, and 
42 in the U.S.A. within another two years. The primary 
purpose of Maddala and Knight's study however, is to 
explain the differences in diffusion rates within countr-
ies. They find that the best explanatory variable for 
the extent of adoption of the process is the total 
increase in crude steel production over the period stud-
ied. _The best explanation of the rate of adoption are 
institutional variables such as lags and rigidities in the 
planning system and barriers to international competitio~~ 
Patent protection was considered not to be a significant 
factor affecting diffusion of this innovation. These 
results are .. somewhat surprising in that they lack the 
expected relationship between relative profitability 
and rates of diffusion. The unavailability of profit-
ability data forced the authors to compare the growth in 
output of L-D steel with the increases in total steel 
production within the nineteen countries studied. 
42. Maddala, G.S. and Knight, P.T. The International 
Diffusion of ..• P. 535. 
43. Maddala, G.S. and Knight, P.T. The International 
Diffusion of ... PP. 557-558. 
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The use of such measures obviously blocks profitability 
from entering the results and biases the results in 
favour of rapidly growing steel producers, and countries 
with high replacement needs but a low rate of increase in 
production. 44 However the causes of the comparatively 
slow rate of diffusion of this technique within the U.S.A. 
has been the subject of some debate. Relative profit-
ability has been just one of the suggested explanations 
for sluggish diffusion of this technique. 45 
The two international diffusion studies are 
primarily studies comparing rates of diffusion within 
several countries. The statement by Maddala and Knight 
••• 
11 The present paper will examine in some detail the 
factors determining the rate and extent of diffusion 
h h h ld f • 1 h • 11 46 t roug out t e wor o a s1ng e new tee n1que ... 
is somewhat misleading. Their paper and Ray's paper are 
comparative intra-region studies of diffusion. They 
provide useful information about typical lag times from 
pioneer introduction to first introduction in several 
countries. They do not explicitly ask why differences in 
these lags occur. They do not ask what are the channels 
44. Maddala, G.S. and Knight, P.T. The International 
Diff;usion of . . . . P •. · 54 9. · 
45. Maddala, G.S. and Knight~ P.T. The International 
Dif;fusion of .... PP. 550~551. 
46. Maddala, G.S. and Knightf P.T. the International 
Diffusion of ..•. P. 532. 
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whereby innovations do flow from one country to another. 
Such questions as these1 are however posed by diffusion 
supply researchers, whose work is reviewed below. 
(3) DIFFUSION SUPPLY LITERATURE 
(a) Intra-Region Studies. 
Comparatively few people have studied the supply 
of innovations to markets or to whole countries. The 
studies which do exist are therefore particularly valuable. 
The name issociated with microdiffusion research of this 
47 
type is that of Brown, a geographer. Working in the 
spatial.diffusion tradition of Hagerstrand, Brown turns his 
attention from the role of information flows amongst 
potential adopters, to the role of propagators of innov-
ations in the diffusion process. 
Diffusion he suggests is a three step process: 
l. the establishment of diffusion agencies (e.g. retail 
outlets) through which the [innovation] is distributed 
-2. the implementation of a strategy by each agency to 
induce adoption among the population in its service 
area 
47. Brown's publications on this topic include : Brown, 
L.A. Diffusion of Innovation:A Macroview. Econbmic 
Development and Cultural Change, 17, 189-211, 1979. 
Brown, L.A.· The Market and Infrastructure Context 
of Adoption: A Spatial Perspective on the Diffusion 
of Innovation. Economic Geography, 51, 185-216, 
1975. Brown, L.A., Malecki, E.J. and Spector, A.N. 
Adopter categories in a Spatial Context, Alternative 
Explanations from Empirical Regularity. Rural 
Sdciology, 41, 99-118, 1976. 
v2. 
3. the (interpersonal) flow of information concerning 
the new innovation among the potential adopter_ group 
members. 48 
Why does Brown postulate this three step model, instead of 
just concentrating on the adoption step as have hundreds 
of other researchers? Because 
These first two steps ..• are aspect of the 
diffusion process that determine the avail-
ability of innovations to potential adopters, 
grossly shape the patterns of diffusion,· and 
broadly speaking comprise the supply side of 
diffusion. Previous work by contrast has 
focussed largely on adoption behaviour, the 
demand side of the equation and ·the third 
step in the diffusion process. 49 
To paraphrase, Brown argues that it is not sufficient just 
to assume that innovations become available to all potential 
adopters in a country at the same time, if the innovation 
50 is other than a news broadcast type innovation. For the 
typical innovation, availability does not occur instant-
aneously and passively. There are active supply influences 
of the sort proposed in 1 and 2 above, which determine the 
time and pattern of availability. 
48. Brown, L.A. Malecki, E.J. and Spector, A.N. Adopter 
Categories ..... 
49. Brown, L.A. The Market and ..... P. 208. 
50. For a study of that very special type of diffusion, 
See Greenberg, B.S., Diffusion of News of the Kennedy 
Assassinati6n. PUblic OpihiOn QUarterly, 28,225-232, 
in which Greenberg attempts to establish how rapidly 
a Sqmple of people become aware of news of President 
J.F. Kennedy's death. 
'\13. 
To test the validity of this model Brown studies 
the diffusion of the practice of artificial insemination 
of dairy cattle throughout a region in Sweden. This 
approach is an indirect one. He seeks to test the import-
ance of location on adopter categories in the presence of 
other variables pertaining to the potential adopter and his 
activities, rather than attempting to determine directly 
whe.ther the establishment of diffusion agencies followed 
some spatial and temporal pattern. He adopts this approach 
because he does not believe that at the level at which 
he is testing ... 
that the use of innovativeness characteristics t9 
account for adopter categories is in error; 
Rather adopter categories can be seen in a broader 
context. On a local scale, where the external 
stimuli for adoption are equal over the whole area, 
the communications model [Hagerstrand] would seem 
to be the most relevant, and innovativeness 
differences should show up in the pattern of dif-
fusion. On a larger scale, such as the total 
hinterland of an urban area or market centre, 
agency strategy results in spatial differences 
in the distribution of external stimuli for adopt-
ion (e.g. adoption facilitating infrastructure)·, 
so that market and infrastructure factors will play 
an important, perhaps dominant role, and impu-
tations of innovativeness differences may be 
grossly in error. On a still larger scale, such 
as the regional, differences in adoption times 
would be largely due to the spatial sequencing 
of diffusion agency establishment, and market 
and infrastructure factors would be almost 
totally operative. 51 
To test the importance of location in adopter categories, 
Brown first subdiv~des the sample of adopters into the 
categories depicted on P. 58 above. He then checks whether 
51. Brown, L.A. Malecki, E.J. and Spector A.N. Adopter 
Categories ... PP. 101-102. 
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these adopter categories exhibit spatial characteristics. 
The evidence suggests that •..•. 
successive adopter categories are characterised 
by shifts in the location of their respective 
mean centres. This indicates a progression of 
a diffusion wave from the southwest to the 
northwest in the study area. 52 
Having established the existence of this ..• "wave-like 
53 neighbourhood effect pattern" the further step requ-
ired is to determine the relative importance of location 
on adopter categories. A forward step~wise discriminant 
analysis is carried o~t leading to the conclusion that 
locational variables •. tend to play at least 
as strong a role in discriminating among the 
adopter categories as do the other variables. 
More generally, however, all three dimensions 
represented by the variables - modernness 
location and economic status - appear to play 
a significant role in discriminating among 
adopter categories. 54 
The suggestion is that the results reflect the infra-
structure development effect where there is a spatial 
pattern of penetration of agencies into an area, followed 
by a filling in process involving the neighbourhood or 
interpersonal communication effect. While the evidence 
is indicative rather than conclusive, the thesis is very 
plausible. Availability will surely have a significant 
52. Brown, L.A. Malecki, E.J. and Spector, A.N. Adopter 
Categories ... P. 106_ 
53. Brown, L.A. Malecki, E.J. a,nd Spector, A.N. Adopter 
Categories •.• P. 106~ 
54. Brown, L.A. Malecki, E.J. and Spector, A.N. Adopter 
Categories, PP. 113-114. 
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impact on both the timing and pattern of di~fusion of 
an innovation. 
(b) . 'd' 55 _ Inter-Reg1on Stu 1es. 
A study which gave explicit recognition to the 
importance of supply effects on diffusion was Griliches' 
study of the diffusion of hybrid corn in the U.S.A. 
56 
In this study Griliches examined the inter-state diffusion 
of hybrid corn, as well as the adoption of hybrid corn by 
persons living within the states. Griliches' work is 
admirable for its comprehensive view of the diffusion 
process. His· perspective is global. His concerns are with 
three stages of the diffusion process. 
1. the time of first availability of hybrid corn for 
each region. 
2. the rate of adoption within each region, and 
3. the equilibrium level of use in each region. 
The data available on the diffusion of hybrid corn Griliches 
reduced to three critical parameters, the origin, the 
slope and the ceiling. These variables correspond to the 
three facets of diffusion listed above. The reasons why 
different values of the "slope" parameter occur have of 
course been discussed in Section 2 above. But the 
55. Inter-Region studies of diffusion of pharmaceuticals 
are reviewed in Chapter 3 above. 
56. Griliches, Z. Hybrid Corn : An Exploration 
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importance of ''origin" was also recognised. The date at 
which hybrid corn was first made available to a state could 
be expected to influence marketedly whether or not an ''early 
adopter" in Alabama adopted the innovation before a "laggard" 
in Iowa did- the state with the first "origin" 57 .once the 
dates of "origin" for each state had been established the 
important task was to determine the reasons for the dif-
ferences in "origins". Hybrid corn was not a single homog-
eneous innovation; different cultivars were bred for each 
region. Thus there were supply constraints; propagator action 
and exp~nditure was needed by agricultural research stations 
and private seed companies to make the innovation available 
for each area. These requirements, it was postulated, may 
have forced the marketers of the innovation to choose to 
supply states with this innovation at varying times. Grili-
ches conjectured that .•• 
The date at which adoptable hybrids became available 
in an area is viewed as the result of seed producers 
ranking different areas according to the expected pro-
fitability of entry and deciding their actions on this 
basis. Tha relative profitability of entry into an 
area will depend on the eventual market in that 
area, marketing cost, the cost of innovating for that 
area, and ... the expected rate of acceptance.58 
Demonstrating that these were the important factors 
affecting times of availability was made difficult by the 
57. Griliches, z. 'Hybrid Corn and the Economics .. P. 276. 
58. Griliches, Z. Hybrid Corn :An Exploration ... P. 507. 
7'J. 
the lack of correspondence between "entry areas'' 
(i.e. states) and the actual corn growing areas. As with 
Brown's study the results are persuasive rather than con-
elusive. However, the results do indicate ... "a strong 
association between the date of origin and average market 
density in the area ,.59 Average market density was a 
measure of the expected profitability of an area. 
Griliches commented that .... 
While these results may not be too conclusive, 
together with information gathered in conver-
sations with executives in the industry and a 
graphical survey ·of the data, they leave little 
doubt in my mind that the development of hybrid 
corn was largely guided by expected pay-off, 
'better' areas being entered first, even though 
it may be difficult to measure very well the60 variables entering into these calculations. 
Market size, entry costs, marketing costs, and expected 
return per unit sale seem likely to be the crucial factors 
which will determine the rankings firms give areas when 
they have to select markets to launch their products in. 
Where there are constraints on the ability of propagators 
of innovations to supply all markets simultaneously, it 
seems likely that these propagators will rank the potential 
markets for "attractiveness" or "profitability", either 
. 1" . 1 1" . 1 61 1mp 1c1t y or exp 1c1t y. 
59. Griliches~ z. Hybrid Corn An Exploration P. 514. 
60. Griliches, z. Hybrid Corn An Exploration P.514,515. 
61. See also Griliches, z. Hybrid Corn and the Economics ... 
PP. 276-277. 
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The process of supply of innovations to different 
countries appeals ~s having close parallels to the supply 
of an innovation to different regions within one large 
country such as the U.S.A. Griliches~ work provides an 
excellent guide to the way in which research on the inter-
national diffusion of innovations such as new pharmaceut-
icals mQght proceed. Innovations which are usually pro-
tected by patents~ require variable amounts of efforts by 
propagators to make them available to different countries 
whose markets vaTy greatly ·in, size, price levels and 
sophistication. Griliches does not explote the require-
ments which force propagators to select markets for 
launching innovations, and consequently is silent on the 
theoretical requirements to be met when decisions are 
made about the ranking of various markets. But he does 
draw sensible conclusions about the likely nature of 
decision making on the supply of such innovations. His 
work is of con~iderable value because it provides a com-
prehensive investigation of diffusion, and is particularly 
·valued for its focus on the supply of innovations. 
(4) CONCLUSION 
Diffusion of innovations of the sort that economists 
usu~lly study appear superficially to be simple, readily 
understand~ble processes. Identifying variable~ which 
correlate quite strongly with rates of adoption is a 
straightforward task, for most such innovations. 
79. 
Adoption does seem to occur in response to pressures of an 
economic sort, namely the promise of higher profits, lower 
costs, superior products, greater output, and it seems 
plausible that rates of response to these stimuli will 
vary according to : extent of exposure to these stimuli; 
levels of education; and socio-economic status. Knowledge 
of spatial and socio-economic location allows understanding 
of how adoption times may vary within a region. That dif-
fusion requires communications about the innovation is 
undeniable. The socio-economic characteristics of the 
potential adopters, and their geographic iocation will 
all influence the timing, rate and pattern of diffusion 
of an innovation within a region. 
But as with the crab on a ridge of a wave-ribbed 
beach, unable to determine whether he is on a local or a 
global maxima, so the "micro-diffusion" researcher is 
troubled by questions about local and global innovativeness. 
For innovativeness is a relative concept which is dependent 
for its meaning upon the actions of other members of the 
defined group. II Thus a laggard in a progressive loc-
ality may well be amongst the innovators when the focus of 
62 attention becomes the national social system ... , and 
vice versa. This point most sociologists who have studied 
diffusion appear not to have understood. Consider a series 
of crabs on a series of non-continguous beaches, charged 
62. Lindner, R.K. and Pardey, P.G. The Micro Process .... 
p. 8. 
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with the task of determining what factors determine feeding 
times of crabs. A lot of scurrying may lead to a lot of 
crabs concluding that they can explain when feeding times 
occur on their individual beaches. But to explain why 
f~eding times differ from beach to beach, a seagull may be 
required. To explain why diffusion of innovations occur 
when it does in different regions, theories explaining why 
innovations are supplied at different times to different 
regions are required. These differences in times of 
availability may themselves be as great as the differences 
between times of adoption by the innovator and the laggard. 
Rogers and Shoemaker may be correct, Griliches can 
only explain about 30 per cent of the differences in 
times of adoption of hybrid corn within a region. 63 But 
Griliches' comprehensive seagull-like overview of diffusion 
will surely lead to better understanding of the total pro-
cess of diffusion than will repeated study of the adoption 
of innovation. 
Where the foci of a.ttention are the relative times 
of availability of innovations, theories about the ·supply 
of innovations are essential. Attention now turns to 
the literature about ·the supply of pharmaceutical innovat-
ions. 
63. Roger, E.M. and Shoemaker, F.L. Communication of 
Innovations. P. 144. 
C H A P T E R 3 
PHARMACEUTICALS DIFFUSION RESEARCH LITERATURE 
(0) INTRODUCTION 
This is a relatively new area for research, in 
which there appear to be only a handful of participants 
who have published papers on this topic. Pharmaceuticals 
diffusion research is almost entirely a spin off from the 
long running debate about the so-called U.S. "drug-lag". 
Combatants in this debate disagree over whether or not the 
U.S. tends on average to have new pharmaceutical products 
launched onto its market later than do some European 
countries, and sharply disagree about what part the stringent 
Food and Drug administration regulations play in causing 
these alleged "drug-lags". The existence of this debate 
has stimulated interest in the international diffusion of 
pharmaceutical products as a research topic. Before com-
mencing this research project, its antecedents are surveyed . 
. (1) A GLOBAL VIEW OF PHARMACEUTICALS DIFFUSION 
It was argued in chapter one-above that ~nnovation 
is the major basis of competition in the pharmacutical 
industry. A large number of new pharmaceutical products 
are introduced to the world's markets each year. Inform-
ation qn the sources of invention, countries of first 
introduction, and extent of diffusion of new pharmaceutical 
products is provided by Reis-Arndt, a West German 
82. 
1 researcher • Table 3.1 shows the countries of invention 
for 1017 pharmaceutical entities invented between 1961 and 
1973. Reis-Arndt claims this is the complete list of new 
human and veterinary pharmaceuticals invented in this 
period, which are not just new variants of existing pro-
ducts. There are problems in identifying where invention 
occurs if a drug is invented by a multinational company, so 
Reis-Arndt adopts the convention of accrediting new pharm-
aceuticals to the country where the headquarters of the 
parent firm are sited. 
Clearly there is considerable concentration in the 
sources of invention. Three quarters of these new pharm-
aceuticals were invented in the research laboratories of 
five countries. For the period studied the U.S.A. has 
always been a dominant source of pharmaceutical inventions. 
The data suggest there has been a significant reduction in 
the rate of invention over the thirteen year period, the 
number of new drugs invented per year declining from a 
peak of ninety-six in 1963 to a low of sixty-two,nine 
years later. 
Table 3.2 presents information on the countries of 
world-wide first introduction for these 1017 new pharma-
ceutical products. The surprising feature of this table 
1. Reis~Arndt, E. Neue Pharmazeutische Wirkstoffe 1961-1973, 
Die Pharmazeutische Industrie, 37, 4, PP. 233-240, 1975. 
I am grateful to Professor P. van Moeseke, Economics 
Department, University of Otago,for translating this 
article from German to English. 
TABLE 3.1 
NEW DRUG ENTITIES BY COUNTRIES OF INVENTION 1961-1973* 
c t oun ry y ear o f I t' nven 10n Totals 
1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 No. 
U.S. A. 31/1 20 22/1 14 13 22 20/1 18/2 18/1 21/1 25 13 10 247/7 
France 11 21 20 8 8 14 19 17/1 22 17 15 13 17 213/1 
Germany 11 14 16/1• 14 10 7 8 12/1 11 7/1 5 4 14/1 133/4 
Japan 7 3 12 ',9 13 8 7 7 5 7 11 8 1 98 
Switzerland 12/1 8 7 5 7 3 8 5/i 3 6 5 3 8/1 80/3 
Italy 4 6 2 4 6 2 5 7/1 8 1 6 9 6 66/1 
U.K. 6/1 3 9 4 4 4 5/1 4 3/1 2 2 3 3 52/3 
East Bloc 3 - 1 5 2 7 7 4 3 1 4 6 3 46 
Scandinavia 3/1 5 4 2 1 3 3 3 2 2 3 1 2 34/1 
Benelux 2 7 2 1 1 4 - 3 2 1 4 1 2 30 
Austria 3 - 1 2 2 1 3 1 - 2 - - - 15 
Other - 2 1 1 - 2 1 2 - 1 2 1 - 13 
Totals 91 89 96 69 73 82 85 80 76 67 82 62 65 1017 
* Numbers after the mainnumbers indicate that more than one company or group of companies 
occasionally synthesized the same substance at the same time. 
Source: Reis-Arndt, E., Neue Pharmazeutische Wirkstoffe 1961-1973 
































TABLE 3. 2 
















Year of First Introduction Totals 
1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 No. 
16 16 24 19 19 23 20 15 14 21 240 
14 14 12 12 15 13 6 5 4 6 153 
6 13 8 11 7 7 8 11 8 2 102 
6 4 8 10 10 7 4 8 6 6 100 
7 4 6 5 1 3 6 6 4 5 92 
1 6 2 7 4 7 5 6 9 4 67 
3 4 1 5 4 2 4 6 2 4 54 
5 2 7 7 4 2 1 4 6 3 45 
2 3 3 - 4 2 1 7 - 6 41 
2 - 3 2 2 1 2 3 1 1 23· 
2 2 1 3 1 - 2 - - - 15 
5 5 7 4 9 9 8 11 8 7 85 
69 73 82 85 80 76 67 82 62 65 1017 
Reis-Arndt, E., Neue Pharmazeutische Wirkstoffe 1961-1973 


















is the lowly position occupied by the U.S.A. The most 
successful inventor of new pharmaceutical products, (23.9 
per cent of the total were invented in the U.S.A.), ranks 
only fifth in terms of number of first introductions. Nine 
per cent of products were first introduced in the U.S.A. 
This occured despite the fact that the U.S. ethical pharm-
aceuticals market is the largest in the world with total 
sales for humans totalling U.S. $6.083 b. in 1974. The 
other rankings for first introductions are generally in 
line with the countries respective successes in inventing 
new products, apart from the lower Swiss and Italian rank-
ings. First introductions are almost as concentrated as 
invention, 67.5 per cent of the first introductions occured 
in only five countries, France, West Germany, Japan, U.K. 
and U.S.A. 
Analysis by Reis-Arndt of these first introductions 
reveals that on average 7.6 per cent of these drugs were not 
first introduced." by their inventors or their subsidiary 
companies. As Table 3.3. shows this tendency is most 
common among U.S.A., Italian and Swiss products, with 11.3 
per cent, 13.6 per cent and 11.3 per cent respectively being 
first introduced by other than their inventors. Again 
Reis-Arndt offers no explanation, a priori or otherwise, 
for these results. Clearly,an as yet unanswered question 
has been raised, viz; why should companies with headquarters 
in the U.S.A., Switzerland and Italy choose much more 
frequently than other countries' firms to allow their 
TABLE 3.3 
NEW PHARMACEUTICAL ENTITIES 1961-1973. FIRST INTRODUCTIONS VIA FOREIGN FIRMS/INSTITUTIONS 
Parent Country of 












Other Countries ** 
Totals 
Number of New 
Entities* 
247 ( 7) 
213 ( 1) 
133 (4) 
98 








































Source : Reis-Arndt, E., Ne:u,e Pharmazeutische Wirkstoffe 1961-1973, Table 3, P. 235 
* Number after the main number indicate that more. than one company or group of companies 
occasionally synthesized the same substance at the same time. 




inventions to be first launched by competitors? 
Interesting information is also provided on the 
extent of diffusion· of the 658 products launched in other 
than eastern bloc countries, up to 31 December 1973. 
Almost 20 per cent of these new substances were marketed 
in only one country, another 30 per cent in from eleven to 
fifty countries, and the remaining 13 per cent were market-
ed in fifty-one or more companies. Table-3.4 illustrates 
the country of origin of these products and their extent 
of diffusion. 
As Reis-Arndt corrunents, if we call a pharmaceutical 
product introduced into more than fifty countries a 
Weltpraparat, or world drug, then of the drugs introduced 
between 1961 and 1973, one in seven became a world drug. 
Of these Wel-tpra'parat, thirty have been accredited to U.S. 
based firms, twenty-four to Swiss firms, eighteen to West 
German firms, and seven to British firms. 
Again tantalising questions are raised but are left 
in limbo. For example, what are the factors which det~ 
ermine why one drug diffuses to one hundred countries, and 
others to one, ten, or twenty countries? Why do 31.2 per 
cent of Swiss inventions become "world drugs" but only 
16.6 per cent of U.S. drugs, 1 per cent of French drugs 
and 0 per ~ent of Japanese drugs? 
Finally, Reis-Arndt analyses the sources of invent-
ions of the drugs introduced into ten of the world's largest 
TABLE 3. 4 
EXTENT OF DIFFUSION OF PHARMACEUTICAL PRODUCTS INVENTED BETWEEN 1961 AND 1973 
Country of 
Number of Countries Products Marketed In 
Invention 1 2 3 4 5 6 7 8 9 10 11-20 21-30 31-40 41-50 51-100 
U.S.A. 22 18 15 9 6 7 6 7 2 2 25 17 8 7 25 
France 36 9 7 4 2 3 4 1 4 - 14 9 2 3 -
West Germany 25 4 7 6 10 3 4 - 1 2 12 4 4 7 15 
Japan 18 2 - 3 3 1 1 1 3 - 5 2 1 - -
Switzerland 8 4 6 4 - 2 1 1 3 - 11 8 3 2 14 
Italy 11 4 5 5 5 1 2 2 3 1 8 6 2 1 2 
Great Britain 2 2 2 1 2 - - 1 1 - 5 3 7 2 4 
Benelux 3 2 3 - 1 - 1 - 1 - 4 1 1 - -
Scandinavia 1 2 1 - 2 2, 4 3 1 1 3 1 ·- 5 3 
Austria 2 2 2 2 - - 1 1 - 1 3 - - - -
Total 128 49 48 34 31 19 24 17 19 7 90 51 28 27 63 
% of Total 19.~. 7,47,3 5w24.72.93;7 2,6 2,9 1.0 13.7 7.8 4.2 lf .1 9.6 
Source Reis-Arndt, E., Neue Pharmazeutische Wirkstoffe 1961-1973 






























markets. The results of this analysis of the extent of 
diffusion to these markets by inventions from the ten most 
inventive, non-eastern bloc countries, is presented in 
Table 3.5 below. 
There is considerable variation in the extent to 
which countries depend on overseas based firms for the 
supply of new pharmaceutical products. Reis-Arndt's data 
indicates that while the U.S.A. itself produced two thirds 
of all new pharmaceutical products launched in the U.S.A., 
Spain,· Brazil, Argentina and Mexico appear to be totally 
dependent on overseas firms to supply them with new pharm-
aceutical products. The remaining five countries occupy 
intermediate positions. Spain, Brazil, Argentina and 
Mexico are technologically dependent countries, the 
other six countries are major centres of pharmaceutical 
research and development. 
Noticeable also is the low figure for total number 
of new pharmaceutical products marketed in the U.S.A. 
during th~s period. The 152 introductions recorded for 
the U.S.A.~is considerably lower than e.g. 336 for France, 
306 for West Germany and 296 for Spain. Points to consider: 
(a) Why should the U.S.A. have such a relatively small 
number of new products marketed there compared to the 
number marketed in the other nine countries? 
(b) Should it be expected that countries which are major 
sources of pharmaceutical inventions will, on average, 
experience only short lag times between first intro-
TABLE 3. 5 
NUMBER OF INTRODUCTIONS OF NEW PHARMACEUTICALS INTO TEN COUNTRIES 
Country Marketed In 
Country of West Great Argen- Maximum 
Invention U.S.A. France Germany Japan Italy Britain Spain Brazil tina Mexico Available 
U.S.A. 100 89 82 51 70 93 78 72 68 85 181 
France 2 94 19 10 30 5. 39 20 20 18 99 
West Germany 5 48 88 28 40 27 47 29 36 32 107 
Japan 2 3 3 39 5 1 8 5 4 7 40 
' I 
Switzerland 22 46 46 21 35 34 44 38 27 35 77 
Italy 1 11 12 11 48 13 40 28 23 24 58 
Great Britain 17 21 22 18 20 35 15 16 15 18 35 
Benelux - 9 6 - 1 6 9 5 2 5 17 
Scandinavia 2 12 19 11 10 9 10 6 8 5 29 
Austria 1 3 9 3 5 3 6 2 3 5 15 
Total 152 336 306 192 264 226 296 221 206 234 658 
% Imported 34.2 72.0 7.1. 2 79.7 81.8 84.5 "100.0 100.0 100.0 100.0 
Source Reis-Arndt, E., Neue Pharmazeutische Wirkstoffe 1961-1973, Table 6,P. 236. 
91. 
·. duction of pharmaceutical products anywhere and 
introduction in their markets? 
Reis-Arndt's work demonstrates that diffusion of 
pharmaceutical inventions to many countries is a common 
event. There is likely to be a considerable amount of 
similarity between markets in the drugs available. Apart 
from a few inventive countries, most countries are tech-
nologically dependent for the great majority of new products 
launched on their markets. 
While Reis-Arndt provides a useful outline of the 
process of international diffusion of pharmaceutical prod-
ucts, and this appears to be one of only two published 
articles describing the world diffusion of pharmaceuticals,2 
empiricism without analysis does not explain the nature of 
the process involved. Lacking are explanations for dif-
ferences in extent, speed and pattern of diffusion. 
Reis-Arndt data illustrates how diffusion occurs, but does 
not explain, or seek to explain, why it occurs in the ways 
it does. One possible reason for observed drug diffusion 
patterns is discussed in the section below. 
2. Reis-Arndt also collaborated in writing an earlier 
article describing the supply and diffusion of pharm-
aceutical products. See, Reis-Arndt, E. and Elvers, D. 
Ergebnisse der Pharma-Forschung: Neue Pharmazeutische 
Wirkstoffe 1961-1970, Die Pharmazeutische Industrie, 
34, 3, PP. 181-186 I 1972. 
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(2) THE U.S. DRUG LAG LITERATURE 
The dominant figure in the debate about the alleged 
U.S. drug lag has been William Wardell, a professor of 
Pharmacology at Rochester University, New York. Wardell 
has conducted sever~l investigations into the dates of 
launch of new chemical entities (N.CE.'s) onto the U.S. 
market during the 1960's and 1970's and compared the u.s. 
introduction dates with introduction dates for N.C.E. 's 
3 
launched in the U.K. during similar periods. 
He has two primary goals, namely to illustrate: 
(a) that the U.S. has, on average, later introduction 
dates than does the U.K.; 
(b) that in several instances important new therapies 
available in the U.K. are not available in the U.S.A. 
3. Wardell has published numerous articles in this field 
over an eight year period. Important among these are the 
following: Wardell, W.M., Introduction of new theraputic 
drugs .in the United States and Great Britain: an inter-
national comparison, Clinical Pharmacology and Thera~­
eutics, 14, PP. 773-790, 1973. British Usage and Ameriri::an 
awareness of some new theraputic drugs, Clinical Pharm-
acology and Therapeutics, 14, PP. 1022-1039, 1973. 
Therapeutic Implications of the Drug uag, Clinical 
Pharmacology and Therapeutics, 15,PP. 73-96, 1974. 
Developments in the introduction of new drugs in the 
United States and Britain, 1971-74, In Helms, R.B. ed. 
D:rug Development and Marketing, Washington, American 
Enterprise Institute, 1975,PP. 165-181. Wardell, W.M., 
Hassor, M., Anavekar, ·S.N. and Lasagna, L. The rate of 
development of new drugs in the United States,l963 through 
1975, Clinical Pharmacology and Therapeutics, 24, PP. 133-
145, 1978. Wardell,·w.M. The drug lag revisited : 
comparison by therapeutic area of patterns of drugs mark-
eted in the United States and Great Britain from 1972 
through 1976. Clinical Pharmacology and Therapeutics, 24, 
PP. 499-524, 1978. A Close Inspection of the PCilm Look", 
Journal of American Medical Association, 239, pp. 2004-
2011, 1978. 
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His ultimate goal is of course, to demonstrate that the U.S. 
suffers because of the existence of a drug lag, that this 
has a significant impact on the knowledge level of doctors, 
their prescribing habits and therefore the health of 
patients. 
Wardell, and other writers, 4 argue that the major 
factor causing the U.S. drug lag, which they claim exists, 
are the stringent F.D.A. regulatory hurdles which have to 
be cleared during clinical testing, and before market 
launch can take. place. Wardell's approach is a straight-
forward one, based on comparison of dates of introduction 
5 
of N.C.E.'s on the U.S. and U.K. markets. He uses the 
U.K. for comparative purposes because of the similarities 
between the two countries medical practices and economic 
structures. First he lists all the N.C.E. 's marketed in 
the U.S.A. and the U.K. during a selected period. Note 
that these lists include all N.C.E. 's marketed in either 
the U.S.A., or the U.K. and are not confined to just those 
products marketed in both countries during the period. 
4. For example, see, Clymer, H.A. The economic and regulat-
ory climate : U.S. and overseas trends. In Helms, R.B. 
ed. Drug Development and Marketing, Washington, American 
Enterprise Institute, 1975, PP. 137-154, and Tishler, 
M. Drug discovery - background and foreground. Clinical 
Pharmacology and Therapeutics 14, PP. 479-486, 1973. 
5. New Chemical Entities, (N.C.E.•s) are distinct new pharm-
aceutical products which provide therapeutic action 
not already available f.rom·some existing similar product. 
Thus a list of.N.C.E.'s becoming avail~ble during a 
certain period will·not include products which are 
trivial variations on existing products, or combinations 
of existing products. 
94. 
Armed with these lists of all N.C.E.'s introduced for 
human therapy, dates of first marketing for these drugs 
are then recorded. Comparisons are then made of the num-
ber first becoming available, or becoming exclusively 
~vailable, in each country. The results of Wardell's 
1973 study of this subject are as below: 
In nine therapeutic categories during the decade 
1962-1971, nearly four times as many new drugs 
(single chemical entities) became exclusively 
available in Britain as became exclusively 
available in the United States. In addition 
where differences occured in the dates of intro-
duction of drugs, introduced in both countries, 
twice as many drugs were introduced first in 
Britain as in the United States. When examined 
by therapeutic category, this drug lag was found 
to be most marked in the areas of cardiovascular, 
gastrointestinal and respiratory medicine,and 
diuretic and anti-bacterial therapy.6 
After demonstrating that a drug lag, existed in the U.S. 
compared to the U.K. , Wa<:i?dell wrote two further articles 
emphasising the impact and importance of these delays in 
7 availability of new drugs. He concluded that the drug 
lag had been 
" accompanied by differences in therapeutic 
approach in.Britain and the United States. 
American physicians were found to be poorly 
informed about drugs used widely and for 
some years abroad but
8
not yet available in the 
United States ... ". 
6. Wardell, W.M., Developments in the Introduction .. P. 166. 
7. Wardell, W.M. British Usage and American Awareness, ... 
and Therapeutic Implications .... 
8. Wardell, W.M. Therapeutic Implications ..... P. 73. 
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Further he argued ~that despite the problem of possibly 
greater toxicity and unforeseen side effects due to the 
introduction of more new drugs in the U.K., 
" ... on balance, Britain appears to have gained 
in comparison from its more permissive policy 
towards the marketing of new drugs coupled with 
a more rigorous program of post-marketing sur-
'll " 9 vel ance . . . . 
Updates of the 1973 study were completed for the 
1972-74, and 1972-76 periods. 10 A summary of the results 
from the 1972-74 study is presented in Table 3.6, showing 
a drug lag for the U.S. when compared to the U.K. similar 
to that found in 1973. Table 3.h demonstrates for one 
group of drugs the simple comparative technique used to 
illustrate the nature of the drug lag. 
The results of the 1972-76 period study concurred 
with results from Wardell's two previous studies. 
In the 1972 to 1976 period, 82 new drugs appeared 
for the first time in either country. Only 29 per 
cent, of these became mutually available in both 
countries# 2.4 times as many becoming available 
first in Britain as in the U.S. Of the 71 per 
cent that became exclusively ava1lable 2.6 times 
as many became available in Britain as in the 
U.S ..... The average lead time for drugs appearing 
first in Britain was 38.1 months (range 4 to 
133 months), while the average lead time 
for those appearing first in the U.S. was 24.8 
months (range 5 to 71 months). Expressed as a 
single index, among those drugs that became 
mutually available there were 23 ,':drug years' 
of prior availability in the U.S., while the 
corresponding figure for Britain (94 drug years) 
9. Wardell, W.M. Therapeutic Implications ..• P. 73. 
10. Wardell, W.M. Developments in the Innovation ... , and 
The Drug Lag Revisited .•... 
TABLE 3. 6 
SUMMARY OF NEW DRUG INTRODUCTIONS IN BRITAIN AND THE UNITED STATES, ~ANUARY 1972 - JUNE 1974 
Theraputic ., Hutual Exclusive 
Category Total Drugs U.K. First U.S. First U.K. u.s. 
Cardiovascular 7 1 0 5 1 
Diuretic 2 1 0 1 0 
.Respiratory 4 3 0 1 0 
Antibacterial and Chemotherapeutic 17 2 4 6 5 
C.N.S. 15 3 3 6 3 
Anesthetic 3 2 0 0 1 
Analgesics, etc. 7 0 0 7 0 
Gastrointestinal 0 0 0 0 0 
T 0 T A L : 55 12 7 26 10 
Source Wardell, W.M. Developments in the Introduction ... Table 1, P. 173. 
TABLE 3.7 










Bretylium tosylate (Bretylate) 
Antianginal 
S -blockers, q. v. 
Vasodilators and other 
Nattidrofuryl (Praxilene) 
















a Aug. 1973 
Lead in Years 
(Months) 
U.K. U.S. 
3 ( 4) 
3 
a - New Indication 
Source Wardell, W.M. Developments in the Introduction, Table 2, P. 173. 
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ll 
was 4·1 times as many ...• 
These latter results suggest that there may have been a 
narrowing of the differences in availability of new pharm-
aceutical products over the two periods studikd. As 
Wardell suggests,·a variety of factors may have caused 
this to occur, including ... 
... more realistic regulatory practices and 
higher quality clinical studies in the U.S., more 
conservative practices [regulatory] in Britain, 
·attention drawn by previous studies to anach-. 
ronisms in the u.s., and industrial changes 
such as more efficient penetration by foreign 
firms. It is difficult ·to determine the relative 
contribution of each of these factors to the 12 
narrowing of the international differences. 
Difficult indeed it is, and Wardell is content to 
use these inter-country comparisons to examine the overall 
outcome of all such factors affecting the processes of 
drug development and marketing. He does not attempt to 
model the inter-country diffusion process, or to establish 
the relative importance of the various factors allegedly 
influ~ncing the diffusion patterns of new pharmaceuticals. 
The notion-that there is a drug lag, and that such 
a lag could be caused by F.D.A. regulations has been 
strongly argued by writers other than Wardell. Tishler, for 
example states, 
... it is the long, arduous, and inordinately 
expensive trip in terms of manpower and dollars 
11. Wardell, W.M. The Drug Lag Revisited ... , PP. 499,502,503. 
12. Wardell, W.M. The Drug Lag Revisited ... , P. 499. 
9 9. 
that has changed the pace of new drug introduc-
tion. It is clear that a major reason for the 
decrease in new, important, single-entity pharm-
aceuticals are the power and activities of the 
Food and Drug Administration. 13 
The evidence to support this view, or that a drug lag 
does in fact exist is far from conclusive, and many F.D.A. 
officials have tried to rebut the case made against the 
F.D.A. The most sophisticated of these arguments has been 
14 
that put forward by Kennedy, Commissioner of the F.D.A., 
who argues that evidence of a drug lag in the U.S., versus 
the U.K., is no evidence of a drug lag in the U.S., versus 
the world. He further argues that evidence of a reduction 
in the rate of launch of new pharmaceutical products in 
the U.S. should be attributed to non-regulatory factors 
such as exhaustion of the stock of knowledge on which pharm-
aceutical inventions are based, and the increased need for 
clinical testing before marketing approval can be granted. 
On the latter topic Kennedy argues, 
Thus, the decline in the rate of new drug 
approval is an international phenomenon, not a 
national one. It depends on our knowledge 
about pharmokinetics, analytical toxicology, 
the need to test for carcinogenic, mutagenic, 
and teratogenic effects, and a concurrent drop 
in our fund of basic [pharmacologic] knowledge. 
15 
In the earlier section of the attempted rebuttal Kennedy 
argued that there is a considerable asymetry in the pattern 
13. Tishler, M. Drug Discovery ... , P. 481. 
14. Kennedy, D., A Calm Look at 'Drug Lag', Journal of 
American Medical Association, 239, PP. 423-426, 1978. 
15. Kennedy, D. A Calm Look ..... P. 425. 
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of introductions across countries, certain countries lead-
ing in some products and therapeutic areas and lagging in 
others. This suggests to Kennedy that non-regulatory 
factors are more relevant than regulatory factors in det-
ermining whe.re and when new pharmaceutical products are 
marketed. Such arguments of course beg the question 
whether despite the asymetry· and asynchrony of introductions, 
the U.S. lags behind the rest of the world in availability 
of pharmaceuticals. Further, as Wardell replies, to 
decide whether or not the.U.S. does have a drug lag, it is 
necessary to compare the availability of drugs in the U.S. 
with the availability in other countries, not compare avail-
ability in each country with the availability in each of the 
others and then claim that they too have a drug lag. After 
rearranging Kennedy's data, Wardell produces the results 
shown in Table 3.8 below. 
This data shows that when availability of drugs in 
the U.S. is compared with availability in five countries, 
the U.S. mar.ket is. relatively deprived of new pharmaceutical 
products. On average, 2.9 times as many drugs became 
exclusively available in France, West Germany, or Great 
Britain as became exclusively available in the U.S.A. 
When a qualitative assessment of the drugs unavailable in 
each market is undertaken, the results reinforce Wardell's 
case that there is a real and important drug lag in the 
U.S. compared to these countries. 16 
16. Wardell, W.M. A Close Inspection ... PP. 2008-2009. 
TABLE 3. 8 
INTRODUCTIONS OF NEW CHEMICAL ENTITIES 
Exclusive to Exclusive to Exclusive to Ratio, Exclusive 
Country Shown Country Shown United States to Country 
Compared With Compared With Compared With Shown . Exclusive . 
de Haen data for 1976 All Five Others United States Country Shown to United States 
Great Britain 10 18 7 2.8** 
France 14 27 11 2.5** 
Germany 14 32 9 3.6** 
Italy 9 18 11 1.6 
Ja.:pan 2 10 13 0.8 
United States 5 
More extensive data for 
Great Britain-United 
States comparison* 
Great Britain (1962-1976) . . . 43 14 3.1 
Great Britain (1972-1976) . . . 72 21 3.4 
** Average of three countries is 2.9. 
' I 
* Nine major theraputic areas that cover most of the areas in de Haen data. 
Source : Wardell, W.M. A Close Inspection ... Table 1, P. 2007. 
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The evidence produced in this debate does appear to 
establish that the U.S. suffers from a drug lag, and this 
has been conceded by successive F.D.A. Commissioners, 
including Commissioner Kennedy himself: 
17 
I think there is no question that the Drug 
Lag exists although it is substantially less 
serious than the Food and Drug Administration 
severest critics make it out to be. 
The debate does not establish what the causes of the drug 
lag are, and does not establish what the major determinants 
of diffusion speed of pharmaceuticals are. Much of the 
debate about the role of the F.D.A. regulations in influenc-
ing the timing of introduct·ion of new pharmaceuticals into 
the U.S.A. is based on circumstantial evidence, i.e. a 
correlation between the introduction of new F.D.A. require-
ments before drugs can be marketed in the U.S.A. and an 
apparent relative worsening in time of availability of 
new drugs in the U.S.A. after 1962. 
Attempts have been made to establish the length of 
time required to gain F.D.A. approval for marketing from 
time of first application for permission to conunence clinical 
. 18 
test1ng, but without similar information about the time 
needed to gain marketing approval in other countries it is 
not possible to claim that regulatory delays have definitely 
17. Kennedy, D., The Industry and Government: Emerging Health 
Policy, quoted in Wardell, W.M. A Close Inspection of the 
'Calm Look", P. 2004. 
18. Lasagna, L. and Wardell W.M., The rate of new drug dis-
covery. In Helms, R.B. ed., Drug Development ahd Market-
ing, Washington, American Enterprise Institute, 
1975, PP. 155-163. 
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been the cause of the U.S. drug lag. More sophisticated 
tests are required to establish which factors determine 
the size of lags before products are launched in a country, 
and these Wardell does not attempt to carry out. Wardell's 
work is notable however for several reason~: 
(a) His series of articles on this topic have alerted 
the medical profession, and the general public of 
America that the U.S.A. is being deprived of new 
pharmaceutical products compared to some European 
countries. 
(b) He has helped focus a great deal of attention on 
the role and work of a regulatory .agency so much so 
that there is now considerable questioning of the 
value of such organisat~ons to society. 
(c) His articles are clear, concise, and appear to be 
based on unshakeable evidence. The absence of 
any challenges over this evidence is a major tribute 
to his meticulous collection, recording, and 
reporting abilities. 
(3) MULTIVARIATE STUDIES OF THE "DRUG LAG" 
Two studies which do use more sophisticated tests 
to investigate the diffusion process are those of Grabowski 
and Vernon, 1977, and Grabowski, 1978. 19 
19. Grabowski, H.G. and Vernon, J.M. Consumer Protection 
Regulation in Ethical Drugs, American Economic Review, 
67,1977, PP. 359-369, and, Grabowski, H.G. Regulation 
and the International Diffusion of Pharmaceuticals, 
unpublished paper presented at American Enterprise 
Confe-renoe,The International supply of Medicines, 
Washington, 1978. 
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Grabowski and Vernon analyse the dates of introduc-
tion of U.S. discovered N.C.E. 's, into the U.K. and U.S. 
markets during the period 1960-1972. It should be noted 
that the amendments increasing the stringency of the F.D.A. 
regulations were introduced in 1962. They found that in 
the early 1960's •.• "the vast majority of U.S. discovered 
N.C.E.'s were introduced into the U.~. only after first 
becoming available in [the U.S.A.]". 20 A dramatic change 
occurred during the period studied so that by the final 
subperiod, 1972-74 " .•• over two thirds of U.S. discovered 
N.C.E.'s introductions in the U.K. were either introduced 
later, or have not yet become available in the United 
21 States." Because these are U.S. discovered N.C.E.'s and 
because of a lack of alternative explanations for the 
behaviour of these U.S. drug companies, Grabowski and 
Vernon conclude that this " ... clearly suggests that regu-
iatory differences across countries have had an important 
impact on where new drugs are first. introduced and the lags 
in introduction acno·ss countries". 22 
The present research attempts to investigate one 
possible explanation of a growing drug lag in the U.S.A., 
namely a reduction in the rate of supply of new U.S. dis-
covered drugs. It has been argued that the U.S. drug lag 
20. Grabowski, H.G.,R,egulation and the International Dif-
fusion • • ~ f P. 2. 
21. Grabowski, H.G.,Regulation and the International Dif-
fusion • • • I P. 2. 
22. Grabowski, H.G.,Regulation and the International Dif-
fusion • • • I P. 2. 
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may reflect a reduction in the rate of production of new 
U.S.-discovered drugs rather than the impact of regulations. 
A mechanism by which such a process might operate is as 
follows. If drugs discovered in a country are marketed 
first in that country then a reduction in their share of all 
new drugs marketed in that country, will, ceteris paribus, 
lead to an increase in the mean lag time for that country. 
Grabowski and Vernon look only at U.S. discovered products, 
and demonstrate that the U.S. has suffered an increasing 
lag before introduction of these products occurs. 
In his 1978 paper, Grabowski develops more comprehe~­
sive analyses, focussing attention on the timing of U.S. 
versus foreign introductions for all N.C.E. 's that were 
introduced into the U.S. during the period 1964-1975. 
Using this sample of products he analyses the pattern of 
lags and leads between the U.S.A., U.K., France, and West 
Germany. As well as providing information describing the 
temporal pattern of diffusion of pharmaceuticals, Grabowski 
presents data outlining the e~tent of diffusion of these 
products between the four countries. For the U.S. -U.K. 
case Grabowski conducts a regression analysis which relates 
the lengths of lags in introductions to various regulatory 
and non~regulatory variables. 
as follows: 
(a) Sources of N.C.E.'s.-
Results o£ his analyses are 
There are two possible ways of accrediting drugs to countr-
ies, either by location of the research laboratory where 
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the drug is discovered, or by nationality of the parent 
firm which discovers the drug. Employing the first cri-
teria, the U.S. parent firm which discovers the drug, and 
employing the second criteria, it invented 52 per cent of 
the sample. These results are similar to those of Reis-
Arndt shown in Table 3.5 above. The U.S. appears to invent 
the majority of the drugs marketed in the U.S., the remain-
der being supplied primarily by the other major pharmaceut-
ical inventors namely the U.K., Switzerland, and West Germany. 
(b) Extent of Diffusion. 
Table 3.9 summarises the results of this analysis. Nearly 
half of the total sample of 169 N.C.E.'s were introduced 
into all three European countries. The greatest number of 
common introductions occurred in the U.S. - U.K. case, 77 
per cent of all products, followed by U.S., -West Germany, 
70 per cent and U.S. - France 56 per cent. 
Table 3.9 also shows the extent of diffusion of 
N.C.E.'s classified by the F.D.A. as being important ther-
apeutic advances, and also shows the extent of diffusion of 
those N.C.E.'s achieving total sales in excess of U.S. $10 
million in their first three years of sales after market 
launch. Selecting on the basis of either of these cri-
teria can be seen to increase sharply the proportion of 
N.C.E.'s which diffuse to all four countries. Thtis 
Grabowski confirms that there is a considerable degree of 
commonality between the N.C.E.'s introduced in the U.S. and 




DIFFUSION OF N C E's TO THREE EUROPEAN COUNTRIES . . . 
. Number (per cent) Introduced In 
Total All Three Two of Three One of Three Relevant Group European European European NC.E.s countries Countries Countries 
. ' 
All N.C.E.s introduced into U.S.A. 169** 81 34 28 
during 1963-75 ( 48) (20) (17) 
All U.S. introduced N.C.E.s clas-
sified by F.D.A. as important 42 28 5 8 
therapeutic advances 1963-73*. ( 67) (12) (19) 
All U.S. introduced N.C.E.s 
with sales ~ $10 million in 
u.s. within three years of 53 37 12 4 introduction 1963-1975. (70) ( 23) (7) 
Source Grabowski, H.G., Regulation and the International Diffusion •••.• , 
Table 3, P. 35. 
* F.D.A. classification of important therapeutic advances.only covers the 
period 1963-1973, not 1963-1975. 
** The components in this row sum to 169, but are shown as 160 in GrabovTski' s 














This is what one would predict for a sample of 
drugs that have all cleared the very stringent 
regulatory hurdles of the F.D.A. At the same 
time, there are also many drugs (particularly 
those with smaller market sales revenues or 
possessing lesser therapeutic significance) 
which have not become available in one or more 
of these three European countries. There are, 
of course, also many drugs introduced in Europe 
that don't become available here.23 
This evidence appears to indicate that factors such as 
therapeutic importance of a product, and expected sales may 
influence the extent of diffusion of pharmaceuticals. 
Perhaps retulations are not the only factor influencing 
diffusion of pharmaceuticals. 
(c) Speed of Diffusion. 
Figure 3.1 shows the distribution of lag times between 
first and fourth introduction for those drugs which are 
launched in all four countries. The mean diffusion 
time is 4.05 years but some drugs take more than a decade 
to diffuse tiD all four countries. The modal time for the 
sample is two years. Note however, that this is a sub-
set of the whole population. No information is given on 
diffusion times for those drugs which diffuse .to fewer 
than four countries. It might be expected that differen-
ces in therapeutic and economic importance of products 
would affect diffusion speeds. Grabowski notes that for 
those N.C.E!s classified by the F.D.A. as important thera-
peutic advances, and wh~ch diffuse to all four countries, 
23. Grabowski, H.G., Regulation and the International 
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Figure 3.1 Distribution of times taken by N.C.E.'s 
to diffuse to four countries. 
Source Grabowski, H.G., Regulation and the Inter-
national Diffusion ... , Figure 2, P. 4a. 
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the mean time to diffuse to all four countries is 3.8 
years. Those N.C.Es achieving sales in excess of u.s. $10 
million in their first three years of U.S. sales have a mean 
. 24 
diffusion time to all four countries of three years. 
Pharmaceutical products appear to diffuse in a manner not 
unlike other innovations: they have variable diffusion spe-
eds; there is typically some significant time lag between 
first and subsequent introductions; and there appears to be 
a tendency for the more important innovations to diffuse 
more widely and perhaps more quickly than their not so 
important counterparts. 
(d) Leads and Lags in N.C.E. Intro~uctiori Times. 
This section of Grabowski's paper is comparable to 
Wardells three studies reporting the existence of a U.S. 
drug lag but extends the comparison to three countries. 
Results are presented in aggregated form in Table 3.10. 
These results suggest that compared to the U.K. and 
West Germany the u.s. does have a drug lag in the sense that 
significantly more of the commonly available N.C.E. 's were 
introduced in those countries before they were introduced 
in the U.S. There is no evidence of a drug lag in the 
U.S. when U.S. introduction dates are compared with French 
introduction dates. When the comparison is extended to all 
24. Grabowski H.G. Regulation and the International Diffusion 
...•. P. 12. 
TABLE 3.10 
COMPARISON OF N.C.E. INTRODUCTION DATES: U.K., WEST GERMANY AND FRANCE 





All Three * 
Number of Number (per cent) Introduced 
Common Not 
N.C.E.s Before u.s. Same Year After u.s. Introduced 
130 69 (53) 26 (2 0) 35 ( 2 7) 39 
111 57 ( 4 9) 27 (24) 27 (24) 58 
94 35 (3 7) 12 (13) 47 (50) 75 
143 84 (59) 29 ( 2 0) 30 (21) 36 
Source Grabowski, H.G. Regulation and the International Diffusion 
....• ,Table 4, P. 36. 
* In this fourth case, the U.S. introduction date is compared 






three countries versus the U.S., the data shows that 2.8 
times as many N.C.E.s were introduced in the U.K., France 
or West Germany before introduction in the u.s., than 
were introduced first in the U.S. It should be noted that 
this occurs despite the fact ~hat over 50 per cent of these 
N.C.E.'s were discovered in a research laboratory in the 
U.S. A. 25 
Disaggregating this data by country of introduction, 
country of innovation, and time period reveals some inter-
esting trends. For the U.K.-U.S. and We~t Germany-U.S., 
comparisons, the overwhelming majority of foreign dis-
covered N.C.E!s were introduced abroad before they were 
introduced in the U.S. About nine out of ten of the for-
eign discovered N.C.E.~ were introduced in the U.K. and 
West Germany before or in the same year as they were intro-
duced in the U.S. The France-U.S. comparison reveals· that 
the corresponding figure is about two thirds introduced 
first abroad. 
26 
Splitting the time period covered into two periods 
(1963-1967, and 1968-1975) reveals that for U.S. discovered 
N.C.E.'s, significantly more of these were introduced 
first in the U.S. during the first time period. In the 
latter period, for the U.K. and West Germany, the reverse 
25. Grabowski, H.G. Regulation and the International Diffus-
ion ••. Table 2, P. 34. 
26. Grabowski, H.G. Regulation and the International Diffus-
ion ... Tables 5, ~'and 7. 
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is true. France appears to be a less attractive market 
to launch products in than the U.S. as fewer of these 
N.C.E.~ are introduced first there in both time periods. 
These results are suggestive, and hint that factors such 
as regulatory requirements and price levels in different 
countries may counteract the natural tendency to introduce 
drugs first in the country in which they are discovered. 
(e) Multiple Regression analysis of U.S.-U.K. N.C.E. 
Introduction Data. 
To provide further insight intb the role of regulation in 
determining the size of drug lags Grabowski conducts a 
regression analysis of the data pertaining to U.S.-U.K. 
N.C.E. introductions. Regulatory stringency is difficult 
to measure quantitatively so Grabowski obviates this prob-
lem by using F.D.A. data on time taken to obtain regulatory 
approval for each product. Regulatory approval time is 
the length of time from date of first N.D.A. submission to 
time of final F.D.A. approval to market the drug. Regulatory 
approval times plus three dummy variables are employed in a 
regression equation of the following form: 27 
1. Lagi = a + b
21 
NDAi + bz FORi + b 3FQALi + b 4MKTi + Ui 
where Lag. = The lag (+ or -) in month between the time of 
l 
introduction in the U.K. and U.S. of the ith 
N.C.E. 
27. Grabowski, H.G. Regulation and the International 
Diffusion ... P. 19. 
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NDA = R.egulatory approval t;Lme for the ith N.C.E. 
roRi = A dummy variable taking on the value 1 if the 
ith N.C.E. is of foreign origin and 0 otherwise. 




the FD~ has ranked the ith N.C.E. as an import-
ant therapeutic advance and 0 otherwise. 
A dummy variable taking on the value 1 if the 
ith N.C.E. achieved 10 million dollars in sales 
during their first three years after introduction 
and zero otherwise. 
Some comments on these dummy variables are warranted. 
The dummy for foreign drugs, ''FOR, . is introduced because 
as previous sections have shown, diffusion times appear to 
differ depending upon whether a drug is invented in the 
U.S. or not. It is uncertain though just what this variable 
catches. Is it just the lag due to a tendency to first 
launch drugs in the country in which they are invented? 
Or does it reflect the F.D.A. requirement that clinical 
trials-must be conducted in the U.S.A., to gain N.D.A. 
approval despite the existence of foreign clinical trial 
data, thus causing foreign invented drugs often to have to 
undergo two sets of clinical trials before they can be mark-
eted in the U.S.? Grabowski appears also to have assumed 
that all "foreign" drugs and their proprietor,...propagators 
are homogenous. Specif;Lcally his model assumes that a 
"foreign" drug ;invented in Italy for exalt1ple, w;Lll be 
launched in a second "foreign'' country such as the U.K. 
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before ~t is launched in the u.s. It may be that drugs 
in~ented in a country are marketed first in that country 
and then after a lag- are marketed in the U.S., but this is 
rather different to the assumption that all foreign dis-
covered drugs will tend to be marketed in the U.K. before 
they are marketed in the U.S. Thus there may be some 
misrepresentation in the results obtained because of the 
aggregation of all foreign drugs into one group and bee-
ause of the catch-all nature of the variable. 
The FQAL variable is introduced because II the 
F.D.A. has frequently maintained that the drug lag is prim-
arily confined to drugs with little or no therapeutic 
28 gain." If this is the case then drugs rated by the 
F.D.A. as important therapeutic advances should have short-
er or non-existent lags than the sample as a whole. The 
FQAL variable is included to test this hypothesis. 
Finally a dummy variable, MKT, is introduced to test 
the hypothesis that" •.. the greater the market potential 
for a new drug, the faster it will diffuse across count-
29 ries". 
Because of the dynamic shifts observed in diffusion 
patterns over the whole period, equation 1 was estimated 
separately for the split periods as well as for the full 
28. Gra,bowsk~, H~G. Regulation and the International 
Diffusion .... P. 20. 
29._ Grabowski, H.·G. Regulation and the International 
Diffusion ... P. 20. 
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thirteen year pe;r:-iod. 
RESULTS: 
For the 1963-1967 period the estimated equation was -
Lag = - 12.6 + 0.67 NDA + 17.6 FOR - 14.5 FQAL + 17.2 MKT 
(2.58) 
t values in parentheses. 
(i. 87) 
R2 = .24 
(1.52) (1.84) 
n = 52. 
The NDA and FOR variables have the expected positive 
sign and their values are statistically significantly at 
normal confidence levels. Th~ results suggest that a one 
month increase in F.D.A. approval time was associated with 
a 0.67 month lag in the U.S. introduction date versus the 
U.K. The co-efficient on the foreign origin variable sug-
gests that" ... ceteris paribus, the additional lag on a 
foreign discovered N.C.E. was approximately one and a half 
years". 30 The positive sign on the potential market 
size variable suggests that drugs with large potential sales, 
have longer lags than do drugs with small potential sales. 
Grabowski suggests that this surprising result may occur 
because this period was one of such flux and uncertainty 
that firms may have had economic incentives to switch to 
foreign market launches for those drugs with greatest market 
31 potential. Thus MKT he suggests may catch some of the 
influences he hopes to net with the FOR variable. 
30. Grabowskif H.G. :Regulat;lon and the I.'nternational 
D:lffusion ••• P. 21. 
31. Grabowski, H .. G. Regulat;lon and the International 
Diffusion ... P. 22. 
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No other formulations of the model for this period 
produced any significantly different results. For the 
1968-1975 period the following equation was obtained -
Lag = 0.26 + 0.51 NDA + 32.8 FOR- 3.54 FQAL - 16.6 MKT 
(2.55) (4.55) (0.36) (2. 0 6) 
t values in parentheses. R2 = 0.38 n = 61. 
These results differ from those of the preceding per~od 
only in the sign for the MKT variable, which is negative 
as a priori arguement suggests will occur. However, mod-
ifying this model by introducing a foreign slope dummy on 
the N.D.A.· variable sharply alters the results, viz.; 
Lag = 11. 9 + 1. 1 FNDA + 0 . 1 NDA '- 6 . 9 FQAL + 6. 5 FOR -14 r 5 MKT 
(3.20) (0.00) (0.74) (0.64) (1.98) 
t values in parentheses. R2 = 47 . n = 61 . 
where FNDA equals foreign dUmmy multiplied by the N.D.A. 
variable. 
The value for FNDA is highly significant, the new 
value for N.D.A. is not significant. These results Grab-
owski finds difficult to interpret as they conflict with 
his earlier analysis. He speculates that the lack of sig-
nificance for the N.D.A. variable in this period may be due 
to regulatory approval times having settled at some consis-
tently high value with the main effect of regulation occur-
ing before evaluation by the F.D.A. occurs. Whereas for-
eign discovered drugs may have still exhibited continual 
variation in regulatory approval times as foreign firms 
continued to grapple with the problem of obtaining market 
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approval. Wardell prov~des some ,evidence that F.D.A. 
regulatory approval times increased sharply during the 
1960's then plateau during the 197Q•s 32 , so Grabowski's 
conjectures about the results appear plausible. The number 
of drugs involved is quite small, particularly the number 
of foreign discovered N.C. E.'s, so not too much weight should 
be placed on these results. However they do seem to 
indicate that foreign discovered drugs found the F.D.A. 
regulations a difficult hurdle to cross. The relative in-
significance of the drug quality variable FQAL, in these 
results should also be noted. There appears to be no 
evidence that drugs of greater therapeutic value obtain reg-
ulatory approval more quickly than do drugs of lesser 
therapeutic value. 
(f) The Drug Quality Issue. 
Because of this contradiction between F.D.A. claims and the 
regression results Grabowski examines in more detail the 
introduction times for important drugs. He compares the 
lead and lag times for these important N.C.E:s between 
the U.S. and the U.K. - the country believed to have the 
most similar standards to the U.S. - and finds there has 
been a marked swingaway from the U.S. as a country to 
first launch important N.E.C.'s in. These results are shown 
in Table 3. lL 








THE F.D.A. AS IMPORTANT THERAPEUTIC GAINS, 1963-1975 
Source 
Number (percent) in the U.K. 
Number of 
Common Before Same After 
N.C.E.s u.s. Year u.s. 
22 7 5 10 
(32) (23) (45) 
16 10 3 3 
( 6 3) (19) (19) 
Grabowski, H.G., Regulation and the International 








The striking feature of this table is the shift 
in the second period-to a situation where~onl<.y 
three of the sixteen common N.C.E.'-s were introduced 
in the U.S.before being introduced in the U.K. All of the 
foreign discovered drugs in this sub-sample were introduced 
in the U.K. at least three years before they became available 
in the U.S. 33 The growth in importance of foreign count-
ries as the source of important new drugs is a major 
factor explaining the change between these two periods. The 
F.D.A. claim that the U.S. does not suffer a drug lag for 
important therapeutic products does· not app.ear to be substan-
tiated. 
(g) Comments on Grabowski 1 s Study. 
Grabowski's 'analysis adds to the weight of evidence sug-
gesting that the time taken to gain regulatory approval is 
an important determinant of date of availability of new 
pharmaceutical products in the U.S. Whether drugs are of 
U.S. or foreign origin appears also to significantly alter 
the time of introduction of these products. The size of 
the therapeutic advance drugs embody and their potential 
sal~s levels appear to influence their extent of diffusion. 
The regression analysis employed is beset with 
problems which lessens its value. Because of the low number 
of observations ayailable to him, Grabowski can only run 
regressions for two sub-periods. This may result in a 
33. Grabow9ki, H.G., Regulation and the International 
biffuslon ..... P.36. 
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mingling of time series and cross section effects contained 
in the data. He is forced by a lack of ready alternatives 
to rely on dummy variables. Their use weakens the ability 
of the model to determine which are the major factors in-
fluencing inter-country diffusion speeds of pharmaceutical 
p'roducts. The two country case studied, U.K.-U.S. mutual 
introductions, may have little generality in terms of est-
ablishing the determinants of inter-country diffusion 
speeds to other countries, and for pharmaceutical products 
in general. The range of variables employed is not wide. 
Such factors as diffusion channels, company strategies, and 
price level in each country may also significantly influence 
diffusion speed. The low R2 values indicate that a great 
deal of variation in diffusion speeds remains unexplained 
by the model Grabowski employs. 
Some considerable time has been spent describing 
and commenting on Grabowski's work because he appears to be 
the only economist who has attempted to apply econometric 
analysis to inter-country diffusion data. Clearly he has 
not answered many of the questicbns. which can be asked about 
inter-country diffusion of pharmaceuticals. His study adds 
to the weight of evidence pointing to a growing drug lag 
in the U.K. associated with the introduction of more rigid 
F.D.A. requirements, and points to the need for more exten-
sive testing with better data to establish what factors 




The modest amount of literature on pharmaceuticals 
diffusion provides a fragmented outline of the broad 
pattern of invention and diffusion of pharmaceuticals, and 
mtlch energy has been expended on documenting the magnitude 
of the lag in introduction of pharmaceuticals to the worlds 
largest market. Only one economometric analysis of the 
-data on international diffusion of pharmaceuticals appears 
to exist. Despite the painstakingly careful nature of the 
research completed by Wardell and others, comparison with 
the diffusion research .literature reviewed in chapter two 
will reveal that pharmaceuticals diffusion research is in 
a very underdeveloped state. 
It is in such a state because of the unusual reasons 
causing its existence. This literature exists because of 
concern in the U.S. about a "drug lag". Excluding Reis-
Arndt's two articles, the literature thus far can be viewed 
as a series of attempts to report the existence of a drug 
lag, and to prove by association that this phenomena is 
caused by the U.S. F.D.A. regulations. Because of the 
effort needed to establish that a drug lag does indeed 
exist, and because it seems so plausible that this lag has 
been caused by F.D.A. regulations the literature is narrow 
in scope. Almost no effort has been invested in determin-
ing what factors do cause the U~S. drug lag in particular, 
and diffusion speeds of th~se products in general. 
History is replete with examples of plausible, but 
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invalid theories, which appear to provide good explanation 
for observed phenomena. Every history of science text 
provides dozens of such examples. A little caution may be 
advisable before we accept that F.D.A. regulations have 
been the factor causing a drug lag in the U.S .. Pharmaceut-
icals diffusion research is as yet in its infancy. To grow 
up it needs to expand its scope and begin to investigate the 
much broader topic of the inter-country diffusion of pharm-
aceuticals. Such an approach requires as a minimum an 
investigation of the diffusion of pharmaceuticals to many 
countries. A more meritorious step would be an explicit 
postulation and test of a model of pharmaceuticals inter-
country diffusion. 
C H A P T E R 4 
A DISCURSIVE ANALYSIS OF DIFFUSION PROCESSES 
..•. a man .•.. can stare stupidly at 
phenomena; but in the absence of imag~ 
ination they will not connect themselves 
together in any rational way. 
C.S. Pierce. 
(0) INTRODUCTION 
This research project was initiated after a number 
of publications appeared sharply criticising some aspects 
of the international pharmaceutical industry. One feature 
of the critical comments was the strong condemnation by 
several authors, of the operations of the international 
pharmaceutical industry in less developed countries. 1 
These publications provided a stimulus to investigate the 
activities of the pharmaceutical industry in a range of 
countries including the less developed countries. A 
topic which both met the above objective and appeared 
amenable to research, was the international diffusion of 
pharmaceutical products. 2 Papers by Wardell, and 
1. These publications included; Lall, S. Major Issues in 
the Transfer of Technology to Developing Countries. 
New Ybrk,UNCTAD,~D/B/C 6/4, 1975~ Ledogar, R.J. Hungry 
for Profits:US Food and Drug Multinational in Latin 
America. New York, IDOC North America Inc.l975. Vaitsos, 
C.V. Intercountry Income Distribution and Transnational 
Enterpr1ses, Oxford, Clarendon Press,l974. O'Brien, P. 
Trademarks, the International Pharmaceutical Industry 
and the Developinc;- Countries, The Hague, Institute of 
Social Sciences Occasional Paper, No. 63, 1977. 
2. Wardell, W.M. Introduction of New Therapeutic Drugs in 
the United States and Great Britain:An International 
Comparison. Clinical Pharmacology and Therapeutics, 
14,5,1973, PP. 773-790. Wardell W.M. British Usage and 
American Awareness of some New Therapeutic Drugs, 
9tinical Pharmacol~gy and Therapeutics, 14,6,1973 PP ±8~~~ 
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Grabowski 3 reinforced the belief that the inter-country 
diffusion of pharmaceutical products was a topic which 
warranted further examination. 
Wardell's series of papers on the delays in launch 
of products onto the U.S. market,· commented on the time 
necessary to obtain F.D.A. approval to launch products 
in the U.S., and compared times of first availability of 
drugs on the U.K. and U.S. markets. Grabowski extended the 
comparison of times of first availability of pharmaceutical 
products to four markets, those of the U.K., U~S.A., 
France and West Germany, and attempted to explain why some 
products diffused more widely than others, and why the 
speed of diffusion of products varied. The publications 
of these two researchers revealed that the inter-country 
diffusion of pharmaceutical products was a promising but 
as yet little explored topic. Clearly many questions 
about the diffusion of pharmaceutical products between 
nations had barely been asked let alone answered. However, 
the topic which provided the majo.r early impetus for this 
project was the debate about the "drug lag" in the U.S.A., 
and questions this raised such as whether the U.S. really 
was late to receive new products compared to other 
countries, and what were the determinants of "average drug 
3. Grabowski, H.G. Regulation and the International Dif- · 
fusion of Pharmaceuticals, Unpublished paper presented 
at A.E.I. Conference, The International Supply of 
Medicines, Washington D.C. 15/9/1978. 
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lag" per country. Data collection was initiated to 
investigate these questions. Data was collected from sev-
eral sources on the introduction dates of products, sales 
values, names of manufacturers, sizes of markets, regu-
latory tightness of each market, and assessments of the 
therapeutic advance of each of the products in the sample 
of products. 
As the data accumulated it became apparent that 
several topics could be investigated, several modes of 
research were possible, and that choices would be necessary. 
As this was considered to be a relatively new area for 
research it appeared sensible to attempt a broad initial 
examination of the phenomena of inter-country diffusion of 
pharmaceutical products. Four fundamental questions were 
posed, the answers to which seemed to be essential to under-
stand these diffusion processes. They were : 
(a) What are the determinants of the speed of inter-
country diffusion of-pharmaceutical products? 
(b) What are the determinants of the extent of inter-
country diffusion. of pharmaceutical products? 
(c) What factors determine the average lag times before 
products are launched in a country? 
(d) What factors determine the proportion of the total 
supply of new pharmaceutical products which are 
launched in a country? 
This research project is an attempt to provide answers to 
these questions. The focus of attention in this research 
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is the time of first availability of products in each mar-
ket. No attempt is made to analyse the inter-'country 
diffusion of pharmaceutical products. Obviously both the 
time of first availability of a product in a country and 
the rate at which use of the product spreads within the 
country will determine the time at which products become 
available to end users. Peltzman4 has demonstrated the 
importance of earliness of first availability in a country 
of pharmaceutical products, and the data available to this 
study lent itself to examination .of time of first avail-
~bility in a country. Thus this is a study of inter-
country, and not intra-country diffusion. 
Terms such as "lag times", and "introduction dates" 
have been used until now without definition. A careful 
exposition of the diffusion process and definition of terms 
used is required. For this purpose a diagramatic expos-
i tion of the stages in product development is sh.C>wn below 
in Figure 4.1. 
Pharmacologic properties of drugs are usually 
discovered in carefully conducted trials and experiments. 
The term discovery date when used in this context means the 
date at which the desirable specific pharmacologic property 
of the chemical (or chemicals) are established. Discovery 
is generally followed by a period of development during 
4. Peltzman, S. An Evaluation of Consumer Protection Leg-
islation : The 1962 Drug Amendments. Journal of Politic-
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which time further experiment and evaluation occurs to 
produce a product in a consistent stable form which can be 
supplied at a satisfactory price. Only when this process 
of development is completed can the chemical be considered 
to be a pharmaceutical product. Most countries now require 
that pharmaceutical companies apply for permission to 
market products in their country. The date of application 
for marketing approval is labelled the "filing date". 
After a lag of variable size permission to market the 
product will generally be granted. This is entitled "ap-
proval date u. 
Presumably the proprietors of pharmaceutical products 
take conscious decisions to market products in each country. 
The decision to launch a product in a market clearly cannot 
take effect until marketing approval is gained, so the 
date of this decision is shown after the approval date. 
Companies may in some instances take these decisions before 
approval date. It seems inevitable that there will be a 
lag be~ween the date of decision to launch a product and 
the actual launch date. This has been labelled the 
operational lag. Further, unless there is simultaneous 
launch of a product on more than one market, there will be 
a unique date and market on which the product is first 
commercially available. This date is called the intro-
duction date. All subsequent launchings of the product 
in other markets will occur after lags of variable mag-
nitude. These lags between the date of very first intro-
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duction of the product in any of the worlds markets, and 
the dates of introduction in subsequent markets are 
entitled "introduction lags" or "lag times". 
The proprietors of these products could normally be 
expected to hold patent rights for the products. The date 
of filing for patent may occur at any date after discovery 
date and is therefore not shown in Figure 4.1. If the 
proprietors hold patents rights for a product, or even 
if they don't, it seems plausible that they will h~ve con-
siderable if not total discretion over "filing date", 
"decision to launch date", "int~oduction date" and the sub-
sequent "introduction lags". All of these variables will 
be capable of influencing the times of availability of 
pharmaceutical products. The foci of attention in this 
research project are the "introduction date", and the 
"introduction lags". Thus only the concluding steps in the 
sequence of steps involved in the supply of new pharmaceut-
ical products to markets are studied. 
The gap between "introduction date", (also called 
"release date" or "launch date") and the dates of sub-
sequent introduction - introduction lag times - can be 
summed to calculate mean lag times per product, or summing 
over all products launched in a country, mean introduction 
lag time per country. These parameters, mean lag time 
per product, and mean lag time per country, are of course 
the parameters referred to in the first and third questions 
posed above. 
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It cannot be claimed that introduction dates and 
introduction lags are the only important elements involved 
in determining time of availability of pharmaceutical 
products. Clearly firms can delay the time of availability 
of a product by delaying "filing date~. Equally, Wardell 
and others have argued that the lag between "filing date" 
and "approval date" can have a major impact upon the date of 
availability of products. This research, however, focuses 
upon introduction dates, and introduction lags, the most 
public of the events in the cycle from discovery onwards. 
The pharmaceutical products whose diffusion patterns 
are studied are available only upon presentation of a medic-
al practitioner's prescription notice in countries such as 
U.K., U.S.A., Australia and New Zealand, and are known as 
ethical products. Products which are available without 
a doctor's prescription in these countries are called 
proprietary products, and are not included in this study. 
Some writers, notably Ledogar 5 suggest that almost all 
-
ethical products can be purchased wit~out a doctor's pre-
scription in many South American countries. This possibil-
ity did not influence the selection of drugs for this study. 
The data collected for this research was drawn from 
a variety of souces, but the major source of information on 
product introduction dates, sales and prices were the 
Intercontinental Medical Statistics (I.M.S.) sample surveys 
5. Ledogar, R.J. Hungry for Profits ... 
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of the pharmaceutical markets in the eighteen countries 
studied. I.M.S. are a market research company who survey 
the sales of pharmaceutical products to retail pharmacists, 
or their equivalents, in approximately thirty countries. 
The information collected on sales of both ethical and 
proprietary products is available for purchase by pharm-
aceutical companies and other organisations. Included in 
these reports on the pharmaceutical markets of each 
country are the dates of first availability of ethical pro-
.ducts as prescription medicines. These dates, which show 
year and month of first availability, were used to rep-
resent "introduction date" in each market. Some of the 
products in the sample may have been available on a res-
tricted scale in hospitals, before they became available 
as prescription medicines outside of the hospital. As 
time of first use of products in hospitals are not included 
in the I.M.S. data the "introduction dates" employed may in 
some instances post date the first use of products in hos-
pitals. 
To summarize, this research is directed at determ-
ining which factors explain times of availability and dis-
persion of ethical pharmaceutical products between countries. 
No attempt is made to examine the diffusion of products 
within countries. Effort is directed toward providing 
answers to four major questions about inter-country dif-
fusion of pharmaceutical products. 
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(1} PROBLEMS OR PSEUDO-PROBLEMS? 
If the speeds of diffusion of all drugs were very 
similar or if the average introduction lag times per 
country showed little variation then the questions posed 
above might be of little interest. Is there evidence that 
there are wide variations in speed and extent of diffusion 
of pharmaceutical products? To determine whether such 
variations do exist in the patterns of diffusion, four null 
hypotheses were set up to provide initial tests of the 
data. 
The null hypotheses were : 
(a} all pharmaceutical products diffuse at the same 
speed 
(b) all pharmaceutical products diffuse to similar 
numbers of countries 
(c) all countries have similar average introduction 
lag times for pharmaceutical products 
(~) all countries receive a similar proportion of the 
total supply ~f new pharm~ceutical products 
launched onto the worldB markets. 
Tests of these hypotheses were carried out by examining the 
diffusion data for a sample of pharmaceutical products. 
The sample of products was chosen from the December, 1976 
I.M.S. list of the 600 leading selling prescription drugs 
in the U.K., where sales are based on sales to retail 
pharmacists and exclude sales to hospitals and the 
National Health Scheme. From this list of 600 products, 
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330were selected whose dates of introduction to the 
U.K. market fell between January 1961 and December 1976. 
This sample frame was chosen in such a way to produce a 
manageable sized sample, and to maximize the chances of 
obtaining information on dates of introduction in other 
markets. The information for many markets declines in' 
quality for years prior to 1970. Selecting the boundaries 
for introduction dates in the U.K. of January 1961 and 
December 1976 provided a sample of products for most of 
whom good information was available. on patterns and time 
of diffusion. The sample was further restricted in size 
by examining the chemical components of the products and 
discarding those which were later released versions of, 
or trivial modifications of existing products. The final 
6 sample size was 227 products. Data on introduction 
dates, sales figures, name of company marketing the product 
and other information were sought for the 227 products, in 
ei$hteen countries. The eighteen countries included in 
the study were :U.K., Colombia, Mexico, Peru, Brazil, 
Venezuela, Argentina, Japan, Indonesia# Philippines, 
Belgium, France, West Germany, Italy, Spain, Australia, 
New Zealand and the U.S.A. 
Examination of this data revealed that all four 
null hypotheses could be rejected. Speeds of diffusion of 
pharmaceutical products were calculated by comparing intro-
6. For a more detailed description of the sample of pro-
ducts used see Chapter five below 
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duction dates for a product in each market it was launched 
in with the first introduction date in any of the worlds 
markets. The lags between first and subsequent intro-
duction dates were summed, and the total divided by the 
number of markets in the eighteen sample countries the 
product was,marketed in, and for which introduction dates 
were available. The speeds of diffusion of these products 
were thus described by a variable which was entitled AVLAG, 
i.e. the average of the lags in months, between first and 
subsequent introductions. 
The range of AVLAGs for these 227 products are shown 
in Table 4.1 below. Note that twenty one products were 
introduced only in the U.K. and thus have no introduction 
lags. However, for those products which were introduced 
in more than one country the range of AVLAGs was quite 
large, from less than two months to more than ten years. 
The mean AVLAG for the sample of products was 34.611 months, 
and the standard deviation 27.046 months. The data in 
-
this table suggests that there is considerable variation 
in speeds'of diffusion of pharmaceutical products. The 
first of the four hypotheses was rejected. Determination 
of the reasons for the variation in AVLAG appears to be a 
valid problem. 
Do all products diffuse to similar numbers of 
markets? Examination of the data on extent of diffusion 
of pharmaceutical products reveals that this is far from 
being the case .. For this sample of 227 products the 
range of number of markets· in which the products are 
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TABLE 4.1 
DISTRIBUTION OF AVERAGE INTRODUCTION LAGS 
PER PRODUCT (AVLAG) 
Number of Relative Cumulative 
Months Products Frequency Frequency 
% % 
0 21 9.3 9.3 
1-12 16 7.0 16.3 
13-24 52 21.6 37.9 
25-36 54 23.3 61.2 
37-48 29 13.7 74.9 
49-60 22 9.7 84.6 
61-72 18 8.8 9 3 .,4 
73-84 7 3.1 96.5 
85-96 3 1.3 97.8 
97-108 2 0.9 98.7 
109+ 3 1.3 100.0 
Total : 227 100.0 
' 
Source Author's analysis of I.M.S. data. 
137. 
sold, is limited by the number of countries for which in-
formation was collected. Thus eighteen is the maximum 
number of markets in which these products could be 
launched. The extent of diffusion of these products was 
established by counting the number of markets in which each 
products was marketed. These values were recorded under 
the variable name NUMSALES. The range of NUMSALES values 
is shown in Table 4.2. The mean number of countries to 
which these products diffused was 9.220, the standard 
deviation 5.471. Clearly for this sample of products, 
extent of diffusion as measured by NUMSALES values show 
very large amounts of variation. It thus seems sensible 
to continue investigation of the factors influencing extent 
of diffusion of pharmaceutical products. Establishing the 
causes of variation in extent of diffusion appears to be a 
valid problem. 
What of the two null hypotheses about diffusion to 
countries? Do all countries receive pharmaceutical products 
with similar average lags between original introduc~ion 
dates and introduction dates in their country? The varia-
tion in mean lags per country for the 227 products are 
shown in Table 4.3. Mean lags per country were calculated 
by summing the lag in months, between the first introduction 
date for each product actually launched in a country and 
the introduction date for that product in that country, and 
dividing this total number of months by the number of 
sample products for which introduction dates were recorded 
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TABLE 4.2 
DISTRIBUTION OF NUMBER OF COUNTRIES TO WHICH PROQUCTS 
DIFFUSE. (NUMSALES) 
Number of Number of Relative Cumulative 
Countries Products Frequency Frequency 
% % 
1 16 7.0 7.0 
2 16 7.0 14.1 
3 21 9.3 23.3 
.4 6 2.6 26.0 
5 12 5.3 31.3 
6 15 6.6 37.9 
7 11 4.8 42.7 
8 14 6.2 48.9 
9 5 2.2 51.1 
10 4 1.8 52.9 
11 15 6.6 59.5 
12 19 8.4 67.8 
13 12 5.3 73.1 
14 10 4.4 77.5 
15 15 6.6 84.1 
16 10 4.4 88.5 
17 8 3.5 92.1 
18 18 7.9 100.0 
Total: 227 100.0 
Source Author 1 s Analysis of I.M.S. data. 
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TABLE 4. 3 
AVERAGE INTRODUCTION LAGS PER COUNTRY (NATLAG) 
NAT LAG Standard Deviation 
Country Months of NATLAG 
U.K. 20.247 27 .. 921 
Colombia 48.942 37.591 
Mexico 35.919 32.736 
Peru 46.764 41.640 
Brazil 44.133 40.631 
Venezuela 55.376 36.875 
Argentina 36.574 33.254 
Japan 44.225 33.700 
Indonesia 60.212 47.278 
Philippines 45.578 40.663 
Belgium 36.803 52.389 
France 45.936 63.483 
West Germany 28.387 38.760 
-
-
Italy 49.963 45.680 
Spain 34.542 35.358 
Australia 32.488 34.648 
New Zealand 32.079 32.606 
U.S.A. 24.427 31.599 
Source Author's Analysis of I.M.S. data; 
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for that market. This variable was entitled NATLAG. 
The mean NATLAG value was 40.421 months and the 
standard deviation 39.267 months. Clearly there is varia-
tion in the mean time per country to receive new products. 
While the range of NATLAG values just exceeds one standard 
deviation, the relative magnitudes differ so much that it 
appears valid to hypothesise that they may be due to factors 
other than chance. Investigation is needed to determine 
which factors might cause such variation. 
Finally, are there variations in the proportion o£ 
the worlds supply of new pharmaceutical products which 
reach each country? For this sample of eighteen countries 
there is considerable variation in the proportion of the 
sample of 227 products which are marketed in eat:h country. 
The number of products diffusing to each country (NUMPROD) 
are shown in Table 4.4. 
The U.K. value has to be ignored here as the nature 
of the sampling frame ensured that all of the sample 
products were introduced in the U.K. However, even ig-
noring the U.K. value, there is considerable variation 
around the mean NUMPROD of 97.117. The range from 52 in 
Indonesia to 151 in New Zealand is surprisingly large. 
Again the null hypothesis was rejected. All countries 
do not appear to receive similar proportions of the worlds 
supply of new pharmaceutical products. 
The data for this sample of products and countries 
suggest that all four null hypotheses should be rejected. 
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NUMBER OF SAMPLE PRODUCTS INTRODUCED IN EACH 
COUNTRY (NUMPROD) 
Number of Per cent 
Country Products Sample 
U.K. 227 100.00 
Colombia 96 37.88 
Mexico 99 43.61 
Peru 55 24.23 
Brazil 98 43.17 
venezuela 85 37.46 
Argentina 94 41.41 
Japan 89 39.21 
Indonesia 52 22.91 
Philippines 90 39.65 
Belgium 127 55.95 
France 109 48.02 
West Germany 93 40.96 
-
Italy - 107 47.14 
Spain 107 47.14 
Australia 127 55.95 
New Zealand 151 66.52 
U.S.A. 72 31.72 
Source Author l.s Analysis of I. M.S. data, 
of 
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Attention is now focussed upon the methodology to be used, 
and the hypotheses postulated about these diffusion proces-
ses. 
(2) METHODOLOGY 
Once the null hypotheses about inter-country dif-
fusion of pharmaceutical products had been rejected decis-
ions had to be made about the methodology to be used to 
investigate the diff~sion of these products. A pure 
inductivist approach is impossible as well as being unat-
tractive.7 It is impossible to observe all relevant facts, 
and equally impossible to churn through all possible modes 
of analysis of the data if the number of variables is large. 
If a body of data contains n variables, then there are 2n 
subsets of that data. If n is large then 2n is 
enormous. Presumably a body of data can be analysed. in at 
least 2n different ways. Some form of deductive approach 
appears to be essential to rationally structure the invest-
igation of inter-country diffusion. Such a decision appear~ 
to be essential for any scientific investigation. Where 
there is room for variation is in the process of hypothesis 
formulation. A deductive approach to science requires the 
formulation either implicitly or explicitly of hypotheses. 
These are tested using some data collected for that pur-
pose, and the hypotheses either rejected or not rejected 
7. Most introductory books on the philosopy of science 
contain an outline of the inductivist method. An example 
of this is Chalmers, A.F. What is this thing called 
science? St. Lucia, University of Queensland Press, 1978 
PP. 1-34.' 
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depending upon the outcome of the tests. 
Much science is undertaken without explicit formal 
postulation of hypotheses prior to beginning analysis. 
Such an approach does require some low-level implicit form-
ulation of hypotheses to provide direction and boundaries 
for the research. This mode of analysis with implicit 
postulation of hypotheses can be labelled the "examination 
and interpretation" approach. Such an approach lends itself 
to shotgun econometrics, i.e. the technique of churning out 
descriptive statistics and ·conjuring up a large number of 
variables to be used in a multiple regression analysis to 
see. what best correlates with what, and to see what best 
"explains" some phenomena. Once the examination is com-
pleted some attempt at interpretation or explanation is 
required to make sense of the mass of results produced. 
The examination and interpretation approach, as described 
above, soundscrude, ad hoc, and unscientific. Results 
are discovered, rather than conclusions deduced. 
ify in this s~tuation is unsatisfactory. 
Serendip~ 
The alternative is to adopt a more formal hypothesis 
postulation, test, conclusion deduction approach. If there 
are underlying non-random forces which shape the patterns 
o& diffusion of pharmaceutical products then these proces-
ses should be capable of representation in mathe~atical 
or symbolic form. It should be possible to postulate 
hypotheses about these diffusion processes and then test 
these against data on inter~country diffusion. The 
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distinguishing characteristic of this approach is the 
explicit formulation of hypotheses. Such hypotheses 
formulation can only occur after some attempt has been made 
to analyse theoretically the processes being investigated. 
In this case it is necessary to at least attempt to under-. 
stand the nature and conduct of firms involved in the 
international diffusion of pharmaceutical products. 
(3) A DISCURSIVE ANALYSIS OF INTER-COUNTRY DIFFUSION 
To understand how the inter-country diffusion of 
pharmaceutical pr6ducts occurs it is essential to focus 
attention upon the behaviour of the firms which make up 
this industry. Attention has to be focussed upon the 
firms and their behaviour because of the characteristics of 
this industry. It is normally argued that •economic' 
activities have both supply and demand aspects, but in this 
industry the supply side of the diffusion process seems 
likely to so outweigh the demand mechanisms as to make them 
insignificant. In particular the inter-country diffusion 
of pharmaceutical products seems likely to result almost 
exclusively from supply processes. Why? Because the 
invention and production of new pharmaceutical products 
is concentrated in relatively few firms hands, and these 
firms have virtually complete control over the production 
and supply of these products. Patent rights will normally 
be taken out by the innovating firms in the potential 
markets for the product, and technological advantage is 
likely to provide protection from innovation, and thus 
145. 
competition, for some time. Because firms have almost 
complete control over where and when products shall be 
produced and marketed, they have unusually large ability to 
8 determine the diffusion pattern of these products. 
Compare this situation with those which have been 
examined in the majority of diffusion studies. A majority 
of those examined had almost no supply restrictions on the 
availability of the innovation. Frequently the diffusion 
of the innovation in these situations could be compared to 
the spread of a contagious disease - diffusion appears to 
occur without control and without conscious application of 
cost and effort by "suppliers" of the innovation. Clearly 
in those situations examination of the "demand" forces is 
likely to be of more use in explaining how diffusion occurs~ 
It should also be noted that the process of technolog-
ical change in pharmaceuticals is usually considered to be 
incremental in nature. New products very rarely represent 
"breakthroughs"; i.e. products which have only distant sub-
stitutes. New products, usually, are only modestly dif-
ferentiated from other existing products. If new products 
represent only modest improvements over existing products 
then it seems implausible that countries will develop and 
8.For a more detailed description of the structure and 
conduct of the pharmaceutical industry see Chapter one 
above. 
9.A more detailed discussion of this topic is contained in 
Chapter two above. 
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exert strong demand pressures for products usually invented 
with little publicity, in overseas countries. Further, the 
demanders of new products are likely to be so dispersed, 
geographically, and in their knowledge about the existence 
of new products, that it is difficult to envisage how such 
fragmented demand forces would bear on the producers and 
potential suppliers of the innovations. 
What does seem very much ~ore likely to occur is 
that patent-holding producers of new prod~cts will deter-
mine the way in which innovations diffuse by deciding where 
and when products will be marketed. Unless the firm is 
imbued with altruistic motives and chooses to make new 
products available to all markets as soon as possible, 
whether by their own marketing efforts or by licensing 
production to other firms, then they are likely to exercise 
their discretionary powers about timing and location of 
marketing of new products, and thus determine the pattern 
of inter-country diffusion of these products. Thus to 
successfully model and explain the inter-country diffusion 
of pharmaceutical products the supply behaviour of the 
innovating companies has to be analysed. This does 
not preclude the possibility of demand pressures altering 
these diffusion patterns - clearly these pressures will 
exist - but it seems inevitable that these will operate 
by influencing the supply behaviour of the innovation sup-
plying firms. Companies are assumed to be profit-maxim-
ising, patent-holding organisations which decide where and 
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when to market products based on their own capabilities, 
and the characteristics of the products and the potential 
markets. Thus,by their propagating actions, firms det-
ermine the diffusion patterns of individual products. The 
sum of their actions regarding the supply of new products 
to individual countries form the overall pattern of dif-
·fusion of drugs to each country. 
What presuppositions might exist about the behaviour 
of innovation-owning firms in this industry apart from 
being profit-maximising and patent-holding? Are there any 
reasons why companies would not act similarly towards all 
products and all markets? Are there any reasons why com-
panies should introduce products as quickly or as slowly as 
possible after their efficiency and safety have been demon-
strated? Are there any factors~which would delay the 
introduction of products after firms have decided to 
launch them in a market? Are there best policies which 
companies might strive to implement? ·nevil's advocates 
can have a field day here simply by asking, why? Why 
should companies market some products much more rapidly 
than they market others? Why should companies market 
consistently earlier in some countries than in other 
countries? The fact that diffusion speeds and introduc-
tion lags per country do vary considerably, suggests that 
the diffusion of pharmaceuticals may not occur in a random 
manner and that there may be economic forces which cause 
innovating companies to act in deliberate predictable 
ways. 
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What might an optimum strategy be for a profit-max-
imising firm which has developed a new pharmaceutical pro-
duct for which it has obtained patent protection. The 
production and introduction of new products which compete 
with and attempt to dispLace existing products in the 
marketplace is believed to be the principal method of 
competition in this <industry. Price is believed to play 
a smaller part in determing product performance in these 
markets than in markets which conform more to textbook 
type perfect competition structure. The introduction of 
new products is therefore of crucial importance to firms 
in this industry if they wish to survive and succeed. A 
firm which has developed and patented a new product will 
be anxious to ensure that it maximises the returns it 
can garner from sales by the new product. The product is 
likely to have a finite length life cycle. Innovation -
competition can be expected to produce new products in 
the future which will displace this product from its 
-
market position. If products do have a life cycle of 
sales of the sort described in Chapter one above, then 
firms are likely to be anxious to maximise the contribut-
ion to profit that these sales can make. A dollar of sales 
in year one of the life of a product is obviously more 
valuable to a firm than a dollar of sales in a later year. 
The firm which has produced a new product by the expend-
iture of funds on research and development will maximise 
the discounted value of the revenue stream from a product 
if it introduces it as soon as possible after approval 
149. 
to market has been granted. This may seem to be an uncon-
troversial deduction to make, but it does, in fact, rest 
upon some as yet unstated assumptions about the possible 
shape of the produc~s life cycle of sales. For this ded-
uction to be valid it is necessary to stipulate or assume 
that the shape of the life cycle of sales is not altered 
by the timing of the products first market launch. 
Further it has to be assumed that the price per unit of 
sales is no different for a product released later, than 
would be achieved by the same product released at the 
earliest possible date. Finally if we wish to make the 
step from maximising the discounted value of sales to 
maximising the discounted gross margins earned by the 
product then some assumptions about the nature of the costs 
are necessary. 
Tackling these problems in the above order, is it 
likely that the shape of the life cycle of sales for a 
product will be significantly altered by variations in time 
of first sales on.the market? If innovation-competition 
exists, then clearly.the answer is yes. But there is a 
more pertinent question: is it possible that by delaying 
introduction of a product the discounted value of total 
sales will exceed the discounted value of total sales 
achieved by marketing the product as early as possible? 
This seems unlikely to occur but could happen if some event 
has occurred during the delay period which increases the 
size of the market for this product. It seems unlikely 
that this will be a frequent occurrence. It seems plaus-
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ible to argue that neither the size of the potential market, 
rior the prices that can be gained by a product, will 
increase sufficiently during a delay in introduction of a 
product to outweigh the reduction in discounted value of 
earning from the_product. Expressing this mathematically, 
and denoting the discounted value of the stream of revenues 
by R, it has been argued that : 
dR 
crt < 0 
because -
1::1 > 1~:1 
and -




where: t is elapsed time after earliest possible 
introduction date, 
P is the price level achieved by the product, 
and, 
M is the size of the potential market for the 
product. 
For (2) and (3) to be overturned it would be nece-
ssary to have a rapidly increasing market for pharmaceut-
icals, and a rapidly increasing price level in real 
terms. Empirical evidence suggests that this has not 
10 been observed in the past. 
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What of the impact of costs upon this attempt to 
unravel the factors influencing optimum strategy for innov-
ation owning firms? The previous analysis has assumed that 
sales occur without costs being incurred. Clearly there 
will be several types of costs which will be associated 
with the marketing of a product. These costs will include 
the following: 
1. market entry costs such as costs involved 
in gaining approval to market a product 
2. market launch costs 
3. production costs 
4. promotion costs 
The present concern about.costs is whether the inclusion 
of these in assessments of the discounted benefits gained 
from launch of a product will alter the tendency to 
introduce new products to a market as soon as possible. 
This could occur if costs diminish in magnitude_if market 
launch is delayed. Given the increase in expenditure 
required to achieve marketing approval over the past two 
decades this seems unlikely to have been the case. Thus 
it is argued that the profit maximising owners of new 
products will, other things being equal, maximise profits 
10. See, Pharmaceutical Manufacturers Association, Fact-
book, 1976, Washington D.C., Pharmaceutical Manufac-
turers Association, 1976, Chapter ·four. 
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by launching products as soon as possible after marketing 
approval has been obtained. 
Can the conclusion be extended to describe the pro-
fit maximising strategy for introduction of a product to 
several markets, and some conclusions thus be drawn about 
the likely determinants of diffusion speeds of pharmac-
eutical products. 
Is it likely that owners of new products will wish to 
introduce new products in all markets as soon as possible? 
Ignoring interrelationships between performance and 
expenditures in separate markets· temporarily, it seems 
that unless there are some peculiarities of the type 
discussed above, profits earned by a product in each 
market will be maximised by marketing the product in 
each market as soon after marketing approval has been 
granted as possible. Thus if the time taken to gain mar-
keting approval were equal in all countries, simultaneous 
market launch of products in all countries might be 
expected. Demonstrably this does not occur. The task is 
to hypothesise what the reasons for variations in speed 
and extent of diffusion of pharmaceutical products might 
be. 
(4) SPEED OF DIFFUSION OF PRODUCTS 
Examining first speed of diffusion, where by speed 
of diffusion is meant the mean introduction lag time per 
product, there are several possible factors which could 
influence speed of diffusion of pharmaceutical products. 
153. 
The first of these factors may be the whim of the innovat-
ing company. Proprietors of these products may just 
choose to adopt different strategies for each product. 
If this descretion is exercised on the basis of whim then 
there is little more that need be said about it. .What of 
the cases where other than whim influences the proprietors 
decisions? 
Marketing new products seems likely to impose streams 
of both benefits and costs on the firm, and as argued above 
there are likely to be at least four different types of 
costs. Will the existence of these costs and revenues 
influence the rate of inter-country dif~usion ·of pharmac-
eutical products? The answer seems likely to depend upon 
the characteristics of the products, the firms and the 
various markets. 
Consider first how the characteristics of the pro-
ducts might influence diffusion speeds. Products seem 
likely to vary from each other in two 9istinct ways. First 
they may have different indications, that is have ·different 
pharmacologic properties. Thus some drugs are used to deal 
with bacterial infections while others are used to control 
arrythmias of the heart. Second, drugs with similar, or 
different indications, may differ in their degree of thera-
peutic novelty and importance. In economic terms products 
may differ in their elasticities of demand, even if their 
indications are similar. Because of differences in 
therapeutic importance and indications, variations in 
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speed of diffusion may occur. Therapeutic importance 
of products may have two possibly opposing effects upon 
speed of diffusion. Products wh~ch are major therapeutic 
advances might confidently be expected to achieve higher 
sales, have higher prices, and thus make greater contrib-
ution to profits than will products with similar indic-
ations but of more modest therapeutic advance. If firms 
are unable or unwilling to attempt to market all products 
everywhere simultaneously, (for reasons discussed below), 
then they seem likely, other things being equal, to attempt 
to market "important" products in more markets per unit of 
time than they will less "important" products. This it is 
argued, will occur because more important products will 
make a greater contribution to profits per unit of time. 
For this to necessarily be the case it must be that these 
more important products have similar marketing costs to 
those of less important products. This may or may not be 
the case, because the costs of gaining marketing approval 
may be influenced by the degree of therapeutic importance 
of the product. If the bodies which regulate the entry 
of new products to markets are more cautious in granting 
marketing approval for important products, because of their 
dissimilarity with existing products, then the costs of 
gaining marketing approval and the time required to gain 
such approval, may well be greater for more important 
than for less important products. So for reasons of.cost 
and actual time taken to gain marketing approval, more 
important products may not necessarily have greater 
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speeds of diffusion than do less important products. The 
strength of these two opposing influences will determine 
the overall outcome. 
Firms may have to make decisions about speeds of 
diffusion of products for two reasons. First, they may 
have cash flow restrictions which impose constraints upon 
their ability to launch new products, if launching new 
products entails considerable expenditure and only lagged 
concomitant revenue flows. Secondly, there is likely to 
be a relationship between promotion costs and subsequent 
revenues earned by products. This relationship seems 
likely to be more favourable for more important products, 
than for "me-toos". The greater responsiveness of sales 
revenues to changes in amount of promotion expenditure 
for more important therapeutic products will, other things 
being equal, cause them to be allocated more funds for 
market introduction and thus have greater speeds of dif-
fusion than will "me-toos". 
Judging what the overall outcome on diffusion speeds 
of the two possibly conflicting forces will be is difficult, 
although amidst a sea of speculations, the guess that mar-
keting approval bodies will be slower to grant such approval 
for more important products seems to be the less certain 
influence. Their caution about granting approval for 
major new products may well be countered by the importance 
of these products, and their more easily demonstrated 
efficacy. 
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The desire of innovating firms to introduce import-
ant new products as rapidly as possible may be further 
reinforced by a belief that there are spinoff benefits 
to be gained from recognition as a market leader, and the 
innovator of pharmacologically important new products. 
Thus on balance therapeutically important new products 
seem likely to have faster diffusion speeds than will 
products embodying smaller pharmacologic advances. 
What of the influence of differences in indications 
and hence potential sales upon diff~sion speeds? Consider 
two products one of which is useful in treating a rare 
disease, and a second product which is equally useful in 
treating a very common ailment. Despite their, assumed, 
similarity of pharmacologic advance they embody, one can 
expect to have very much greater sales than the other. 
Will companies constrained by cash flow requirements choose 
to market these products in similar numbers of countries 
per unit time? If choices have to be made between alloc-
ation of ~xpenditure for marketing expenses of new products, 
then the product with greater expected sales will provide 
the better return to such expenditure. Products with 
greater expected sales per unit of time may be expected 
to diffuse more rapidly, other things being equal, than 
will products with lesser expected sales per unit time. 
For this to occur it is necessary that firms either have as 
good foresight about future sales of large selling products 
as they have for lower selling products, or that they can 
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extrapolate from early sales data as well for high selling 
as low selling products. These do not seem to be particu-
larly controversial assumptions. The sales potential for a 
product in a therapeutic category such as anti-malarials is 
clearly much less than the sales potential for a broad 
spectrum antibiotic which represents similar pharmacologic 
advance to the anti-malarial product. 
One characteristic of the products which seems 
certain not to influence their speed of diffusion are the 
amounts of expenditure on research and development needed 
to produce them. Profit-maximising innovating companies in 
this industry are likely to be able to distinguish very 
well between sunk costs and future returns. 
How may the characteristics of the firms effect 
diffusion speeds of products? Consider in this instance 
two innovations with similar expected sal.es which embody 
similar pharmacologic advance, but owned by firms who 
differ in size and number of overseas distribution outlets. 
A small nationally oriented company which develops a new 
product may be constrained in its ability to market the 
product in overseas countries because of its lack of 
resources, contacts and knowledge. Whereas a large multi-
national corporation which develops a similar product is 
likely to possess the financial and human resources, and 
have existing distribution outlets in many countries such 
that it can market the product sooner in more countries 
than could a company lacking those resources, and inex-
158. 
perienced at launching new products. To successfully 
market a new product in several overseas markets the 
nationally oriented firm will have to either develop 
overseas marketing and distribution facilities, or else 
enter into a licensing agreement allowing some other 
organisation to market the product in overseas markets. 
Setting up overseas marketing infrastructures and licens-
ing other firms to market products both seem likely to be 
time consuming activities. The diffusion of products 
developed by small nationally-oriented firms thus seems 
likely to occur at a slower rate than will the diffusion 
of products developed and marketed by firms with greater 
resources and existing overseas marketing facilities. 
It may be, of course, that some firms who develop 
new products may just choose to concentrate their activities 
on their home, or a small number of markets. The extent, 
and speed of diffusion of these products may be less than 
expected just because of these preferences of some firms. 
The markets to which products diffuse were argued 
to be a third possible influence on mean diffusion speed 
of these products. The time taken to gain marketing 
approval may vary between countries. If products differ 
in the mix of countries to which they diffuse then this 
may influence their observed mean introduction lag. To 
be able to evaluate whether this does occur data will be 
needed on the time required to obtain marketing approval 
in each country. Diffusion speeds of products will vary 
159. 
if some products are marketed in countries with long mar-
keting approval times and others are marketed in countries 
with short marketing approval times. This seems unlikely 
t6 .be ~ usual pattern but the possibility cannot be 
discounted. 
It has been argued in the paragraphs above that new 
pharmaceutical products will not all diffuse to overseas 
markets at similar speeds. There have been argued to be 
several possible types of influences on the speeds of 
diffusion of these products. Hypotheses can be distilled 
from the above speculative discussion of qeterminants of 
diffusion speeds. The hypotheses postulated are : 
Hypothesis 1 
Products which embody greater therapeutic advances 
will, other things being equal, diffuse more rapidly 
than will products embodying more modest therapeutic 
advances. 
Hypothesis 2 : 
Products with greater total sales potential will, 
other things being equal, diffuse more rapidly than 
will products with lower total sales potential. 
Hypothesis 3 : 
Products produced and owned by companies with exten-
sive overseas marketing outlets will diffuse more 
rapidly than will products produced and owned by 
companies possessing few overseas marketing outlets. 
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Attempts are made to test these hypotheses in Chapter five 
using the data from the sample of pharmaceutical products 
described above. 
(5) EXTENT OF DIFFUSION OF PRODUCTS 
The speed at which pharmaceutical products diffuse 
is of course, just one facet of the diffusion process. 
Products also diffuse to variable numbers of markets, 
thus extent and direction of diffusion are further facets 
of the diffusion process. The number of markets in whic.h 
pharmaceutical products are sold seems likely to be 
determined by the factors which were argued to be deter-
minants of speed of diffusion of these products.· If firms 
in this industry are profit maximisers then they are likely 
to attempt to market their products in all markets where 
the returns from the product make a positive contribution 
to profits. It is argued that the characteristics of the 
products, the firms and the markets will again ensure that 
products do not all have similar diffusion patterns. 
Beginning with the characteristics of the products, 
how will these influence the extent of diffusion of pharm-
aceutical products? It seems plausible to argue that 
firms will extend the diffusion of pharmaceutical products 
so long as increasing the number of markets in which the 
product is sold, results in increases in profits. It has 
already been argued in the preceding section that larger 
selling products and products embodying greater therapeutic 
advances, will diffuse more rapidly than will lower sel-
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ling products and me-toos. If there are monotonic re-
lationships between, sales and contribution to profits, 
and therapeutic advance and contribution to profits, 
then bigger-selling products, and greater therapeutic 
.advance products, should make positive contribution to 
profits in more markets than will smaller selling products, 
and me-toos. This tendency should be reinforced by the 
fact that these bigger selling products, and therapeutic-
ally more important products, will have retained their 
innovative advantages-at the time marketing is considered, 
because they diffuse more rapidly and thus there has been 
less time for erosion of therapeutic advantage to occur. 
These profit maximising forces should be further 
reinforced if firms believe that there are spin-off bene-
fits to be gained from being observed to be the inventor 
and marketer of important new technological advances. 
Spin-off benefits may accrue in the form of enchancement 
of firms image, consolidating their positions as important 
innovative companies and thus leading to increases in sales 
of their other products. Thus it is postulated that pro-
ducts which embody greater therapeutic advance, and pro~ 
ducts with greater expected sales, will be likely to make 
positive contribution to profits in more markets than will 
products with lower expected sales, and products embodying 
little pharmacologic advance. The former products are 
expected to diffuse to more markets than will the latter 
products. 
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How will the structure of the firms who produce and 
own these products influence their extent of diffusion? 
The reasoning is analogous to that which was advanced on 
speed of diffusion of products. Large multinational 
firms in this industry will be experienced at marketing 
new products in very many markets scattered around the 
globe. They are likely to be aware of the problems, 
requirements, and regulations to be met before products 
can be marketed in these diverse locations. Because of 
their size, and experience they are likely to have well 
developed procedures to ensure that products can be mark-
eted as soon as possible in the markets desired. Multi-
national pharmaceutical companies by definition, sell 
products in many locations. They therefore have existing 
marketing and distribution channels in many countries. 
If a multinational company wishes to market a product it 
has developed in many locations then it should be able to 
do so relatively simply by making use of existing pro-
cedures and marketing channels. Thus they should be able 
to minimise the costs of diffusion of products to many 
countries, and because they can introduce products more 
quickly than will nationally-oriented firms, the 
therapeutic advantage of a new product will have been 
less eroded at the time of introduction to the n'th market, 
than would be the case if the product had been marketed 
by a nationally oriented firm. Thus because multinational 
firms can introduce products worldwide more quickly, and 
at lower cost, they will be able to launch new products in 
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more markets than will nationally oriented firms. 
What can be said about the direction of diffusion 
of pharmaceutical products? It might be expected that 
countries would differ widely in their demand for the 
various types of pharmaceutical products, and the evidence 
does indicate some variation in the relative importance of 
classes of products in various markets. 11 Cardiac drugs 
for example are more important in high income countries, 
and anti-infectives, vitamins, and anti-parasiticals are 
more important in less developed countries. Surprisingly 
however, few products seem to be sold only in certain types 
of countries. This may be partly due to the fact that 
very many less developed countries have a high-income 
developed sector within their economies. The tastes, 
incomes and illnesses of the people in these sectors may 
be quite similar to the tastes, incomes and illnesses of 
people in high income countries, and thus the drugs used 
similar in both sorts of country. However, it is 
possible that differences in demand pattern may influence 
the extent and direction of pha~maceuticals diffusion. 
Thus anti-malarial products seem unlikely to be as univ-
ersally required as general anti-biotics. The extent of 
diffusion of some products may be influenced by that fiac-
tor. Proceeding from the above paragraphs, four hypothe-
ses are postulated on extent of diffusion of pharmaceutical 
products. 
11. See Table 5.2 below. 
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Hypothesis 4 
Products embodying. greater therapeutic advance 
will, other things being equal, diffuse to more 
markets than will products embodying more modest 
therapeutic advances. 
Hypothesis 5 
Products with greater expected sales will,·other 
things being equal, diffuse to more markets than 
will products with lower expected sales. 
Hypothesis 6 
Products developed and marketed by firms with 
extensive international marketing outlets will, 
other things being equal, be marketed in more 
countries than will products developed and marketed 
by firms lacking in such international marketing 
outlets. 
Hypothesis 7 
Products with therapeutic actions which are univ-
-
ersally demanded will, other things being equal, be 
marketed in more markets than will products with 
more geographically confined demand. 
These hypotheses are tested in Chapter six below. 
(6) LENGTH OF AVERAGE INTRODUCTION LAG PER COUNTRY 
It was argued in preceding sections that countries 
could be viewed as being passive recipients of new products 
supplied to them by pharmaceutical companies. The concern 
in this section is to analyse the possible reasons for 
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variations in average introduction lag per country. 
The term average introduction lag per country refers to 
the mean value in months between first introduction 
date of products and their introduction date on the part-
icular country's market. The spread of average introduc-
tion lag times, and the consistency with which certain 
countries are early to receive new products and laggards 
are late, together suggest that analysis of the factors 
influencing introduction lag may be fruitful. 
The assumptions made in the preceding sections about 
the objectives of and constraints on the actions of firms 
in this industry are maintained here. Particularly it is 
assumed that firms are unable to introduce their products 
in all markets simultaneously, are therefore forced to rank 
potential markets in some way, and launch products sequent-
ially in those markets on the basis of the market rankings. 
What factors might profit maximising firms consider 
when attempting to rank markets for attractiveness? The 
concern of these companies seems likely to be to select 
markets to sell products in, so that some balance between 
short and long term profit-maximisation is achieved. What 
factors will affect the level of profits achieved by sales 
of a product in a market? 
elude the following: 
The list seems likely to in-
1. Time and monetary costs of gaining marketing 
approval. 
2. Ease of supply to, and ease of marketing and 
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distribution of the product in the market. 
3. Size of market. 
4. Price levels in the market. 
5. Amount of competition in the market. 
6. "Non-.economic" factors. 
The effects of these factors upon mean introduction lag 
times are discussed in turn below. 
Gaining marketing approval for pharmaceutical pro-
ducts appears·to be very difficult in some countries such 
as the U.S.A. and Japan and very much easier in others 
12 such as Hong Kong. Hong Kong in fact imposes no re-
quirements to be met before products can be marketed 
there. Considerable debate has occured about the role 
of the F.D.A. requirements in slowing the release of 
drugs onto the U.S. market. Some participants in the 
debate, notably Wardell, have asserted that the reason 
for the "long" average introduction lag time for the U.S. 
has-been the increase in requirements to be met before 
13 drugs can be marketed in the U.S.A. 
12. See, International Federation of Pharmaceutical 
Manufacturers' Association, The Legal and Practical 
Requirements for the Registration of Drugs (Medical 
Products) for Human Use. zurich, IFPMA., 1975. 
13. Wardell, W.M. A Close Inspection of the Calm Look. 
Journal of American Medical Association, 239, 19, 1978, 
PP. 2004-2011• Lasagna, L. and Wardell, W.M. The Rate 
of New Drug Discovery, in Helms, R.B. Drug Development 
and Marketing, Washington, A.E.I. 1975. 
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Research indicates that the mean time needed to obtain 
marketing approval for a product, timed from date of first 
application to the F.D.A. to conduct clinical trials, 
was approximately six years in the early 1970's, and has 
· d · 1 th s1'nce then. 14 1ncrease 1n eng 
Such barriers to entry of new products may lengthen 
the mean introduction.lag time per country in two ways. 
They may simply make it impossible to market products in 
the country without some minimum introduction lag occurring 
because it takes that long to gain marketing approval. 
Secondly, exacting marketing approval requirements may 
decrease the attractiveness of such markets and thus 
cause potential suppliers of new products to introduce 
their new products in other, now more attractive markets, 
before they attempt to introduce products in :the countries 
which have stringent regulations. Thus it seems plausible 
to argue that such barriers to launch of new products will 
lengthen the mean introduction lag time for countries such 
as the U.S.A. and other countries with stringent pre-mark-
eting requirements. 
The relative ease or difficulty involved in marketing 
products in a country may affect its attractiveness to 
potential suppliers of new products. Firms who develop 
and produce new products will be attracted to launch them 
14. Wardell, W.M. The Rate of Development of New Drugs in 
the United States, 1963 through 1975. Clinical Pharm-
acology and Therapeutics 24, 2, 1978, P. 140. 
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in markets where they can easily distribute and sell 
the products and begin to earn profits to finance further 
research and product development. It may be that the 
"home" country of the innovating firm is the market they 
know best, have the best developed marketing infrastruct-
ure in and thus can most readily earn profits in. It 
could therefore be expected that there will be a bias 
toward short average introduction lag times in those 
countries where the headquarters or research locations of 
the firms which develop new products are located. Research 
and development in pharmaceuticals is concentrated in a 
few countries U.S.A.; U.K.; West Germany; Switzerland; 
Italy; Japan; and France dominate pharmaceutical innov-
ation.15 These countries might be expected to obtain the 
products invented in research laboratories in their own 
countries before other countries receive them. If this 
occurs it will contribute toward a ~horter mean introduc-
tion lag time for these few countries. Such a tendency 
is likely to be more pronounced when product& are prod~ced 
by firms which do not have extensive overseas marketing 
infrastructures, because there is likely to be a delay 
before overseas sales commence, if marketing infrastructures 
overseas have to be established, or licence agreements 
negotiated. There may be a further source of delay if 
the innovating company decides to launch a product over-
15. See Table 3.1 above. 
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seas only after evaluating its performance on the first 
market it was sold on, the home market. Thus these fac-
tors may reinforce the bias in favour of short mean intro-
duction lag times in innovative countries. 
The importance of source of innovation in determ-
ining mean introduction lag time will depend upon the 
ratio of domestically discovered to overseas discovered 
products marketed in a country, and the consistency with 
which innovating companies launch products first in the 
country where their headquarters are sited. For a country 
such as the U.S.A. the ratio. of domestically-invented 
to overseas invented products may approach one to one, 
but the small amount of data available on this topic 
suggests that only in the U.S.A., U.K., Switzerland, 
France, West Germany and Japan does the ratio exceed one 
16 to twenty. Thus only in these seven countries would it 
be expected that there will be a shorter mean introduction 
lag because of the tendency for innovating companies to 
.market their new products on "home" markets first. 
It may be argued that the notion of a "home" market 
is false, both because multinational firms do not have a 
"home" market with which they are more familiar, and 
because these companies may produce new products in loc-
ations other than the "home" country. These objections 
16. Cooper, M.H. Substitute Competition Government Regu-
lation and the International Pharmaceutical Indtistry. 
University of Otago, Economics Discussion Paper No. 
7701. 
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both appear to have some validity, but are not sufficient-
ly strong to destroy the usefulness of the concept. While 
it may be true that a multinational company may have 
research facilities in several locations and may have 
equally well organised marketing infrastructures in many 
countries, it is still true that these companies do have 
a head office in some "home" country to which subsidiaries 
defer and from which decisions on where to launch new 
products emanate. When new products are discovered in 
research laboratories in other than the "home" country, 
these research laboratories are likely to be situated in 
one of the other six major innovating countries because 
firms concentrate their research activities in those co-
untries. Thus it is argued there will be shorter mean 
introduction lags for these innovative countries because 
of the tendency to market products first either in the 
"home" country, or in the country where they were dis,. 
covered. 
Will the difficulty or ease-of marketin~ and dis-
tribution affect companies ranking of markets apart from 
their preference for home markets? Pharmaceutical pro-
ducts are low mass, low volume, high value products 
ideally suited to export from a central production location 
to distant markets. The costs and ease of supply to 
various markets seem likely to be reasonably similar for 
all markets, and therefore unlikely to significantly 
affect the attractiveness rankings of markets. The fact 
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that multinational pharmaceutical firms may have market-
ing and distribution infrastructure established in some 
regions and not others may, however, impose some rigidities 
on the behaviour of these firms when they make their dec-
isions about the marketing of products in many locations. 
This may have a significant impact on individual firms 
rankings of potential markets. American firms, for 
example, fuay have highly developed marketing subsidiaries 
in South America. European companies may have strong mar-
keting networks within Europe but few outlets in other 
areas. .British firms may concentrate their efforts in 
Commonwealth countries. Such influences may dominate other 
factors when firms rank potential markets. However, the 
concern is with mean introduction lag time per country, 
and it seems likely that all dependent countries will 
receive new products from a range of supplying countries and 
the danger of bias due to the existence/non-existence of 
marketing infrastructures in a particular country will be 
negligible. 
There may still be variations in the ease with which 
products can be marketed in individual countries. Japan, 
for instance, appears to require overseas firms to license 
domestic firms to market products there. This may delay the 
marketing of overseas produced products in Japan because 
negotiating license agreements will be a time consuming 
process, and because licensing products will reduce the 
profitability of sales in that market and thus reduce the 
attractiveness of that market. For these reasons countries 
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which impose such requirements seem likely to have longer 
mean introduction lag times then they otherwise would have. 
Marketing products in less developed countries may 
be less attractive than marketing products in high income 
"Westernized" countries. The innovative pharmaceutical 
companies are almost all based in six or seven industrialised 
high income countries, geographically distant from the 
lower income countries in South America, Asia and Africa. 
Pharmaceutical companies may find such markets relatively 
unattractive because of the poor returns gained from 
sales in those countries. The profitability of sales in 
those markets may be lessened by high costs of marketing 
and distribution due to differences in language, legal 
and commercial systems, lack of well developed health 
systems, poorly trained pharmacists and doctors. The 
evidence suggests that price levels in these markets are 
on average a little lower .than are prices in the innovative 
countries. 17 The net returns from sales of pharmaceutical 
products in these countries is l~kely to be squeezed from 
both the costs and revenues sides and thus the markets may 
appear unattractive to firms contemplating marketing pro-
ducts in them. 
17. A comparison of prices in sixteen markets is provided 
in Chapter seven below. Specifically see Table 7.18. 
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How will the size of markets and price levels affect 
the attractiveness of markets to potential suppliers of 
new pharmaceutical products? Will firms be attracted 
to launch their products more rapidly in markets where 
sales are expected to be larger, than in markets with 
smaller expected sales? Will the knowledge that some 
markets have high prices encourage firms to launch their 
products in those markets before they launch them in 
countries:with lower prices? To make sensible comments 
on the likely effects of market size and price levels 
upon the "attractiveness ranking" firms give to potential 
markets, some assumptions have to be made about CO$tS of 
supply to the markets, and transfer prices. Clearly 
net returns from marketing products in a country are 
determined by the combined influences of prices and costs. 
For this section of the analysis,costs of supply are 
assumed to be equal for all markets, and transfer pricing 
is assumed to be neutral in effect. Thus the position 
and shape of the demand curve is assumed to be the only 
reason for variation in returns from marketing in each 
country. 
Companies seem likely to conjecture, explicitly or 
implicitly, about the probable shapes and positions of 
demand curves for their products in each market. To say 
that one market is potentially larger than another without 
mentioning prices is meaningless. One market may validly 
be described as larger than another if at any given price 
a greater quantity can be sold in the. larger market 
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than can be sold in the smaller market. The demand 
ctirves of such larger markets may be said to "dominate" 
those of smaller markets. Given the assumptions made 
above about cost similarity it seems plausible to argue 
that companies w~ll rank larger markets more highly than 
smaller markets because each unit sold will return them 
more net profit than would be obtained from a similar 
volume of sales in the smaller market. Profit-maximising 
firms will increase sales in each market until marginal 
cost equals marginal revenue .. Neo-classical analysts may 
therefore suggest that when the adjustment process is 
complete firms will be indifferent between markets, because 
the returns from the last unit sold are equal in all 
markets. This is true but surely a non sequitur as the 
greater net returns from each intra-marginal unit sold in 
larger markets are an obvious attraction which firms are 
unlikely to disregard. However, the requirement of 
"dominated" demand curves appears to be essential before 
it can be argued that one market will be preferred to 
another for size or price level reasons. 
It does appear that prices do vary widely between 
pharmaceutical markets, and that volumes vary even more 
widely. 18 Demand curves for many products on the U.S. mar-
ket, for example, seem likely to ''dominate" demand curves 
for the same products on all other markets. Pharmaceutical 
18. Information on price levels and tdtal sales magnit-
udes are provided in chapter seven below. 
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companies seem likely to be able to rank markets in order 
of their potential contribution to profits, through sales 
of a product in each market. It seems- implausible that 
innovation owning companies will be unable to decide which 
market to next launch a product in,because sales of a pro-
duct in each market will eventually increase to the point 
where marginal revenue equals marginal cost. Thus if the 
demand curves for one market dominate those in another, 
then the profits to be gained through sales of a product 
in the larger market will also dominate profits gained 
through sales in the smaller market. If innovation owning 
firms are forced to choose where next to launch a product, 
the lure of greater expected profits in one market are 
likely to influence them to prefer that market, and thus 
contribute to a shorter mean introduction lag for larger 
markets than for smaller markets. 
The shape and position of demand curves in each 
market will be-influenced by ·the amount of competition in 
-
each market. Markets appear to vary considerably in the 
number arid strength of local firms supplying them with 
pharmaceutical products. The number of products for 
sale in each market ranges from a high of approximately 
10,000 in Brazil, to approximately 1,500 in New Zealand. 19 
The strength of local suppliers is probably greatest in 
the U.S.A. where they supply half of the new products 
19. Author's analysis 0f I-.M..S. data. 
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launched on that market and attain a dominant share of 
sales in many therapeutic classes, and weakest in almost 
totally dependent countries such as New Zealand, Colombia 
and the Philippines. Markets are very much more frag-
mented in South American countries than they are in mar-
kets such as Australia or New Zealand. The amount of 
fragmentation, and strength of competition in each market, 
will influence the shape and position of the demand curves 
of new products, and thus the attractiveness of marketing 
a product in a country. 
There may also be non-~conomic.factors which influence 
firms decisions about where and when to market products. 
A wide range of factors may alter firms perceptions of the 
attractiveness of potential markets. These factors might 
include the legal, commercial and political environments 
in a country, the cultural and climatic characteristics, 
and the type of health systems present. Companies contem-
plating launching products in a country may be influenced 
by these features of the marketing environment. The major 
sources of supply of new pharmaceuticals for most countries 
are firms based in seven innovative countries. Without 
exception these seven are high income "western" countries~ 
with highly developed legal, commercial,political and 
health care systems. In contrast many of the countries 
in which firms may contemplate launching products have 
poorly developed health care, legal, commercial and 
political systems. Differences in language, culture, and 
climate may accentuate these divergences between condit-
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ions in the innovative countries and the dependent 
countries. Because of these differences innovative firms 
may be deterred from launching products in countries 
where the environment differs greatly from those ·they are 
familiar with. Thus firms may find some countries more 
attractive places to market products in than others and con-
centrate their efforts on those markets they are most at 
home in. If this is the case, and insofar as these 
characteristics cannot be subsumed under such headings as 
cost of marketing and distribution, then they are non-
econiDmic in nature. Such factors may be important causes 
of variation in mean introduction lag per country. 
Based on the above discussion of the possible influe-
nces on mean introduction lag per, country, the following 
hypotheses are proposed for subsequent testing. 
Hypothesis 8 
Countries where the time and monetary costs of 
gaining marketing approval are large, will, other 
things being equal, have longer mean introduction 
lag times for new pharmaceutical products than 
will countries with modest marketing approval 
costs. 
Hypothesis 9 
Countries whose pharmaceutical markets are "large" 
will, other things being equal, have shorter mean 
introduction lag times for new pharmaceutical 
products than will countries with "smaller'' markets. 
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Hypothesis 10 
Countries which are among the major sources 
of innovation of new pharmaceutical products, 
will have shorter mean introduction lag 
times, other things being equal, than will 
innovation-dependent countries. 
Hypothesis 11 
Countries where the marketing environment is 
least like that in the innovating countries, 
will, other things being equal, have longer 
mean introduction lag times than will countries 
where the marketing environment is most like 
that in the innovating countries. 
These hypotheses are tested in Chapter seven below. 
(7) NUMBER OF NEW PRODUCTS DIFFUSING TO EACH COUNTRY 
Some participants in the debate about the impact of 
F.D.A. regulations on the diffusion of new pharmaceutical 
products to the U.S.A. market, have argued that not only 
have these regulations increased the length of the mean 
iritroduction lag for the U.S.A., they have actually pre-
20 vented some products from being marketed in the U.S.A. 
The two claims are similar, but not necessarily indentical. 
It is possible to cause a delay in introduction of all 
produ6ts, but still allow them eventually to be marketed 
20. For the latest of a long series of articles making this 
point see, Wardell, W.M. A Close Inspedtion 
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in a country. However, in the case of the U.S.A. both 
types of influence may have been at work. Particularl~ 
it is possible that some drugs have·.no.tbeen granted market-
ing approval,thus reducing the proportion of new proudcts 
diffusing to the country. Also,·because of the increase 
in length of mean introduction lag per country, the cGsts 
of gaining marketing approval may deter potential'suppliers 
of new innovations from attempting to market products in 
a country with such exacting regulations. An increase 
in the costs of gaining marketing approval, combined with 
an increase in time before sales revenues commence, is. 
likely to persuade firms to market their products else-
where. Thus by these two mechanisms: the inability to 
gain marketing approval; and the increase in costs due 
to these regulations, countries with such barriers are 
likely to receive a smaller proportion of the supply of new 
pharmaceutical products than will countries with less 
exacting regulations. 
Clearly countries differ in.their degree of tech-
nological dependence for new pharmaceutical products. 
It was argued in the preceding section that the production 
of new pharmaceutical products is concentrated in firms 
based in seven countries. All countries apart from 
these seven have to rely on overseas firms to supply them 
with hew pharmaceutical products, and only in a handful of 
countries is the supply of new pharmaceutical products by 
domestic firms likely to exceed 20 per cent of the total 
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supply of new products. The seven relatively more 
technologically independent countries will have a head 
start as far as receiving a large share of the total supply 
of new pharmaceuticals goes, because by definition they are 
the sources of innovation and products produced by "their" 
firms are likely to be marketed in their home markets. 
The technologically dependent countries have no guarantee 
that they will have any new product marketed in their 
country, they may therefore receive fewer new products 
just because all products have to come from overseas. 
The size of each pharmaceutical market and the pot-
ential profits to be earned were argued in the preceding 
section to be important factors influencing the ranking 
firms gave to markets. The magnitude of potential 
profits also seems likely to be a crucial factor in the 
determination of the proportion of the total supply of 
new products which are launched in each country. Innovation 
owning companies will be likely to consider marketing 
their products in.all markets where sales make a net con-
tribution to profits. If costs are again assumed to be 
similar in all markets, then the greater profits to be 
earned in "larger" markets are likely to provide induce-
ment for more products to be launched in those markets than 
in "smaller" markets. The fixed costs of gaining marketing 
approval, and market launch, will be more easily recouped 
21. Cooper, M.H. Substitute Competition ... P. 3. 
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by sales in markets whose demand curves dominate those 
of smaller markets. 
However, there is a factor which may disrupt the two 
influences discussed above. The amount of competition 
in any market may be of prime importance to firms contem-
plating launching a product in a particular market. The 
amount of competition in a market will of course determine 
the slope of the demand curve for the product a firm hopes 
to market 1n a country. There are two rather different 
types of competition whose:sul:)leties deserve mention. First, 
the countries which are the dominant sources of innovation 
in pharmaceutica1s, have capable, aggressive, domestic 
pharmaceutical industries which will pro~ide rugged com-
petition for a firm contemplating marketing a product in 
one of these seven countries. It is likely that local 
firms will have heavily entrenched positions in these mar-
kets, and particularly new products marketed by non-domes-
tic firms will have to compete against the strength, ex-
pertise and local-market.knowledge of domestic firms, as 
well as the competition offered by other non"-c1omestic 
firms. Thus the prospect of marketing new products in 
one of these seven innovative countries may be a partic-
ularly daunting one. This may counter the tendency for 
these innovative countries to have more new products 
launched in their markets just because they are the sources 
of innovation and thus have "their'' own new products mar-
keted in their country. 
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The other notable form of competition in these mar-
kets is the extreme fragmentation of markets which occurs 
in many South American and Asian countries. The· amount 
of imitation and local production which occurs in some 
therapeutic classes in these countries is astonishing. 
Anti-infectives, tonics, and vitamins may have over a 
h d d . . k 22 . p. t. f un re compet1tors 1n some mar ets. 1ra 1ng o new 
innovations may occur in these markets, particularly if 
patent laws are only partially observed. Such potential 
challenges may deter companies from launching products 
in these markets, unless the products have characteristics 
which distinguish them sufficiently from existing products, 
or unless the strength of the companies name is sufficient 
to ensure that they capture a significantly large share 
of the market to make market launch profitable. In con-
trast, very much less fragmented markets such as the New 
Zealand one, where domestic competitors are small and 
passive, and patent laws are faithfully observed, will be 
relatively easy markets to launch products in. 
These two aspects of competition may deter some 
companies from marketing products in countries where such 
competition exists, and thus reduce the number of new 
products marketed in those companies. The two forms of 
competition may be best treated in conjunction with other 
influences on the supply of new products to a country. 
22. Author's analysis of I.M.S. data. 
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Seven countries dominate the supply of new pharmaceutical 
products, and this it was argued would lead to those 
countries securing a greater supply of new pharmaceutical 
products than would otherwide be expected. The effect of 
greater compe.tition by these innovative firms in the seven 
markets, can best be treated by viewing it as a counter-
vailing force to the propensity for local firms to invar-
iably launch products in their home markets, a tendency 
which it was argued would boost the number of new pro-
ducts marketed in these countries. 
Similarly the deterring effects' •Of fragmentation, 
imitation, and lack of observance of patent laws may best 
be dealt with by considering it in conjunction with the 
"non-economic" factors mentioned in the preceding section. 
Some markets may have few products marketed in them bec-
ause they are unfamiliar, legal, commercial, and political 
environments for innovative companies to market products 
in, and are therefore risky markets. Combine these 
f~ctors with the diff~rences in income per ca~ita levels, 
health systems, and forms of competition in these markets, 
and a valid reason for not venturing into such markets is 
apparent. Less developed countries may receive smaller 
proportions of the total supply of new pharmaceutical 
products than might otherwise be expected, because they 
appear unattractive marketing environments to innovative 
companies whose head offices, and majority of sales are 
in "western", high income countries. 
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The hypotheses postulated for subsequent test 
relating to proportion of the supply of new products 
diffusing to each country are 
Hypothesis 12 
Countries where the time and monetary costs of 
gaining marketing approval are large will, other 
things being equal, receive a smaller proportion 
of the total supply of new pharmaceutical pro-
ducts than will countries with modest ·marketing 
approval costs. 
Hypothesis 13. 
Countries whose pharmaceutical markets .are 
"large" will, other things being equal, receive 
a larger proportion of the total supply of new 
pharmaceutical products than will countries with 
"smaller" markets. 
Hypothesis 14 
Countries where the l!larketing environment is least 
like that in the innovating countries~ will, other 
things being equal, receive smaller proportions of 
the total supply of new pharmaceutical products, than 
will countries where the marketing environment is 
similar to that in the innovating countries. 
These hypotheses are tested in Chapter eight below. 
C H A P T E R 5 
SPEED OF DIFFUSION OF PRODUCTS 
(0) INTRODUCTION 
Tests of hypotheses do not provide clear unequivocal 
answers to the questions asked about the phenomena being 
studied. Data used to test hypotheses is often of a make-
do nature, results may conflict with one another, and the 
problem of what constitutes support for, or evidence against 
a hypotheses is ever present . Remember, the Paris Academy 
. of Science ceased offering a reward for the refutation of 
Newton's theory of gravity and planetary motion after the 
theory had been "proved" to be correct by the appearance, 
as predicted, of Haley's Comet. Tests of hypotheses may 
demonstrate if they are incorrect, they cannot prove that 
hypotheses are correct. Hopefully the evidence presented 
in the following chapters will be useful in in~icating which 
hypotheses can be rejected because they are incorrect. 
(1) DATA SOURCES AND DATA DEFICIENCIES 
The data used to test the hypotheses conjectured in 
this research project is undoubtedly less than ideal for 
that purpose. The major data source is the Intercontin-
ental Medical Statistics (I.M.S.) audits of the pharma-
ceutical markets in various countries. These audits 
contain information on prices, sales levels, sales growth 
rates, market and sub-market sizes, company performances, 
introduction dates of products, information on new pro-
ducts and so forth. A very large amount of information 
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is contained in these surveys of the pharmaceutical markets. 
The geographical dispersion of the markets, and the number 
of firms and products in the. markets compels I.M.S. to 
1 employ sample survey techniques to obtain their raw data. 
Results obtained from the sample surveys are then e~trapo-
lated to provide representative data for the national 
markets. The use of sample surveys and extrapolation to 
provide information representative of a national market is 
a potential source of inaccuracies in the data. The sales 
figures for example which are used in this project are open 
to error from this source. However much of the data used 
will be free from such error as it does not require extra-
polation. Particularly, introduction dates require no 
"scaling up", and should be free from extrapolation error. 
Th~re may be inaccuracies in the dates of introduction used 
because of the way in which I.M.S. collects and records 
information about introduction dates. Three potential 
sources of error are : 
(a) I.M.S. survey techniques may not accurately record 
dates of first introduction in all cases. However a 
check via alternative sources of information re-
vealed that variations of more than two or three 
months were rare. Some errors in I.M.S. data can be 
detected by comparing introduction dates in all 
1. For example, a count of the number of products listed 
in the Brazil I.M.S. audit reveals that there are approx-
imately 10,000 pharmaceutical products on the Brazillian 
market.· 
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countries, patent dates, and nationality of the 
parent company. Hence a "first launch" date such 
as April 1953 for an American company's product in 
say Belgium, when there are no other launch dates 
recorded earlier than say 1962 can be rejected as being 
an I.M.S. error with little fear of committing a type 
1 error. 
(b) The introduction dates shown in the I.M.S. audits 
are the dates of first availability on the prescription 
markets of the country. Products may be released 
earlier, or only on the hospitals markets of a country 
and thus not be included in these I.M.S. audits. 
The introduction dates used in this research project 
may thus not be the date of earliest availability 
from any source. 
(c) I.M.S. audits do not record introduction dates for 
all products in all markets. Particularly in less 
developed countries introduction dates are often 
not recorded despite the fact that the products are 
present and do have sales figures recorded for these 
markets. Thus the total number of sales observations 
for these products exceeds the total number of intro-
duction dates observations. 
Despite these possible sources of error the rarity of 
conflict in introduction dates between I.M.S. sources and 
188. 
2 
alternative sources, provides reassurance that the data 
on introduction dates used in this research is accurate. 
The I~M.S. surveys do not cover identical pharma-
ceutical markets in each country, as some audits cover 
only the ethical markets (prescription sales only) , while 
others appear to cover prescription, non-prescription, 
and in some cases hospital sales. Ideally sales figures 
for similar sections of the markets only would be used, but 
where this was not-available total market sales figures 
were used. As "ethical" sales normally constitute the 
largest component of the total pharmaceuticals market the 
lack of similarity of sales data between markets is not a 
3 major problem. 
The second source of primary data for this research 
project was information gained directly from six of the 
worlds leading pharmaceutical companies. Specifically 
representatives of these companies were asked to rank 
eighteen markets for the_degree of "tightness" of their 
pharmaceutical regulations. The intention was to obtain 
2. Alternative sources of information on introduction dates 
were: direct correspondence with some of the major pharm-
aceutical companies, i.e. the proprietors of products 
in this sample; and W.M. Wardell the principal research-
er on introduction dates of products into the U.S.A. 
and U.K. The data obtained from both of these sources 
confirmed the accuracy of the I.M.S. data. 
3. Typical figures for the proportion of total pharmaceut-
ical sales which are ethical pharmaceuticals are: Peru 
75.9 per cent~ Italy 84.0 per cent; and Japan 89.0 per 
cent. Source - information contained in the I.M.S. 
audits of these markets. 
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an accurate assessment of the nature of these regulations 
from the pharmaceutical companies. This may well have been 
achieved - there is a high degree of concordance between 
assessments - but more than six responses would have been 
preferable. As no further responses could be elicited from 
the companies the information provided by the six companies 
had to be relied upon to provide the assessment of stringency 
of regulations. The rankings used may not be the same as 
would have been obtained if more companies had provided 
data on this topic. 
Similarly the data on therapeutic value of the indiv-
idual products is based on assessment provided by one Univ-
ersity of Otago Pharmacologist. Clearly there is a risk 
that dependence on one persons subjective judgment may lead 
to a bias in results obtained. More assessments would have 
been preferable to reduce the chances of that occurring, but 
as no further assessments could be obtained, reliance had 
to be placed on the one list of ratings. Reassurance that 
the assessments were accurate was provided by comparing the 
ratings obtained with the ratings given by a panel of doc-
·4 
tors in a similar study. Where there was an overlap in the 
samples of products examined the assessments of therapeutic 
value show a high level of concordance. 
The data collected to test the conjectured hypothes-
es relates to a sample of the pharmaceutical products 
4. Reekie, D.W. Pricing New.Pharmaceutical .. Approximately 
half of the products included in the present study were 
also given therapeutic value ratings in the Reekie study. 
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launched onto the world's markets during a twenty-one year 
p~riod. The sample frame used was the following; From the 
list of 600 leading selling pharmaceuticals on the U.K. 
prescription medicines market, 330 products were selected 
with first introduction dates on the U.K. market between 
January 1961 and December 1976. The sample of 330 products 
was reduced to 227 products by inspecting the constituents 
of each product and rejecting from the sample those which 
were judged to be imitations of other earlier introduced 
products, or which were considered to be combinations of 
5 ingredients contained in existing products. The justif-
ication for this procedure was the desire to study the 
diffusion patterns of products which provide new therapeu-
tic benefits. Distinct, single products are most readily 
identifiable as products which provide new therapeutic 
benefits. The expiry of patent protection for a major 
product usually heralds the launch of products whose active 
ingredients are identical to those of the major product. 
5. The chemical constituents of the products were estab+ 
lished by use of two publications, MIMS, Monthly Index 
of Medical Specialities, 19, 7, July 1977, and The Merck 
Index, ninth edition, Rahway, New Jersey, Merck and 
Company, 1976. The chemical constitutents of all products 
of the British ethical pharmaceuticals market are listed 
in the MIMS publication. Armed with this knowledge a 
check can be carried out in the Merck Index to establish 
whether there were existing products which contained the 
same constituents. The Merck.Index is a pharmacopeoia con-
taining detailed informat1on on the structure and prop-
erties, including therapeutic properties, patent dates, 
and brand names marketed under, of almost 10,000 chemic-
als. The information contained in the Merck Index en-
tries was employed to attempt to establ1sh whether each 
product was a "me-too'' or a unique new product at time 
of first launch. 
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Where such replica products were identified they were dis-
carded from the sample. Similarly products which were 
judged to be minor modifications of existing products were 
also discarded from the sample. The major exception to 
the rule of rejecting products which were combinations of 
already available constituents was the inclusion of oral 
contraceptive products. These are combinations of hormones, 
which are naturally occurring substances. These products~ 
do provide therapies which were previously unobtainable, 
.they were therefore included in the sample as their world-
wide diffusion was considered to provide significant new 
therapeutic benefits. 
The sample was again reduced in size when further 
inspection of the data revealed that several products were 
introduced in only the U.K. or a small number of markets. 6 
As diffusion means literally, ... "to send forth, or send 
abroad" ... , those products which did not go forth were 
also discarded from the sample. Only products for which 
introduction dates were recorded in three or more of the 
I.M.S. audits of the eighteen sample countries were in-
eluded in the sample data analysed. Thus the 190 pro-
ducts in the final sample had recorded introduction dates 
for from three to eighteen of the eighteen sample countries. 
The eighteen national markets studied have reas-
onably well distributed geographic locations, and well 
6. See Table 4.2 above. 
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dispersed per capita incomes and levels of development. 
The sample countries include six European, two North 
American, five South American, two South Pacific, and 
three Asian countries. An eighteen country, one hundred 
and ninety product sample is probably large enough to ade-
quately test hypotheses about worldwide diffusion of pharm-
aceutical products. 
The data used to test the postulated hypotheses in 
this research project is in some instances less than 
perfect for the task required of it. Inadequacies in the 
data weakens researchers ability to rigorously test hypo-
theses, because a lack of support for a hypothesis may be 
a comment about the data and not a refutation of the 
hypotheses. Tests of hypotheses with less than ideal data 
are believed to be more useful than mere speculation based 
on selectiv~ly chosen "facts". However, the weaknesses 
of the data must be kept in mind when interpreting the 
results. 
(2) DESCRIPTION OF THE SAMPLE PRODUCTS AND COUNTRIES 
A brief description of the sample products, and the 
markets studied, is necessary to illustrate their respec-
tive characteristics. Examining first the sample of 190 
products, how are they distributed by therapeutic categor-
ies? There are at least two possible therapeutic clas-
sification systems which can be employed to categorise 
pharmaceutical products: the •type of chemical' system; and 
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the 'location of action• system. Employing the latter of 
these two systems, which is the system used by I.M.S. to 
classify products, the distribution of products among the 
various broad categories is as shown in Table 5.1 below. 
TABLE 5.1 
Distribution of Products in Sample by Therapeutic Class 
Therapeutic Number of Relative 
Class Products Frequency % 
A 22 11.58 
B 2 1. OS 
c 38 20.00 
D 14 7.37 
G 19 10.00 
H 3 1.58 
J 23 12.11 
M 12 6.31 
N 35 18:42 
p 
0 0.00 
R 17 8.95 
s 3 1. 58 
v 2 1. OS 
Total 190 100.00 
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This classification system grdups products into thirteen 
broad categories, The brief labels for the classes 
A alimentary tract and metabolism products 
B blood and blood forming organs products 
C cardiovascular products 
D dermatological products 
G gynaecological products 
H skeletal system products 
J anti-infective products 
M muscular system products 
N nervous system products 
P parasitological products 
R respiratory system products 
S sensory organ products 
V various 
7 are: 
The distribution of• number of: sample products among 
these thirteen classes shown in Table 5.1 may be compared 
with the distribution of shares of total sales among the 
thirteen classes in sixteen of the eighteenmarkets stud-
ied. These market shares are shown in Table 5.2, and corn-
7. The classification system employed by I.M.S. was adopted 
for this study because it provides a clear rational inde-
pendent classification of drugs by an expert group. Thus 
by adopting the I.M.S. classification for the sample of 
products the problem of non-experts such as the author 
providing classification are avoided. I.M.S. classificat-
ions are much more detailed than the thirteen category 
system outlined above, extending to twenty-four sub 
classes in a major group such as drugs affecting the 
nervous system. However only the thirteen broad classes 
were used in the present study. 
Table 5.2 
Percentage Shares of Total Market by Therapeutic Class 
N. Z. 
Aust- Bel- Ger- Mex- Bra- Col- Venez- Phili- Indo-
ralia gium France many Italy Spain U.K. U.S.A. ico zil ombia ·Peru uela ppines esia 
A 10.4 14.2 15.7 21.3 20.3 28.0 19.9 13.1 19.2 21.5 24.4 20.5 22.0 23.3 18.6 21.2 
B 0.8 1.4 1.7 3.6 2.2 3.4 4.2 2.1 0.9 3.2 3.4 3.8 4.3 4.4 3.3 3.4 
c 21.1 18.9 20.8 23.5 26.5 10.7 8.8 20.0 14.0 5.5 8.0 6.3 5.2 6.8 2.8 3.5 
D 7.6 5.9 3.5 4.2 5.9 4.7 4.5 6._~, 0.9 6.1 6.0 7.7 6.9 9.4 7.3 5.6 
G 5.6 6.9 5.3 3.8 5.9 3.3 2.6 4.8 7.3 8.3 7.5 7.0 .7.9 6.7 1.1 2.3 
H 0.7 1.0 1.7 1.6 1.5 2.1 2.2 1.1 0.8 2.0 2.1 2.3 2.8 3.0 4.0 4.3 
J 16.1 16.7 17.9 10.4 5.7 7.6 23.5 11.5 13.1 20.7 16.6 17.5 19.9 16.9 25.1 29.7 
M 5.8 6.7 7.0 4.6 6.7 4.6 5.0 8.9 7.1 4.1 4.1 3.2 . 3. 8 3.7 2.5 4.3 
N 16.5 13.6 15.3 13.6 12.7 12.9 12.9 17.0 28.2 9.0 10.2 11.3 7.9 8.5 8.3 9.9 
' 
p 1.0 0.8 0.1 0.2 0.1 0.1 0.2 0.5 0 .·8 1.9 2.0 3.5 0.7 1.6 0.9 0.9 
R 12.5 11.4 7.7 8.5 9.1 14.0 12.9 12.3 3.6 9.8 10.7 9.3 . 13 ~ 0 9.8 15.8 11.6 
s 1.5 2.1 1.0 1.2 0.9 2.0 0.9 1.1 2.1 1.9 1.8 1.8 1.8 1.7 0.4 1.5 
v 0.5 0.6 2.4 3.5 2.6 6.4 6.2 1.1 1.9 6.0 3.2 5.6 4 .;3 4.1 10.1 1.6 
Source ··Authors analysis of I.M.S. data. 
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parison reveals that the distribution of numbers of sample 
products is reasonably similar to the distribution of market 
shares in the sixteen markets. Only the gynaecological 
products and parasitological products fall outside the range 
of values shown in the shares in the sixteen markets. 
·clearly there is considerable variation between markets in 
size of market share going to various classes, but the 
sample of products seem, numerically, to be broadly rep-
resentative of the distribution of products by therapeutic 
class in the sixteen markets for which data was available. 
The absence of any parasitological products from the 
sample is regrettable but unlikely to be of great conseq-
uence as they are a minor proportion of sales in all markets 
studied. Thus the distribution Df sample products among 
the broad therapeutic classes seems likely to provide an 
adequate representation of the range of products which 
diffuse to the sample countries. 
What of the distribution of 'nationalities' of 
products? There is a danger that in selecting a sample 
without stratification of the population,there may be 
biases or misrepresentation of certain groups. Particular-
ly in this case there is a danger that the sampling frame 
used may have biased the sample toward 'British' drugs. 
~Nationality' of products can be assigned by at least 
three methods: country in which the parent company dis-
covering the product is located; country in which the 
research laboratory in which the product is discovered is 
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sited; and country in which the product is first marketed. 
Use of each of these three rules for assignation of nat-
ionalities may produce differing results, although the 
analysis by Reis-Arndt
8
, surveyed in Chapter three above, 
suggested that use of either the f~rst or second rule pro~ 
duced very similar patterns of 'nationality'. 
Designation of nationalities by use of the third 
rule - country of first release - was most convenient in 
this project. Applying that rule the distributions of 
nationality are shown in Table 5.3 below. 
Application of the 'country of first release' rule 
produces the not unexpected result for this sample of 
products, of a dominance of U.K. products. This suggests 
that the sample may be biased quite markedly toward 
'British' drugs which might lead to results which do not 
accurately reflect the actual world patterns of diffusion. 
An alternative means of establishing nationality is 
to link country of origin, with home base of the firm which 
first introduces a product. If the firms which discovered 
products were invariably the firms which first introduced 
the products then the above rule would be indistinguishable 
from that used by Reis-Arndt. 9 This is unlikely to always 
be the case, but use of the 'country of home base of first 
8. Reis-Arndt, E., Neue Pharmazeutische Wirkstoffe ... 
9. See comments on Reis-Arndt work in Chapter three above. 
TABLE 5.3 
1Distribution of Products by Country 
of First Release 
Number of Relative 
Country Products Frequency 
% 
U.K. 63 33.15 
Colombia 0 0.00 
Mexico 5 2.63 
Peru 3 1. 58 
Brazil 4 2.10 
Venezuela 0 0.00 
Argentina 1 0.52 
Japan 2 1. 05 
Indonesia 2 1.05 
Philippines 2 1. 05 
Belgium 9 4.74 
France 9 4.74 
w. Germany 27 14.21 
Italy 5 2.63 
Spain 6 3.16 
Australia 15 7.89 
New Zealand 5 2.63 
U.S.A. 25 13.16 
Subtotal 183 
Hong Kong 1 0.52 
Switzerland 16 8.42 
Tbtal* 200 
198. 
* Greater than 190 because of simultaneous first release 
of some products in more than one country 
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introducing firm' rule appeals as being likely to provide 
a reasonable approximation for the results obtained from 
use of the 'country of discovery rules'. Use of this 
proxy produces the distribution of nationalities shown in 
Table 5.4. belo~. 
TABLE 5.4 
Distribution of Nationalities of 
Products on basis of home base of 
First Release Firm 
Number of Relative 
Nationality Products Frequency 
U.K. 32 16.84 
Mexico 2 1. OS 
Japan 1 0.53 
France 14 7.36 
w. Germany 24 12.63 
Italy 5 2.63 
Spain 3 1.58 
Australia 2 1.05 
U.S.A. 68 35.79 
- Switzerland 24 12.63 
Sweden 4 2.11 
Netherlands 10 5.26 
Denmark 1 0.53 
Total 190 100.00 
% 
The above distribution is very much like the dis-
tribution of nationalities of products produced by other 
researchers, particularly the proportion of American pro-
ducts is a much more realistic figure than the 13 per cent 
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in Table 5.3. However it is apparent that the sample does 
have an over-representation of 'British' products. Con-
ventional wisdom has it that the U.K. has been the source 
of about 5 or 6 per cent of the new drugs produced during 
the relevant period. The~ ~6 per cent accredited 
to the U.K. in this sample of products is likely to reflect 
the influence of the sampling frame used, i.e. the 600 
leading selling products in the U.K. market. Thus this 
sample of 190 drugs products is argued to have an over 
representation of British drugs. This over representation 
may cause the results obtained from the hypoth~sis testing 
to diverge from the results which would be obtained from 
a sample more representative of the total world supply 
of pharmaceutical products. 
essary that: 
For this to occur it is nee-
(a) the proportion of drugs from the various countries 
which diffuse to a market differs from the proport-
ions in the sample 
(b) the diffusi0n pattern for drugs from the misrep- -
resented sources, differs from those of the sample 
drugs. 
Comparison of Table 5.4 with Tables 3.1 and 3.2 
suggests that the sample of products employed in this 
research project is not precisely representative of the 
worlds supply of new pharmaceutical products. Therefore 
some countries supply of new pharmaceutical products will 
meet condition (a) above. Whether this will be of any 
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significance will depend on the extent to which condition 
(b) is met. For example, if diffusion times differ little 
between different nationality drugs then the misrepresent-
ation is likely to be of little importance. If however, 
the "ove~ represented" products have on average very rapid 
diffusion times, and the "under represented" slow diffusion 
times, then the result·will be to impart a bias toward rapid 
diffusion times. Is this likely to occur? Analysis of 
mean diffusion times for products of different nationality 
I 
reveals some variation between "nationalities". 
The range of ·mean lag times ~or products from the 
countries which are significant sources of new products is 
32.62 months for drugs from switzerland, to 51.745 months for 
10 
drugs from West Germany . Drugs from these two countries 
are not believed to be significantly misrepresented by the 
sample of products employed in this research. Drugs from 
the three countries which are believed to be misrepresented 
by the sample of products, U.K., U.S.A., and France, have 
mean dtffusion lag times of 34.228 months, 39.830 months, 
and 35.066 months respectively. Clearly an "excess" of 
U.K. products and a "shortage" of U.S.A. or French products 
in the sample will cause little distortion in the results 
obtained,because diffusion speeds of products from these 
three countries appear to be very similar. Thus the con-
cern that the sample of drugs employed in this research 
10. See Table 5.18 below. 
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will not accurately represent the world patterns of diffus-
ion is sensible, but there appears to be no compelling 
reason for believing the sample drugs will misrepresent the 
actual patterns of diffusion. Where there is over or under 
representation of products from countries such as the U.K., 
or France, care is taken to ensure that the conclusions 
derived from the analysis are tentative in nature. 
(3) ANALYSIS OF PRODUCTS SPEEDS OF DIFFUSION 
The first section of the analysis is the investig-
ation of speeds of diffusion of pharmaceutical products. 
Two themes permeate the analysis: 
(a) The diffusion of pharmaceutical products is a corn-
mercial process, because firms in this industry are 
profit orientated particularly when making decisions 
about diffusion of products. 
(b) Other factors such as the characteristics of the 
-
propagating firms, the nationality of the prqducts, 
their date of first launch, may also influence 
the pattern of diffusion of pharmaceutical products. 
Considering theme (a) first, the thesis is that firms will 
put more effort into supplying to the world's markets 
those products which hold out the greatest hope of pro-
viding profits, whether because of their expected sales 
volume, or because of their expected gross margin per unit 
of sale. Thus it has been argued that products with 
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greater expected sales, and products embodying greater 
therapeutic advance will be supplied more quickly to the 
world's markets than will products with lesser expected 
sales. The assumption has been made that the therapeutic 
step a product embodies influences its price and therefore 
the gross margin per unit sold. Reekie provides some 
11 evidence that this is in fact the case. This is not 
surprising. Superior products surely will have lower 
price elasticity of demand, other things being equal, than 
will inferior products. 
To determine the impact of "therapeutic advance" 
upon speed of diffusion of individual products, assessments 
had to be made of the "therapeutic advance" of each product. 
T.he sample products were given "therapeutic advance" 
ratings by a member of the Pharmacology Department at 
Otago University. Rating pharmaceutical products for 
"therapeutic advance" has been attempted by other research-
ers. The methodology and criteria employed by N.E.D.O. 
and Reekie were used to provide ratings for the 190 sample 
12 products. Specifically the following instructions were 
given to the Pharmacologists who were asked to rank the 
products. 
11. Reekie, D.W., Pricing New ... 
12. N.E.D.O., Innovative Activity in the Pharmaceutical 
Industry, London, National Economic Development Office 
1973,and Reekie D.W., Pricing New ... 
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Definitions for the five rankings of "therapeutic value". 
RANK 
1 Fundamental new medicine, of major clinical importance. 
2 Important new medicine, offering substantial advantages 
for a majority of patients. 
3 Useful new medicines, offering advantages for a min-
ority of patients. 
4 New medicines offering only marginal advantages over 
previously available therapies. 
5 New medicines offering little or no advantage over 
previously available therapies. 
The rankings given should be based on the therapeu-
tic value of each drug at their date of first launch. 
Thus a fundamental advance at its time of introduction 
13 
should be ranked "1" even if it has now been superseded. 
The assessment of therapeutic values by the Pharm-
acology Department staff member resulted in the following 
distribution of rankings. 
TABLE 5.5 
Distribution of Therapeutic Advance 
Rank1ngs 
Rank I Number of Products Relative Frequency 
1 5 2.63 
2 28 14.74 
3 62 32.63 
4 87 45.79 
5 8 4.21 
Sample Total 190 100.00 
% 
13. Quotation from the explanatory notes sent to the Pharm-
acology Department staff. 
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The distribution of therapeutic advance rankings differs 
from the distribution of ranks given by the assessors in 
14 
the Reekie Study. The sample of drugs in the Reekie 
study is smaller, 125 products, and covers products 
lauBched in the U.K. market between 1960 and 1972. The 
Reekie study employed criteria identical to those used in 
this present research. Ninety-five products are covered 
by both studies. The distribution of rankings given in 
the Reekie study are shown in Table 5.6 below. 
TABLE 5.6 
DISTRIBUTION OF THERAPEUTIC ADVANCE RANKINGS, REEKIE STUDY 
Rank Number of Products Relative Frequency % 
1 19 15.20 
2 23 18.40 
3 22 17.60 
4 28 22.40 
5 33 26.40 
Sample 125 100.00 
Total 
Several reasons may be advanced to explain the 
differences 1n distribution of ranks. These include, 
differences in sample composition, the different dates at 
which the two assessments were carried out, and differences 
in beliefs about therapeutic advances between the two 
assessing panels. Differences in sample frames could be 
expected to provide partial explanations for differences 
14. Reekie, D.W. Pricing New .... 
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in distributions. While the Reekie sample includes all 
new products launched onto the U.K. market during the 1960-
1972 period, the sample selected for use in the present 
study excluded over 140 products from the initial sample 
because they were beli.eved to be "me-toos". This is like-
ly to be the explanation for the small number of products 
given a therapeutic advance ranking of five in this study, 
versus the 26.40 per cent given that ranking in the Reekie 
study. Both panels agree that there are relatively few 
products which represent major ther~peutic advances. 
There appears to be no reason to believe that the rank-
ings given by the .University of Otago assessor are other 
than objective, consistent and accurate. These rankings 
were used to test the impact of therapeutic advance upon 
speed of diffusion. 
A decision was made to employ arithmetic means in 
this analysis. Hence the concern is with explaining mean 
lag times per product, or mean lag times per country, 
rather than attempting to explain individual lag times for 
each product to each country. This decision is a natural 
consequence of the decision to postulate hypotheses about 
lag times per product, and mean lag times per country 
rather than hypothesizing about, (and attempting to explain) , 
individual lag times per product to a country. The con-
centration of attention on average speeds and average lags 
leads to use of averages of sales for each product, product 
group, and so forth as required. 
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Average lag times were calculated for each product 
in the sample by comparing the date of first recorded 
introduction of each product with the dates of introduction 
to the other markets included in this project. The lag 
times in months, between first release, and subsequent 
releases were summed and the arithmetic means calculated. 
These mean lag times for each product are denoted by the 
variable name AVLAG. 












and no other recorded introduction dates would have its 
AVLAG calculated in the following way. First note the 
earliest date of introduction, clearly the product was 
first introduced in.April 1972 in the U.K. This parameter; 
the date of earliest recorded market launch on to a nat-
ional market, was denoted by the variable name RELEASE. 
The lag in months between RELEASE and the introduction 
dates in each country were calculated, and in the example 












The sum of these lags is 94, there are only f·ive recorded 
introduction dates, therefore mean lag time, AVLAG,is 
94 
5 = 18.90 months. 
The calculation of averages sales for each product, 
AVSALES, simply required summing the sales figures recorded 
in each country, and dividing by the number of countries 
in which the product had recorded sales. The sales figures 
employed in this research project are the I.M.S. estimates 
of sales for each product in each market for the preceding 
twelve months. For the U.K., New Zealand, Australia, 
Brazil, Venezuela, Indonesia, ahd Philippines markets the 
-sales figures are for the year preceding December 31, 1976. 
For the remaining eleven markets studied the sales figures 
are for the year preceding December 31, 1977. The lack 
of uniformity of sales years is regrettable, but seems 
unlikely to impart any major bias to the results. The 
effects of idiosyncracies in the data are further discussed 
below when attempts are made to evaluate tests of the 
hypotheses .• 
Therapeutic advance embodied in products has been 
conjectured to be a determinant of diffusion speeds of 
pharmaceutical products. The following mean AVSALES 
and AVLAGs were calculated for the five therapeutic 
advance ranks, as shown in Table 5.7 below. Lag times in 
this analysis are in months, and sales figures in millions 
of U.S. dollars. Thus the five products given a thera-










Means of AVLAG and AVSALES per Therapeutic 
Advance Rank 
Standard 
Mean Deviation Mean 
AVLAG AVLAG AVSALES 
25.6428 18.2564 5.9827 
38.3852 18.9151 1. 5083 
38.9531 22.8387 1.6327 
41. 6205 29.4786 1. 6779 
47.2021 28.9341 1. 0574 














of just over two years, and mean average sales per market 
of almost six million dollars 
Are there significant differences between the mean 
AVLAG values? Are therapeutic advance rankings useful in 
·explaining variations.: in AVLAG values? Analysis of var~ 
iance tests provide the following results: 
Analysis of Variance and Test of Linearity 
Source Sum of Squares 
Between Groups 1813.582 
Linearity 1333.070 
Deviation from 480.512 
Linearity 
R = 0.1032 
Within Groups 123404.360 








453.395 0.680 0.6068 
1333.070 1.998 0~1591 
160.171 0.240 0.8683 
R Squared = 0.0106 
667.051 
Eta Squared = 0.0145 
Examination of the results reveals that the differences 
between means is not statistically significant, the F. 
value computed is very small. The R value calculated,· 
0.1032 indicates there is only a very low correlation 
between therapeutic advance ranking and AVLAG, an·d indeed 
only one per cent of the variance in the dependent variable 
AVLAG can be explained linearly by the independent var-
iable TADVANCE. The Eta squared statistic indicates that 
only 1.45 per cent of the variance in AVLAG can be explained 
in total by TADVANCE. Therapeutic advance rankings appear 
to be a dismal failure at explaining variations in the 
speeds of diffusion of these 190 pharmaceutical products. 
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Is this result caused by systematic bias within the 
TADVANCE classes swamping any tendency for products with 
higher TADVANCE rankings to diffuse more rapidly than pro-
ducts with lower TADVANCE rankings? The result could 
have been caused by, for example, the prpducts with high 
TADVANCE rankings also happening to fall in the therapeutic 
classes which have low sales volumes. Examination of the 
data in Table 5.7 indicates however, that while there is a 
non-linear relationship between TADVANCE rankings and the 
mean AVSALES for each rank, there is a ·tendency for p~od-
ucts with higher TADVANCE rankings (where a ranking of one 
is higher than a ranking of two or three), to have greater 
AVSALES than do products with lower TADVANCE rankings. 
This is indicated by the correlation coefficient between 
15 TADVANCE and AVSALES of -0.1136. As might be expected, 
products with greater therapeutic advance, on average have 
greater sales than do products embodying lesser therapeu-
tic advance. Thus there appear to be no systematic bias 
against the hypothesized influence of TADVANCE on AVLAG 
from that source. 
The possibility of other biases against the influence 
of therapeutic advance on diffusion speeds was investigated 
by examining the correlation coefficients between TADVANCE 
and other variables used in this analysis. 
15. See the matrix of correlation coefficients including 
that between TADVANCE and AVSALES, in Table 5.8 below. 
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The signs of all these coefficients are as expected. 
Age of products is denoted by the variable name RELEASE, 
and appears to be unrelated to TADVANCE as the coefficients 
in Table 5.8 indicate. 
TABLE 5.8 
TADVANCE Correlation Coefficients 
TADVANCE 
TADVANCE 1.0000 
AVSALES - 0.11359 
LIFE SALE - 0.19530 
RELEASE - 0.01032 
NUMSALES - 0.24541 
AVLAG 0.10318 
There appears to be no reason to believe that the observed 
relationship between TADVANCE and number of countries pro-
ducts sell in, NUMSALES, will cause the relationship bet-
ween TADVANCE and AVLAG to appear to be weaker than it 
actually is. 
A variable which explains only 1 per cent of the 
variation in diffusion speeds of pharmaceutical products 
appears so unimportant it can tentatively be concluded 
that diffusion speeds are virtually unaffected by levels 
of therapeutic advance. Examination of the mean values 
of AVLAG for the five TADVANCE classes in Table 5.7 
indicates that only the "outliers" in TADVANCE ranks one 
and five have diffusion speeds which differ from that of 
the remaining products. Products in TADVANCE ranks two 
three and four appear indistinguishable from one another 
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in diffusion speed. 
Are diffusion speeds influenced by expected sales 
levels of the products? Ideally to test this hypothesis 
proprietors' estimates of expected sales for each product 
would be obtained. Clearly obtaining such estimates is an 
impossibly difficult task. An obvious alternative strat-
egy would be to collect lifetime sales d'ata for each pro-
duct and use this as proxies for firms estimates of 
expe~ted lifetime sales. However collecting even this 
information would be a challenging task, particularly if 
data collection is a manual process. The third best 
solution adopted in this case was to make use of annual 
sales data for each product. This data may bear only 
indistinct relationship to expected sales for each 
product and thus allow only the most crude of tests for 
the hypothesis that products with greater expected sales 
have faster diffusion speeds than do products with lesser 
expected sales. An attempt is made below to improve the 
quality of d-ata used to test this hypothesis. The 
correlation coefficient between AVLAG and AVSALES was com-
puted to be - 0.10783. This is of the expected sign.but 
of disappointingly low magnitude, although given the 
nature of the data used the result is not too surprising. 
The coefficient is statistically significant at the five 
per cent level, for a one tailed test. 
Alternative measures were taken to determine if the 
low correlation coefficient was caused by the nature of the 
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data used to test the hypothesis. First,the possibility 
of the "over representation" of British drugs biasing the 
results was investigated. The U.K. sales figures for the 
products in this sample are of necessity reasonably high 
because the criteria for selection in the sample included 
the requirement that products had to be in the U.K. 600 
leading selling products list. Thus it may be that the 
U.K. sales figures for the products may distort the results 
by their dominance of lesser sales in other markets. 
An initial test calculated was the correlation co-
efficient between U.K. sales figures and AVALG. The 
coefficient calculated, - 0.04858 is not statistically sig-
.nificant. 
An alternative meahs of testing whether the U.K. 
sales figures dominated sales in other markets was invest-
igated by restricting the sample to those products which 
diffused to nine or more of the sample countries. The 
Pearson correlation coefficient in this case is -0.19568. 
This is more impressive evidence of a relationship between 
AVLAG and AVSALES, being statistically significant at the 
1 per cent level on a one tailed test. If actual achieved 
sales are indicators of expected sales, then there appears 
to be some evidence that products with greater expected 
sales levels diffuse more rapidly than do products with 
lesser expected sales. 
An alternative hypothesis was also tested, namely 
that it is sales in the market products are first sold in, 
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which indicates what expected sales will be and thus det-
ermine diffusion speeds. Tests of this hypothesis pro-
duced the chastening result of a correlation coefficient 
of 0.13919. This is of the opposite sign to that predicted 
and thus the hypothesis is rejected. 
The possibility that the comparative weakness of 
the results may be due to the quality of the proxy used for 
expected sales could not be discounted. The sales figures 
used are one year's sales out of a lifetime of perhaps 
twenty years or more sales. Firms considering launch~ng 
new products onto the world's markets are hypothesized to 
vary their efforts to launch new products, and hence dif-
fusion speeds, in relation to expected lifetime sales. 
The annual sales data used to test the above hypothesis 
needs to be transformed to provide more accurate tests. 
An attempt was made to produce estimates of lifetime sales 
figures for the 190 sample products based on the annual 
sales data collected. 
The process .whereby estimates of lifetime sales are 
calculated from annual sales figures can be described with 
reference to the productlife cycle diagram below. The 
lifetime sales profiles of these products are constructed 
from series of annual sales values. The annual sales 
figures are snapshots taken at varying stages in the 
lifecycles of the products. The annual sales figures will 
be varying fractions of lifetime sales, and thus will each 






10 15 20 
Time after launch in years 
FIGURE 5.1 
Typical Liftime Sales Profile for a Pharmaceutical Product 
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life-cycle of sales is known, and the age of each product 
is known, (its position on the life-cycle diagram), then 
it should be possible to scale up the one year's sales fig-
ures to provide better proxies for expected lifetime sales. 
Conventional wisdom has it that pharmaceutical pro-
ducts do not have long lifetimes, and examination of the 
data in Table 5.14 reveals that only one of the products 
in the sample was first launched more than twenty years before 
collection of data for this research took place. The 
selection criterion for this research are likely to bias the 
sample toward those older products which have greater than 
average market success, and thus an average product life 
may be expected to be less than twenty years. Assuming an 
average product life of fifteen years, and making use of the 
average sales for the 190 sample products of U.S. $17253m, 
a lifetime sales figure for products on these eighteen mar-
kets can be calculated at U.S. $25,8795m, or approximately 
U.S. $25m. To produce lifetime sales estimates for the pro-
ducts in the sample, scale factors have to be devised to con-
-
vert annual sales data to lifetime sales estimates for pro-
ducts of each age. This simply requires constructing a 
table of scalars to multiply the annual sales data by. 
Conventional wisdom has it that pharmaceutical product 
Life cycles are approximately of the shape shown in Figure 
5.1. The scalars chosen merely have to reflect the 
relationship between annual sales and estimated lifetime 
sales for the various product ages. 
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A typical lifetime sales profile can be constructed 
by considering what proportion of lifetime sales, annual 
sales will be, in each of the years after first launch. 
A table of these proportions and the resulting scale fac-
tors, are shown in Table 5.9 below and are represented 
graphically in Figure 5.2. An approximately smooth seq-
uence of scale factors has been constructed to convert 
annual sales figures to lifetime sales estimates. Thus 
a product in the sample which was first launched during 
1965 .for example would have an estimated lifetime sales 
of thirteen times its AVSALES value. The resultant values 
were denoted by the variable name LIFESALE. The scale 
factors were used to calculate the LIFESALE values for each 
product, the mean LIFESALE was calculated to be U.S. $23.499 
million and the standard deviation of these LIFESALE's 
u.s. $38.602 million. This mean value is reasonably 
close to the estimated average LIFESALE value of U.S. 
$25 million calculated above. The actual values of indiv-
idual LIFESALES are unimportant of course, what is import-
ant are the relationships between the various LIFESALE 
values. Finally, after all this elaborate construction 
and daring conjecture, how do the LIFESALE values fare 
as predictors of speed of diffusion of pharmaceutical 
products? Correlation coefficients between LIFESALE and 
other variables in this analysis are as below. 
TABLE 5.9 
Scale Factors Used to Produce Lifetime 
Sales Figures 
Year of Annual Sales as 
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FIGURE 5.2 Annual Sales as proportion of Lifetime Sales,and 
Scale Factor used to produce LIFESALE Values 














Correlation Coefficients, Sales Variables 
with four variables 
LIFE SALE AVSALES 
TADVANCE -0.19527 -0.11359 
RELEASE -0.14619 0.00519 
NUMSALES 0.35545 0.32959 
AVLAG -0.05979 -0.10783 
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The correlation coefficient between LIFESALE and 
AVLAG is of smaller magnitude than the AVSALES - AVLAG co-
efficient and is not significant at the 5 per cent level. 
The construction of the LIFESALE values does not appear to 
have provided a more useful predictor of speeds of dif-
fusion. The signs of the correlation coefficients for 
LIFESALE with the four variables shown above are as expec-
ted, but LIFESALE does not appear to be a noticeably more 
successful proxy for expected sales of pharmaceutical pro-
ducts than is AVSALES. Comparison of Figures 5.3 and 5.4 
reveals a marked similarity in dispersion of LIFESALE and 
AVSALES values when plotted against AVLAG. This similar 
performance of LIFESALE and AVSALES as explanatory variab-
les for AVLAG appears to be inevitable. 
Do the tests conducted assist us to decide whether 
the hypothesis that products with greater expected sales 
will, other things being equal, diffuse more rapidly bet-
ween markets than will products with lesser expected 
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sales? First, the tests provide no reason to reject the 
hypothesis. The correlation coefficients between AVSALES 
and AVLAG and between LIFESALE and AVLAG are invariably of 
the sign expected. These tests appear to provide evidence 
of a tendency for higher selling products to diffuse more 
rapidly than do lower selling products. Is this evidence 
in support of the hypothesis? For this to be the case it 
is necessary that the sales data used accurately represents 
the proprietors expectations of the sales to be achieved by 
these products. There are no guarantees that this is the 
case. The data used are surrogates for expected sales, 
they may not provide fair proxies for the expected sales 
of products. 
Assuming that the data used does allow meaningful 
tests of the hypothesis, is there evidence of a strong 
relationship between speed of diffusion and expected sales? 
All the evidence points to the answer being in the negative. 
The correlation coefficients calculated between the speeds 
of diffusion and the sales parameters are not-of great 
magnitude. They do not appear to be good predictors of 
speeds of diffusion. Examination of the AVLAG ~ AVSALES, 
AVLAG- LIFESALE scattergrams, Figures 5.3 and 5.4,does not 
suggest a clearcut relationship between speed of diffusion 
and these sales variables. Indeed the picture they pre-
sent of almost no relationship between these variables may 
accurately indicate the nature of things. 
Attempts to generate better evidence to support the 
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hypothesis by using only selected cases,for example restric-
ting the sample to those 104 products which diffuse to 9 
or more markets, does provide stronger evidence that dif-
fusion speeds are related to sales levels of products. 
But even for this group of products sales levels have only 
modest ability to predict diffusion speeds. 
One major assumption remains to be exposed to 
scrutiny. The data used to conduct the above tests is 
drawn from a range of years. Simple correlation coeffic-
ient tests of the type above make the implicit assumption 
that the relationships between the relevant variables are 
constant over time. This may not be the case. There may 
well be time series effects which obscure the underlying 
relationships between the variables under scrutiny. One 
method of allowing for this possibility is to run partial 
correlation tests which adjust for the time series influ-
ences. When partial correlation tests are run between the 
sales variables and speed of diffusion, controlling for 
the time series effects, the following partial correlation 
coefficients are generated: 
AVLAG 
AVSALES -0.1194 p = 0.05 
LIFE SALE -0.1472 p = 0.02 
These results do not suggest that there are time 
series effects which significantly distort the relation-
ships between the sales values and the diffusion speeds of 
these products. The results reiterate that the relation-
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ship between these variables is relatively weak. The 
hypothesis that diffusion speeds will be positively related 
to expected sales levels of products cannot be rejected, 
but sales variables appear to have very modest ability to 
predict diffusion speeds. 
What of the third hypothesized determinant of dif-
fusion speeds? It was postulated that products invented· 
and marketed by companies with extensive overseas distrib-
ution channels would have higher diffusion speeds than 
wou·ld products marketed by firms lacking in extensive inter-
national marketing networks. 
As has been argued above assigning a product to a 
country or a firm requires judgment. Products are often 
marketed by different firms in different countries, and a 
firm with headquarters in one country may develop a product 
in a second country,and launch it in a third~ Arbitrary 
rules can be adopted to accredit products to companies and 
countries. In this case products f&rst marketed by a 
particular firm were described as being the property of 
that firm. For example it was ruled that if a product 
was first marketed by say Syntex, then Syntex had complete 
control over that and subsequent market launches. 
When this rule was applied the sample of 190 pro-
ducts were "owned" by 72 companies. The means of the 
average lag times for products owned by these seventy-two 
firms are shown in Table 5.11 below. 
TABLE 5.11 227. 
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Number of Mean AVLAG 'Std. Dev. 
Firrn Products (Months) AVLAG 
Richardson Merrell 2 33.161 10.542 
Roche 9" 27.952 15.391 
Roussell 4 35.296 9.055 
Sandoz 5 24.438 6.523 
Servier l 68.285 0.000 
Sargent l 54.166 0.000 
Schering 7 31.740 13.095 
S.K.F. 4 41.720 36.241 
Specia l 39.363 0.000 
S. P.R. l 46.800 0.000 
Squibb ·a 47.609 42.508 
Searle 3 37.849 22.665 
s.u.B~ l 26.750 0.000 
Sukyaki l 56.091 0.000 
Syntex 2 27.150 6.087 
Thorn 3 74.386 19.806 
T.R.O. l 63.500 0.000 
U.N.I. l 32.285 0.000 
Upjohn 4 38.789 14.228 
W.B.P. l 31.667 0.000 
Well come 4 42.022 24.324 
Winthrop 4 39.366 20.307 
Warner 2 68.000 2.828 
Wyeth 4 31.364 21.249 
X.Y.Z. l 127.667 0.000 
Z.Y.X. ,. l 99.750 0.000 
Sample -
Total 190. 40.087 25.739 
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Clearly some of the firms mean AVLAG values are 
calculated from diffusion patterns of only a very few pro-
ducts. The mean AVLAGs calculated may just reflect random 
differences in diffusion speeds. But there does appear to 
be considerable variation between mean AVLAG values for 
some apparently similar firms. For example, May and Baker 
a very large France based firm has products with a mean 
AVLAG of 14.5972 months, and Bayer an equally large 
Federal Republic of Germany based firm has products with 
mean AVLAG of 73.4379 months. Such differences in mean 
AVLAG require explanation. 
Testing the hypothesis that presence or absence of 
extensive world-wide marketing channels influences dif-
fusion speeds of pharmaceutical products ideally requires 
data about the nature and number of pharmaceutical compan-
ies overseas subsidiaries and marketing channels. Very 
sketchy and incomplete information is in fact available for 
16 U.K. and U.S.A. based companies only. Comprehensive data 
on the number and location of overseas subsidiaries for 
all the pharmaceut~c~l firms listed in Table 5.11 was not 
available for this research project. An alternative 
strategy was therefore adopted, which was to assume that 
16. Some information on the number of and location of over-
seas subsidiaries of U.K. and U.S.A. based firms is con-
tained in; Cooper, M.H. and Culyer, A.J. The Pharmaceut-
ical Industry, London, Economists Advisory Group, 1973r 
and Bohmfalk, J.R. Multinationals in World Markets, 
New Yor~,Edwards and Hanly Institutional Research, 
1975, respectively. 
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company size was a proxy for extent of overseas distrib-
ution channels - hereafter referred to as "multinationality 11 • 
First, the seventy-two firms were divided into three 
groups on the basis of their positions on a ranking of the 
world's largest pharmaceutical companies based on their 
17 total 1970 sales. The expectation was that the larger 
the firm, as measured by sales, the better developed its 
overseas marketing channels would be, and hence the 
shorter the mean diffusion time for its products. However 
when the seventy-two firms were divided into three groups -
those ranked first to twentieth, those ranked twenty-first 
to fortieth, and the rest - and the mean AVLAGs compared, 
the results are a little disappointing. As Table 5.12 
illustrates, there is no difference in the mean of the 
AVLAGs between the first two groups and only a 14 month 
greater mean AVLAG for the smallest firms than for the 
largest firms. 
TABLE 5.12 
Comparison of AVLAGs for Products Marketed 
· by three Groups of Companies 
Companies Number of Sum of Mean 
in Ranks Products AVLAGs AVLAG 
1 - 20 94 3335 35.4798 months 
21 - 40 35 1239 35.9829 months 
40 + 61 3043 49.8786 months 
17. The rankings are contained 1n Cooper, M.H. Substitute 
Competition ..• P. 6. 
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This 14 month longer mean AVLAG for products marketed by 
the relatively smaller firms is 40 per cent greater than the 
mean AVLAG for the products marketed by the larger firms. 
Is there statistically significant evidence that 
larger firms tend to market their products more rapidly 
than do smaller firms? A chi-square test was conducted 
to test the null hypothesis that diffusion speeds are equal 
for products marketed by firms of varying sizes. To con-
duct the test the AVLAGs were classified into three cate-
gories, fast, medium, and slow. AVLAGs in the range 0-36 
months were labelled fast, 37-54 months intermediate, and 
greater than 55 months slow. 
However the chi-square test indicates that at 
normal confidence levels there is no evidence of diffusion 
speeds being influenced by size of firms marketing the 
products. The chi-square test value calculated of 
6.6662 falls far short of the critical value of 12.592 
for 6 degrees of freedom and 95 per cent confidenc~ level. 
Amalgamation of the large firm and medium firm classes to 
conduct a chi-square test with two classes of firms, large 
and small, and the three AVLAG classes, results in a chi-
square value being calculated which is also not statistic-
ally significant at the 5 per cent level. The chi-square 
value calculated of 6.475 fails to exceed the critical value 
of 7.815 for a test with three degrees of freedom. Thus 
the tests conducted so far indicate the null hypothesis 
should be accepted. The evidence may be suggestive, 
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smaller firms on average have AVLAGs 14 months longer than 
do larger firms, but statistical tests indicate that these 
differences in diffusion speed may just be due to chance. 
An alternative method of classifying companies for 
multinationality was sought. It was postulated that 
number of products attributed to each firm may indicate 
their relative size and multinationality. Firms were 
grouped according to the number of products they had attrib-
uted to them, and the mean AVLAG for each group calculated. 
The results of.these calculations are shown in Table 5.13. 
TABLE 5.13 
Mean AVLAGs for Firms Launching Various 
Numbers of Products 
Number of Products Number of Mean AVLAG 
Per Firm Firms Per Group 
(Months) 
9 1 27.9524 
8 4. 36.9379 
7 1 31.7403 
6 1 31.9931 
5 3 43.6607 
4 10 39.1182 
3 10 41.9224 
2 9 40.1318 
1 33 47.5539 
Sample 
Total 72 40.0878 
Is there any evidence that firms with larger 
numbers of products have shorter mean diffusion times? 
Inspection of the data in Table 5.13 suggests that there 
i~ no such clear tendency. Analysis of variance test 
confirms this impression. 
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Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.:F. Square F. Sig. 
Between Groups 4693.414 8 586.677 0.881 0.5336 
Linearity 43.632 1 43.632 0.066 0.7983 
Deviation from 4649.782 7 664.255 0.998 0.4346 
Linearity 
R = -0.1870 R Squared= 0.0349 
Within Groups 120524.528 181 665.881 
Eta = 0.1936 Eta Squared.= 0.0375 
While inspection of the data may suggest a tendency for 
firms who market larger numbers of the sample product to 
launch their products more rapidly than do firms with 
smaller numbers of products, statistical test does not 
indicate that there are any significant differences in 
the behaviour of the firms. 
Insofar as these two forms of test of the influence 
of multinationality on diffusion ~peeds of products are 
concerned there is. little evidence to suggest that the 
firms with more extensive overseas distribution channels 
do market their pharmaceutical products more rapidly 
than do less well established firms. Certainly the proxy 
variables employed here - size of firm, and number of 
sample products firms market - are impotent as predictors 
of diffusion speeds of these products. 
Thus far the attempts to test the three "speed of 
diffusion" hypotheses have met with at best only modest 
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success. The variables tested have proved to be capable 
of explaining only a few per cent of the total variation in 
speeds of diffusion. Unwillingness to concede that the 
variation in diffusion speeds is due entirely to chance 
lead to a search for alternative explanations of speeds 
of diffusion of pharmaceutical products. Four further 
factors were examined to discern whether they exerted 
significant influence on diffusion speeds. The four 
factors considered were: 
1. ages of the products 
2. "nationality" of the products (and their owner firms) 
3. the therapeutic classes of the products, and 
4. the number of markets the products are sold in. 
What hypotheses are being postulated here? These are 
speculative hypotheses at best, almost guesses, and it 
seems simpler to initially set up null hypotheses. Thus 
to state explicitly, none of the above four factors has 
any influence on speed of diffusion of pharmaceutical pro-
ducts. Howeve~ ai~ernative hypotheses_ must also be 
posited. The rationale for selecting these four factors 
to test and not some others must be explained. 
Age of products may cause variations in diffusion 
speeds for the following reason. There may be a time 
series effect of progressively faster, or slower rates 
of diffusion occurring through time. Thus products rel-
eased say twenty years ago may have diffused relatively 
slowly on average, while products released during the 
235. 
1970's may on average have diffused quite quickly. Thus 
such a tendency may help explain variation in speeds of 
diffusion of a sample of pharmaceutical products whose 
introduction dates span almost two decades. 
How may "nationality" ·of products and their owner 
firms affect speeds of diffusion of pharmaceutical products? 
Variation in speeds of diffusion may be caused by differing 
attitude.s of proprietors of these products. For example 
drugs invented by Swiss companies may have high average 
diffusion speeds because the Swiss drug companies may be 
compelled to market products quickly in a number of count-
ries to obtain satisfactory sales levels for these products. 
Selling only in Switzerland may provide comparatively little 
return because of the very small size of the Swiss market. 
Alternatively, products invented by U.S.A. based firms may 
be launched at a much more leisurely pace because merely 
getting the product established on the U.S. market, the 
world's largest, may provide very significant sales of the 
product. 
Apart from these economLc factors motivating firms 
to act differently, there may be less obviously econO.mic 
factors at work. West German firms for example may just 
be less interested in markets other than their horne market, 
and thus their products have slow diffusion speeds. Only 
examination of the data will reveal whether such procliv-
ities exist. 
Products in some therapeutic classes may have 
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systematic tendencies to diffuse faster or slower, than 
products in other classes. Why might this occur? It 
may be that the number of products is small in some clas-
ses, the competition gentle, and expected sales for a new 
product modest. In such classes the pace of diffusion 
may typically be slow, whereas in large classes where 
competition is more fierce, but potential sales more im-
pressive, the stimulus to market products rapidly may be 
much greater. Thus part of the variation in diffusion 
speed of these products may be due to differences in speed 
of diffusion between therapeutic classes. Finally it 
may be that there is a relationship between number of mar-
kets a products is launched in and average speed of dif-
fusion. Products which are launched in large numbers of 
markets appeal as being likely to be important products 
whether by virtue of the therapeutic advance they embody, 
or by virtue of the sales they achieve, or both. Such 
products it has been argued.above, 18 will have.s.horter mean 
diffusion times than will less important products. Thus 
the number of markets .a product is launched in is argued 
to be a surrogate measure of importance of products and 
thus related to speed of diffusion. 
These four factors are tested below to determine 
whether they exhibit any systematic relationship with 
18. See the discussion of reasons for hypothesis formulation 
in ch~pter four above, particularly relating to hypo-
theses one and two. 
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speed of diffusion of pharmaceutical products. First, the 
effect of age of products on speeds of diffusion was ex-
amined. Ages of products were established by use of the 
data on year of first release, and the mean AVLAGs for 
products of each age were computed. Table 5.14 below 
displays the results of these computations and Figure 
5.5 provides a graphical representation of these mean 
AVLAGs. 
Visual inspection of the data and Figure 5.5 indic-
ates a marked tendency for diffusion speeds to accelerate 
over the period studied. Mean diffusion speeds for pro-
ducts released in the 1970's appear to be approximately 
twice as fast as those for products released during the 
1960's. Testing these means by analysis of variance pro-
cedures produces the following results. 
Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. Sig. 
Between Groups 41211.921 20 2060.596 4.145 0.0000 
Linearity 27534.339 1 27534.339 55.392 0.0000 
Deviation from 
Linearity 13677.582 19 719.873 1.448 0.1107 
R = -0.4689 R Squared = 0.2199 
Within Groups 84006.021 169 497.077 
Eta = 0.5737 Eta Squared= 0.3291 
Clearly bhere is a highly significant relationship 




























Mean AVLAG's for Products Launched 
in years 1956-76 
Number Mean Standard 
of AVLAG Deviation 
Products (Moriths) AVLAG 
1 83.0000 0.0000 
3 54.0171 18.8931 
2 111.3667 11.2666 
6 49.3571 19.1127 
9 69.9235 26.3608 
23 45.3157 19.5155 
8 40.3947 14.2533 
10 49.7668 27.0822 
13 43.6699 22.5396 
11 49.7126 22.5553 
15 34.2215 16.7734 
12 40.4080 21.0116 
14 45.9524 51.1042 
9 28.9J35 15.3505 
9 34.5497 12.7779 
11 29.3332 7.9628 
9 27.6323 11.4385 
12 23.1689 6.8068 
7 14.8635 3.0459 
4 15.7292 1. 7839 
2 8.2879 0.5357 
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FIGURE 5.5 Mean AVLAGS for products launched in various years 
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release, and speeds of diffusion, as measured by average 
lag time per product. Further there is no evidence that 
this result is due to some statistical quirk produced by 
aggregating products into age groups. There appears to be 
typically only relatively small variation from the age 
group mean AVLAGs,for the coefficients of variation within 
the twenty-one groups are, without exception, below 0.64, 
which is the sample total coefficient of variation. Simil-
arly when the 190 products are grouped by release dates into 
four approximately equal length time periods, the median 
values of the AVLAGs reflect similar trends to that of the 
means. 
Table 5.15 presents further clear evidence that pro-
ducts launched at any time during the period studied, have 
diffused to the worlds pharmaceutical markets more rapidly 
than have their predecessors. 
The correlation coefficient between AVLAG and 
RELEASE is approximately -0.47, the R pquared value 0.22. 
Thus 22 per cent of the variation in AVLAGs can be "explain-:-
ed" by differences in age of products. There is a clear 
time trend in the data which explains a significant pro-
portion of the total variation in speeds of diffusion 
of pharmaceutical products. Contrary to conventional 
wisdom, the evidence thus far indicates that speeds of 
diffusion of pharmaceutical products have been increasing 
over the past twenty years. Conventional wisdom has it 









Mean, Median and Standard Deviation of AVLAGs 
for Products Launched during four time Periods 
Number Std. Dev. 
of Mean Median AVLAG 
Products AVLAG AVLAG ... 
31 59.871 59.750 26.971 
68 43.015 38.500 20.723 
56 36.577 31.518 28.961 
35 20.829 19.000 9.319 










diffusion to the worlds markets by regulations designed 
to ensure that products meet safety and efficacy require-
ments. Why does this contradiction arise? Further 
investigation was conducted to determine whether the 
strong correlation between age of products.and speed of 
diffusion is due to the nature of the tests employed, or 
is merely due to some peculiarity of a subset of the data. 
First it was conjectured that perhaps the result 
was merely due to the earlier released products having more 
time to diffuse to more markets, and these extra markets· 
would bias the results towards longer lag times for the 
older products. The absence due to lack of time after 
release, of these outliers might cause the spurious 
result that younger products diffuse more rapidly than 
earlier released products. 
Analysis reveals that this speculation is only 
partially correct. The correlation coefficient between 
age of product (RELEASE) and the number of markets pro-
ducts sell in (NUMSALES) is in fact -0.23403. Thus there 
is some evidence that the earlier products were released 
the larger the number of markets they tend to sell in. 
However the correlation coefficient between number of 
market~ products sell in (NUMSALES) and speed of diffusion, 
(AVALG) is -0.04773. This appears to negate the possib-
ility that the initial test biases the results towards 
a shorter AVLAG for younger products. This conclusion 
is confirmed by conducting a first order partial correlation 
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coefficient test, controlling for NUMSALES. The correlation 
coefficient calculated, -0.4958, is of greater magnitude 
than that computed initially between AVLAG and RELEASE, 
and thus statistically even more significant. 
Two further tests were carried out. First res-
tricting the sample to only those products which were 
~arketed in nine or more markets (104) products)~ the 
correlation coefficient between RELEASE and AVLAG is 
-0.4884. This is statistically significant at the 1 per 
cent level. 
Alternatively, testing the relationship between 
RELEASE and AVLAG when RELEASE is confined to the products 
launched between 1964 and 1972, the 103 cases produce a 
correlation coefficient of -0.2149. This value is sig-
nificant at the 1 per cent level. Thus when the sample 
is further scrutinised, and sub-samples selected to reduce 
the chance of bias due to non comparability of drugs of 
varying ages, the time trend is still observed. 
Caution and skepticism suggested that a second form 
of check should be conducted to establish whether the 
evidence that pharmaceutical products have been diffusing 
more rapidly onto the world's markets, the more recently 
they have been launched, does in fact correctly describe 
the change in speeds of diffusion of pharmaceutical pro-
ducts. 
The principal cause for concern with the results 
presented so far, is that lag times and diffusion speeds 
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are determined byreference to first launch date of each 
p:toduct. Much of the concern about "drug lags" alluded to 
in earlier chapters, centres on the very lengthy delays 
which are alleged to occur between "discovery" in a lab~ 
oratory of the therapeutic va~ue of a substance, and the 
release of a commercial product containing the substance. 
The method by which diffusion speeds are determined in·· the 
present research, by calculating the delay between first 
and subsequent market launches, excludes the delays which 
may occur between "discoveryi' and first marJ<et launch, and 
thus may obscure the real changes in delay before drugs 
become available. If there has been, as is claimed, 
increases in the magnitude of lags between discovery and 
initial market launch, this may occur without influencing 
diffusion speeds as calculated in this research. Clearly 
it is possible that there have been two trends occurring 
simultaneously, a lengthening of the typical delay between 
discovery and first market launch, and a concomitant 
acceleration in the speeds of diffusion subsequent to the 
first market launches. The data presented so far indic-
ating that diffusion speeds have doubled over the twenty-
one year period studied, may divert attention from the fact 
that the mean delay between discovery and time of avail-
ability of pharmaceutical products on the world's markets 
may have lengthened over the period studied. As somebody 
said, statistics are like a bikini, what they reveal is 
interesting, but what they conceal is vital. To determine 
whether or not the statistics on diffusion speeds do conceal 
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something vital an alternative method of assessing diffusion 
speeds was invoked. 
The method employed uses information on patent dates 
as proxies for discovery dates, to allow calculation of the 
lag between patent dates and first launch dates. But are 
patent dates useful proxies for discovery dates? The 
frank answer to this is it is not known. Firms who 
"discover" pharmaceutical products may file for patent 
protection at times within their discretion. Whether they 
file for patent protection as soon after discovery as pos-
sible, or later, is not known. It is quite possible that 
changes in the commercial environment in this indus~ry may 
have caused changes in firms policies on timing of filing 
for patents. However it is possible that firms have not 
significantly changed their policy over the period studied. 
Scrutiny of patent dates may therefore provide useful in-
sight into the lags between discovery dates and times of 
availability of these products on the world's markets. 
The null hypothesis proposed is that there will 
have been no change in the time period between first patent 
date and date of first launch of products over the 
period studied. Two implicit assumptions in this hypo-
thesis should be stated explicitly before proceeding. 
First, it is assumed that patent filing has occurred at a 
similar point during the lifecycle of products, throughout 
the period studied. Second, it is assumed that patent 
filing occurs before first launch date. Investigation 
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revealed this second assumption has on occasions been 
violated. 
Patent data for pharmaceutical pr·oducts is contained 
19 in The Merck Index, an encyclopedia of chemicals and 
drugs. Th.is authoritative publication contains mono-
graphs on approximately 10,000 chemicals and drugs, includ-
ing information on ownership and filing dates of .first, 
and important subsequent patents. Using these monographs, 
the first patent dates for the sample products were det-
ermined and these dates compared with first market launch, 
RELEASE, dates. First patent dates were not available 
for all 190 sample products; a significant proportion 
either did not have patent protection, or are variants on 
the original patented products. As Table 5.16 below shows 
first patent dates were established for 116, or 61 per 
cent, of the total sample of products. 
Inspection of the data contained in Table 5.16 indic-
ates a very marked change in lag times has occurred during 
the period .. Until 1965 patent filing and first market 
launch app~ar to have occurred within close proximity of 
one another; on occasions drugs were launched before 
patent filing, but typically first launch occurred less 
than two years after patent filing had occurred. 
However,l965 appears to have marked the end of this 
relationship, for in 1965 the mean lag between patent 
19. The Merck Index, .... see further reference footnote 5. 
TABLE 5.16 
Mean Lag between First Patent dates and 
First Launch dates. Products Grouped by 
Year of First Launch 
247. 
Year Number of Mean Lag 
Products (Months) 
1958 1 0.000 
1959 4 0.000 
1960 6 11.166 
1961 16 8.437 
1962 5 30.000 
1963 5 19.400 
1964 7 12.857 
1965 7 34.142 
1966 6 56.-833 
1967 8 35.000 
1968 4 31.250 
1969 7 34.428 
1970 8 46.750 
-
-
1971 .9 55.666 
1972 5 55.200 
1973 8 53.125 
1974 6 51. 500 
1975 3 54.666 
1976 1 29.000 
Sample 
Total 116 31.991 
248. 
filing date and first launch date soared to thirty-four 
months, and for the succeeding ten years averaged approx-
imately forty-six months. Despite misgivings about the 
precision of the data, the magnitude of the change in mean 
lag over the period is so marked that it appears certain a 
fundamental change in company behaviour has occurred. 20 
If the assumption made above holds, i.e. that patent filing 
occurs at the same stage of products development throughout 
the period, then there appears to have been a significant 
lengthening of the gap between discovery and time of first 
availability of these products. When these "discovery 
to first availability" lags are added to the mean AVLAGs 
computed for products of various ages,a surprising result 
occurs. 
As Table 5.17 demonstrates the combined lag values 
for products released over this period appear to have been 
remarkably constant. The data for years 1958 and 1976 can 
be ignored as there are too few products launched in those 
years to provide representative results. But in the per-
20. A similar method of calculating the lag between dis-
covery and first launch date is employed in Cromie, 
B.W., The effect of British Regulations,in,Teeling-Smith 
G. and Wells, N., ed., Medicines for the Year 2000. 
London, Office of Health Economics, 1979. PP. 75-83. 
Cromie uses date of first publication of an article in 
a scientific journal as a proxy for discovery date. 
His data also indicates a dramatic change in lag time 
between discovery and marketing date occurred after 
1964. The length of this lag has increased rapidly 
since 1964, a result which appears to provide consid-




Discovery-to-launch lags added to AVLAGs 
Year of first Mean Discovery- Mean 
launch to-launch Lag AVLAG 
1958 0.000 111. 366 
1959 0.000 49.357 
1960 11.166 69.923 
1961 8.437 45.315 
1962 30.000 40.394 
1963 19.400 49.766 
1964 12.85.7 43.669 
1965 34.142 49.712 
1966 56.833 34.221 
1967 35.000 40.408 
1968 31.250 45.952 
1969 34.428 28.933 
1970 46.750 34.549 
1971 55.666 29.333 
1972 55.200 27.632 
1973 53.125 23.168 
1974 55.500 14.863 
1975 54.666 15.729 
























21. The figures in this Table are drawn from Table 5.16 for 
the "discovery-to-launch" lags, and Table 5.14 for the 
mean AVLAG values. 
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iod 1960 to 1975 the sum of lags values range from 53.572 
months to 91.054 months, with a mean of 74.249 months. 
Thus there appear to have been two counteracting forces 
at work during the period. While the gap between patent 
filing and first launch appears to have increased ·dram-
atically, there has been a concomitant steady decrease in 
the mean AVLAGs over the period. The combined results of 
the two trends appears to have been a relatively constant 
lag between patent filing and typical time of first avail-
ability on .the world's markets. 
This data was assembled to provide a check for the 
interim conclusion reached above that_drugs are now dif-
fusing more quickly on average to the worlds pharmaceutical 
markets than they did on average during the 1950's and 
1960's. There are reservations as to whether the data 
does provide a valid check, the crucial problem is the 
assumption that patent filing occurs at a constant point 
in the development cycle of products. There is some evid-
ence that this is not the case because patent filing occurs 
for some products in the 1950's after first launch date. 
Thus the change in lag between patent date and first 
launch date may at least partially reflect change in patent-
ing policy of firms. It may be that innovating firms now 
feel compelled, for whatever reasons, to patent new pharm-
aceutical products earlier in the development cycle than 
previously. 
However this data does also indicate the possibil-
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ity that the interim conclusion reached above of increased 
diffusion speeds may be incorrect. It may well be that 
the typical lag from "discovery" of products to availability 
of products on the worlds markets has not changed over the 
period studied. Without better data on discovery dates 
no firm conclusions can be drawn on this subject. The 
.only firm conclusions which can be drawn are that the clear 
tendency for AVLAG values to decline over the period stud-
ied have also been accompanied by a clear tendency for 
the lag between patent filing dates and first launch dates 
to increase. The combined result of these trends appears 
to have been an almost constant lag between patent filing 
and typical availability dates. 
Use of the variable RELEASE appears to be particu-
larly useful in "explaining" variations in diffusion 
speeds of pharmaceutical products. Twenty-two per cent 
of the total variation in diffusion speeds can be ~explained" 
by this variable. This apparent success is however some-
what illusory. As Griliches conceded22 , finding correlates 
with diffusion speeds does not necessarily explain very 
much. There are two objections which ~an be raised against 
the claim that age of products "explains" a significant 
proportion of variations in speed of diffusion. 
The first objection is that examination of the 
22. Griliches, Z., Profitability versus Interaction .. P. 237. 
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diffusion speeds of products of various ages reveals that 
later release products diffuse more rapidly than their 
predecessors. This is a description and not an explanation 
of why diffusion speeds have changed. Explaining why dif-
fusion speeds have changed over time. can only be established 
by further.research effort. 
The second objection ag~inst the claim of explanat-
ion is that the tests applied so f·ar have been on time 
series dominated data. How do ages of products fare when 
it comes to explaining cross section dominant data? 
Correlation coefficient between RELEASE and AVLAG, for 
cohorts of products released during short periods such as 
three years are, as might be expected, not significantly 
different from zero. This of course is another way of 
saying age of products cannot explain why diffusion speeds 
vary, £or products of similar age. However,RELEASE has 
proved the most useful variable so far in explaining 
variations in diffusion speeds among the 190 sample prod-
ucts. 
Emboldened by the success of the variable RELEASE 
in explaining variations in speed of diffusion, attention 
now turns to the second of the auxiliary variables pro-
posed, namely country of origin of products. National-
ities were assigned to each of the products on the basis 
of location of the headquarters of the company first launch-
ing each product. Use ~f this rule enables the distrib-
ution of nationalities, and mean AVLAGs per nationality 
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to be established. The results of these computations are 
shown in Table 5.18 below, and indicate that there are no 
eye-catching marked variations in mean diffusion speeds. 
Ignoring for the moment the classes containing only a 
handful of products it is noticeable that drugs first laun-
ched by Swiss based firms are fastest to diffuse, while 
those from neighbouring Italy and West Germany are slowest 
to diffuse. This result is in line with the comments made 
above when these auxiliary hypotheses were proposed, i.e. 
it was argued that Switzerland based companies may, bee-
ause of the small size of their horne market, be compelled 
to market products rapidly in many countries to obtain 
sufficient sales volume. Companies based in larger-market 
countries may not be compelled to act by such forces. 
However there is little evidence of a consistent tendency 
for products from larger horne markets countries to diffuse 
more slowly than do products from smaller horne market 
countries. Further, analysis of variance indicates there 
is no statistically significant difference between these 
mean values. 
Analysis of Variance Results 
Sum of :Mean 
Source Squares D.F. 
. ,J 
Square F. Sig. 
Between Groups 9812.507 12 817.709 1. 254 0.2499 
R = 0.0939 R Squared = 0.0088 
Within Groups 115405.435 652.008 
Eta = 0.2799 Eta Squared = 0.0784 
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TABLE 5.18 
Mean AVLAGs for Products Grouped by Nationality 
Numb~r Number 
of of Mean Std. Dev. 
Nationality Products Firms AVLAG AVLAG 
Switzerland 24 4 32.620 15.241 
U.K. 32 9 34.228 16.880 
France 14 9 35.066 17.215 
Sweden 4 1 37.207 22.098 
Spain 3 3 41.924 13.941 
Italy 5 5 55.768 23.146 
West Germany 24 9 51.745 40.324 
Netherlands 10 3 52.870 20.672 
Denmark 1 1 24.000 0.000 
Mexico 2 1 27.150 6.087 
Japan 1 1 56.090 0.000 
Australia 2 2 40.333 34.412 
-
U.S.A. 68 24 39.830 27.565 
Sample Total 190 72 40.088 25.739 
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There is an alternative way in which nationality can 
be assigned to products. If a product is first launched 
in for example Sweden,then it can be described as being.a 
Swedish product. This may be a useful means of disting....,. 
uishing between products for the following reasons. 
First it may be that assigning nationalities to products by 
use of the previous criteria is misleading. It is pos-
sible that a product presently described as for example, 
American, because it was first launched by a U.S. based 
firm, may in fact have been discovered, developed, and 
first launched in for example, the U.K. The British 
branch of the firm may have considerable autonomy in dec-
ision making concerning the distribution of the product, 
and thus the product be subjected to "British" firm dif-
fusion procedures. As the Reis-Arndt data in Table 3.2 
above shows, significant proportions of pharmaceutical pro-
ducts are not launched first in the country where their 
parent firms have their headquarters. The second reason 
for assigning nationalities to products on the basis of-
country of first release, is the possible effect of dif-
ferences in countries pre-marketing safety and efficacy 
requirements. The debate which stimulated interest in 
diffusion speeds, and hence this research project, the 
U.S. 1'Drug Lag" debate described in chapter three above, 
is centred on the impact of U.S. regulations on time of 
availability of drugs on the u.s. market. The impact of 
these regulations on time of availability of drugs 0n the 
U.S. market is discussed in chapters seven and eight below. 
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The concern here is to point out that countries differ 
widely in the pre-marketing requirements they impose. These 
regulations may affect diffusion speeds of products in 
several ways. Products may gain some sort of bill of 
health because they have been cleared for marketing in a 
country with stringent safety requirements. If such clear-
ances can be obtained quickly and then influence the time 
required _to gain subsequent marketing approvals, then pro-
ducts first launched in such countries may diffuse rapidly 
to other markets. As the discussion in chapter eight 
indicates, such linkedpre-marketing regulations do exist. 
Alternatively if a product is developed ·in a country, and 
is subjected to lengthy pre-marketing testing, the effect 
may be to cause sluggish diffusion to subsequent markets 
because the therapeutic advance, and potential profitability 
of the product are likely to have been eroded by the intro-
duction in these succeeding markets of competitive pro-
ducts. There will thus be less stimulus to invest 
-resources in the rapid diffusion of the product to overseas 
markets. Of course, these are but conjectures, and the 
next step is to test whether the data indicates if they 
are correct or not. 
The mean AVLAGs for products first released in the 
various countries are displayed in Table 5.19 below. 
Analysis of variance is again used to determine whether 
there are significant differences between the means. The 
differences in mean AVLAGs apparent in Table 5.19 are shown 
TABLE 5.19 257. 
Mean AVLAG's for Products First Launched 











































1 21. 0000 
190 40.0878 
Analysis of Variance 
Sum of 
Squares D.F. 
Between Groups 36605.006 
R = 0.3850 
17 



























2153.236 4.179 0.0000 
R Squared = 0.1482 
Eta Squared= 0.2923 
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to be statistically significant, the F value computed in 
the analysis of variance is very large, and the R squared 
value suggests that approximately 15 per cent of the var-
iation in AVLAGs is explained linearly by the variable 
ORIGIN, the variable name given to denote country where 
products are first launched. This result indicates that 
ORIGIN is more strongly correlated with AVLAG than all 
variables previously tested apart from RELEASE. This is 
an unexpected result, and further investigation is re.quired 
to establish the importance of the result. 
First a check is needed to ensure that the result 
is not due to collinearity with some other variable. 
Correlation coefficients between ORIGIN and six other 
variables are shown in Table 5.20 below. The explanatory 
variable with which ORIGIN is most strongly correlated 
is RELEASE, which has already proved to be the best predic-
tor of AVLAG values tested so far. !s the ORIGIN-AVLAG 
correlation coefficient the result of collinearity with 
the variable RELEASE? Two tests were run to provide 
answers to this question. First,a first order partial 
correlation coefficient test was run controlling for RELEASE. 
This produced a correlation coefficient between AVLAG and 
ORIGIN of 0.2307 which is significant at the 1 per cent 
level, but is marketedly less than the value of 0.38498 
for the uncontrolled correlation. The second test in-
volved splitting the sample of products into two groups, 
those launched before January 1969 and those launched 
TABLE 5.20 
Correlation Coefficients between seven Variables 
RELEASE LIFE SALE AVSALES ORIGIN NUMSALES 
AVLAG -0.47033 -0.05979 -0.10783 0.38498 -0.04773 
RELEASE 1.00000 -0.14519 0 .. o 0519 -0.42724 -0.23403 
LIFE SALE 1. 00000 0.90099 0.10004 0.35545 
AVSALES 1.00000 0.03676 0.32959 
ORIGIN 1.00000 0.03723 
NUMSALES 1. 00000 













after December 1968. This dividing line was chosen 
because it is approximately the mid point of the period 
during which the sample drugs were launched. The. two 
groups have the following features. 
PRE 1969 






127 47.3419 27.7086 0. 5852 
POST 1968 
63 25.4646 11.5873 0.4550 
The change 'in coefficients of variation between the two 
periods indicates less variation in speeds of diffusion in 
the second period. This is reflected very clearly in the 
the analysis of variance results for the two periods. 
Pre 1969 Post 1969 
F. Value Significance F. Value Significance 
2.690 0.0016 1. 435 0.1819 
R = 0.3486 R Squared = 0.1215 R = 0.2071 R Squared = 
0.0429 
Origin of products appears to be much more strongly cor-
related with speeds of diffusion in the pre 1969 period 
than after that date. There appears to have been a 
tendency for drugs of whatever ORIGIN to diffuse at similar 
speeds during the latter period. This tendency may part-
ially be explained by the fact that thirty of the sixty."':' 
three sample drugs launched in the second period were 
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first launched in the U.K., and thus could be expected to 
diffuse at similar speeds. 
These tests indicate that the importance of ORIGIN 
as an explanatory variable, declines during the sample 
period. They do not indicate that ORIGIN assumes the 
importance it does merely because of a fortuitous assoc-
iation between launch dates and countries of first launch. 
This leaves unanswered the question why is ORIGIN important 
in determining diffusion speeds during the 1960's? There 
appears to be little evidence to support the conjectured 
reasons for importance of ORIGIN, apart from the noticeably 
large mean AVLAG value for products whose ORIGIN is the 
U.S.A. As Table 5.19 illustrates, drugs launched in the 
U.S.A. have the second largest mean AVLAG. This is con-
sistent with the notion that product~ £rom countries with 
large markets may diffuse slowly because sales in the 
initial market may provide adequate returns, and there 
thus be ·less compulsion to launch the product rapidly in 
several overseas markets. But this is pure guesswork, 
the reasons why ORIGIN is relatively strongly correlated 
with AVLAG remain a mystery. 
The third of these auxiliary hypotheses is now 
tested. Drugs can be classified by their pharmacological 
properties. .Two methods of classification are : by type 
of pharmacological action; and by area where they act in 
the body. It is convenient for this study to make use of 
the classifications employed by I.M.S. based on area in the 
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body where drugs act. Using these classifications, the 
190 sample products fall in twelve of the thirteen major 
therapeutic classes, and have the mean AVLAGS displayed in 
Table 5.21 below. 
TABLE 5.21 
Mean AVLAGs for Products in23 twelve Therapeut1c Classes 
Therapeutic Number of Mean 
Class Products AVLAG 
A 22 .44.9129 
B 2 59.8939 
c 38 38.8621 
D 14 41.9437 
G 19 38.3999 
H 3 60.9111 
J 23 35.6787 
M 12 50.5183 
N 35 34.3309 
R 17 39.2619 
s 3 43.4825 
v 2. 53.1042 

















There appears to be a considerable degree of uniformity 
in these mean AVLAG values, and analysis of variance in-
dicates that there are no significant differences between 
the means. 
23. See ~able 5.1 for a listing of the area in the body 
where ~~ch ~f th~ classes of drugs acts. 
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Analysis of Variance 
Sum of Mean 
Source Squares D.F. Square F. 
Between Groups 6054.710 11 550.428 0.822 0.6179 
R = -0.0582 R Squared = 0.0034 
Within Groups 119163.232 178 669.456 
Eta= 0.2199 Eta Squared = 0.0484 
A correlation coefficient of -0.0582 does not indicate a 
.strong relationship between the therapeutic classes which 
products fall in and their speeds of diffusion. · Thus the 
hypothesis that the therapeutic classes products fall in 
will be determinants of diffusion speeds is not supported. 
Finally, the third of these auxiliary hypotheses 
is that number of markets products sell in will be useful 
' predictors of speeds of diffusion. Is the number of 
markets products sell in a surrogate measure of importance 
or profitability of products and thus a useful predictor 
of diffusion speeds? 
Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D. F. Square F. Sig. 
Between Groups 10714.735 15 714. 316 1.085 0.3730 
Linearity 285.225 1 285.225 0.433 0.5112 
Dev. from 10429.510 14 744.965 1.132 0.3331 
Linearity 
R = -0.0477 R Squared = 0.0023 
Within Groups 114503.207 174 658.064 





















Mean AVLAGs for groups of products 
diffusing to various numbers of 
markets (NUMSALES) 
Number of Mean Std. Dev. 
Products AVLAG AVLAG 
16 28.7292 15.7472 
6 25.2083 20.5593 
12 45.5375 30.9148 
15 54.5756 55.6740 
11 42.7208 33.1882 
14 38.6765 19.3441 
5 46.4794 28.9124 
4 44.6285 13.9997 
15 49.4298 20.7718 
19 43.6227 17.6032 
12 37.2538 18.9726 
10 42.2539 17.9138 
15 37.6140 21.3376 
10 35.1390 17.1352 
8 36.9383 20.2026 
18 31.5227 16.4719 
190 40.0878 25.7396 
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The analysis of variance results and correlation' coefficient 
value indicate that the variable NUMSALES is a poor pre-
dictor of diffusion speeds. The NUMSALES - AVLAG hypo-
thesis is also rejected. 
The evidence presented thus far provides a modest 
amount of support for two of the hypotheses proposed, 
and very little support for the remaining hypotheses. 
While the correlation coefficients have almost invariably 
been of the expected sign, only the variables RELEASE, and 
ORIGIN have correlation coefficients with AVLAG of greater 
magnitude than 0.20. 
However there does remain a possible means of sal-
vaging support for these hypotheses. The data used in 
the tests above is a mixture of time series and cross sec-
tion influences, where the time series trend has been 
captured by use of the variable RELEASE. Genuine tests 
of the cross section influences have been neglected however. 
There are two possible ways of coping with the strong 
time trend.. The first, use of partial correlation tech-
niques, has been used on occasions to improve the tests 
·of the hypotheses. This technique has some limitations, 
primarily that of assuming that the influence to be held 
constant has a linear effect on the dependent variable. 
This may often not be the case. Relationships may not be 
uniform throughout a period such as the twenty-one year 
period studied here. Thus the second way in which time 
trend influences can be coped with is by breaking up the 
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period studied into several short periods, thus restricting 
the influence of the time trend. It is possible that 
stronger evidence for the hypotheses can be adduced by 
testing them on cohorts of products released during approx-
imately five year periods. An attempt was made to verify. 
this possibility by calculating correlation coefficients 
between AVLAG and the independent variables for drugs 
released during four time periods. The periods were 
from : January 1956 to June 1961; July 1961 to October 
1966; November 1966 to November 1971; December 1971 to 
December 1976. The correlation coefficients for each of 
the periods are shown below. 
The hypotheses suggest that the coefficients for 
variables LIFESALE, AVSALES and NUMSALES will have negative 
signs, and those for MULTI and TADVANCE positive signs. 
The real world is apparently not very consistent for a 
noticeable feature of the results is the changes in signs 
across the.periods, for five out of eight of the variables. 
-
Notable too for their relative stability of sign and mag-
nitude are the coefficients for three variables, RELEASE, 
LIFESALE and ORIGIN. 
How are these results to be interpreted? The var-
iables MULTI and TCLASS can be discarded immediately because 
they both change sign twice in four periods, and do not 
in any period have values which are statistically signif-
icant at the 5 per cent level. The variables AVSALES 











Correlation Coefficients with AVLAG for products released 
during four time periods 
1956-61 1961-66 1966,..;.71 
AVLAG AVLAG AVALG 
l. 0000 1.0000 l. 0000 
0.2945 -0.0209 0.0738 
.... 0.1364 -0.1885 -0.1077 
-0.1548 -0.1930 _-0 .1084 
-0.2195 -0.1643 .-0.1878 
0.3154 0.2806 0.2120 
-0.1630 -0.0327 0.0850 
0.1620 -0.2944 -0.0077 
-0.4469 -0.0787 -0.2294 
n = 31 n = 68 n = 56 
24. The full matrices of all correlation coefficients are 


















the four periods. The coefficients have a negative sign 
ai hypoth~sized for the first three periods, changing to 
positive sign in the f£nal period. However while AVSALES 
has a correlation coefficient of significant magnitude in 
the second period, NUMSALES coefficient is stati~tically 
significant at the 1 per cent level.in the first and third 
periods. If the results for the last period are ignored 
then there may be claimed to be some modest amount. of 
evidence to support the hypotheses regarding AVSALES and 
NUMSALES. But the rapid change in size of coefficients 
for NUMSALES between first, second, and third periods 
indicates that it is not a consistently good predictor of 
diffusion speeds. Equally the diminutive size of the 
AVSALES coefficient suggests that, perhaps because of the 
nature of the data, it is not a powerful predictor of dif-
fusion speeds. 
LIFESALE, the synthetic variable manufactured to 
test further the expected sales - diffusion speeds hypothe-
sis performs in almost identical fashion to AV$ALES for 
the first three periods. In the concluding period it is 
of the hypothesized sign and reaches its greatest magnitude, 
' 
-0.2584, which is statistically significant,(one tailed 
test), at the 1 per cent level. The consistency of these 
results provides evidence of a relationship as hypothesized, 
between expected sales and AVLAG. Products with greater 
sales, (as measured by this variable), do appear to diffuse 
more rapidly on average than do their lesser selling 
269. 
counterparts. The hypothesis is not rejected. 
What of the therapeutic importance variable, TADVANCE, 
how does it fare? The correlation· coefficients are of the 
hypothesized positive sign and of sufficient magnitude to 
be statistically significant at the 1 per cent level in 
both the first and last periods. The correlation coeffic-
ients in the intervening two periods are effectively zero. 
It is tempting to conclude that there is evidence of a 
relationship as hypothesized between therapeutic advance 
and diffusion speed, and that this relationship becomes 
most manifest in the final period. This could be con-
strued as evidence that the wo~ld's regulatory bodies, and 
the pharmaceutical companies, have combined to ensure that 
the more important pharmaceutical products are made avail-
able more rapidly, during the later stages of the research 
period than are less important products. As the Appendix 
Table A.l makes clear, the sharp increase in magnitude of 
the TADVANCE - AVLAG correlation coefficient accompanies· 
an increase in TADVANCE - LIFESALE coefficient, but occurs 
despite a change from positive to negative sign coefficient 
between TADVANCE and RELEASE. The increase in magnitude 
of the TADVANCE - AVLAG correlation coefficient occurs for 
reasons other than the time series effect and may well 
indicate an increasingly important relationship between 
therapeutic advance and diffusion speeds. 
The correlation coefficient for the final two var-
iables, RELEASE and ORIGIN, differ in: sign; change 1n 
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magnitude; and ease of explanation. There has undoubtedly 
been a steady increase in speed of diffusion throughout 
the study period. Thus the RELEASE - AVLAG coefficient 
has a negative sign throughout the four sub periods. The 
ORIGIN - AVLAG coefficient on the nther hand steadily 
diminishes in magnitude throughout the two decades studied. 
Whatever the explanation for the observed relationship it 
appears that country of first launch for products has 
ceased to play an important part in determining diffusion 
speeds of pharmaceutical produ6t~ in the 1970's. No matter 
where products.were first launched in the 1970's they tended 
to diffuse at similar speeds. 
How successfully can diffusion speeds be predicted 
by use of these variables in multiple regression analysis? 
Confining the regression to use of four variables, produces 
the results displayed below. 
1956-1961 











R Square = 0~2919, Adjusted R Square • 0.1789, 
Standard Error = 25.21023 
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1961-1966 











R Square = 0.18764, Adjusted R Square = 0.1412 
Standard Error= 18.8720 
1966-1971 









R Square = 0.1365, Adjusted R Square = 0.0701 
















R Square = 0.4297, Adjusted R Square= 0.03347 
Standard Error= 5.9698 
Significant at the 5 per cent level 
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It is evident that ability to predict diffusion speeds by 
use of four variables is not great, the highest R squared 
achieved is 0.429~ ·in the final sub-period. Thus within 
the sub-periods, influences other than those captured by 
the variables used in this study appear to be major deter-
m±nants of the speeds of diffusion of these products. When 
a multiple regression analysis is conducted for the entire 
twenty-one year period the following results are derived. 













R Square= 0.2959, Adjusted R Square = 0.2738 
* Significant. at. t.he 5 per cent level 
Use of five variables in this regression analysis results 
in approximately 30 per cent of the variation in~diffusion 
speeds being explained by variations in the five independent 
varibles. This is not a particularly impressive result, 
but it is to be expected in the light of the preceding 
analysis of variance and correlation coefficient analysis. 
/ 
As expected only the two variables RELEASE and ORIGIN are 
statistically significant explanatory variables for AVLAG. 
Speeds of diffusion of these sample pharmaceutical products 




Three primary hypotheses regarding speeds of dif-
fusion of pharmaceutical products are tested to determine 
whether they are useful predictors of diffusion speeds. 
There appears to be no evidence to support the hypothesis 
that products marketed by firms with the most extensive 
distribution channels, diffuse any more rapidly than do 
products marketed by smaller companies who are presumed to 
have less well developed overseas marketing structures. 
It was hypothesized that products w1th greater expected 
sales would diffuse more rapidly than their less prpmising 
counterparts. Attempts to test this hypothesis revealed 
a moderate sized but consistent tendency for this to occur. 
Do products which are pharmacologically the most 
important diffuse more rapidly than do "me-toos" ? The 
evidence is somewhat mixed but a correlaLion coefficien·L 
of magnitude 0.3896 in the final sub-period studied, sug-
gests that therapeutic advance played an increasingly 
important part in .determining diffusion speeds. When 
four auxiliary hypotheses are tested no evidence is found 
to suggest that products from different therapeutic clas-
ses diffuse at differing speeds. Products which diffuse 
most widely do not appear to consistently diffuse more 
rapidly than do products marketed in fewer countries. 
For reasons which at present can only be guessed at,dif-
fusion speeds appear to vary depending upon where products 
are first marketed. This influence appears to diminish 
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in importance throughout the period. A consistent trend 
throughout the twenty-one year peiod, as measured in this 
project, is for diffusion speeds to increase. This tendency 
dominates all other influences on diffusion speeds. This 
time series effect appears to occur simultaneously with a 
tendency for lag time between first patent date and first 
launch date to increase. At.tempts to explain diffusion 
speeds using several variables in multiple regression 
analysis achieve only modest success. Typically, less 
than 50 per cent of the variation in diffusion speeds of 
these pharmaceutical products can be explained linearly 
by the variables employed in this study. 
C H A P T E R 6 
EXTENT OF DIFFUSION OF PRODUCTS 
(0) INTRODUCTION 
The hypotheses propounded on the extent of diffusion 
of pharmaceutical products are analogous to the hypotheses 
about speed of diffusion, and which are tested in chapter 
five above. The analysis of factors causing variations in 
extent of diffusion follows a similar pattern to the 
analysis of factors causing variation in speeds of diffusion. 
The term "extent of diffusion" is used to describe 
the number of countries in which products are marketed. 
Almost certainly many ·of the 190 sample products will be 
marketed in many more countries than the eighteen included 
in this research project. The expectation is that the 
data used here is representative for the extent of diffusion 
of all products to all markets. Thus the important feat-
ure which it is hoped the data displays is relative dif-
ferences in the extent of diffusion. 
There are two possible measures of extent of dif-
fusion available to this research study. The first is a 
variable labelled NUMDATES, which is a count of the number 
of countries where introduction dates have been recorded 
for each product. The second variable, labelled NUMSALES, 
is a count of the number of markets in which sales figures 
have been recorded for each product. The I.M.S. audits of 
the various pharmaceutical markets frequently list products 
and their sales figures without also listing their first 
introduction dates. Thus NUMSALES for a product are 
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invariably as large and often of greater magnitude than 
are NUMDATES values. NUMSALES is a superior indicator of 
extent of diffusion and consequently is the variable used 
for that task. 
The hypotheses postulated were : 
1. Drugs embodying greater therapeutic advance 
will, other things being equal, diffuse more 
widely than will products embodying more 
modest therapeutic advance. 
2. Products with greater expected sales will, 
other things being equal, diffuse to more 
markets than will products with lower 
expected sales. 
3. Products marketed by firms with extensive 
marketing infrastructures will, other things 
hP. i.ng P.qnal, diffuse more widely than will 
products marketed by firms lacking extensive 
marketing infrastructures. · 
4. Products with therapeutic actions which are 
universally required will, other things being 
equal, diffuse more widely than will products 
with more geographically confined demand. 
(1) TESTS OF THE HYPOTHESES 
Is there substantial variation in the NUMSALES 
values which needs to be explained? The frequency distrib-
ution of NUMSALES values is exhibited in Table 6.1 below. 
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TABLE 6.1 
Frequency Distribution of NUMSALES 
Relative Cumulative 
NUMSALES Number of Frequency Frequency 
Values Products % % 
3 16 8.42 8.42 
4 6 3.16 11.58 
5 12 6.32 17.90 
6 15 7.89 25.79 
7 11 5.79 31.58 
8 14 7.37 38.95 
9 5 ·2.63 41.58 
10 4 2.11 43.69 
11 15 . 7. 89 51.58 
12 19 10.00 61.58 
13 1?. 6.32 67.90 
14 10 5.26 73.16 
15 15 7.89 81.05 
-
16 10 - 5.26 86.32 
17 8 4.21 90.53 
18 18 9.47 100.00 
Sample 
Total 190 100.00 
How successful are the hypotheses in explaining these 
variations in extent of diffusion? First the role of 
TADVANCE (therapeutic advance rating) is examined, again 
using the TADVANCE ratings employed in chapter five above. 
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The mean NUMSALES were computed for the five TADVANCE 
classes and are shown in Table 6.2 below. 
TABLE 6.2 
Mean NUMSALES values for TADVANCE classes 
Standard 
TADVANCE Number of Mean Deviation 
Rating Products NUMSALES NUMSALES 
1 5 15.0000 3.0822 
2 28 10.9643 5.0661 
3 62 12.0161 4.5610 
4 87 9.5057 4.5594 
5 8 8.8750 2.9490 
Sample 
Total .190 10.6842 4.7415 
There appears to be some evidence that products assessed 
as embodying greater therapeutic advance at time of launch 
do diffuse to more markets than do their less lustrous 
fellows. Are these differences statistically significant? 
Analysis of variance and tests of linearity results are 
as below. 
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Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. Sig. 
Between Groups 400.482 4 100.121 4.813 0.0010 
Linearity 255.908 1 255.908 12.301 0.0006 
Dev. from 144.574 3 48.191 2.317 0.0772 
Linearity 
R=0.2454 R.Squared = 0.0602 
Within Groups 3848.570 185 20.803 
Eta·- 0.3070 Eta Squared = 0.0943 
Clearly there is a highly significant relationship·between 
TADVANCE ratings and extent of diffusion as measured by 
NUMSALES. However, in an all too familiar outcome the 
amount of variation in NUMSALES explained linearly by this 
independent variable is only 6 per cent of the total. The 
Eta squared value indicates that only 9 per cent of the 
variation is explained in total by TADVANCE ratings. 
Is this result influenced by a time series trend of 
the sort which was discovered in the speed of diffusion 
analysis, or by collinearity between TADVANCE and other 
variables? First order partial correlations were run to 
check for collinearity, controlling for ORIGIN, AVSALES, 
MULTI, and RELEASE. The outcome of these procedures is 
shown in Table 6.3 below.· 
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TABLE 6.3 
First order partial correlation coefficients, 
NUMSALES - TADVANCE 
Controlling for D.F. Coefficient Significance 
ORIGIN 187 -0.2458 p = 0.000 
AVSALES 187 -0.2217 p = 0.001 
RELEASE 187 -0.2549 p = 0.000 
MULTI 187 -0.2467 p = 0.000 
Controlling for these four variables, linearly, appears to 
make almost no difference to the correlation coefficients. 
Thus there does appear to be a statistically significant 
association between TADVANCE and NUMSALES values. Is this 
relationship constant throughout the twenty-one year period? 
The correlation coefficients between these two variables in 
the four sub-periods studied in chapter five, i.e. 1956-61, 
1961-66, 1966-7l, 1971-76, are:-0.4867; -0.2067;, -0.2658, 
1 
-0.1693. These results confirm that ·there is an inverse 
relationship, as hypothesised, between TADVANCE and NUMSALES. 
The apparent decline in magnitude of correlation coeffic-
ients between the first and subsequent sub~periods sho~ld be 
treated with some caution. There is likely to be a bias 
against greater magnitude TADVANCE - NUMSALES correlation 
1. The coefficient for the period 1956-61 is statistically 
significant at the 1 per cent level, the coefficient for 
1966-71 statistically significant at the 5 per cent 
level (one tailed test). 
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coefficients in the later sub-periods because of the lesser 
amounts of time during which diffusion could occur. This 
may reduce NUMSALES values for the high TADVANCE rating 
products, which given time, would diffuse to many countries. 
The consistent negative sign and statistically sig-
nificant magnitude of the correlation coefficient between 
TADVANCE and NUMSALES indicates that therapeutic advance 
does influence extent of diffusion of pharmaceutical 
products in the manner hypothesised. 
Do the sales levels products are expected to 
achieve, influence how widely products disseminate? Again 
we have to use AVSALES and LIFESALE values as surrogates 
for expected sales. The correlation coefficients between 
NUMSALES and these two sales variables are as below. 












There does appear to be a relationship of the form hypo-
thesised between NUMSALES and sales levels of these pro-
ducts. Again two forms of tests were conducted to ensure 
that these results did not occur because of some chance 
factors. Three first order partial correlation coefficients 
were calculated controlling for age of product, country of 
first release, and therapeutic rating. 
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TABLE 6.4 
First order partial correlation coefficients, 
NUMSALES - AVSALES 
Controlling for Coefficient D.F. Significance 
RELEASE 0.3403 187 p = 0.000 
'- ORIGIN 0.3307 187 p = 0.000 
TADVANCE 0.3133 187 p = 0.000 
Clearly controlling for these three variables in this 
linear manrier does not cause any substantial alteration to 
the coefficients computed. 
What of the effect of splitting the twenty-one 
year period studied into four sub-periods? The correlation 
coefficients are shown in Table 6.5 below. 
TABLE 6.5 
Correlation Coefficients for four sub-periods, 
NUMSALES Sales Variables 
-
Sub-Period Number of NUMSALES-AVSALES NUMSALES-LIFESALE Products 
1956-61 31 0.5410 ** 0.5287 ** 
1961-66 68 0.3512 ** 0.3386 ** 
1966-71 56 0.2327 ** 0.2490 ** 
1971-76 35 0.4329 -** 0.2508 ** 
** - Significant at the 1 per cent level (one tailed 
test) 
While there is some variation in magnitude of the coeffic-
ients computed, in all periods they are of statistically 
significant 
283. 
size and of the sign hypothesized. Thus there seems to be 
plenty of evidence suggesting that expected sales values do 
influence the extent of diffusion of pharmaceutical products. 
The hypothesis that products with greater expected sales will 
be ~arketed in more countries than will products with lower 
expected sales is not rejected. The sales variables 
employed, AVSALES and LIFESALE, appear to be capable of 
explaining up to 29 per cent of the variation in NUMSALES 
within a sub-period, and up to 13 per cent of the total 
variation in NUMSALES over the full twenty-one year period. 
It was hypothesized that drugs marketed by companies 
with extensive marketing networks would diffuse more widely 
than would products marketed by companies lacking in these 
multi-country marketing infrastructures. Using the 
variable MULTI, the impact of company size on extent of 
2 diffusion is analysed. MULTI classifies companies which 
first launch products on the basis of how many products 
they first launch. The mean NUMSALES values for each 
MULTI class are exhibited in Table 6.6 below. Does class-
ifying products in this way help to explain variations in 
extent of diffusion? Analysis of variance and test of 
linearity results are as below. 




Mean NUMSALES values for Products Grouped by MULTI 
Classification 
MULTI Number of Mean Standard Deviation 
Classification Products NUMSALES NUMSA'LES 
9 9 15.4444 3.0867 
8 32 11.4063 4.4927 
7 7 13.2857 2.9277 
6 6 9.5000 6.8044 
5 15 11.8000 4.9598 
4 40 10.4250 4.2540 
3 30 10.1333 5.1577 
2 18 11.3333 5.0176 
1 33 8.3030 4.0038 
Sample 190 10.6842 4.7415 
Total 
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Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. Sig. 
Between Groups 501.572 8 62.686 3.028 0.0032 
Linearity 8.903 1 8.903 0.430 0.5128 
Dev. from 492.668 7 70.381 3.399 0.0020 
Linearity 
R=0.0458 R. Squared :0.0021 
Within Groups 3747.481 181 20.704 
Eta ;:; 0.3436 Eta Squared = 0.1180 
These results ·indicate that there is a slight tendency for 
products first launched by companies which are the most 
frequent launchers of new products, to diffuse to more 
markets than do products first launched by firms who less 
frequently launch new products. This tendency appears to 
be statistically significant, but the variable MULTI has 
aninconsequential amount of explanatory power here. Thus 
classifying pharmaceutical products on the basis of 
frequency with which the first launch company does launch 
new products, appears to contribute very little to 
explaining why the extent of diffusion differs between pro-
ducts. Is this result due to blurring of the relation-
ship between NUMSALES and MULTI by the time series effects 
in the data? Breaking the twenty-one year period into 
the four sub-periods previously used in this research, 
reveals there have been changes in the relationships bet-
ween NUMSALES and MULTI. 
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TABLE 6.7 
Correlation Coefficients for four sub-periods, 
NUMSALES with MULTI 
Sub-Period Number of Correlation 
Products Coefficient 
1956-61 31 0.3919* 
1961-66 68 0:1078 
1966-71 56 -0.0835 
1971-76 35 -0.1345 
* - Statistically significant at the 5 per cent 
level (one tailed test). 
Only one of these coefficients is statistically significant 
at the 5 per cent level. More interesting is the decline 
in magnitude, and change in sign of the coefficient over 
time. It is difficult to think of an explanation why 
such change should occur. The safest conclusion to 
draw is that there is no evidence of a consistent tendency 
for products first launched by firms with high MULTI 
ratings to diffuse more widely than do products launched 
. 3 
by firms with low MULTI rat1ngs. 
An alternative means of classifying firms is by 
their total world sales figures. The seventy-two firms 
3. A high rating in this instance, is a rating such as 
eight or nine, a low rating, one, two or three. 
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who first launched the 190 sample products were subdivided 
on the basis of their rankings in the 1970 listing of 
total world sales. The seventy-two firms were divided 
into three groups, those in the top twenty ranks, those in 
ranks twenty-one to forty, and those below rank forty.' 
Products launched by firms in each of the three groups have 
known NUMSALES values. These were averaged and the results 
are shown in Table 6.8 below. 
The expectation is that the companies with largest 
sales will have the most highly developed international 
marketing infrastructures and thus will market products 
they first launch more extensively than do companies with 
smaller total sales, and it is conjectured, less extensive 
international marketing infrastructures. However, as 
Table 6.8 illustrates, these expectations are not matched 
by reality. The mean NUMSALES values for the three groups: 
11.340i 11.228; and 9.360, do not indicate that there is a 
marked tendency for products first marketed by firms with 
the largest world sales, to be marketed in more countries 
than are products first m~rketed by firms with lower world-
wide sales. Thus the extent of diffusion of pharmaceutical 
products does not seem to be influenced by the size of 
the first launch company. It may be of course that the 
methods of classification used here: number of products 
firms launch; and total world sales rankings, are poor 
proxies for the level of international marketing infra-
structure these firms have. If that is so then the tests 
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TABLE 6.8 
Means of NUMSALES for products first 
·launched by firms in 1970 sales ranks groups 
Ranks 1-20 Ranks 21-40 
Number Number 
Firm of Mean Firm of Mean 
Name Products NUMSALES Name Products NUMSALES 
Roche 9 15.444 Boeh Ing. 2 17.500 
M.S.D. 8 14.625 Wellcome 4 15.250 
Hoechst 3 15.333 Beecham 5 11.000 
Ciba 8 12.875 Searle 3 12.000 
Geigy 2 13.000 J.&Johnson 1 8.000 
Wyeth 4 8.000 R. Merrell 2 11.500 
Lilly 3 "9.667 Lepetit 1 18.000 
Pfizer 4 12.000 Astra 4 9.500 
Warner 2 4.500 Carlos-Erba 1 11.000 
Sandoz 5 11.400 I.C.I. 6 9.500 
Upjohn 4 11.250 Syntex 2 14.500 
Abbott 1 3.000 Nicholas 1 3.000 
Squibb 8 8.000 Fisons 2 8.000 
Bayer 5 - 13.000 Reckitt & 1 3.000 
- Colman 
Bristol 3 9. 333 . 
Glaxo 8 10.125 
May & 3 4.666 
Baker 
Schering 7 13.285 
Lederle 3 11.333 
S.K.F. 4 8.250 
Sub group 94 11.340 Sub group 35 11.228 
Total Total 
Ranks 41+ 
38 Firms, 61 Products, Mean NUMSALES - 9.360 
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conducted above may not provide any real test of the 
hypothesis. As no better information is available on infra,.. 
structures of individual firms, this is a possibility that 
has to be accepted. 
The fourth hypothesis is that the extent of diffusion 
of pharmaceutical products varies depending upon the thera-
eputic class of products. It is argued that some products 
will be marketed in relatively few markets because their 
pharmacological properties are required in only a few count-
ries, whereas other products may have universally useful 
indications. 4 When the 190 sample products are grouped into 
twelve broad therapeutic classes, the mean NUMSALES values 
shown below can be computed. Visual inspection of the data 
contained in Table 6.9 indicates there is little evidence of 
variation between classes in extent of diffusion, and this 
is confirmed by the analysis of variance results. There 
appears to be no significant differences in the extent of 
diffusion between products in the various therapeutic 
classes. Grouping products by therapeutic class, on the 
broad basis employed here, does not assist in explaining var-
iations in extent of diffusion. 
4. A product is, in medical terms, said to be ''indicated 11 
if it has pharmacologic properties which are useful in 
that particular case. ''Contra-indications II are cases 
where there are overriding factors which prevent use of 
the product despite it having properties which would 




Mean NUMSALES for products in twelve therapeutic 
classes 
Therapeuti"c Number of Mean Std. Dev. 
Class Products NUMSALES NUMSALES 
A 22 9.7727 3.9271 
' 
B 2 14.5000 4.9497 
c 38 10.2105 5.2203 
D 14 8.9286 4.2511 
G 19 11. 6316 4.1259 
H 3 8.6667 5.5076 
.. 
J 23 12.9130 5.0264 
M 12 10.1667 5.2541 
N 35 10.9429 4.5306 
R 17· 10.4118 5.1242 
s 3 7.6667 0.5774 
.... 
v 2 12.0000 5.6569 
Sample 190 10.6842 4.7415 
Total 
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Analysis of variance 
sum of Mean 
Source sg:uares D.F. Sguare F. Sig. 
Between Groups 280.194 11 25.472 1.142 0.3311 
R. = 0.0625 R Squared = 0.0039 
Within Groups 3968.858 178 22.297 
Eta· = 0.2568 Eta Squared = 0.0659 
It might be objected that the classification system 
employed, which is based on the I.M.S. thirteen class system, 
is too crude to catch the variations in NUMSALES due to 
differences in indications. Thus the fact that products in 
the class N for example have a mean NUMS.ALES value of 10.9429 
may disguise the fact that products in subclasses within the 
broad class may vary greatly in their NUMSALES values. 
This is of course, quite correct, but subdividing products 
into seventy-two subclasses does little to improve the 
results. These are shown below. 
Analysis of Variance 
Sum of Mean 
Source. Squares D. F. Square F; Sig. 
Between Groups 1643.542 71 23.148 l.048 0.4052 
R = 0.0623 R Squared = 0.0039 
Within Groups 26505.511 118 22.081 
Eta = 0.6219 Eta Squared = 0.3868 
Clearly, dividing the sample products into these seventy-
two subclasses does not assist in explaining linearly var-
iations in NUMSALES. mhe majority of variation occurs 
within sub-
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classes as the Eta squared statistic indicates. In effect 
the therapeutic class of products does not appear to be a 
useful predictor of the extent of diffusion for these 
pharmaceutical products. 
So much for the tests of the basic hypotheses on the 
extent of diffusion. What alternative hypotheses can be 
proposed for test? In Chapter S,age, nationality, and 
NUMSALES of products were examined to determine whether 
they helped explain the variation in speeds of diffusion. 
A similar approach is pursued in the analysis of extent of 
diffusion. Thus it is hypothesized that age of products, 
nationality - or country of ORIGIN of products, and the 
speed of diffusion of products will influence their extent 
of diffusion. 
The analysis of speeds of diffusion data revealed 
that there was evidence of a strong time series effect 
influencing AVLAG values. The later during the twenty-one 
ye.ar study period that drugs were first released the 
faster was their speed of diffusion. A similar pattern may 
exist in the data on extent of diffusion. Thus a check is 
conducted to determine whether there is evidence of a time 
series effect on the extent of diffusion. 
It is hypothesized that nationality, (or ORIGIN), of 
products, may influence the number of markets in which pro-
ducts are sold, because pharmaceutical industries of various 
countries differ in the degree to which they are inward 
looking. To give examples, the French pharmaceutical 
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industry is reputed to be particularly inward looking, 
while the Swiss pharmaceutical indistry is reputed to be 
particularly internationalist in outlook. The data is 
examined to see whether these impressions are accurate. 
In the analysis of speed of diffusion, NUMSALES was 
employed to determine whether it was a useful predictor of 
diffusion speeds. There was found to be a weak relation-
ship between extent and speed of diffusion of pharmaceutical 
products. Thus AVLAG can be expected to be a weak predic-
tor of NUMSALES also. Tests are conducted to determine 
whether these three auxiliary hypotheses are supported by 
the data. 
Is there a time series effect influencing the data 
on extent of diffusion?
5 
No dramatic changes in extent 
to which drugs diffuse can be detected from the data in 
Table 6.10. In this table drugs are grouped by year of 
first release and mean NUMSALES values for each cohort of 
products are computed. Examination o~_ the data suggests 
there is a tendency for later-released products to -diffuse 
to fewer markets than do their older fellows. The correl-
ation coefficient between NUMSALES and year in which the 
product is first launched, (denoted by the variable AGE), 
is 0.2288, which confirms the impression gained by visual 
inspection of the data. But this apparent tendency for 
5. Appendix Table A.lcontains matrices of correlation co-
efficients between NUMSALES and the variables employed 
in this chapter, for each of the four sub-periods. 
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'I'ABLE 6.10 
Mean NUMSALES for ~roducts first launched in years 
1956-1976 
Year of Number 
First of Mean Std. Dev. 
Launch Products NUMSALES NUMSALES 
1956 1 6.000 0.000 
1957 3 13.3333 2.0817 
1958 2 6.0000 1. 4142 
1959 6 13.3333 5.9889 
1960 9 10.8888 3.1798 
1961 23 11.6522 4.7636· --
1962 8 10.6250 3.7009 
1963 10 13.1000 5.2799 
1964 13 11.4615 5.5320 
1965 11 12.0000 3.0984 
1966 15 10.0667 5.0493 
1967 12 10.8333 4.9144 
1968 14 12.0000 4.8516 
1969 9 11.3333 5.4083 
1970 9 11.8888 5.0360 
1971 11 8.6364 4.7175 
1972 9 9.1111 4.8074 
1973 12 9.3333 4.1194 
1974 7 6.5714 2.8200 
1975 3 4.7500 1.5000 
1976 3 8.5000 3.5355 
Sample 190 10.6842 4.6197 
Total 
295. 
later-released products to be marketed in fewer markets is 
st~tistically non-significant, and can be readily explained 
away. Diffusion takes time to occur, and the older products 
have had more time in which to diffuse to a greater number 
of markets than have the younger products, and thus could 
be expected to have greater NUMSALES values. Given that the 
mean AVLAG time for these products if over forty months we 
should ignore the mean NUMSALES figures for the final 
three years shown in Table 6.10. If products released in 
1975, 1975 and 1976 are excluded from consideration then 
mean NUMSALES values for the remaining cohorts of products 
appear to be very nearly constant. 
Examination of the correlation coefficients between 
NUMSALES and RELEASE during the four sub-periods prevelas a 
change from a modest-sized positive-sign coefficient, to a 
moderate-sized negative-sign coefficient. 
The coefficients for the four sub-periods are : 
0.14100; 0.01395; -0.07895, -0.24153. Again this trend, it 
may be argued, relfects the effect of diminished amounts 
of time for later-released products to diffuse to as many 
markets as do their earlier released fellows. There appears 
to be little reason to believe that there is a significant 
time series effect influencing NUMSALES values. However, as 
the data ~tands at present, age of products does appear to 
have some limited ability to explain variations in the 
NUMSALES values recorded for these sample products. Data on 
NUMSALES values collected for these same sample products, 
when they have all had sufficient time to diffuse to the 
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eighteen markets, may well reveal that products released 
during the 1970's were marketed as widely as products 
released during the 1950's and 1960's. 
Do products of differing "nationaltiy" vary in the 
extent to which they diffuse to the worlds markets? Assign-
ing nationalities to products on the basis of location of 
headquarters of the firm which first launched each product 
(NATNALTY), means NUMSALES values displayed in Table 6.11 
are produced. 
TALBE 6.11 
Mean NUMSALES for products of various nationalities 
(N:ATNALTY) 
NATNALTY 
Number of Mean Std. Dev. 
Products NUMSALES NUMSALES 
U.K. 32 9.5625 5.6622 
France 14 7.7143 3.4514 
Sweden 4 9.5000 4.9329 
Spain 3 7.0000 2.0000 
Italy 5 10.8000 4.5497 
w. Germany 24 13.6250 3.7044 
Netherlands 10 11.4000 3.2387 
Denmark ::-1 7.0000 0.0000 
Mexico 2 1'4.5000 2.1213 
Japan 1 12.0000 0.0000 
Australia 2 9.0000 8.4853 
U.S.A. 68 9.8676 4.5216 
Switzerland 24 13.5417 3.9889 
Sample 








R = -0.0808 
3534.824 






Square F. ~ 
59.519 2.980 0.0008 
R Squared = 0.0065 
19.971 
Eta Squared = 0.1681 
Before commenting on these results it is sensible to illus-
trate the results which are produced by assigning national-
ities to products on the basis of location of market where · 
they were first launched, (ORIGIN). 
TABLE 6.12 
Mean NUMSALES for products of various nationalities 
(ORIGIN) 
Number of Mean Std. Dev. 
ORIGIN Products NUMSALES NUMSALES 
U.K. 60 8.9500 5.0871 
Mexico 4 10.5000 2.8868 
Peru 3 14.0000 4.0000 
Brazil 4 12.5000 3.8730 
Arg~ntina 1 17.0000 0.0000 
Japan-- 2 14~5000 3.5355 
Indonesia 2· 9.5000 2.1213 
Philippines 1 13.0000 0.0000 
Belgium 9 13.4444 4.3044 
France 6 9.1111 4.1062 
w. Germany 26 14.0385 3.8312 
Italy 5 9.6000 2.5100 
Spain 6 8.3333 3.5590 
Australia 14 9.6429 5.2712 
New Zealand 5 11. 6000 4.0373 
U.S.A. 25 9.0400 3.7912 
Switzerland 14 14.0000 3.1132 
Sample 190 10.6842 4.7415 
Total 
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:R = 0.0211 
3281.830 









R Squared = 0.0004 
18.970 
Eta Squared = 0.2276 
What conclusions can be drawn out of this mass of figures? 
The most obvious features of the data are ; first, which 
ever way nationalities are assigned to products those products 
labelled 11 Swiss", or "German", on average diffuse more wid-
ely than do other products. Secondly, products labelled 
"British", "French", or "American" are marketed in fewer 
countries on average than are other products. 
These seem to be the only conclusions which can 
safely be drawn from this data. There are so few products 
of other nationalities that it would be dangerous to base 
-
conc~usions on the mean NUMSALES values computed for nat-
ionalities other than those already mentioned. 
The analysis of variance results suggest that while 
there are significant differences between these mean NUMSALES 
values, the explanatory value of both NATNALITY and ORIGIN 
is almost exactly zero. Are the correlation coefficients 
consistently low through the whole period? Dividing the 
twenty-one year period into the four sub-periods used pre-
viously, viz: 1956-61, 1961-66, 1966-71, 1971-76, produces 
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correlation coefficients between NUMSALES and ORIGIN of: 
-0.3684, -0.0002, -0.0955, 0.0140. Only the correlation 
coefficient in the first sub-period is of any consequence. 
It is statistically significant at the 5 per cent level. 
The overall picture is one of lack of explanatory power, 
combined with an impressionistic conclusion that products 
from Switzerland and West Germany diffuse more widely than 
do those products from the U.K., U.S.A., and France. The 
fact that products from these five countries appear to dif-
fuse to varying numbers of countries appears to contribute 
little to explaining why products differ in their extent of 
diffusion. 
In the analysis of speed of diffusion it was argued 
that NUMSALES values might be indicators of commerical 
success of products and thus useful predictors of speed 
of diffusion. A weak relationship between these variables 
was established in chapter five, and it is a simple matter 
to reverse the perspective and demonstrate that AVLAG is 
correlated with extent of diffusion. 
The correlation coefficient between NUMSALES and 
AVALG over the complete twenty-one year period is -0.0477 
which indicates only a very weak relationship exists 
between these two variables. Again breaking the period 
studied into four sub~periods the correlation coefficients 
are; -0.4469, -0.0787, -0.2294, and 0.2786 respectively. 
These coefficients indicate that for the first three sub-
periods the relationship is of the form hypothesized, but 
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the final sub~period coefficient casts some doubt on the 
validity of the claim that drugs which diffuse more rap-
idly also diffuse more widely. The most that could pru-
dently be claimed is that there is some limited evidence 
in support of the hypothesis. There appear to be no 
obvious explanations for the change in coefficient between 
the third and fourth sub-periods. 
How much of the total variation in extent of dif-
fusion can be explained by these variables in a multiple 
regression analysis?· Because of the changes in magnitude, 
and sometimes sign, of these variables over the whole twenty-
one year period it is again sensible to run separate reg-
ression analyses for each of the foursub-periods employed 
above. The regressions are confined to use of the four 
most successful variables and results are shown below: 
1956-1961 
NUMSALES = 16.8072 + 0.7780 AVSALES- 0.0448 AVALG 
(0.3535) (0.0242) 
(2.2008) * (1.8516)* 
- 1.4416 TADVANCE + 0.3473 MULTI 
(0.7619) (0.2314) 
(1. 892.1-) * (1. 5008) 
R Square = 0.5334, Adjusted R Square = 0.4556 
Standard Error = 3.3572 
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1961-1966 




- 0.7240 TADVANCE- 0.0035 AVLAG 
(0.6563) (0.0258) 
(1.1031). (0.1388) 
R Square= 0.1535, Adjusted R Square= 0.1051 
Standard Error = 4.4265 




- 0.0315 AVLAG- 0.0747 MULTI 
(0.0222) (0.2172) 
(1.4189) (0.3441) 
R Square = 0.1689, Adjusted R Square = 0.1049 
Standard Error = 4.6449 
NUMSALES = 8.7293 + 1.8649 AVSALES = 0.1984 AVLAG 
(0.5543) (0.0812) 
(3.3644)* (2.4433)* 
- 1.4464 TADVANCE - 0.3961 MULTI 
(0.5977) (0.2161) 
(2.4199)* (1. 8329) 
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R Square= 0.4492, Adjusted R Square= 0.3574 
Standard Error = 2.8988 
* Significant at the 5 per cent level. 
These results indicate that the relationships between extent 
of diffusion and these four variables are not constant 
throughout the total twenty-one year period. Only in the 
first and last sub-'periods are R Squares of useful magnitude 
produced. Thus, combined use of these four variables is 
only modestly successful in explaining variations in NUM-
SALES during the four sub-periods. Some of the comparative 
success achieved is attributable to use of the variables 
MULTI and AVLAG. These variables,as has been demonstrated 
in this chapter, have somewhat inconsistent relationship 
with NUMSALES. Thus the ability of the hypothesized var-
iables, AVSALES, TADVANCE, MULTI and AVLAG to explain varia-
tions in NUMSALES is not particularly impressive. 
When a multiple regression analysis for the ·corn-
plete twenty-one year period is conducted, using the same 
four variables, the results below are produced~ 
1956-1976 
NUMSALES = 13.2039 + 0.5316 AVSALES - 1.1513 TADVANCE 
(0.1186) (0.3702) 
(4.4822)** (3.1099)** 
+ 0.0846 MULTI + 0.0015 AVLAG 
(0.1148) (0.0125) 
(0.7376) (0.1200) 
R Square = 0.1549, Adjusted R Square= 0.1367 
Standard Error = 4.4054 
** Signficant at the 1 per cent level. 
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While this result cannot be taken too seriously because of 
changes in sign of some of the variables during the period, 
it does reinforce the impression already gained, that the 
variables employed here are not good predictors of ~xtent 
of diffusion of pharmaceutical products. 
(2) SUMMARY 
Four primary hypotheses about the factors influenc-
ing extent of diffusion of pharmaceutical products are 
tested in this chapter. The test.s conducted indicate that 
the sales levels achieved by products and >.the levels of 
therapeutic advance they embody are useful predictors of 
extent of diffusion. While the magnitude of the carrel-
ation coefficients between these independent variables and 
NUMSALES, the dependent variable, vary over the twenty-one 
year period, they do have the expected signs in all four 
sub-periods. Thus the hypotheses relating extent of 
diffusion to the sales and therapeutic advance variables 
are not rejected. The _third primary hypothesis tested, 
that products marketed by firms with extensive international 
marketing infrastructures will diffuse the most widely 
provides something of an enigma. The correlation coef-
ficient between the independent variable MULTI and NUMSALES 
is, in the first subperiod, of the hypothesized sign, but 
then declines in magnitude and changes sign in the third 
subperiod. The nature of the change may indicate that a 
fundamental change has occurred during the twenty-one year 
period, but without further testing no firm conclusion 
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about the change can be drawn. The data used to test this 
relationship is the least satisfactory of the data employed 
to test hypotheses in this chapter, but on the basis of the 
tests conducted here, there appears to be little evidence 
to support the existing hypothesis. While it is true that 
products of different "nationalities" and products with 
'different pharmacological qualities vary in their extent of 
diffusion, the "nationality" of products, and their thera-
peutic indications, are not useful predictors of extent of 
diffusion.· 
There is evidence that products released in the 
finalsub~perioddiffuse to fewer markets than do their 
earlier released products, but this is argued to be evidence 
of a lack of time for these later released products to dif-
fuse to as many markets as have earlier released products. 
Thus there is argued to be no conclusive evidence of a time 
trend affecting the extent of diffusion data. There is some 
limited evidence that those products which diffuse most 
rapidly, are also .the products which diffuse most widely, 
a result which appears to be in accord with the neo-classical 
tenor of the hypotheses postulated in this research project. 
Attempts to predict NUMSALES values by use of four 
variables in multiple regression analysis are not particu-
larly successful, the· best R squared obtained being 0.5334. 
Thus a considerable amount of variation in extent of dif-
fusion of pharmaceutical products remainsunexplained by 
the variables employed in this project. 
C H A P T E R 7 
DRUG LAGS PER COUNTRY 
(0) INTRODUCTION 
The perspective changes in this chapter. Attention 
is now focussed on the lag times between first launch of 
products and their dates of first launch in each of the in-
dividual markets. These lags between first worldwide 
launch, and launch in the individual markets, are aggregated 
for all products which are launched in each market, and 
mean lags per country are calculated for each country. 
The mean lags computed are denoted by the variable name 
NATLAG. The purpose of this chapter is to examine, and 
attempt to explain, variations in NATLAG between countries. 
Differences in NATLAG values between the U.S.A. and U.K. 
are the issue in the ''drug lag" debate described in chapter 
three above. One objective is to examine more closely 
the claimed explanations for the U.S.A. drug lag. 
Four hypotheses about determinants of NATLAG were 
postulated in chapter four. 
l Briefly the hypotheses were 
l. NATLAGS will be greatest where the time and monetary 
costs of gaining marketing approval are greatest. 
2. Countries with larger pharmaceutical markets will 
have shorter NATLAGs. 
1. These hypotheses are more formally stated in chapter 
four above. 
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3. Countries which are major sources of innovation of 
new pharmaceutical products will have shorter NATLAGs. 
4. Countries which have marketing environments least 
like those in the innovating countries will have 
longer NATLAGs. 
These hypotheses are tested below. 
(1) TESTS OF THE HYPOTHESES 
·Based on the diffusion data collected for the 190 
sample products, the NATLAG values for each country .are 
computed. NATLAG values are calculated by the following 
process. For each of the sample products actually mark-
eted in a country, the total number of months lag between 
first launch anywhere in the world, and launch date in 
the particular country being studied is calculated. The 
lags calculated for each product launched in that country 
are then aggregated, and divided by the total number of 
products launched in that country, to produce a mean lag 
time between world first launch date and launch date in 
the particular country. The mean lag times, henceforth 
known as NAT~AG for the eighteen sample countries, are 
shown together with the number of sample products actually 
launched in each country, in Table 7.1 below. 
In this chapter attempts are made to establish 
whether the variations in NATLAG shown above can be 























I I TABLE 7.1 
Mean Lag Time per Country (NATLAG) 
Mean Lag 
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Attention first centres on the time and monetary 
costs involved in obtaining marketing approval in the 
various countries. 2 Wardell and others , have argued that 
countries such as the U.S.A. which are claimed to have 
very exacting time-consuming regulations controlling the 
marketing of pharmaceutical products, suffer from a "drug-
lag" because these regulations delay the launch of new 
pharmaceutical products. In the terms used in this 
chapter, stringent marketing approval regulations are 
assumed to cause increases in the length of NATLAGS. 
Do countries with more stringent regulations, and 
thus high monetary and time costs to be met before market-
ing approval is obtained, have long NATLAGS? To test this 
hypothesis some procedure for rating countries regulatory 
systems is required. An attempt was made to establish 
stringency ratings for these eighteen countries regulatery 
systems by obtaining assessments of their stringency from 
industry sources. As representatives of the pharmaceutical 
companies are the people who have to guide new pharmaceutical 
products through the marketing approval regulations, they 
are obviously well qualified to comment on the toughness 
or otherwise of these regulations. Particularly, rep-
resentatives of multinational pharmaceutical companies who 
market new pharmaceutical products in many of the worlds 
2. See the references to and discussion of the literature 
on this debate in chapters three and four above. 
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markets are likely to be well placed to rate regulations 
for tightness or stringency. To assist with this task 
representatives of ten of the world's largest pharmaceut-
ical companies were asked to rate pharmaceutical marketing 
reg~lations in the eighteen countries studied. Specific-
ally representatives of these ten companies were requested 
to both rank countries regulations for tightness, or 
stringency, relative to the other survey countries, and 
also to provide regulatory tightness ratings for these 
eighteen countries. The letters sent to the represent-
atives of these companies included the following instructions: 
(a) The relevant period to the appraisal should be the 
3 early 1970's. 
(b) Please answer on a 1 to 5 scale,where 1 is the most 
tight and 5 is the least tight system. Appraisal· 
should be with reference to all the world'"S systems 
3. The early 1970's were chosen as the period for which 
appraisals should be made, for two reasons. First,it was 
known that changes had been made to some countries regu-
lations during the 1960's. These new regulations were 
believed to have caused substantial changes in the regu-
latory climate in those markets. It was hoped that the 
point chosen - early 1970's -would accurately describe 
the regulatory climate which prevailed in these markets 
during the 1970's. Second, for those markets where there 
had been no major changes in regulations during the 
period studied, assessment of the regulations near the 
middle of the twenty-one year period was hoped to pro-
vide some assessment of the "average" regulatory 
climate for the complete period. The fact that these 
regulatory assessments do relate to one period is shown 
below to be important when attempting to interpret the 
results of analysis. 
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and not just the selection of the countries above. 
Thus a one rating should not be given because the 
co"untry concerned has the tightest system of those 
listed above. This rating should only be given if 
is amongst the world's most restrictive regu~atory 
systems~· 
(c) Short notes indicating the main reason for the 
rating would be appreciated, e.g. country Y 
does not recognise foreign appra±sals. 
(d) Please put the countries in rank order of regulatory 
tightness. The country entered as number 1 will 
have the tightest system of those on the list. 
Country 19 will have the least restrictive system. 
Where countries are very similar in their regulatory 
outlook please give them equal rankings. Note 
unlike (b), the regulatory tightness rating, concern 
here is relative not absolute. Thus the country 
listed as one, is merely required to have a regu-
latory system which is the tightest of the countries 
4• 
on the list. 
It should be noted that no specific instructions were 
given on how to decide on the ratings and rankings. These 
are subjective assessments based on the experience of the 
companies in getting products launched on these markets. 
4. Extract from the covering letter sent to the 
pharmaceutical companies. 
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However the covering letter sent to these companies did sug-
gest that ... 
Factors likely to influence your appraisal of regu-
latory procedures may indclude: data requirements; 
procedures relevant to clinical trials; the number 
of stages and holdups at each stage; the degree of 
bureaucracy involved; attitudes towards foreign 
data or appraisals;:the quality of the review person-
nel and the level of co-operation and trust they 
exhibit toward the applicant; and adversary or 
positive attitude by the regulators; the average 
delay between application and marketing approval; 
5 and the type of product concerned. 
Seven of the pharmaceutical companies replied to the survey 
and their responses are shown in Tables 7.2 and 7.3. 
Several points about Table 7.2 require explanation. 
There are nineteen countries included in the table of rank-
ings. Switzerland was included in the list of countries to 
consider because it was believed that it might be an important 
reference country when companies were assessing both the rank-
ings and ratings for the eighteen survey countries. However 
as Switzerland is not included in the list of countries whose 
data is included in this study no overall rank or rating 
is computed for Switzerland. 
5. Extract from the instructions sent to the pharmaceutical 
companies. 
TABLE 7.2 
Rankings for Regulatory Tightness 
espon en s R d t 
Country A B c D E F G Sum of Mean Rank 
Ranks Rank 
U.K. 6 4 7 3 3 3 5 26.0 4.33 04 
Colombia 16 18' I 16 16.5 14.5 18.5 15 99.5 16.58 16 
Mexico 15 15 18 13.5 18 15 17 93.5 15.58 15 
Peru 17 16.5. 19 16.5 18 18.5 14 105.5 17.58 17 
Brazil 13 12 15 15 7 13 13 75.0 12.50 12 
Venezuela 7 5 5 10.5 16 13 10 56.5 9.41 10 
Argentina 11 8 11 13.5 7 9.5 9= 0.0 10.00 11 
Japan 1 2 2 2 3 1 2 11.0 1.83 02 
Indonesia 19 19 17 19 18 16.5 N.A. 108.5 18.08 18 
Philippines 18 14 13 18 14.5 16.5 12 88.0 14.66 14 
Belgium 10 10 8 7 5 9.5 8 49.5 8.25 07 
France 9 6 3 5 11 4.5 4 38.5 6.41 05 
West Germany 5 13 10 8.5 7 7.5 9= 51.0 8.50 08 
Italy 4 9 6 6 9 11 3 45.0 7.50 06 
Spain 12 16.5 14 10.5 13 13 N.A. 79.0 13.16 13 
Australia 3 3 4 4 3 4.5 6 21.5 3.58 03 
New Zealand 8 7 9 12 12 7.5 7 55.5 9.25 09 
U.S.A. 2 1 1 1 1 2 1 8.0 1.33 01 
Switzerland 14 11 12 8.5 10 6 16 61.5 10.25 N.A. 
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One responding company was unable to provide rankings 
for Indonesia or Spain. Thus response by Company G was 
not included in the assessments used to determine overall 
rankings and ratings for the eighteen countries. Where 
countries were given equal rankings, e.g. respondent E 
gave three countries rankings of seventeenth equal, the 
mean value of the rankings taken up by the equal ranked 
countries were given to each country. Thus two countries 
ranked tenth equal use up ranks ten and eleven and thus 
were each given ranking 10.5. Overall rankings were calcu-
lated for each country by summing the. rankings given by 
respondents A - F, dividing by six tb obtain a mean ranking 
I 
per country, then ranking countries on the basis of those 
mean rankings. Thus the country with the lowest mean 
ranking, U.S.A., was given an overall ranking of one, the 
country with the second highest mean ranking, Japan, was 
given overall rank two and similar procedures determined 
the remaining sixteen rankings. 
Are these rankings meaningful and useful? Visual 
inspection of the responses shown in Table 7.2 suggests 
there is a considerable degree of uniformity of rankings 
for each country. This impression is confirmed by stat-
istical test. The coefficient of concordance (\17) between 
,I 
responses lS 0. 85. 
The request that representatives of these companies 
both rank and rate regulatory systems in these countries 
was a deliberate policy. Whereas the rankings are rel-
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ative to other countries in the survey, ratings are 
global. The request for ratings was valuable because it 
indicated whether the eighteen countries regulatory systems 
cover the whole range of regulatory tightness. As Table 
7.3 illustrates survey ~ountries are represented on all 
ratings. Thus the complete range of regulatory tight-
ness is encompassed by the regulatory systems employed in 
the eighteen survey countries. 
Again some comment is required on this Table. 
Respondent company G was unable to provide a rating for 
Spain, so the responses of this company were.not used to 
determine overall ratings. The Swiss ratings are inclu-
ded for comparitive purposes only. Overall ratings for 
the eighteen survey countries were computed by summing 
the ratings given to each country by respondents A - F, 
and dividing by six to obtain a mean rating. Where these 
means were not integers they were rounded to integers by 
increasing their value if greater than or equal to x.S, 
and reducing their value if less than x.S. 
These assessments of regulatory tightness are used 
to test the hypothesis that countries where the time and 
monetary costs of gaining marketing approval are high, 
will, other things being equal, have long NATLAGs. Measures 
such as those described above - mean regulatory tightness 
rankings and ratings ~ are proxies for the time and mon-
etary costs of obtaining marketing approval in each 
country. These measures, henceforth labelled REGRANK 
TABLE 7.3 
Ratings for Regulatory Tightness 
Respondents 
Country A B c D E '· F G 
U.K. 2 1 3 2 2 1 2 
Colombia 3 5 5 5 4 4 4 
Mexico 3 5 5 4 5 4 4 
Peru 3 5 5 5 5 4 4 
Brazil 4 3 5 4 3 4 4 
Venezuela 2 2 2 3 4 2 3 
Argentina 3 3 4 4 3 3 4 
Japan 1 1 1 1 2 1 1 
Indonesia 5 5 5 5 5 4 4 
Philippines 4 4 4 5 4 4 4 
Belgium 3 3 3 4 3 2 3 
France 3 2 2 3 3 2 1 
w. Germany 2 4 3 4 3 2 3 
Italy 2 3 2 3 3 2 1 
Spain 3 5 4 4 4 3 N.A. 
Australia 1 1 2 3 2 1 2 
New Zealand 3 2 3 4 3 2 2 
U.S.A. 1 1 1 1 1 1 1 




































































and REGRATE, are based on subjective assessments of regu-
latory tightness. They are subjective assessments, they 
are for one point in time only, and they are provided by 
only six pharmaceutical companies. These three character-
istics are 1ess than desirable features of the ratings, but 
the ratings are used because they are the best information 
available for assessing regtilatory tightness. 
The REGRATE and REGRANK values for each count~y were 
tested to gauge their ability to explain variations in 
NATLAG. The first step in this procedure is to list 
countries by their REGRANK value togethe~ with their NATLAG 
values. These values are shown in Table 7.4. The hypo-
theses is that countries with low REGRANK's - those with 
the tightest regulatory systems - will have the longest 
mean lag times or NATLAG's. Examination of the data in 
Table 7. 4 suggests very strongly that this hypothesis :is 
not supported by the evidence. There appears to be a 
very strong inverse relationship between regulatory 
tightness rankings and mean lag times per country. If 
the mean lag times per country are also ranked, the country 
with the shortest NATLAG - the U.K. - being given NATLAG 
rank 1, and the country with the longest NATLAG -
Indonesia - being given NATLAG rank 18, then rank correl-
ation tests can be conducted between REGRANK and NATLAG 
ranks. 
A Kendall's rank correlation test reveals a correl-
ation coefficient of 0. 3464 which is statistically signif-
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icant at the two per cent level. A Spearman's test for 
rank correlation provides a coefficient of 0.4737 which 
has a 0.024 probability of occurring by chance. Thus 
the REGRANK values suggest that the hypothesis should be 
rejected. 
TABLE 7.4 
Comparison of REGRANKS and NATLAGS 
-NAT LAG NATLAG 
REG RANK (Months) Rank 
l 25.100 2 
2 45.663 ll 
3 33.185 4 
4 23.768 l 
5 45.936 13 
6 49.963 16 
7 36.710 8 
8 27.859 3 
9 37.358 9 
10 55.376 17 
ll 36.574 7 
12 43.670 10 
13 34.542 5 
14 45.854 12 
15 35.919 6 
16 48.942 15 
17 46.764 14 
18 60.212 18 
Classifying countries by REGRATE provides the results 
shown in Table 7.5 below. 
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TABLE 7.5 
Mean NATLAG per REGRATE 
Number of Mean NATLAG Std. Dev. 
REGRATE Countries (Months) NAT LAG 
1 2 35.3815 14.5402 
2 5 37.8852 10.4139 
3 4 39.3258 11.5443 
4 5 41.6054 6.5079 
5 2 53.4880 9.5092 
Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. ~ 
Between Groups 434.907 4 108.727 1.083 0.4047 
Linearity 318.689 1 318,689 3.175 0.0981 
Dev. from 116.218 3 38.739 0.386 0.7650 
Linearity 
R = 0.4280 R Squared = 0.1832 
Within Groups 1304.860 13 100.374 
Eta = 0.5000 Eta Squared = 0.2500 
Visual inspection of the data in Table 7.5 and the analysis 
of variance results confirm the conclusion reached over the 
REGRANK results. The countries with the most tight regu-
latory systems tend to have the shortest NATLAGs. Thus 
the analysis of variance result shows a correlation co-
efficient between REGRATE and NATLAG of +0.4280. This 
of course is of the opposite sign to that hypothesized, 
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which suggests that the hypothesis should be rejected. 
The variable REGRATE appears to be capable of single-
handedly explaining over 18 per cent of the variation in 
NATLAG values. While these results are not statistically 
significant, there is no denying their message that count-
ries with tight regulatory systems do not have long mean 
delays before drugs are launched in their markets. 
This is a stunning result which demands further 
investigation. It should immediately be pointed out that 
the hypothesis as postulated in chapter four does contain 
the contingency clause, •... "other things being equal ". 
So before rejecting the hypothesis out of hand it should 
be established that other things are equal. Second, it 
should again be pointed out that the regulatory tightness 
ratings are for one period, and may not accurately reflect 
the regulatory tightness over the whol~ period. Third, 
the NATLAG values to be explained are means of the lag times 
for all the sample products released in each country. 
-
The analysis in chapters five and six apove has clearly 
demonstrated that many of the relationships studied evolve 
throughout the study period. Particularly, a dominant 
feature of the data is the tendency for later released 
products to diffuse more rapidly, have shorter AVLAGS, 
than do earlier released products. The mean diffusion 
lag times per country - NATLAGS - may disguise the fact 
that there are absolute and relative size changes occurring 
in NATLAGs over the twenty-one year period. Thus the 
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effect which it is hypothesized regulatory tightness will 
have on NATLAG's, may occur but be concealed by the use 
of summary statistics such as NATLAG. 
Testing the last of these possibilities first, what 
changes occur when NATLAG's are computed for each of two 
sub-periods? The NATLAG's were computed for each country 
for those products whose first worldwide launch was before 
January 1, 1969 and those products first launched after 
that date. This date was chosen as the dividing line 
beteween sub-groups because it is believed to approximate 
the point when significant changes in diffusion speeds 
occurred. Table 5.14 suggests a noticeable change in 
AVLAGs occurred at about this time. January 1, 1969 
is also a convenient dividing line to use because although 
it is not too distant from the period to which the regu-
latory tightness assessments refer, i.e. early 1970's, it 
is still sufficiently near the middle of the study period 
for one third of the sample products to be first launched 
after that date. Thus there are sufficiently large num-
bers of sample products in both sub-groups for comparis-
ons to be made. 
Table 7.6 below lists the NATLAG's per country in 
each sub-period, the number of products launched in each 
country in each sub-period, and shows the change in NAT-



















New Zealand 42.124 
U.S.A. 24.889 
TABLE 7 .'6 
NATLAGs per Co:untry for Drugs Launched in two 
sub-periods 
Pre 1969 Post 1968 
NUMPROD LAG RANK NATLAG NUHPROD LAG RANK 
!2'7 3 11.365 63 1 
59 13 37.963 27 18 
61 8 24.289 38 6 
37 14 31.167 18 14 
66 12 21.903 31 4 
70 17 29.467 15 12 
67 6 25.630 27• 8 
67 10 36.105 19 17 
36 18 20.875 16 3 
56 16 25.364 33 7 
81 9 18.581 43 2 
75 11 31.382 34 15 
62 2 27.733 30 10 
73 15 32.912 34 16 
75 5 24.406 32 5 
83 4 31.049 41 13 
97 7 28.294 51 11 
54 1 25.813 16 9 























Clearly there are some dramatic changes in NATLAG 
between the two periods. The general trend of a marked 
reduction in NATLAG's in the second period has exceptions 
only in the cases of the U.S.A., Australia, and West Germany, 
the NATLAG for the U.S.A. actually increasing in the second 
period. 
Some remarkable changes in LAGRANK also occur bet-
ween periods. LAGRANK is the rank given to each country 
on the basis of its NATLAG value, the country with the 
shortest NATLAG being given LAGRANK one. Brazil changes 
from .LAGRANK twelve to LAGRANK four, Indonesia from LAGRANK 
eighteen to LAGRANK three, Australia from LAGRANK four 
to LAGRANK thirteen, and the U.S.A. from LAGRANK one to 
LAGRANK nine. Given that these changes in NATLAG occur 
during the twenty-one year period, is it sensible to test 
the hypothesis that regulatory tightness influences NATLAGs, 
by attempting to correlate REGRATE values with mean diffus-
ion lag times per country? These mean lag times conceal 
the changes of various sizes which occur in NATLAG's 
during the twenty-one year period. It seems plausible to 
argue that if regulations do influence NATLAG values then 
in a period when NATLAG values are rapidly changing it may 
be more sensible to compare REGRATE values with changes 
in NATLAG's. Pearson correlation coefficients were cal-
culated between REGRATE and: NATLAG for the complete 
period; for the drugs released before 1969, henceforth 
called EARLYLAG; for drugs released after 1968, henceforth 
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called LATELAG; and with the change in NATLAG's between 
periods, henceforth called CHANGLAG. The results of these 
correlations are shown below. 
TABLE 7.7 
Correlations Coefficients, lag times 
w1th REGRATE 
NAT LAG EARLYLAG LATELAG 
REGRATE 0.4280 0.5359 -0.1348 




These. results are illuminating! Whereas NATLAG and 
EARLYLAG are positively correlated with REGRATE, the 
LATELAG - REGRATE coefficient has a negative sign. This 
indicates that for drugs released in the second period, 
countries with tighter regulations tend to have longer 
mean lag times before drugs are launched in their markets, 
than do couhtries with less tight regulations. Similarly 
-
the CHANGLAG - REGRAT~ correlation coefficient of 0.5853 
has a positive sign, is highly s~gnificant and indicates 
very clearly that the lower numerically, the REGRATE value 
a country has, the less change there is between EARLYLAG 
and LATELAG values. These results can be argued to be 
persuasive evidence that the hypothesized effect of regu-
latory tightness on mean lag times per country does 1n 
fact occur. It has not, o£ course, been proved th~t the 
reason for the relative worsening of position of the 
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countries with tight regulations is due to their tighter 
regulations. Howeve~ some of the other possible explan-
ations for the above results can be disposed of. The 
first possibility is that the results occur because of 
chance. This could occur if the dividing line between 
sub-periods fortuitously created two sub-groups which 
produce the above results. This possibility can be 
checked by selecting other dividing lines. When the twenty-
one year period is subdivided into four sub-periods empl-
oyed in chapters five and six, the NATLAGS for each sub-
period are as displayed in Table 7.8. For twelve of the 
eighteen countries NATLAG :declines steadily through the 
four sub-periods. Five countries have NATLAGS which are 
shorter than in the preceding period in all but one sub-
period. Only in the case of the U.S.A. does NATLAG 
increase over the preceding period in two of the periods. 
These trends suggest that the results above are unlikely 
to be due to. just a fortuitous choice of dividing line in 
the data. 
A second possibility is that the result is due to 
some influence such as differences in market size upon 
NATLAG's. The effect of market size upon these results 
can be gauged by use of partial correlation coefficients 
controlling for market size. 
Table 7.9. 
These results are shown in 
1956-61 NUM- Change in 
NATLAG PROD NATLAG 
U.K. 39.310 29 -11.043 
Colombia 65.444 9 -12.312 
Mexico 52.625 8 -7.702 
Peru 183.000 2 -130.750 
Brazil 92.333 12 -41.283 
Venezuela 74.588 17 -14.495 
Argentina 53.500 14 ~13. 238 
Japan 42.353 17 +5.822 
Indonesia 126.833 6 -57.793 
Philippines 102.100 10 -49.412 
Belgium 54.667 18 -16.911 
France 59.000 14 -13.689 
w. Germany 36.071 14 -6.728 
Italy 67.579 19 -9.404 
Spain 51.250 16 -16.250 
Australia 46.318 22 -17.467 
New Zealand 67.091 22 -34.796 
U.S.A. 14.333 18 +11.187 
' ' 
TABLE 7.8 
NATLAGS for Four Sub-periods 
1961-66 NUM- Change in 1966-71 
NATLAG PROD NATLAG NA.TLAG 
28.267 75 -8.688 .19. 579 
53.132 38 -8.519 44.613 
44.923 39 -15.193 29.730 
52.250 24 -17.932 34.318 
51.050 40 -23.521 27.529 
60.093 43 -24.236 35.857 
40.262 42 -13.637 26.625 
48.175 40 -2.713 45.-462 
69.040 25 -35.216 33.824 
52.688 32 -21.402 31.286 
37.756 45 +0.757 38.513 
45.311 45 +3.766 49.077 
29.343 35 -4.010 25.333 
58.175 40 -19.718 38.457 
35.000 44 -5.206 21.794 
28.851 47 +3.879 32.730 
32.295 61 +7.346 39.641 
25.520 25 +9.219 34.739 
































































Partial Correlation Coefficients Con-
trolling For Market S1ze 
NAT LAG EARLY LAG LATELAG 
REGRATE 0.4097 0.4729 0.0777 





Controlling for market size appears to do very little 
to overturn the result.obtained above of regulatory tight-
ness ratings being strongly correlated with the change 
in mean lag times per country for products released in 
two sub-periods. 
Of course what is important is the change in REGRATE 
- NATLAG coefficient between the first and second sub-
perions. Controlling for influences such as: market 
size; how innovative each country is; how similar the mar-
keting environment is in each country to that existing in 
the markets of the innovative countries, i.e. all the 
factors hypothesized to influence NATLAGs, will not explain 
the change in NATLAG between the two periods, unless these 
factors also change signficantly between periods. 
Assuming for the moment that no such changes occur, then 
by default it can be argued that it is regulation which 
cause the change in NATLAG's. Proponents of this argu-
ment appear to have to argue that regulations introduced 
in the 1960's began to have effect on drug diffusion which 
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were most noticeable in the 1970's. This is quite 
plausible but the case cannot be claimed to be proved. 
It does seem reasonable to draw an interim conclusion that 
evidence can be adduced to support the hypothesis that 
time and monetary costs of gaining marketing approval, as 
represented by regulatory tightness ratings, do appear to 
influence mean diffusion lag times per country. The 
question whether the U.S.A. suffers from a "drug lag", and 
whether this is caused solely, or partially, by its 
stringent regulations is h~ld in abeyance at present. The · 
remaining three hypotheses are now tested. When some con-
elusions are reached about the influence of all four 
hypothesized determinants of mean diffusion lag time, and 
the analysis of determinants of number of products diffus-
ing to each country is completed, attention returns to the 
question of the "drug lag". 6 
Size of pharmaceutical market in each country was 
hypothesized to influence mean diffusion lag time per 
country. Examination of the data in Table 7·. 1 might be 
argued to lend support to this hypothesis, for it does 
appear that the large market countries such as the U.S.A. 
West Germany and the U.K. have relatively short NAGLAG's, 
and countries with small pharmaceutical markets such as 
Indonesia, Peru, and Colombia, have relatively long NAT-
LAG's. More precision is required however to establish 
6. The "drug lag" question is dealt with in Chapter eight 
below. 
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that there is such a consistent relationship between 
market size and NATLAG. Defining market size is not as 
simple a task as it might at first appear, but in this 
case data availability compels use of I.M.S. figures on 
total ethical pharmaceutical sales in each market. There 
are some problems with this data. The I.M.S. audits of 
those pharmaceutical markets normally distinguish between 
prescription medicines sales - ethical sales - and non 
prescription sales, the latter normally referred to as 
proprietary products. The I.M.S. audits do not normally 
include sales of ethical products to hospikals. In the 
case of Japan however the hospital sale figures are 
included in the sales figures. This results in an upward 
bias in the total sales figure for Japan vis a vis that of 
other countries. The U.S.A. pharmaceutical market is 
generally agreed to be the world~ largest; the figures in 
Table 7.10 indicate that the Japanese market is larger 
but this reflects the inclusion of hospital sales in the 
Japanese figure. The Japanese data is therefore excluded 
from some tests of the relationship between NATLAG and 
market size. 
There is also concern that in some of the audits of 
South American markets proprietary medicines are included 
with ethicals again giving an upward bias to total sales 
figures. However this is of very much less concern 
because proprietary products sales typically amount to 
only a small percentage of ethical sales, thus the bias 
329. 
to the total sales figures will be slight. 
Do the figures in Table 7.10 lend credence to the 
idea that larger markets have shorter NATLAG's, other 
things being equal, than do smaller markets? Visual in-
spection suggests so, but the correlation coefficient com-
puted between NATLAG and TOTLSALE is only -0.1889. This is 
of the sign hypothesized but is not statistically sig-
nificant at the 5 per c~nt level. This surprisingly weak 
result may be at least partially caused by: the quality of 
the data used; the influence of other factors ori the rel-
ationship; and the nature of the test itself. These 
possibilities are checked to determine how they influence 
the result. 
The first possibility to check for is that the 
disappointingly small correlation coefficient between 
NATLAG and TOTLSALE,the variable name for total pharmaceut-
ical sales, may be influenced by the questionable Japanese 
TOTLSALE figure. Excluding the Japanese data, a seventeen 
country correlation coefficient of·-0.4586 is computed. 
This is a dramatic improvement over the previous correlation 
coefficient, has only a 0.032 probability of occurring by 
chance, and indicates that TOTLSALE's figures alone can 
explain 21 per cent of the variation in NATLAG values. 
A second reason why the initial NATLAG - TOTLSALE 
correlation coefficient is of disappointingly small mag-
nitude may be because of the influence of differences in 
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It was argued in chapter four th~t TOTSALEis figures by 
themselves might not accurately indicate the magnitude of 
the potential profits to be earned in each market. Inform-
ation on relative price levels is also needed. The possib-
ility that differences in price levels may influence the 
NATLAG-TOTSALE result, can be checked by conducting a first 
order partial correlation coefficient test, controlling 
for price. 
To control for prices in a partial correlation test, 
indices of relative prices for pharmaceuticals in each of 
these markets are required. Such indices of relative 
prices have been computed for sixteen of the eighteen 
markets. The method by which these indices are obtained 
has been described elsewhere7 , but can briefly be described. 
Baskets of pharmaceutical products are priced in the ref-
erence country and each country in turn. Prices are whole-
sale prices to pharmacists, net of taxes, and are obtained 
from the I.M.S. audits of these pharmaceutical markets. 
The common oaskets of p~oducts have their prices weighted 
by sales in one of the pair of countries, then the total 
cost of the common baskets are compared. The reference 
prices in this sixteen country prices comparison were the 
New Zealand market prices. All price levels in the other 
fifteen markets are expressed as a percentage of New 
Zealand prices after weighting byr in each case( the average 
7. The method of prices comparison is similar to that des,... 
cribed in Cooper, M.H., European l?h~rtnaceutica1 Prices 
1964--'74, London, Croom Helm, 1975. 
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of sales in the pairs of countries. The relative price 
indices for the sixteen markets for which information could 
be obtained are shown below. The prices are for year 
ending 1976. 
TABLE 7.11 
Price Comparison of Common Baskets 
of Pharmaceut1cal Products 



































No price information was obtained for Japan or 
Argentina, but using the data from sixteen countries the 
correlation coefficient between price levels and NATLAG 
is computed to be ~0.17428. This is of the sign which might 
be expected. Countries with higher prices tend to have 
shorter mean diffusion lag times. If higher prices imply 
higher profits this result is unsurprising. 
What of the effect of differ:ences in price levels 
upon the NATLAG""'TOTLSALE relationships? Controlling for 
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prices in a first order partial correlation test produces 
a coefficient of -0.5201. This value has a probability 
of 0.028 of occurring by chance. There appears to be con-
siderable evidence that potential profits to be earned in 
each market, as represented by total sales and price data, 
are strongly correlated with NATLAG values. 
What of the possible distorting effect of other 
influences on NATLAG's? Three other influences on NATLAG 
were hypothesized; costs of gaining marketing approval -
which has been proxied by the variable REGRATE; whether or 
~ot countries are sources of innovation; and similarity 
of marketing environment to that in the innovative count-
ries. The effect of these three possible influences can 
also be gauged by use of partial correlation coefficients 
controlling for these three factors. 
To be able to control for the possible influence of 
innovativeness of countries on NATLAG, each country has to 
be given an "innovativeness" rating. A possible means of 
establishing innovativeness ratings is by reference to the 
number of products invented in each country over the rele-
vant period. Inspection of Table 3.1 reveals that drug 
innovation is concentrated in seven countries, of whom six 
are included in this research project. Apart from these 
highly innovative countries, a nurnber of other countries 
produce a small number of new products, and the remaining 
countries are totally dependerit on overseas sources for 
supply of new· pharrnaceut;i.cal products. I't seems sens.ible 
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to divide the eighteen sample countries into three groups 
based on their innovativeness records. Thus the U.S.A., 
Japan, ;France, West Germany, Italy and U.K. are given 
rating one, Argentina, Australia, Spain, Belgium, Mexico 
8 given rating two, and the remaining countries rating 
three. These ratings are henceforth referred to by their 
variable name INNOVATE. 
Finally how can measures be devised to describe 
the similarity of each country's market to the markets in 
the innovative countries? The simplest solution to this 
problem is to make use of some proxies. Three will be 
tested: Gross Domestic Product per head (GDPPHEAD) i ethical 
pharmaceutical sales per head (SALEPHED); and number of 
persons per medical practitioner (POPPDOC); variable names 
9 in parentheses. 
Controlling for each of these factors in turn 
produces the following first order partial correlation 
8. The six countries given an innovativeness rating of.one 
each produce at least 4.9 per cent of the total number 
of new products Reis-Arndt identifies as having been pro-
duced during the period 1961-73. The countries given an 
innovativeness rating of two, either appear in Table 
3.1 as having produced less than 4.9 per cent of the 
supply of new drugs, or else are included in that Table 
in the group "other". Countries given innovativeness 
rating three did not produce any new products during the 
1961~73 period. 
9. See the discussion below on choice of these variables to 
represent marketing environments. Table 7.17 shows the 
data used to test the impact of these -marketing environ~ 
-ment variable~. · 
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coefficients between NATLAG and TOTLSALE, again excluding 
the Japanese data. 
TABLE 7.12 
Partial Correlation Coefficients, 
NATLAG-TOTLSALE 
Controlling For 
REGRATE INNOVATE GDPPHEAD SALEPHED POPPDOC 
NAT LAG -0.2239 -0.0807 0.0005 -0.3312 -0.4101 
p=0.202 p=0.383 p=0 • .499 p=O.l05 p=0.057 
The effect of controlling for all of the five variables is 
to produce correlation coefficients of smaller magnitude 
than in the uncontrolled correlation, none of which are of 
statistically significant magnitude. It has to be conceded 
that the correlation coefficient of -0.4586 between NATLAG 
and TOTLSALE may be due to collinearity of TOTLSALE.with 
the five variables controlled for above. Particularly 
INNOVATE and GDPPHEAD appear to exert considerable influence 
on NATLAG; when these are controlled for the NATLAG-TOTLSALE 
coefficients are close to zero. These results do not mean 
that no significance can be attached to the NATLAG-TOTLSALE 
coefficient, but does imply that caution should be exer-
cised in claiming that market size is a major determinant 
of mean diffusion lag ti,mes. The influence attributed 
to TOTLSALE's may be due largely to other factors such as 
INNOVATE ratings and GDPPHEAD values which are themselves 
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closely linked to TOTLSALE. 
The third reason why simple tests of the NATLAG -
TOTLSALE hypothesis may produce disappointing results is 
that the numbers being correlated do not accurately 
represent the relationships the hypothesis describes. For 
example the TOTLSALE figues are for one year only whereas 
the NATLAG values are means of diffusion lag times for 
products launched over a twenty-one year period. As has 
already been demonstrated there are considerable differ-
ences in NATLAG values when the time period is split into 
two sub-periods. More sensible comparisons might be 1976 
sales figures with post 1968 mean lags (LATELAG~s), and 
comparison of 1968 sales figures with pre 1969 mean lags 
(EARLYLAG's). No complete run of 1968 sales figures is 
available but use of 1976 TOTLSALE figures, (excluding the 









Remarkably, despite comparing 1976 TOTLSALE's figures with 
pre 1969 mean lag times, a highly significant coefficient is 
computed. This appears to suggest that TOTLSALE's figures 
in 1976 have relative sizes similar to the TOTLSALE's 
f~gures ~n the 1960's for these countries. If 1976 TOTLSALE 
figures are good proxies for 1960's TOTLSALE figures, then 
it·appears that mean lag times were strongly correlated with 
market size in the 1960's. The LATELAG- TOTLSALE coefficient 
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is virtually zero, indicating that whatever relationship 
there was between market size and mean lag times in the 
1960's, this has been completely disrupted in the 1970•s. 
How are these results altered by controlling for the 
five variables employed in the partial correlation co-





Partial Correlation Coefficients 
EARLYLAG - TOTLSALE, and LATELAG-
TOTLSALE, controlling for f1ve 
variables 
Controlling For 
REGRATE INNOVATE GDPPHEAD SALEPHED 
-0.2510 -0.1575 -0.0117 -0.3694 
p=O.Ol74 p=0.280 p=0.483 p=0.080 
0.0435 0.1898 0.0721 0.0095 






Controlling for INNOVATE and GDPPHEAD in particular, 
sharply reduces the EARLYLAG - TOTLSALE coefficient, but 
SALEPHED and POPPDOC have considerably less influence. 
REGRATE could not be expected to influence results in a 
meaningful way here, because as already demonstrated it 
has a correlation coet.t.ic~ent w~th NATLAG of the opposite 
sign to that expected. 
To conclude, when the dubious quality Japanese data 
is excluded, the variable TOTLSALE appears capable of 
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explaining a considerable amount of the variation in 
NATLAG and EARLYLAG, but there is some evidence of collin-
earity between TOTLSALE and other variables such as GDPPHEAD. 
The hypothesis that pharmaceutical companies will be attr-
acted to launch their products-more rapidly in larger 
markets than in smaller markets is not rejected. It is 
unclear how much of the apparent relationship between TOT-
LSALE and mean diffusion lag time variables is attributable 
directly to the size of markets and how much to other 
related features of markets. 
The third hypothesized influence on mean diffusion 
lag times was innovativeness of the countries. Countries 
which invent some of the products launched on their own 
markets may have an advantage over less innovative countries, 
in that some products are launched first in their markets 
because they are locally invented resulting in shorter 
NATLAG's for these countries. Thus it is argued that a 
country such as the U.S.A. will have shorter NATLAG than 
-
would otherwise be expected beqause a considerable proportion 
of drugs marketed in the U.S.A. are invented and then first 
launched in the U.S.A. For these products there is no lag 
between first launch and launch in the U.S.A., thus short-
ening the mean diffusion lag for the U.S.A. Is there a 
correlation between I_NNOVATE ratings and NATLAG values? 
10 Using the INNOVATE ratings employed a,bove, the correlation 
coefficients below are calculated. 
10. See footnote 8, this chapter. 
TABLE 7.14 
Correlation Coefficient, INNOVATE with 
Mean Lag Tunes 
NAT LAG EARLYLAG LATE LAG 
INNOVATE 0.5277 0.5696 0.0296 
p=O.Ol2 p=0.007 p=0.454 
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The message from these results appears to be sim-
ilar to that from the TOTLSALE - NATLAG analysis. There 
is evidence of a strong relationship of the form hypoth-
esized between INNOVATE and both NATLAG and EARLYLAG, but 
the LATELAG values do not appear to be at all influenced 
by INNOVATE ratings. It is tempting to conclude again 
that in the post 1968 period, mean diffusion lag times were 
undergoing considerable changes, perhaps due to the effects 
of regulation in some countries, and these changes distort 
the previously existing relationships between mean diffusion 
lag times and these independent variables. The EARLYLAG -
INNOVATE correlation coefficient indicates that the countries 
who produce most of the worlds new products do on average 
have shorter mean diffusion lag times than do the less 
innovative countries. 
This ;r:esult may of. course be brought about by col-
linea;r:ity with other factors such as TOTLSA,LE, GDPPHEAD 
or POPPDOC. All o£ these variable~ are quite strongly 
correlated with INNOVATE as Table 7.16 below indicates. 
TABLE 7.15 
Mean Lag Times Per Country - FDRUGLAG 
Country FDRUGLAG Rank NUMFPROD12 
U.K. 35.559 3 127 
Colombia 48.942 14 86 
Mexico 35.919 4 99 
Peru 46.764 13 55 
Brazil 43.670 10 97 
Venezuela 55.376 17 85 
Argentina 36.574 5 94 
Japan 46.750 12 84 
Indone.sia 60.212 18 52 
Philippines 45.854 11 89 
Belgium 36.710 6 124 
France 50.069 15 100 w. Germany 39.431 9 65 
Italy 52.412 16 102 
Spain 34.542 2 107 
Australia 33.185 1 124 
New Zealand 37.358 7 148 
U.S.A. 39.044 8 45 
12. NUMFPROD is the variable name used to describe the 






Matrix of Correlation Coefficients* 
NATLAG GDP .GDPPHEAD TOTLSALE SALEPHED POPPDOC 
NAT LAG 1.00000 -0.44379 -0.61779 -0.4586 -0.19988 0.53302 
GDP -0.44379 1.00000 0.72237 0.9195 0.24969 -0.15020 
GDPPHEAD -0.61779· 0.73370 1. 00000 0.7108 0.54011 -0.39717 
TOTLSALE -0.18897 0.64473 0.49521 1.0000 0.76516 -0.19510 
SALEPHED -0.19988 0.24969 0.54011 0.2511 1.00000 -0.37508 
POPPDOC 0.53302 -0.15020 -0.39717 -0.1444 -0.37508 1. 00000 
REGRATE 0.43340 -0.54283 -0.72954 -0~5527 -0.61652 0.49464 
INNOVATE 0. 52770 -0.50850 -0.67680 -0.6448 -0. 69580 0.36890 
* Data from eighteen countries used to compute these correlation 
coefficients except for the TOTLSALE coefficients where the 










0. 76 310 1. 0000 
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However, an alternative means of determining whether in-
novative countries have significantly shorter mean diffusion 
lag times because they produce some of their own new products 
is.to compare the mean diffuse lag times for all products, 
NATLAGs, with mean diffusion lag times when drugs first 
launched in the innovative countries are excluded from the 
. f h . 1 . 11 calculat1on o t e1r mean ag t1mes. These latter 
values are denoted by the variable name FDRUGLAG. 
When these six countries have the products first released 
in their individual markets excluded from calculation of 
their mean diffusion l~g times, this results in a com-
pression of mean lag times (FDRUGLAG's). 
The range is now 33.185 months to 60.212 months, 
compared to the 23.768 months to 60.212 months NATLAG 
range shown in Table 7.1. Examining more closely the 
change in mean lag times for these six countries affected, 
the U.K., U.S.A., and West Germany lag times are approx-
imately 50 per cent greater than previously, the lag times 
o£ France, Italy, and Japan are largely unchanged. Thus 
it does seem that part of the variation in NATLAG values 
can be explained by the fact that countries who are them-
selves sources of innovation, have significantly shorter 
11. Only countries with an l.NNOVATE :rating of one, have pro-
ducts whi.ch p,re first la,unched in thei.r markets exclu-
ded f:rom ca,lculation of their ;E'DRUGLAG's. lt is argued 
that countries such as New Zealand, Venezuela, an~ 
Spain are totally dependent on overseas countries for 
supply of new pharmaceutical products. Thus products 
first launched in markets such as Ne~ Ze~land, 
Venezuela and Spain are all imported to those countries. 
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lag times because they do not have to wait for these 
dbmestically produced products to be launched in their 
markets. 
The final hypothesis to test in this chapter is that 
countries with marketing environments least like the market-
ing environments in the innovating countries will tend to 
have the longest mean diffusion times. "Marketing ~nviron-
ments" is not a particularly precise phrase, and attempting 
to quantify directly the similarity or otherwise of 
marketing environments is not a simple task. The tenor of 
this hypothesis is that despite the apparent attractive-
ness of some markets due to their size and price levels, 
there may be features such as difficulty of marketing in 
those countries, which lessen their attractiveness. What 
is required are variables which indicate something of the 
likely costs of marketing in each country. It is argued 
that the most visible differences between marketing en-
vironments of the innovating countries and the dependent 
countries, are levels of income per capita and differences 
in medical systems. The innovating countries are high 
income countries, have high expenditures on medical systems, 
and on pharmaceutical products in particular. If the 
innovating firms have marketing skills which are designed 
for marketing their products in high income countries, 
these markets may be much mo~e attractive to the suppliers 
of new pharmaceutical products than are markets in low 
income countries where medical expenditures are lower, and 
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use of pharmaceutical products is much less frequent. 
Three variables are employed to test this hypothesis: 
Gro~s Domestic Product'per capita, GDPPHEAD; ethical pharm-
aceutical sales per capita, SALEPHED; and number of 
persons per medical practitioner, POPPDOC. The data ob-
tained to test the hypothesis by use of these three var-
iables is shown in Table 7.17. The data is drawn from 
a variety of years, but it is hoped that this does not 
greatly diminish the usefulness of the tests. 1976 sales 
figures are the only sales data which are available for 
all countries. Early 1970, G.D.P, population, and medical 
practitioner data, were selected for use because they were 
believed to be most likely to provide data representative 
of these features of the markets over the whole twenty-
one year period. 
What results are produced when these marketing 
environment indicators are correlated with NATLAG? 
Table 7.18 provides these results. 
First1 it can be commented that LATELAG appears to 
be uncorrelated to the variables being tested, suggesting 
again that some destabilizing force has influenced the 
mean lag times for drugs released after 1968. Second, 
two of the variables POPPDOC and GDPPHEAD, appear to be 
quite strongly correlated with mean diffusion lag times 
for drugs released before 1969. These relationships are 
sufficiently strong to ensure th~t statistically signif-
icant correlation coefficients are produced between 
TABLE 7.17 
Marketing Environment Indicators 
1970 
GDP 1970 GDP/Head 
Country U.S·. $b u.s .. $ 
U.K. 096.57 1743 
Colombia 007.02· 0342 
Mexico 033.49 0661 
Peru 005 .. 54 0412 
Brazil 044.97 0486 
Venezuela 011.42 1098 




Indonesia 008.82 00?4 
Philippines 006.97 0164 
Belgium 029.23 3026 
France 141.57 2788 
West Germany 188.41 3103 
Italy 085.98 1602 
Spain 036.89 1092 
Australia 036.99 2597 
New Zealand 005.66 2014 
U.S. A. 981.00 4788 
Source : U.N. Statistical Yearbook 1974. 
* Various years but all early 1970's~ 
1970 1976 Ethical 
Population Pharmaceutical 




































































Correlation Coe~ficients, Mean Diffusion 
Lag Times with Level o~ Development Indicat·ors 
NAT LAG EARLYLAG LATE LAG 
POPPDOC 0.5324 0.6347 -0.2118 
p=O.Oll p=0.002 p=O.l99 
SALEPHED -0.1955 -0.3029 0.2720 
p=0.219 p=O.lll p=O.l37 
GDPPHEAD -0.6122 -0.6813 -0.0072 
p=0.003 p=O.OOl p=0.489 
NATLAG and these two variables. The correlation co-
efficients are of impressive magnitude, GDPPHEAD for 
example is capable of "explaining" over 38 per cent of the 
variation in NATLAG and 46 per cent of the variation in 
EARLYLAG. 
Do these results occur because of collinearity with 
other variables? Three hypotheses already tested in this 
chapter have been shown to have some influence on mean 
diffusion lag times. Are they also responsible for the 
results achieved with these marketing environment variables? 
It is not sensible to try to control for REGRATE in a 
partial correlation test because it does not have a 
relationship of the ~orm hypothesized unless sophisticated 
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tests~are constructed. However TOTLSALE and INNOVATE do 
appear to influence mean diffusion lag times as hypothe-
sized. A further possible influence on mean lag times are 
price levels for pharmaceuticals in each country. These 
three factors, TOTLSALE, INNOVATE and PRICE can all be 
controlled for in first order partial correlation coe£-
ficient tests. The results, when each of these factors 
are controlled for, are shown in Table 7.19. 
Rather surprisingly these partial correlation tests 
suggest that the strong relationships between the mean 
diffusion lag variables, NATLAG and EARLYLAG, and the 
marketing environment variables, POPPDOC and GDPPHEAD, 
are not due to collinearity of the independent variables 
with TOTLSALE, INNOVATE or PRICE. All the first order 
partial correlation coefficients between the above two 
pair of variables are of a magnitude which has less than 
0.053 probability of occurring by chance. Again LATELAG 
proves to be unexplainable by the variables employed here, 
and SALEPHED does .not produc.e coefficients of statistically 
significant magnitudes. 
Given the success of POPPDOC and GDPPHEAD in explain-
ing mean diffusion lag times it is tempting to conclude that 
marketing environments, as proxied by these variables, do 
have a signi~;i,cant impact on mean diffusion lag times per 
countx.'y. Two cautions should be offered however. first 
it may be tha,t the· variables ·employed here are not part .... 
icularly good indicators of the type of marketing environ-
348. 
TABLE 7.19 
Partial Correlation Coefficients 
Controlling for three variables 
Controlling for TOTLSALE (results when Japanese data excluded 
in parenthesis) 
NATLAG EARLYLAG LATE LAG 
POPPOOC 0.5148 co. 5110) 0.6158 (0.6234) -0.1642 ( -0 .1994) 
p=O.Ol7 (0. 022) p=0.004 (0.005) p=0.264 (0. 230) 
GDPPHEAD -0.6091 (-0.4759) -0.6446 ( -0 .5307) -0.1865 (-0.0714) 
p=0.005 (0.031) p=0.003 (0.017) p=0.233 (0.396) 
SALEPHED -0.0836 (-0.1972) -0.1250 ( -0. 2419) 0. 0720 (0. 0304) 
p=0.375 (0.232) p=0.316 (0.183) p=0.392 (0.456) 
Controlling for INNOVATE 
NATLAG EARLYLAG LATELAG 
POPPDOC 0.4278 0.5557 -0.2397 
p=0.043 p=O.OlO p=O .177 
GDPPHEAD -0.4079 -0.4888 0.0174 
p=0.052 p=0.023 p=0.474 
SALEPHED 0.2815 0.1583 0.4077 
p=O.l37 p=O .272 p=0.052 
Controlling for PRICE (excluding Japanese and Argentina data) 
NATLAG EARLYLAG LATE LAG 
POPPDOC 0.5295 0.6287 -0.2547 
p=0.021 p=0.0006 p=O.l80 
GDPPHEAD -0.6268 -0.7101 0.0530 
p=0.0006 p=0.002 p=0.426 
SALEPHED -0.3463 -0.4390 0.1833 
p=0.103 p=0.051 p=0.257 
-
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ment in each country. . There may well be variables which 
are more accurate indicators of this feature of markets. 
Only further hypothesis formulation and test will establish 
whether this is so. Second it may be that the character-
istics of·markets represented by variables such as POPPDOC 
and GDPPHEAD, are inaccurately described by the term 
"marketing environments". Again, the reasons why these 
independent variables are so successful in explaining mean 
diffusion lag times can only be established by further 
hypothesis formulation and test. 
(2) REGRESSION ANALYSIS 
By dint of some protracted detective work it has 
been established that the four hypothesized determinants 
of mean diffusion lag per country all play some part in 
explaining variations in NATLAG and EARLYLAG. How useful 
are those variables in jointly explaining variations in 
mean diffusion lag times? 
Testing this via multiple regression analysis is 
a simple task. The variable REGRATE is not included as 
an independent variable in this analysis because the cor-
relation coefficient calculated between REGRATE and NATLAG 
is of the opposite sign to that hypothesized. It appears 
specious and misleading to include such a variable in an 
analysis directed at detep.TI),i,ning how much of the variation 
in a dependent variable can be explained by variations in 
dependent variables. Thus the variables POPPDOC, GDPPHEAD, 
SALEPHED, ~NNOVATE and TOTLSALE were employed as 
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"explanators" of NATLAG._ In an analysis in which data 
from all eighteen countries is included, four variables 
can account for approximately 60 per cent of the variation 
in NATLAG. 











Significant at the 5 per cent level 
R Square= 0.5991, Adjusted R Square=0.4757, Standard 
Error=7.3245 
This ability to "explain" 60 per cent of the varia-
tion in NATLAG has to be treated with caution. As only a 
small number of observations are available to conduct the 
regression on, the adjusted square value of 0.4757 is of 
noticeably smaller magnitude than the unadjusted R square. 
Thus.approximately half of the variation in.NA'l'LAG values 
appears to be accounted for by the combined variation of 
the above four variables. Noticeably, all three marketing 
environment variables are included as regressors ahead of 
TOTL$A,LE and J:NNOVATE, indicat:i,ng how strongly they are 
correlated with NATLAG, 
The possibility that the indifferent showing of 
TOTLSALE may be caused by the suspect Japanese total sales 
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figure was checked by restr~cting th~ analysis to sixteen 
countries. By excluding A,rgeritina from the analysis as 
well, ~t is possible to both include price data ~ which 
is available f;or only sixteen countries - and also to avoid 
the.possible bias due to the suspect Argentina POPPDOC data. 
However this sixteen country regression analysis produces 
similar results to those for eighteen countries. 
NAG LAG = 28.6710 -0.0038 GDPPHEAD + 0.0009 POPPDOC 
(0.0023) (0.0005) 
(1. 652) (1.800) * 
+ 0.3099 SALEPHED + 4.8565 INNOVATE 
(0.2243) (3.5309) 
(1.381) (1.375) 
*-Significant at the 5 per cent level 
R Square= 0.6023, Adjusted R Square= 0.4577, 
Standard Error = 7.8347 
Because of the reduced number of observations, the 
adjusted R square is of even smaller magnitude in this 
sixteen country analysis than in the eighteen country reg-
ression. Thus only modest success can be claimed for 
the independent variables in explaining mean diffusion lag 
times in these l~near regression analysis. 
(_3} $UMMAAY 
rour hypotheses ape tested in this ch~pter. Testing 
these hypotheses is complicated by the nature of the data; 
352. 
the time trend effect noted in chapter five has a parallel 
here. ~elationships which are observed to occur as 
hypothesized in the period up until 1969, appear to disin~ 
tegrate after that date. This effect may be due to the 
growing impact of changed regulatory climate.causing major 
changes in the pattern of diffusion of pharmaceutical 
products, but such a conclusion is as yet no more or less 
than speculation. There does appear to be a considerable 
amount of evidence that pharmaceutical firms market new 
products sooner in larger markets where income levels and. 
health expenditure levels are high, than they do in 
smaller markets where incomes and health expenditure levels 
are lower. These large high income countries are also 
the major sources of innovation, and there is evidence 
that their shorter mean diffusion lag times are due partly 
to the fact that innovative countries tend to have new 
products launched first on their own markets. The paradox 
uncovered during testing is that countries assessed as 
having the tightest regulatory systems controlling marketing 
of new products, also tend to have the shortest mean dif-
fusion lag times. This apparent contradiction of the 
hypothesis about the impact of such regulations on mean 
diffusion lag times appears to be explainable in two ways. 
First, regulations may be strict but actually do little to 
delay the introduction date of new products-. This is very 
likely to be the ca,se in some markets such as the U.K. 
Second, the paradox can be resolved by splitting the time 
period into two sub-periods and observing the change in 
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lag times between these sub~per.tods. Correlation tests 
comparing change in mean lag times between the sub.-periods 
with regulatory tightness ratings, indicate that those with 
the greatest reduction in mean lag time, from the pre 1969 
period to the post 1968 period, were those countries with 
the least tight regulatory systems. However further 
conunent on the "drug lag" debate is reserved until chapter 
eight below. 
C H A P T E R 8 
NUMBER OF PRODUCTS LAUNCHED IN EACH COUNTRY 
(0) INTRODUCTION 
In this final analytical chapter attention is foc-
ussed on the number of products diffusing to each country. 
The hypotheses postulated in chapter four relating to this 
aspect of diffusion are tested, before an assessment is 
made of the evidence on the "drug-lag" debate. 
Three hypotheses were postulated about factors bel~ 
ieved to influence the number of· products launched in each 
country. Briefly the hypotheses were : 
1. Countries where the time and monetary costs of 
gaining marketing approval are high will have a 
smaller proportion_ of the supply of pharmaceutical 
prodcuts launched on their markets than will countries 
where these costs are lower. 
2. Countries with larger markets will have a larger 
proportion of the supply of pharmaceutical products 
in their markets than will countries with smaller 
pharmaceutical markets. 
3. eduntries with marketing environments least like 
those in the countries which are the sources of 
innovation of pharmaceutical products will have 
smaller proportions of the supply of pharma-
ceutical products launched in their markets than 
will countries with marketing environments similar 
to those in the innovating countries. 
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Again the data available to test these hypotheses is, 
despite some effort, probably less than perfect for this 
task. The primary sources o£ information are again the 
I.M.S4 audits of the pharmaceutical markets in the sample 
countries. The variable NUMSALES employed in chapter six 
has an analogue here, for attention is focussed on the 
number of sample products which are recorded by I.M.S. as 
being marketed in a country. Thus the number of products 
for which sales data are recorded in a country are denoted 
by the variable name NUMPROD. Supplementing the I.M.S. 
audits as sources of information were the following 
personal communication with Professor W.M. Wardell, 
University of Rochester; personal communication with rep-
resentatives of pharmaceutical companies; and a further 
series of I.M.S. publications entitled CHEMINDEX. 1 These 
supplementary sources of information were valuable because 
establishing whether a product is marketed in a series of 
countries is a difficult task. Product names are not 
invariant across countries, thus establishing whether 
products are present in a market or not requires knowledge 
of the generic components of a brand named product and all 
the brand names under which that product is marketed. The 
I.M.S. CHEMINDEX was particularly helpful in determining 
which of the 190 sample products were marketed in Japan 
where brand name changes are very common. The communications 
1. I.M.$., Chemihdex Japan, I'.M.S.,London, 1977. 
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with the representatives of the pharmaceutical companies 
and W.M. Wardell 2 provided some new information, but 
generally con~irmed the accuracy of the detection proced-
ures based on the I.M.S. audits of these markets. It is 
possible that instanees of sample products being marketed 
in these eighteen countries without being included in the 
NUMPROD figures occurs, but such events are believed to 
be rare. Thus the NUMPROD values for each country are 
employed to test the above hypotheses. The expectation 
is that these hypothesized determinants of number of products 
diffusing to a country will prove capable of explaining a 
significant proportion of the variation between countries' 
NUMPROD values. 
(1) TESTS OF HYPOTHESES 
The costs of gaining marketing approval for pharma-
ceutical products have been argued to be determinants of 
NUMPROD values. In the previous chapter these costs were 
proxied by rankings and ratings of regulatory tightness in 
each of the sample countries. These REGRANK and REGRATE 
values are again used to test the hypotheses that costs of 
gaining marketing approval in various markets, influences 
diffusion of pharmaceutical products to these markets. 
Given the rather startling results for the initial tests of 
2. Professor W.M. War,i?dell has a data, bank containing inform-
ation on the brand names, dates and country of tirst 
worldwide launch, and dates of launch in the U.S .. A. for 
a,ll products released in the U.S.A. since 1960. 
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the hypotheses using REGRATE and REGRANK in chapter seven 
above, it should not be too surprising if similar outcomes 
occur when simple hypotheses about the relationship between 
REGRATE, REGRANK and NUMPROD are tested. 
Numbers of sample products diffusing to each country 
are shown in Table 7.1 above. Grouping the eighteen 
sample countries by REGRATE values, the mean NUMPROD values 
for each class are as shown in Table 8.1. 
TABLE 8.1 
Mean NUMPROD value for countries grouped 
b REGRATE )). score 
REGRATE Number of Mean Std. Dev. 
Score Countries NUMPROD NUMPROD 
1 2 78.0000 11.3137 
2 5 124.8000 37.4697 
3 4 112.2500 29.2617 
4 5 95.6000 8.3546 
5 2 53.5000 2.1213 
Sample 
Total 18 100.7778 32.3593 
While there is a problem with this data, as explained 
below, it does clearly indicate that a simple test such 
as this does not provide evidence that countries with 
tighter regulationsreceive fewer new products than do count-
ries with freer regulations. The analysis of variance 
results suggests that the opposite tendency occurs. 
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Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. Sig. 
Between Groups 9053.861 4 2263.465 3.364 0.0425 
Linearity 2289.846 1 2289.846 3.403 0.0880 
Dev. from 6764.015 3 2254.672 3.351 0.0524 
Linearity 
R = -0.3587 R Squared = 0.1286 
Within Groups 8747.250 13 672.865 
Eta = 0.7132 Eta Squared = 0.5086 
These results are of dubious value both because the 
data is suspect on one count, a~d because analysis in 
earlier chapters indicates that these sort of tests are 
too simplistic to detect the influence of regulatory tight-
ness on number of products diffusing to countries. The data 
in Table 8.1 is of dubious value because the U.K. NUMPROD 
figure is included. Because the sampling frame used in 
this study was the list of leading selling products in the 
U.K., all 190 sample products by definition, are marketed 
in.the U.K. Thus the NUMPROD value for the U.K. does not 
reflect the influence of any factors, such as REGRATE, and 
thus should be removed from the data used to test the hypo-
theses about NUMPROD. When this step is taken the results 
are not significantly altered. The mean NUMPROD value for 
countries with REGRATE of two becomes 108.5 products, the 
Pearson correlation coefficient for these seventeen cases 
is ~0.3093. This is still of the opposite sign to that 
hypothesized and is not statistically significant at the one 
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per cent level. Two obvious routes for further analysis are: 
first to examine the NUMPRODS which are calculated when the 
data are split into two sub~periods; and second to examine 
the NUMPROD values for each country when products first 
launched in the innovative countries are excluded from the 
calculations of NUMPROD's. These latter values are entit-
led NUMFPROD's. When the data is split into two sub-
groups, those products released before and after January 1 
1969, the NUMPROD values shown in Table 8~2 are produced. 
As well as listing the number of products launched in each 
country, Table 8.2 also shows what percentage of the 
possible number of sample products were launched.in each 
country in each sub-period. 3 Based on these percentages, 
ranks are given to countries other than the U.K. The 
country which has the highest percentage of sample 
products launched in its market is given rank one, the 
country with the second highest percentage given rank two, 
and so on down the ranks. 
Noticeable features of the data in Table 8.2 are 
the improvement in ranking of Mexico and Philippines, 
between periods, and the very much lower values for "percent 
of possible'' for Japan, Venezuela, and U.S.A. in the second 
period than in the first period. While casual empiricism 
is no way to conduct science it does seem pertinent to 
point out that Mexico and Philippines were given REGRATE 
3. The possible number of products in each sub-period are 
127 and 63 ·~ the number of sample products released in 



















New Zealand 97 
U.S.A. 54 
TABLE 8.2 
NUMPROD's for drugs released in two sub-periods 
before 1969 Drugs 
Per cent of 
Possible Rank NUMPROD 
100.0 N.A. 63 
46.4 13 27 
48.0 12 38 
29.1 16 18 
51.9 10 31 
55.1 7 15 
52.7 8= 27 
52.7 8= 19 
28.3 17 16 
44.1 14 33 
67.7 2 43 
59.0 4= 34 
48.8 11 30 
57.5 6 34 
59.0 4= 32 
66.9 3 41 
76.4 1 51 
42.5 15 16 
Released after 












































four, and Japan and the U.S.A. REGRATE one. This may 
indicate that the countries with the tightest regulatory 
systems tended to fare relatively worse in the second sub-
period while the countries with the freer regulatory system 
fared relatively better. Table 8.3 provxdes more evidence 
on which to base judgment. 
The data in the final column of Table 8.3 provide 
some satisfaction. They provide evidence that REGRATE 
values are correlated with changes in NUMPROD values bet-
ween periods. The results illustrated in the above Table 
can be compared with the data in Table 7.6 which demonstrates 
that REGRATE values are correlated with changes in NATLAG. 
Thus to state explicitly, simple tests of the relationship 
between regulatory tightness ratings and NUMPROD values 
do not provide evidence to support the hypothesis postulated 
about the relationship between these variables, but more 
sophiticated analysis indicates a relationship of the form 
hypothesized between regulatory tightness ratings and 
-
changes in NUMPROD values between ~ub-periods. Analysis of 
variance tests confirm that there is an inverse relation-
ship between REGRATE scores and the values for CHANGEPOP 
the variable name used to denote changes in mean per cent 
of possible NUMPROD values between sub-periods. While the 
F value computed is not statistically significant the sign 
of the correlation coefficient and its magnitude provide 
some grounds for arguing that regulatory tightness dif~ 
ferences between countries do appear to have influenced 
TABLE 8.3 
Mean NUHPROD and Per cent of Possible NUMPROD 
in two sub-periods, and change in Per cent of 
Possible NUMPROD between sub-per1ods~ Products 
grouped by REGRATE scores4. 
Drugs Released before 1969 Drugs Released after 
Mean Mean 
1968 
Change in mean 
REGRATE Mean Per cent of Mean Per €:l:ent of Per cent of Pos-
Scores NUMPROD Possible NUMPROD Possible sible between 
periods 
1 60.50 47.6 17.50 27.7 - 19.9 
2 75.00 59.0 34.00 53.9 - 5.1 
3 78.75 62.0 34.75 55.2 - 6.8 
4 63.40 49.9 32.20 51.1 + 1.2 
5 36.50 28.7 17.00 27.0 - 1.7 
Sample 
Total 66.23 52.1 29.70 47.1 - 5.0 
4. U.K. data not included in this table because by definition all sample products 
were released in the U.K. 
sub-
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NUMPROD values over time in a manner consistent with the 
initial hypothesis relating regulatory tightness and NUM~ 
PROD. 




Between Groups 0.067 4 
Linearity 0.043 1 
Dev. from 0.024 3 
Linearity 
R = -0.4843 
Within Groups 0.117 12 










R Squared = 0.2346 
0.010 
Eta Squared = 0.3633 
What results are produced when the products which are 
first launched in the innovative countries are excluded from 
the calculation of NUMPRODS for the innovative countries? 
These values, which are entitled NUMFPROD, are calculated 
to determine whether data on NUMPROD are "distorted" by a 
tendency in _innovative countries for a significant proport-
ion of products launched in those countries to be domestically 
produced. The NUMFPROD values for the complete twenty-one 
year period are displayed in Table 7.15. It must be report-
ed that six countries were categorised as being "innovative": 
U.K.; France; Italy; Japan; West Germany; and U.S.A. Thus 
only for these countries are products first launched in 
their markets excluded to allow calculation of NUMFPROD. 
:For the remaining twelve survey countries NUMPROD and 
NUMFPROD values are identical. Thus NUMFPROD values are 
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an attempt to. gauge how many of the sample products diffuse 
from overseas sources to each market. 
By excluded these "locally produced" prod·ucts from 
calculation for the innovative countries it is apparent that 
the range of values for NUMFPROD is less than the range of 
values for NUMPROD. But the objectives of calculating these 
NUMFPROD values is to determine whether there is a relation-
ship between REGRATE values and NUMFPROD, indicating that 
differences in regulatory tightness influence numbers o~ 
products diffusing to each country. Grouping by REGRATE 
score produces the data in Table 8.4 below. 
TABLE 8.4 
Mean NUMFPROD for countries grouped by 
REGRATE Score. 
REGRATE Number of Mean Std. Dev. 
Score Countries NUMFPROD NUMPPROD 
1 2 64.5000 27.5772 
2 4 105.0000 13.1149 
3 .4 105.5000 37.4565 
4 5 95.6000 8.3546 
5 2 53.5000 2.1213 
Sample 
Total 17 91.5294 27.0558 
5. The U~K. data is again excluded ;Erom this Table because 
all·products by definition must be lauched in the U.K. 
The U.K. NUMFPROD value is not influenced by factors 
such as regulatory tightness. 
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Analysis of Variance and Test of Linearity 
Sum of Mean 
Source Squares D.F. Square F. Sig. 
Between Groups 5943.035 4 1485.759 3.090 0.0578 
Linearity 240.999 1 240.999 0.501 0.4925 
Dev. from 
Linearity 5702.036 3 1900.679 3.953 0.0357 
R = -0.1434 R Squared = 0.0206 
Within Groups 5769.200 12 480.767 
Eta = 0.7123 Eta Squared = 0.5074 
Clearly this data does not provide any evidence of 
a linear relationship between REGRATE and NUMFPROD values, 
a conclusion similar to that reached about the relationship 
between REGRATE and NUMPROD values. Continuing the 
analysis along a parallel course to that of NUMPROD - REG-
RATE, splitting the data into two sub-groups, on the basis 
of release dates of products, produces the NUMFPROD data 
shown in Table 8.5 
The colums headed "Per cent of Possible'' indicate 
for each country the following rates; NUMFPROD divided by 
number of sample products in that sub-group which could 
potentially diffuse to the country from overseas. For the 
non-innovative countries the denominators are 127 for the 
first sub~period and 63 for the second period. For the 
innovative countries the denominators are reduced from 
127 and 63 by the numbers of products first released in 
' ; 
TABLE 8.5 
NUMFPROD for drugs released in two sub-periods 
Drugs Released before 1969 Drugs 
Per cent of 
Country· NUMFPROD Possible Rank NUMFPROD 
U.K. 94 100.0 N.A. 33 ' 
Colombia 54 . 46.4 9 27 
Mexico 61 48.0 8 38 
Peru 37 29.1 14 18 
Brazil 66 51.9 7 31 
Venezuela 70 55.1 5 15 
Argentina 67 52.7 6 27 
Japan 65 34.6 13 19 
Indonesia 36 28.3 15 16 
Philippines 56 44.1 10 33 
Belgium 86 67.7 2 43 
France 69 37.5 11 31 
w. Germany 3·8 22.9 16 27 
Italy 68 36.7 12 34 
Spain 75 59.0 4 32 
Australia 85 66.9 4 41 
New Zealand 97 76.4 1 51 
U.S.A. 33 19.5 17 12 
Released after 1968 











































respective markets in the relevant sub-periods. Ranks are 
awarded on the basis of highest rank going to the country 
I 
New Zealand, which has the highest percentage figure for 
the relevant sub-period and so on down the ranks. Again 
the U.K. was not given a rank because by definition all 
sample products were marketed in the U.K. 
Some of the more notable features of Table 8.5 are: 
the remarkably high percentage of these sample products 
which are marketed in New Zealand; and the equally remark-
ably low percentage of these sample products which diffuse 
to the U.S.A. from abroad. The most notable changes in 
ranks which occur between sub-periods are those of Italy, 
France, West Germany and Venezuela. The significance of 
these changes in ranks is further examined in the dis-
cussion of "drug lags" below, for the present the concern 
is to again check whether the changes in NUMFPROD's 
between sub-periods are correlated with REGRATE scores in 
the way NUMPROD scores were. The evidence in Table 8.6 
suggests there is no such simple relationship. 
TABLE 8.6 
Change in "Per cent Possible" NUMFPROD 
figures between sub-periods, Countr1es 
Grouped by REGRATE score 
REGRATE Mean change in "Per cent 
Score Possible" 
1 ,..... 3.8 
2 +10~1 
3 ,..... 1.0 
4 + 5.6 
5 - 1.7 
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Clearly removing the "home produced'' drugs from the 
calculation of number of products diffusing to innovative 
countries does not provide any assistance in establishing 
the influence of regulatory tightness upon number of pro-
ducts diffusing to these countries. 
What can be concluded about the hypothesis linking 
marketing approval costs and number of products diffusing 
to countries? There is no evidence of a linear relation-
ship between marketing approval costs and number of pro-
ducts d~ffusing to countries. A moments thought suggests 
that this is not a surp~ising result because the data used 
to test this hypothesis is drawn from diffusion patterns 
over a twenty-one year period. It is likely that the im-
pact of more stringent regulations controlling the intra-
duction of new products only began to have a significant 
impact on diffusion patterns in the late 1960's some years 
19 2 d h d d 
. 6 
after the 6 amen ments to t e U.S. Foo an Drug Act: 
Thus the impact of these regulations could be expe.cted to 
be to change the rate at which new products were marketed 
in countries who introduced more stringent regulations. 
Tests indicate a tendency for REGRATE scores to be cor-
related with changes in the number of products diffusing to 
these sample countries. The correlation coefficient is 
statistically significant at the 2 per cent level and the 
6. These amendments to the Food and Drug Act are popularly 
referred to as the Kefauver-Barris Amendments after 
their sponsoring Senators. 
369. 
similarity of thi$ result to that established between 
REGRATE and change in NATLAG in chapter seven provides con-
siderable support for the hypothesis that differences in 
marketing approval costs will influence the number of pro-
ducts diffusing to individual countries. Whether or not 
these marketing approval costs - regulations, have caused 
a "drug lag" in countries such as the U.S.A. is discussed 
later in this chapter. 
The second hypothesized determinant of number of pro-
ducts diffusing to markets was size of the market in·each 
country. It was argued that countries with larger markets 
would attract companies to launch more new products in 
them because of the potentially greater profits to be earned 
there. This proposition is very simply tested. Table 
8. 7 compared market size-s and NUMPROD values for the 
seventeen relevant countries. Casual inspection indicates 
that support for the hypothesis is not provided by this 
data. The country with the smallest market, New Zealand, 
receives the largest number-of sample p~oducts, while the 
U.S.A. receives only seventy of the sample products. The 
Japanese total sales figure, is of questionable value, so 
excluding the Japanese data from the analysis the correl-
ation coefficient between NUMPROD values and TOTLSALE 
values can be computed and is -0.1553. This is of the 
opposite sign to that hypothesized, so initial tests do 
not support this hypothesis. 
TABLE 8.7 
Comparison of Market Sizes and NUMPROD 
Values 
Country TOTTI SALE NUMPROD 
u.s .. $m 
Japan 7, 996 86 
U.S.A. 5,283 70 
West Germany 2,618 92 
France 2,249 109 
Italy 1,585 107 
Spain 1,141 107 
Brazil 967 97 
Argentina 533 94 
Mexico 524 99 
Belgium 405 124 
Australia 238 124 
Venezuela 163 85 
Colombia 147 86 
Philippines 146 89 
Peru 143 55 
Indonesia 107 52 
New Zealand 45 148 
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Obviously there may be intervening factors which 
disguise the relationship between market size and NUMPROD 
values. Partial correlation tests were conducted to 
check i.f the disappointing results obtained were due to 
three influences. One possible distorting influence is 
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that alluded to in the third hypothesis about NUMPROD, 
namely the nature of the marketing environment. Thus 
partial correlation tests are run controlling for POPPDOC 
- a variable used to represent the characteristic of the 
marketing environmept. Secondly, inspectiDnof the data 
in Table 8.7 suggests that the innovative countries have 
relatively low NUMPROD values despite their huge markets. 
It may be that the innovative countries have relatively 
low NUMPROD scores because they have a greater tendency to 
self sufficiency than do the non~innovative countries. 
This possible influence is allowed for by controlling for 
INNOVATE 7 in a partial correlation coefficient test bet-
ween NUMPROD and TOTLSALE. Finally, it might be argued that 
market size figures alone do not indicate the returns to 
be gained from sales in a market, price levels will also 
influence these returns. Thus differences in price levels 
should a~so be allowed for in tests of the impact of 
TOTLSALE's on NUMPROD. Again this is tested by calculation 
of a partial correlation coefficient. The results of thes 
tests are shown in Table 8.8. 
TABLE 8.8 
Partial Correlation Coefficients for NUMPROD~TOTLSALE 
Controlling for 
POPPDOC ~0._3395 p - 0.108 
INNOVATE '""'0.4529 p = 0.045 
PRICE '""'0.1517 p - 0 .. 302 
7. The method of assignment o,f l'NNOVATE ratings is des-
cribed in Ch~pter seven above. 
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These coefficients indicate that the initial NUMPROD 
- TOTLSALE correlation coefficient of ~0.1553 is close to 
zero in magnitude, at least partly, because of the col-
linearity of TOTLSALES with POPPDOC, INNOVATE, and PRICE. 
When the influence of these variables controlled for in 
partial correlation tests the NUMPROD-TOTLSALES correlation 
coefficients are of greater magnitude and still of the 
opposite sign to that hypothesized. 
Alternatively, when the relationships between EARLY-
8 NUM and TOTLSALES, and LATENUM and TOTLSALES are tested, 
the correlation coefficients calculated are -0.0956 and 
-0.2579 respectively. Thus the tendency for countries with 
larger markets to receive fewer new products than do count-
ries with smaller markets appears to be more marked for 
products released in the latter part of the period studied. 
The conclusion drawn is a surprising one. Countries 
with larger markets do not appear to receive as many new 
products as do countries with smaller markets. All at-
tempts to overturn this result by controlling for differences 
in price levels, innovativeness of the countries or market-
ing environments meet with failure. The result cannot be 
attributed to differences in regulations controlling market-
ing of products in these countries because,as has already 
8. EARLYNUM and LATENUM are the variable names given to denote 
the number of products launched in countries which were 
first launched before, and after January 1, 1969 respect-
ively. 
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been demonstrated, countries with tight regulatory systesm 
tend to have high NUMPROD values. The correlation coeffic-
ient between REGRATE values and NUMPROD is -0.3093, and 
between REGRATE and TOTLSALES ~0.6435. Thus arguing through 
a chain of linkages here, high TOTLSALES values are assoc-
iated with low"REGRATE scores and low REGRATE scores are 
associated with high NUMPROD values. But the negative sign 
NUMPROD - TOTLSALES correlation coefficient indicates that 
countries with large markets tend to have relatively low 
NUMPROD values. Why this is so can only be guessed at. 
There appears to be no evidehce to support the hypotheses 
that countries with large markets will have .more products 
launched on their markets than will countries with small 
markets. 
Differences in marketing environment were postulated 
to be determinants of the number of products diffusing to 
countries. Thus it was argued that countries whose markets 
had characteristics which would make them appear least like 
the markets in the innovative countries would receive fewer 
products than ~ould countries with markets similar to those 
in the innovative countries. These differences in marketing 
environments were proxied in Chapter seven by three variables, 
POPPDOC, SALEPHED, and GDPPHEAD, and given their success in 
explaining NATLAG variations it is not surpsing they are 
also employed to explain NUMPROD variations. Pearson cor-
relation coefficients for these three variables with the 
three dependent variables, NUMPROD, EARLYNUM, and LATENUM 
are shown below. 
TABLE 8.9 
Correlation Coefficients, Numbers 
of Products with Market1ng Env1ronment 
Indicators9 
POPPDOC GDPPHEAD SALEPHED 
NUMPROD -.:...0.5184 0.3160 0.4042 
p=0.020 p=0.117 p=0.060 
EARLYNUM -0.5541 0.3994 0.4692 
p=0.013 p=0.063 p=0.033 
LATENUM -0.3833 0.1726 0.2752 
p=0.071 p=0.261 p=O.l51 
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The signs of these correlation coefficients are all 
as hypothesized. There appears to be more evidence that 
differences in marketing environments are influential in 
determining how many products are launched in countries 
than there is indicating that market size influences these 
numbers. ·The consistently greater magnitude correlation 
-
coefficients between EARLYNUM and the independent variables, 
than between NUMPROD or LATENUM and the independent variables, 
indicates that earlier released drugs were more influenced 
by these differences in marketing environments than were 
later released drugs. Th±s result parallels that found in 
chapter seven where mean lag times per country were more 
9. U.K~ and Japanese data are again excluded from this 
analysis because of deficiencies in the data for these 
two countries. 
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strongly correlated with these three independent variables 
for drugs released before 1969 than for drugs released after 
1968. Again this appears to indicate that some major change 
in the market environment for pharmaceutical products occur-
red at or around 1969. 
The magnitudes of the computed correlation coeffici-
ents are not great, only POPPDOC and SALEPHED having cor-
relation coefficients which are statistically significant at 
the five per cent level. But their consistent signs and 
values provide some grounds for believing that marketing 
environments do influence ,the number of products launched 
in countries. These results may be partly caused by col-
linearity between the independent variables and other 
variables. Partial correlation coefficients were calcu-
lated controlling for three variables, TOTLSALE, INNOVATE, 
and PRICE. 
Controlling for INNOVATE appears to make little 
difference to the magnitude of the correlation coefficients. 
In all cases the coefficients are a little smaller than 
are the standard results displayed in Table 8.9. When 
the influences of TOTLSALE and PRICE are controlled linearly 
the first order partial correlation coefficients are of 
greater magnitude than are the coefficients shown in 
Table 8.9. In particular,controlling for TOTLSALE results 
in all coefficients having magnitudes which have less than 
a 5 per cent probability of occurring by chance. 
TABLE 8.10 
Partial Correlation Coeffients10 Controlling for three var1ables 
Controlling for INNOVATE 
POPPDOC SALEPHED 
NUMPROD -0.4958 0.4447 
p=0.030 p=0.048 
EARLYNUM -0.5266 0.5192 
p=0.022 p=0.024 
LATENUM -0.3711 0.3135 
p=0.087 p=O.l28 
Controlling: for TOTLSALE 
POPPDOC SALEPHED 
NUMPROD -0.5793 0.5711 
p=O.Ol2 p=O.Ol3 
EARLYNUM -0.5953 0.6029 
p= 0.010 p=0.009 
LATENUM -0.4718 0.4869 
p=0.038 p=0.033 
Controlling for PRICE 
POPPDOC SALEPHED 
NUMPROD -0.5492 0.4940 
-
p=0.021 - p=0.036 
EARLYNUM -0.5802 0.5618 
p=O.Ol5 p=O.Ol8 
























10. First order partial correlation coefficients in each 
case. Data from Japan, U.K. and Argentina excluded 
from calculations o~ partial correlations when con~ 
trolling for PRICE because of data deficien6ies. 
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There appears to be considerable evidence that dif-
ferences in marketing environments, as represented by 
these three independent variables, are associated with 
differences in numbers of products diffusing to countries. 
The relationship is of the form hypothesized for products 
released in both sub-periods, although the correlation co-
efficients are of lesser magnitude for products released in 
the second sub-period. In a result similar to that estab-
lished in chapter seven, the variables used to represent dif-
ferences in marketing environments are more strongly cor-
related with the dependent variable than are any other 
variables hypothesized to be determinants of number of 
products diffusing to countries. 
One auxiliary hypothesis is proposed for testing. 
Innovative countries may obtain more of the supply of new 
pharmaceutical products because the firms in these countries 
will tend to release all products they invent in these home 
countries, whereas non-innovative countries which do not 
have such captive suppliers of new products are dependent 
on the decisions of overseas firms for their supply of new 
products. Is there any evidence to support such a hypo-
thesis? Support is modest for this hypothesis, for the 
Pearson correlation coefficient is -0.1297 which for n = 17 
is not statistically significant though it is of the sign 
hypothesized. Based on the INNOVATIVE ratings used in 
this study there is no evidence that the more innovative 
countries have significantly more new products launched 
in their markets than do the less innovative countries. 
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A moments reflection will suggest that this is not a sur-
prising result for INNOVATE ratings are quite strongly cor-
related with TOTLSALE figures, the correlation coefficient 
is -0.7041 for the seventeen country case, and given that 
countries with high TOTLSALES figures tend to have low NUM-
PROD figures the chances of a strong negative correlation 
between NUMPROD and INNOVATE are very low. Innovativeness 
of countries does not appear to be an important determinant 
of number of products diffusing to countries. 
Only modest success can be claimed for the variables 
hypothesized to be determinants of number of products dif-
fusing to the various countries. There is no simple rel~ 
ationship between NUMPROD and REGRATE values. The TOTLSALE 
- NUMPROD correlation coefficient is consistently of the 
opposite sign to that hypothesized. The marketing environ-
ment variables again prove to be more strongly correlated 
with NUMPROD than are any other variables tested. How much 
succ~ss is achieved in a multiple regression analy~is 
using these independent Variables to "explain" variations 
in NUMPROD? Choice of variables is restricted to those 
which appear to be related in a consistent manner with 
NUMPROD. Thus REGRATE is not used as an explanatory variable 
because there is no consistent meaningful relationship 
between REGRATE and NUMPROD. TOTLSALE is included as an 
explanatory variable because there appears to be a consis-
tent relationship between NUMPROD and TOTLSALE throughout 
the period. Use of four variables provides the following result11 . 
11. Data for the U.K. and Japan excluded from the regression. 
NUMPROD = 114.7836 -0.0021 POPPDOC 
(0.0011) 
(_1. 909) * 










R Square = 0.6060, Adjusted R Square = 0.4627 
Standard Error = 18.2263 n = 16 
* - Statistically significant at the five per cent level 
The R Square and Adjusted R Square values are of quite 
useful magnitude. These best four variables appear to be 
quite successful jointly in explaining variations in 
NUMPROD values. The magnitude of the standard error of 
the regression is 19 per cent of the mean value of NUMPROD. 
Addition of a further variable SALEPHED results in an 
infinitesimal increase in magnitude of R Square, and a 
small decrease in the adjusted R Square value. Thus use of 
the above four variables appears to provide the best linear 
prediction equation possible ·with the variables employed in 
this research. Obviously factors other than those tested 
in this chapter and used in the regression equation affect 
numbers of products diffusing to the various countries. 
Further research will be necessary to determine what those 
factors are. 
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(2) DRUG LAGS AND THEIR CAUSES 
In the preceding sections of this chapter the ob~ 
jective was to establish what factors determine the number 
of products which diffuse to countries. Only modest success 
could be claimed for those efforts, as only equally modest 
success rewards efforts to establish the determinants of 
mean lag time per country in chapter seven. The precise 
nature of the factors controlling inter-country diffusion 
of pharmaceutical products remains unclear. Attention now 
turns to the so called "drug lag" debate and the claimed 
12 causes of drug lags. Wardell and other commentators, 
have argued that the U.S. does suffer from a drug lag and 
that the causes of this are the exacting regulations con-
trolling release of new pharmaceutical products onto the 
U.S. market. The objective now is to examine the data 
on diffusion more closely to see if the claims made about 
drug lags and their causes are substantiated by the evidence 
available in this study. 
The data in Tables 7.1 and 8.2 provide somewhat 
contradictory evidence on how well the U.S.A. fares in 
obtaining new pharmaceutical products. Table 7.1 indicates 
that over the whole twenty-one year period the U.S.A. has a 
mean diffusion lag time second only to the U.K., while 
Table 8.2 demonstrates that only Indonesia and Peru received 
lower numbers of these 190 sample products than did the 
U.S. A. However these summary statistics are of less 
12. See footnote 2 Chapter four. 
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interest than are trend data. The key feature to remember 
from this debate on drug lags is that drug lags are claim-
ed to have arisen some time ·after the 1962 amendment of the 
u.s. Food and Drug 1aw. Thus it is useful to again look 
at changes in relative positions of these eighteen countries 
to attempt to discern whether the U.S.A. suffers a relative 
worsening of position in obtaining new pharmaceutical pro-
ducts. Some evidence on this topic is provided in Tables 
7.6 and 8.2, demonstrating that the U.S.A. NATLAG value is 
relatively much worse for the later released drugs, but that 
its NUMPROD value is low for both groups of drugs. · Comment 
needs to be made on this difference in relative positions 
before analysis proceeds further. Based on the data in this 
project it can be argued that the U.S.A. has for a consider-
able period of time had a lower proportion of the supply of 
new pharmaceutical products launched on its markets than 
have many other countries. This may reflect the fact that 
the U.S.A. as the majo~ innovator of new pharmaceutical 
products is more self sufficient in supply of these products 
than are other c9untries. Or it may be that the U.S.A. 
has always had fewer products available on its market than 
have other countries. There is no evidence presented 
thus far in this or the preceding chapter to indicate which 
of the above possibilities is more likely. But reference to 
the data in Table 3.5 provides some evidence that the U.S.A. 
has for some time had a relatively low proportion of the 
world supply of new pharmaceutical products launched on to 
its market. Only 152 of the 658 new pharmaceutical pro-
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ducts launched in western countries between 1961~73 were 
launched in the U.S.A. Reis-Arndt concluded. This proport-
ion can be compared to the 70 out of 190 sample products 
launched in the U.S.A. during the period 1956-76 as estab-
lished by this research project. The proportions are 23.1 
per cent and 36.8 per cent respectively. The somewhat 
higher proportion of sample products launched in the 
U.S.A. indicated by this project may be due to the fact that 
the sample of products was trimmed to remove products bel-
ieved to provide least therapeutic advantage over existing 
products. There is a stronger tendency for products of 
greater therapeutic importance to diffuse to countries 
such as the U.S.A. than there is for products of lesser 
therapeutic importance. Some evidence was presented in 
chapter six which indicated that products with higher TAD-
VANCE ratings do tend to diffuse more widely than do pro-
ducts with lower TADVANCE ratings. Further analysis is 
conducted below to determine whether there is evidence that 
the U.S.A. receives larger proportions of the therapeutically 
more important products than it does of the less important 
products. 
Before returning to the analysis of trends in the 
data the conclusion ne~ds to be restated. Based on the 
evidence available to this project it appears that the U.S.A. 
has for many years received a smaller proportion of the 
supply of new pharmaceutical products than have countries 
with similar per capita income levels. Whether or not 
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the U.S.A. is becoming worse off because of such a tendency 
is further examined below. What does appear clear lS that 
it is quite possible for a country such as the U.S.A. to 
obtain a relatively small proportion of the· total supply of 
new pharmaceutical products and also to obtain thes~ pro-
ducts relatively quickly on average. A short mean diffus-
ion lag time coupled with a small number of products dif-
fusing to a country does not necessarily indicate a 
contradiction. Short mean diffusion lag times need not 
necessarily be accompanied by high NUMPROD values or vice 
versa. 
What of the trends, do they indicate whether or not 
the U.S.A. suffers from a drug lag? Table 7.8 provides a 
useful starting point for analysis, for in that Table 
NATLAGS and NUMPRODS are shown for the eighteen countries 
in four sub-periods. If ranks are given to countries on 
the basis of their relative position in each sub-period, 
with rank one going to the country with shortest NATLAG or 
highest NUMPROD then the rankings shown -in Table 8.11 are 
produced. 
There are few unequivocal conclusions which can be 
drawn from this Table, apart from the fact that on all 
counts Japan appears to have become steadily worse off 
throughout the twenty-one year period. The rankings appear 
to provide a complex pattern for the U.S.A., but it will 
be argued that there is evidence of a simple worsening of 





















Rankings for NATLAG and NUMPROD in four sub-periods 
NATLAG Rankings NUMPROD Rankings 
1956-61 1961-66 1966-71 1971-76 1956-61 . 1961-66 . 1966-71 
3 2 1 1 N.A. N.A. N.A. 
ll 15 16 14 14 12 11 
7 9 5 6 15 11 4= 
18 13 10 15 17 17 15 
15 l2 4 2 12 8= 8= 
14 17 12 13 6= 6 16 
8 8 3 11 9= 7 10 
4 11 17 18 6= 8= 13 
17 18 9 5 16 15= 17 
16 14 7 10 13 14 6= 
9 7 14 4 4= 3= 1= 
10 10 18 8 9= 3= 1= 
2 4 2 9 9= 13 12 
13 16 13 17 3 8= 6= 
6 6 6 12 8 5 8= 
5 3 8 16 1= 2 4= 
12 5 15 7 1= 1 1= 
























ponents to it; drugs may be slow in arriving in a country, 
or they may not be marketed at all in a country. The 
evidence presented in Table 8.11 indicates that if the U.S. 
has a drug lag it manifests in the form of products failing 
to be marketed in the U.S.A., rather than having long mean 
diffusion lag times. Of course these two facets of drug 
lags are equivalent for the non appearance in a country of 
a drug can be described as an infinitely long lag time. 
The method by which mean lag times per country are measured 
in this project indicates that the U.S.A. has ·a relatively 
long mean diffusion lag time in only one sub-period. This 
is a spurious result which occurs because the very few 
relevant products which are marketed in the U.S.A. in this 
twenty-one year period have short mean diffusion lag times. 
This disguises the fact that an increasingly large pro-
portion of products are not being marketed at all in the 
U.S.A. in the final two sub-periods. Indeed for··the 
group of products released in the final sub-period only one 
country, Japan, had a smaller number of these products 
launched in its market by the time data collection for this 
project halted. Reference to the actual numbers of pro-
ducts reinforces this point; only four of the potential 
twenty-nine sample products released in this sub-period 
were marketed in the U.S.A. Thus the drug-lag claimed to 
exist by wardell and others, does appear on the ba~is of 
the data presented here, to be a real phenomenon. 
Tt might be claimed that the U.S.A. has always been 
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more self sufficient in the supply of new pharmaceutical 
products than are other countries, and that the absence of 
some products from the U.S. market does not mean that U.S. 
consumers suffer beca~se of the absence of some products. 
This possibility does exist. It may be that the U.S.A. does 
product alternatives to the sample products which are not 
marketed in the U.S.A. It might further be argued that 
the 120 sample products which are not marketed in the U.S.A. 
are not of great therapeutic importance and therefore U.S. 
consumers do not suffer greatly because of the absence of 
these products. This possibility may arise if the products 
are nqt marketed in the U.S.A. are predominently or solely 
those with low TADVANCE ratings. A check on this reveals 
however, that of the 120 sample products not marketed in 
the U.S.A., 54 have TADVANCE ratings of one, two or three, 
and 66 have TADVANCE ratings of four and five. TADVANCE 
three products were described as being13 " useful new 
medicines offering advantages for a minority of patients", 
TADVANCE two products " .• important new·medicines, offering 
substantial advantages for a majority of patients", and 
TADVANCE one products " .. fundamental new medicines, of 
major clinical importance." Thus it appears that the U.S.A. 
is likely to have deficiencies in its armoury of medicines 
for some illnesses because of the absence of these products. 
Table 8.12 below lists the numbers of sample products mar-
keted in the U.S.A. from each TADVANCE group. 
13. Extract from the instructions sent to assessor of 
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Noticeably higher TADVANCE ratings are accompanied by 
higher percentages of these products being marketed in the 
U.S.A. But clearly there are products which are likely 
to be valuable medicines which are not available in the 
U.S.A. To list some- examples of sample products not mark-
eted in the U.S.A., these include; Biogastrone, Duogastrone, 
Esbatal, Hypovase, Rynacrom, Beconase, Becotide, Ventolin 
and Nuelin. No other country included in this study with 
per capita income levels similar to those of the U.S.A. is 
so deprived of important pharmaceutical products. Table 
8.13 lists the number of products in each TADVANCE class 
marketed in each country, The evidence presented in 
Table 8.13 indicates that ten countries are better provided 
with pharmaceutical products, of TADVANCE rank one, or two 
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than is the U.S.A. Only Colombia, Peru, Venezuela, 
Argentina, Indonesia and the Philippines appear to have 
received fewer of these products than has the U.S.A., 
However these whole-of-period summary figures do not illus-
trate the nature of the U.S. drug lag as clearly as do 
changes in relative position in the latter part of the 
survey period. 
TABLE 8.13 
Number of Products marketed in each 
country ln TADVANCE groups 
TAPVANCE Group 
. Country 1 2 3 4 5 Total 
U.K. 5 28 62 87 8 190 
Colombia 4 10 32 36 4 86 
Mexico 5 13 38 37 6 99 
Peru 1 5 19 28 2 57 
Brazil 4 17 37 34 5 97 
Venezuela 3 9 37 33 3 85 
Argentina 3 13 34 42 2 94 
Japan 4 14 34 33 1 86 
Indonesia 0 7 19 26 0 52 
Philippines 3 11 34 39 2 89 
Belgium 5 19 44 51 5 124 
France 5 17 41 43 3 109 
w. Germany 5 12 35 38 2 92 
Italy 5 14 40 43 5 107 
Spain 5 14 37 49 2 107 
Australia 4 24 45 45 3 124 
New Zealand 5 27 56 57 3 148 
U.S.A. 4 13 24 27 2 70 
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The data in Table 7.8 and 8.11 best illustrate how the 
various countries have fared in each of the four sub-periods. 
Perhaps the most striking feature of these tables is the 
dramatic decline in fortunes of Japan until in the final 
sub-period it has the longest NATLAG, and the lowest NUMPROD 
of any country. Japan is the only country with a lower 
NUMPROD value in the final sub-period than the U.S. has. 
Thus the two countries with the largest pharmaceutical 
markets in the world languish behind the rest of the world 
in availability of new pharmaceutical products. The fact 
that these two countries were also the only countries to 
be given regulatory tightness ratings of one should be 
remembered, as attention .is focussed on the question of 
causes of drug lags. 
Critics of the American F.D.A. regulations have 
argued that these regulations have been the factor which 
14 
caused the drug lag to develop. In the face of a mount~ 
ing tide of evidence even defenders of the F.D.A. have been 
-
forced to co~cede.that drug regulations have delayed the 
marketing of some drugs in the U.S.A. 15 What evidence 
has been marshalled in this study to further demonstrate 
that the regulatory climate in the U.S.A. has been the 
factor causing the U.S. drug lag? No direct evidence has 
been presented showing that regulations have caused mean 
14. See footnote 5, chapter three. 
15. See Wardell, W.M. A Close Inspection .... P. 2004. 
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lag times to increase, or have prevented products from 
being marketed in the U.S.~. The evidence that has 
been presented is supportive in nature. Attempts to es-
tablish evidence of an association between regulatory 
tightness ratings and changes in NATLAG and NUMPROD values 
met with some success. While the coefficients calculated 
were not of great magnitude, 0.5853 and -0.4844 respectively, 
both are statistically significant at the 5 per cent level. 
These relationships have been established on the basis of 
data for seventeen countries, not just for the U.S.A. 
Is there more specific evidence linking regulations 
with changes in diffusion patterns for individual countries? 
Inspection of the data in Tables 7.8 and 8.11 reveals that 
the two countries rated as having the most stringent regu-
lations in the early 1970's, Japan and the U.S.A., both 
experience major changes in NUMPROD ranking in the later 
sub-periods. Changes in NUMPROD rankings for two other 
countries stand out in Table 8.11. While Mexico moves 
from rank fifteen to rank four, Venezuela move-s from rank 
six to rank fourteen. No specific information relating 
to changes in regulations in these two countries can be 
provided but evidence can be provided on differences in 
regulations controlling marketing of pharmaceutical pro-
ducts. Comprehensive information on these regulations 
is provided in the publication, Legal and Practical Require-
ments for the Registration of Drugs (Medical Products) for 
Human Use, published by the International Federation of 
Pharmaceutical Manufacturers Association (I.F.P.M.A.) 
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in 1975 16 The data in this publication relates to a 
similar period to that for which the regulatory tightness 
assessments were obtained from the pharmaceutical compan-
ies. From the I.F.P.M.A. publication can be gleaned the 
fact that the time necessary for obtaining registration of 
drugs from date of submission of full data including res-
ults of clinical'trials, in practice averaged four months 
in Mexico and ranged from six months to two years in 
17 
Venezuela. 
These differences in approval time do not in them-
selves tell us too much about the impact of regulations 
on diffusion, but a second source of information adds to 
the weight of evidence indicting regulations. Two of the 
pharmaceutical companies who provided regulatory tightness 
ratings also provided comments together with the ratings. 
Regarding Venezuela the comments were; "need U.S.A. 
approval", and "independent assessment severe plus U.S. 
approval usually required".
18 
Venezuela appears to have received fewer new pro-
ducts than every country except Japan and Indonesia after 
1966. This poor performance occurs after Venezuela has 
16. International Federation of Pharmaceutical Manufacturers 
Association, Le al and Practical Requirements for the 
Registration of Drugs (Medical Products. fo:r Human Use, 
Zurich, I.F.P.M.A. 1975. 
17. I.F.P.M.A., Legal and Practical PP. 84,....85. 
18. Extract from responses by companies A and B. 
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linked its regulations controlling the marketing of 
pharmaceutical products with the F.D.A. regulations in 
the U.S.A. Thus the three countries where marketing of 
pharmaceuticals is controlled by the most stringent regu-
lations, Japan, U.S.A. and Venezuela, are the three count-
ries to experience marked declines in number of products 
diffusing to their markets compared to other countries. 
If guilt can be "proved" by association then regulations 
appear to be in danger of being found guilty of delaying 
and/or preventing the marketing of new pharmaceutical pro-
ducts in these countries. 
One possible explanation for .the decline in number 
of products being marketed in the U.S.A. is that the u.s. 
pharmaceutical industry was less innovative in the 1970's 
than it was in the 1960's. The U.S. pharmaceutical indus-
try appears historically to have been capable of supplying 
a very much larger proportion of the drugs on its domestic 
market than has any other countries pharmaceutical industry. 
A decline in innovativeness of its-industry may have res-
ulted in a much worse decline in number o£ new products 
being launched on its market than in other markets because 
the U.S. is most heavily dependent on its own industry 
to supply it with new products. It is not difficult to 
produce evidence of a decline in U.S. innovativeness. 
As in chapter five, products are assigned to countries 
on the basis of country of first launch, ORIGIN, and on 
the basis of location of headquarters of firm making first 
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release, NATNALTY. Using the first criteria, twenty~one 
products were of U.S. ORIGIN, and first released before 
1969, but only four products were of U.S. ORIGIN, and 
released after 1968. Using the second criteria, fifty~ 
two products were of U.S. NATNALTY and released before 1969, 
and twenty-three of U.S. NATNALTY and released after 1968. 
Expressing· these numbers as percentages of the number of 
sample products released in the relevant periods they are: 
16.5 and 6.3; and 40.9 and 36.5 respectively. The inter-
esting feature of these percentages is not the fact that 
there is a decline in the second sub-period, but the very 
much greater decline in ORIGIN than in NATNALTY percentages. 
This can be interpreted to imply that there has been only 
a very minor decline in innovativeness of U.S. pharmaceutical 
firms, but there has been a marked shift away from the U.S.A. 
as a country to first release new products in. Whereas 40.4 
per cent of products produced by U.S. firms were also first 
launched in the U.S.A. before 1969, only 17.4 per cent of 
products produced by U.S. firms after 1968 were also first 
released in the U.S.A. Again this does no_t "prove" that 
regulations have been the factor causing these changes in 
country of first launch, but it does appear to cast con-
siderable doubt upon the idea that the U.S. drug lag has 
been caused by a decline in innovativeness of U.S. pharma-
ceutical firms. The notion is further threatened by the 
fact that the U.S. also receives a lower percentage of the 
non-U.S. drugs released after 1968 than it recieves of those 
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released before 1969. Using the ORIGIN criteria the 
decline is from 42.5 per cent to 31.1 per cent, and using 
the NATNALTY criteria the decline is from 25.4 per cent to 
20.3 per cent. There appears to be considerable reason 
to doubt the idea that the U.S. drug lag has been caused by 
a decline in innovativeness of U.S. pharmaceutical firms. 
Evidence suggesting that regulations may be the factor 
which has caused the U.S. drug lag to appear is readily pro-
duced, and consistently demonstrates association between 
stringent regulations and delays in launch date in the 
U.S. of new drugs. 
(3) SUMMARY 
Two objectives were pursued in this chapter. First, 
three hypotheses about the determinants of numbers of pro-
ducts diffusing to countries were tested. Results of 
these tests indicate that the variables employed to rep-
resent differences in marketing environment in each country 
were more successful than any other variables in "explaining" 
variations in NUMPROD. Particularly the variable POPPDOC, 
number of persons per medical practitioner in each country, 
is strongly correlated with NUMPROD values. Countries with 
low POPPDOC figures, and high G.D.P. and total pharmaceutical 
sales per capita, appear to have more pharmaceutical products 
launched in their markets than do countries with lower 
G.D.P. and pharmaceutical sales per capita, and fewer 
medical practitioners per capita. Somewhat surprisingly, 
the evidence suggests that the hypoth~sis linking market 
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sizes and number of products diffusing to each country, 
should be rejected. There appears to be some evidence 
that countries with smaller markets receive more new pharm-
aceutical products than do countries with larger markets. 
This may partly be due to the fact that the countries with 
the largest markets are also the most innovative countries, 
and may supply more of the pharmaceutical products on their 
markets themselves than do other countries. Representatives 
of pharmaceutical companies were asked to rate and rank 
markets for regulatory tightness. Their responses were 
used to test the hypothesis that countries where the time 
and. monetary costs of gaining marketing approval were high 
would recieve fewer new products than would countries where 
these costs were lower. Correlation coefficients of stat-
istically significant magnitude were calculated between 
changes in NUMPROD values and regulatory tightness ratings. 
Evidence was presented which demonstrates that countries 
with the tightest regulatory ~ystems, the U.S.A. and Japan, 
are the two countries who suffer the sharpest declines in 
NUMPROD values during the twenty-one year period studied. 
Association does not prove causation, but there appears to 
be considerable evidence in support of the hypothesis 
that the U.S. drug lag has been caused by the F.D.A. regu-
lations, and an absence of evidence disputing the hypothesis. 
Attempts to ''explain'' the NUMPROD values calculated 
from data on drug diffusion over a twenty,....one year period 
should not be expected to be very successful, because 
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changes in diffusion behaviour occur over time. However, 
a four variable multiple regression analysis is capable 
of "explaining" 60 per cent of the variation in numbers 
of products diffusing to seventeen countries. 
C H A P T E R 9 
REVIEW 
(0) INTRODUCTION 
In this final chapter an attempt is made to review 
and comment on the disparate threads of the analysis. The 
important results derived in the analysis are briefly 
restated, some comment is made on these results and the 
tests from which they are deduced. Two issues subservient 
to the major thrust of this project are briefly discussed 
before some concluding observations on this and potential 
future research complete the chapter. 
(1) OUTCOMES OF THE HYPOTHESIS TESTING 
Hypotheses were tested relating to four aspects 
of inter-country diffusion of pharmaceutical products. 
These hypotheses were formulated and tested in an attempt 
to explain how, and why inter-country diffusion occurs in 
the ways it does. The unifying theme of these hypotheses 
is that diffusion of pharmaceutical products does not 
occur in a random manner. Diffusion is argued to be a 
series of events which reflects the outcomes of conscious 
decision-making by the proprietors of new pharmaceutical 
products. In particular it was assumed that firms in this 
industry would have a goal of profit maximization, and would 
act to launch new pharmaceutical products in ways which 
helped achieve that goal. The central importance given ·to 
the role of profit maximization as a determinant of dif-
• 
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fusion patterns is not an arbitrary choice, rather it 
reflects the importance of profit-related variables in the 
results of other economists' studies of diffusion. Two 
examples can be briefly restated to verify this point. 
Manse~ield consistently found that the speed of adoption of 
innovations was related to the expected profitability to be 
derived by adopting the innovation. 1 Griliches' conclus-
ion on the way in which choice of regions in which to 
market new cultivars of hybrid corn was made was, " ... while 
the results may not be too conclusive ... they leave little 
doubt in my mind that the development of hybrid corn was 
largely guided by expected pay-off, 'better' areas being 
entered first, even though it may be difficult to measure 
very well the variables entering into these calculations. 112 
Thus the hypotheses postulated for test in this 
project were derived from discussion of the mechanisms 
by which diffusion of new pharmaceutical products could 
influence profits of the propagating firms. Chapters five 
to eight provide the results of the tests of these and 
some auxilliary hypotheses. 
What are the outcomes of the tests of these hypo-
theses? It is difficult to answer unequivocally whether 
hypotheses have been refuted or not. Severe problems facing 
any researcher are, what is a satisfactory test of a 
1. See footnotes 19-24, Chapter two. 
2 • Griliches, Z., Hybrid Corn: An Exploration ... P. 514. 
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hypothesis, and what evidence provides a refutation of a 
hypothesis? However the results obtained in this research 
provide Some information about which hypotheses appear to 
be supported, and which not supported by the data. Where 
there is considerable doubt about the meaning of the res-
ults, the question of refutation or not of the hypotheses is 
left open. 
The most striking feature of the results obtained 
from tests of the speed, and extent of diffusion,hypotheses, 
is their inconsistency. When correlation coefficients 
are computed for four sub-periods the magnitudes and signs 
of these coefficients in many instances change between 
sub-periods. This may indicate that the relationship 
between the relevant variables change over time, or that 
there is no constant relationship, the change in results 
between sub-periods merely reflecting outcomes due to 
chance. 
There does appear to be consistent evidence in 
support of some hypotheses. The hypotheses which.sug-
gested that products assessed as being more important 
therapeutic advances would diffuse both more rapidly and 
more widely appear to be supported by the data. The 
NUMSALES - TADVANCE hypothesis in particular seems to be 
very firmly supported by the results of the tests conduc-
ted in chapter six. The AVLAG - TADVANCE hypothesis has 
less impressive support, but in two of the sub-periods 
correlation coefficients of the correct sign and modest 
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magnitude are computed. There appears to be no reason 
to reject the hypotheses relating TADVANCE to AVLAG and 
NUMSALES. 
The hypotheses relating expected sales levels of 
products and their speed and extent of diffusion, suffer 
from inadequacy of the data available to test these two 
hypotheses. The variables employed to test these hypo-
theses, AVSALES and LIFESALE, may not be accurate proxies 
for expected sales, but there is some evidence that sales 
levels of products are correlated with speed and extent 
of diffusion in the way expected. Again the evidence is 
strongest in support of the NUMSALES - sales level hypo-
thesis. The tests conducted above can only be described 
as attempts to test these hypotheses, but on the basis of 
the results obtained there does appear to be some evidence 
in support of the hypotheses. Certainly there appears to 
be no reason to reject the hypotheses. 
It was hypothesised that products marketed by com-
panies with extensive overseas marketing infrastructures 
would diffuse more rapidly and more widely than would 
products marketed by firms lacking in such infrastructure. 
Attempts to test these hypotheses can only be described 
as token efforts. Without hard data on the extent of 
overseas distribution channels for the relevant firms 
only speculative conclusions can be drawn about these 
hypotheses. It does seem fair to conclude that there is 
no evidence that products marketed by firms with larger 
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global sales diffuse more rapidly or more widely than do 
firms with smaller global sales. 
Of the auxiliary hypotheses tested about speed and 
extent of diffusion of pharmaceutical products one pro-
duced results of some interest. Country of origin of 
pharmaceutical products appears to be a determinant of speed 
of diffusion of these products. The correlation coeffic-
ients between ORIGIN and AVALAG decline steadily in mag-
nitude through the four sub-periods, but the relative 
consistency of the relationship makes it difficult to 
ignore. It is difficult to explain why the country of 
origin of pharmaceuticals should influence speeds of dif-
fusion. Further investigation is required to establish 
that the result is not just due to chance, and if not, to 
establish why country of origin does influence diffusion 
speeds. 
The tests conducted in chapter six do not provide 
any evidence to support the hypothesis that drugs with more 
geographically confined demand will diffuse to fewer mar-
kets than do drugs with more universal demand. There 
appear to be no statistically significant differences in 
mean NUMSALES values for products in the various therapeu-
tic classes. This conclusion seems tantamount to reject-
ion of a tautology, but some caution is needed here. It 
may be that there are almost no products with location 
specific demands, and thus the terminology in which the 
hypothesis is couched may be misleading. Certainly the 
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results produced above indicate that subdividing drugs 
into seventy-two categories does not provide evidence that 
there are statistically significant differences in mean 
NUMSALES between these groups of products. 
Undoubtedly the most interesting result established 
by the investigations in chapters five and six was the 
evidence of a marked time series trend in AVLAG values. 
This result needs careful restatement. The closer to 
the end of the survey period products are first launched, 
the faster are their speeds of diffusion. The evidence 
in support of this conclusion appears to be quite unshake-
able. But accompanying this apparent trend toward ever 
faster speeds of diffusion, there appears to be a trend 
of increasing delays between discovery and first launch of 
products. Thus the combined effect of these two opposing 
tendencies may be for the typical lag between discovery 
and time of first availability on a market to remain virt-
ually constant throughout the period studied, 
These may be the most important results provided by 
this study. An underlying assumption of this analysis is 
that delays in time of availability of new pharmaceutical 
products results in foregoing of therapeutic benefits by 
society. One conclusion which might be drawn from the 
result above is that the combined effect of the two trends 
ensures society is no more deprived of therapeutic bene-
fits, because of delays between discovery and time of 
availability, at the end of the survey period than it was 
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at the beginning of the survey period. This· conclusion 
may run counter to conventional wisdom. It appears that 
responses by pharmaceutical firms, which have resulted in 
compression of the time between date of first launch and 
typical launch date, have successfully countered the 
apparent tendency for lag time between discovery and first 
launch to lengthen. If a lengthening of the discovery-to 
first-launch phase has been caused bY changes in the regu-
lations controlling the marketing of products, and these 
changes in regulations have led to improvements in the 
safety of these products, then society may not suffer as 
large net costs as initial investigation might suggest. 
But much more detailed analysis is needed to adjudicate on 
this issue. 
In the analysis of factors influencing mean diffus-
ion lag per country, and number of products diffusing to 
each country, interest is not surprisingly, focussed on 
the role of regulations. The evidence which is produced 
does indicate association betwe~n regulatory tightness 
ratings and changes in NATLAG and NUMPROD. No evidence 
has been presented on the changes in regulations control-
ling marketing of drugs for each country, apart from some 
brief statements about the 1962 amendments to the U.S. 
Food and Drug Act. The correlation results provided in 
chapters seven and eight above, simply indicate correl-
ation between regulatory tightness ratings awarded to 
countries relating to the early 1970's, and changes 
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in NATLAG and NUMPROD. The presumption is that these changes 
in dependent variables are lagged responses to changes in 
regulations in some or all of these survey countr~es. Thus 
the evidence indictirig regulations for their part in 
creating drug lags is circumstantial in nature. But there 
appears to be no reason to doubt that they have been very 
important factors influencing diffusion of products to 
these countries. 
Regulations are also suspected to be the factors 
which cause apparent disintegration of many of the relation-
ships between independent and dependent variables in the 
post 1968 period. Variables such as POPPDOC and GDPPHEAD 
which are very strongly correlated with both NATLAG and 
NUMPROD in the pre 1969 sub-period, appear to be almost un-
related to NATLAG and NUMPROD in the post 1968 sub-period. 
The only plausible explanation which can be advanced for 
these dramatic changes in relationships, is that changes in 
regulations during the 1960's began to have a major impact 
on the diffusion of pharmaceuticals by the end of the 1960's, 
and thus prevented the previously observed relationships 
from occurring. 
The tests of the hypotheses regarding NATLAG, for 
drugs released in the first sub-period, provide consistently 
good results. TOTLSALE and INNOVATE both appear to be carrel-
ated with NATLAG as hypothesized, and POPPDOC and GDPPHEAD 
are strongly correlated with NATLAG until 1969. A measure of 
the strength of these relationships is provided by the fact 
that despite the apparent absence of relationship between the 
indepdendent variables and NATLAG 
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in the post 1968 period, correlation coefficient using the 
total sample of products still provide support for the 
hypotheses. Equally significant are the outcomes of the 
multiple regression analyses reported in chapter seven. 
Using four variabl~s, up to 60 per cent of the variation 
in NATLAG values can be explained. Mean diffusion lag 
times per country appear to have been vety_.predictable 
until regulations became more stringent and thus disrupted 
the existing diffusion processes. The hypotheses relating 
mean diffusion la·g times to: size of markets; innovativenes 
of each country; and the marketing environment factors, all 
appear to be supported by the data from diffusion of pro-
ducts released before 1969. Countries with larger mar-
kets which also tend to be the most innovative countries, 
do appear to have received new products sooner than did 
smaller market countries. Countries with marketing 
environments characterised by high levels of income per 
capita, and relatively few persons per medical practitioner 
appear~to have received new products sooner on average than 
did countries lacking those characteristics. If the data 
employed accurately represents the magnitudes of potential 
revenues, and costs of marketing in each country, then it 
appears that these two factors exerted considerable in-
fluence on the mean lag time before products were intro-
duced in each country. 
The results from the tests of hypotheses concerning 
number of products diffusing to each country are not so 
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clearcut. The hypothesis that countries with larger mar~ 
kets would have more new products launched in their mar-
kets than would countries with smaller markets, is not 
supported by the evidence. Indeed the evidence suggests 
that the hypothesis should be rejected. One possible 
explanation for this outcome is that the countries with 
the largest markets are also the most innovative countries, 
and may have relatively fewer products launched in their 
markets for the following two reasons. First, their 
greater innovativeness may imply more competition on their 
markets thus deterring some firms from launching new pro-
ducts on their markets. Second, their greater innovative-
ness may result in their domestic firms supplying them with 
alternative products to some of those products produced over-
seas, thus reducing the need for products to diffuse to 
their markets from overseas sources. Further research is 
The characteristics of the marketing environment in 
each country do appear to be important determinants of the 
number of products diffusing to each country. POPPDOC, 
SALEPHED, and GDPPHEAD are all strongly correlated with 
NUMPROD. Countries with marketing environments character-
ised by high incomes per capita, high expenditures on 
pharmaceuticals per capita, and relatively few persons per 
medical practitioner, do appear to receive a larger pro-
portion of the supply of new pharmaceutical products than 
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do countries whose markets lack those characteristics. 
NUMPROD values are reasonably predictable. Use of 
four variables in a multiple regression analysis produces 
an R Squared value of 0.6060. A large proportion of 
the variation in NUMPROD values appears to have been ex-
plained by the variables employed in Chapter eight. 
Hypotheses postulated to explain how the diffusion 
of pharmaceutical products occurs have met with varying 
success. Some hypotheses have been stron~~y supported by 
the data, others have been found to be incorrect, and a 
third group have needed reformulating to avoid being re-
jected. Attempts to explain differences in diffusion 
characteristics by use of "economic variables" does 
however, leave a considerable amount of variation unex-
plained. Only further hypothesis formulation and test 
will determine what factors cause this remaining variation. 
The most interesting results obtained by the above 
analysis were also the most unexpected. 
Analysis predicated on different assumptions than 
those employed in this project may provide further "unex-
pected" results. 
(2) THE DRUG LAG DEBATE 
There is considerable evidence that the U.S.A. is 
now relatively worse off than it was in the 1960's as 
regards availability of new pharmaceutical products. All 
the evidence points to the cause of this change in pos-
ition being regulations introduced in 1962 to control the 
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marketing of new pharmaceutical products. Similar conclus-
ions have been reached by other researchers. For example 
a recent U.S.A. House of Representatives Sub-Committee on 
Science, Research and Technology which investigated the 
F.D.A. 's new drug approval processes concluded, 
there is for certain categories of drugs, 
a 'drug lag' within the United States as 
compared with some other technically advanced 
countries •.. [The major, but not exclusive 
reasonsfor this] ... revolve about F.D.A. 's 
drug approval process and include : (1) 
internal management problems within the 
F.D.A.; (2) complexity and extensiveness of 
F.D.A. 's guidelines and regulations; and (3) 
adversarial relationships. between F.D.A. and 
the pharmaceutical industry.3 
There appears to be no doubt that amendments to the U.S. 
Food and Drug Act introduced in 1962 have caused a major 
reduction in the supply of new products reaching the U.S.A. 
These regulations and changes in regulations in other 
countries, appear to have lengthened the lag time between 
discovery of products and their dates of first launch. 
The ramifications of this increased lag appear to be at 
least threefold. Fist, there appears to have been a res-
ponse to these increased lags by pharmaceutical companies, 
who have compressed the mean time between first launch date 
and date of typical availability of products on the world's 
markets. This response may stem from an understandable 
desire by pharmaceutical companies to launch their products 
as rapidly as possible to provide funds to maintain the 
3. Quoted in Scrip, No. 566. February 18, 1981 P. 9. 
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operations of their companies. The overall result of 
these opposing but related trends may have been almost con-
stant mean lag time between discovery and typical time of 
availability in the world~s markets. 
The second ramification of the change in regulations 
controlling the marketing of drugs appears to be a sharp 
increase in the costs associated with development and test 
of products before they are marketed. One of the world's 
major pharmaceutical companies has claimed that" .... at 
current estimates, it takes approximately $60m and nine 
years of hard work to bring a single new drug entity to 
the point where it can be prescribed in clinical practice." 4 
Such costs and delays are likely to be deterrents to 
research for new pharmaceutical products and thus may 
contribute to reductions in the supply of new pharmaceutical 
products. 
A third response to changes in regulations may be 
a switch in location of research and development and 
country of first launch of new products. The Reis-Arndt 
data in Table 3.1 indicated that 9 per cent of the products 
launched between 1961-73 were first launched in the U.S.A. 
An I.M.S. publication, Wor~d Pharmaceutical Introductions, 
reported that in 1977 only 3.5 per cent of the hew 
d . d . . h 5 pro uct 1ntro uct1ons were 1n t e U.S.A. Evidence was 
4. Qu6ted in Scrip, No. 566, February 18, 1981 P. 9. 
5. Quoted in Scrip, No. 566, Februray 18, 1981 P. 9. 
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presented in Chapter eight above on decline in numbers of 
new products first launched in the U.S.A. Sixteen per 
cent of the sample products first launched before 1969 were 
first launched in the U.S.A., but only 6 per cent of sample 
products first launched after 1968 were first launched in 
the U.S.A. 
No attempt is made to estimate the likely costs and 
benefits resulting from response to changes in regulations 
but it seems pertinent to point again to the conclusions 
Peltzman reached about their net costs. 6 The cos·ts of 
regulations which Peltzman identified, foregoing of thera-
peutic benefits because of.delays in introduction of new 
products, greatly exceeded the benefits achieved of impro-
vements in safety of drugs marketed. To those costs 
might be added the extra R & D expenditure required to 
produce new products, and the further foregoing of thera-
peutic benefits because of the reduction in output of new 
products. The net effect of these more stringent regu-
lations seems unlikely to be an imprqvement in consumer 
welfare. 
The contribution of this project to the drug-lag 
debate is to compare the supply of new pharmaceuticals to 
the U.S.A. with the supply of new pharmaceuticals to sev-
enteen other countries, and to subject the hypothesis that 
regulations have been the cause of the U.S. drug lag to 
test. The results indicate that the U.S.A. does receive 
6. Peltzman, S. Regulation of Pharmaceutical .•......... 
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far fewer new drugs than do almost all of the other seven-
teen countries studied. Further, there appears to be 
overwhelming amounts of evidence that the U.S. drug-lag 
has been caused by the regulations controlling marketing 
of products in the U.S.A. Both of these issues appear no 
longer to be subjects of debate. 
(3) SUPPLY OF NEW PRODUCTS TO DEVELOPING COUNTRIES 
An issue raised in Chapter three was the question of 
supply of pharmaceutical products to developing countries. 
Specifically the question asked was, are these countries 
well served by the existing patterns of diffusion of phar-
maceutical products? It appears erroneous to classify 
all developing countries as a homogeneous group, for their 
NATLAG's and NUMPROD's are not all consistently "better" 
or "worse" than are those of the developed countries. 
Inspection of the data in Table 7.5 indicates that for drugs 
released after 1968; Spain, Philippines, Indonesia, Argen-
tina, Brazil and Mexico all have shorter AVLAG's than do 
U.S.A., New Zealand, Australia, Italy, France, West Germany 
and Japan. Only Colombia, Peru and Venezuela of the 
developing countries appear to be laggards on these criteria. 
Further, scrutiny of the data in Table 7.7 reveals that in 
the last of the four sub~periods, Colombia, Peru and 
Venezuela are again the developing countries with the 
longest NATLAG's. However the range of NATLAG values 
is not large. Ignoring the U.K. figure, the range of 
NATLAG values in the last of the sub-periods is 13.636 
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months for Brazil to 32.667 months in Japan. Thus effect-
ively all countries have similar length AVLAG's, and in 
particular, developing countries do not appear to have long 
lags before products are launched in their markets. 
However the NUMPROD values do indicate that the 
developing countries are relatively worse off than the dev-
eloped countries. The range of NUMPROD values is large. If 
the NUMPROD values of each country are expressed as relevant 
percentages of the total number of products launched in the 
relevant periods then ~he range in the 1966-71 period is 
29.82 per cent to 68.42 per cent. But in the 1971-76 usb-
period the range is 10.34 per cent to 89.65 per cent .. Inspec-
tion of the da·ta in Table 7. 7 reveals that the developing 
countries may not have noticeably long AVLAG's but they do 
tend to receive smaller proportions of the supply of new 
pharmaceuticals than do the developed countries. In the 
1971-76 sub-period, nine of the sample countries received 
more of the relevant products than did Colombia, Peru, Brazil, 
Venezuela, A~gentina and Indonesia. Only Mexico and Spain 
of the developing countries appear to receive comparable 
numbers of these products to the number of products typic-
ally received by the developed countries. Thus if the exist-
ing diffusion patterns are to be judged how well they serve 
the developing countries by number of products actually 
reaching the developing countries, then they appear not to 
be as well served as developed countries. Whether or not the 
absence of some products necessarily means that these dev-
eloping countries are worse off than they would 
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be if they received more products may be the subject of 
debate. Further analysis is required to determine whether 
absence of some products does mean that developing countries 
are worse off. Without further investigation little com-
ment can be made about how well the existing diffusion 
patterns serve the developing countries. 
(4) CONCLUDING COMMENTS 
Two aspects of this project, with hindsight, evoke 
feelings of regret. First there are some severe problems 
of deficiencies in data. The data in some instances may 
not exist, and may never have been readily available. But. 
part of the data deficiencies can be attributed to failure 
to explicitly formulate hypotheses before data collection 
began. If it is not known which type of data will be 
required then it is very difficult to ensure that all the 
data which is subsequently required is obtained during data 
gathering forays. More foresight should have resulted 
in fewer data deficiency problems. 
The second factor which causes some regret is the 
necessarily confined focus of the research. Initial im-' 
petus for this project was the debate about the activities 
of multinational pharmaceutical companies in developing 
countries. Assessing the validity of all the allegations 
made about the pharmaceutical industry's operations is 
obviously an enormous task. Because of the magnitude 
of that task this project has been confined to investig-
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ation of one facet of the international industry's activ-
ities. By focussing on the inter-country diffusion of 
pharmaceuticals to a range of countries, which specifically 
includes nine developing countries, an attempt has been 
made to il~uminate one aspect of the international supply 
of pharmaceuticals. Regretably many aspects of the inter-
national supply of pharmaceuticals remain unresearched. 
The task of further investigating the activities of the 
multinational pharmaceutical industry beckons eager 
researcheis. 
TABLE A. 1.1 
CORRELATION COEFFICIENTS FOR NINE VARIABLES. DRUGS RELEASED BEFORE 06:1961 
AVLAG TADVANCE LIFESALE AVSALES RELEASE ORIGIN MULTI TCLASS NUMSALES 
AVLAG 1.0000 0.2945 -0.1364 -0.1548 -0.2195 0.3154 -0.1630 0.1620 -0.4469 
TADVANCE 0.2945 1. 0000 -0.3008 -0.3080 -0.1395 0.1004 -0.0602 0.1710 -0.4867 
LIFE SALE -0.1364 -0.3008 1.0000 0.9981 -0.0745 -0.0914 0.3194 -0.3391 0.5287 
AVSALES -0.1548 -0.3080 0.9981 1. 0000 -0.0326 -0.0760 0.3156 -0.3453 0.5410 
RELEASE -0.2195 -0.1395 -0.0745 -0.0326 1.0000 0. 2558 -0.2102 -0.0642 0.1410 
ORIGIN 0.3154 0.1004 -0.0914 -0.0760 0.2558 1. 0000 0.0352 -0.0355 -0.3684 
MULTI -0.1630 -0.0602 0.3194 0.3156 -0.2102 0.0352 1. 0000 -0.1820 0.3919 
TCLASS 0.1620 0.1710 -0.3391 -0.3453 -0.0642 -0.0355 -0.1820 1.0000 -0.1077 
NUMSALES -0.4469 -0.4867 0.5287 0.5410 0.1410 -0.3684 0. 3919 -0.1077 1.0000 
' I 
TABLE A. 1.2 
CORRELATION COEFFICIENTS FOR NINE VARIABLES. DRUGS RELEASED BETWEEN 07:1961 AND 10:1966 
AVLAG TADVANCE LIFESALE AVSALES RELEASE ORIGIN MT.JLTI TCLASS NUMSALES 
AVLAG 1. 0000 -0.0209 -0.1885 -0.1930 -0.1643 0. 2806 -0.0327 -0.2944 -0.0787 
TADVANCE -0.0209 1.0000 -0.2901 -0.2825 0.0826 0.0559 0.0761 0.1974 -0.2067 
LIFESALE -0.1885 -0.2901 1.0000 0.9878 -0.0747 0.1102 -0.0523 0.0790 0.3386 
AVSALES -0.1930 -0.2825 0.9878 1.0000 0. Ol·OO 0.1048 -0.0463 0.0790 0.3512 
RELEASE -0.1643 0.0826 -0.0747 0.0100 1.0000 -0.1276 -0.0917 -0.0276 0.0139 
ORIGIN 0.2806 0.0559 0.1102 0.1048 -0.1276 1. 0000 -0.0777 -0.2869 -0.0002 
MULTI -0.0327 0.0761 -0.0523 -0.0463 -0.0917 -0.0777 1.0000 0.1294 0.1078 
TCLASS -0.2944 0.1974 0.0790 0.0790 -0.0276 -0.2869 0.1294 1. 0000 0.1785 
NUMSALES -0.0787 -0.2067 0.3386 0.3512 0.0139 -0.0002 0.1078 0.1785 1.0000 
TABLE A. l. 3 
CORRELATION COEFFICIENTS FOR NINE VARIABLES. DRUGS RELEASED BETWEEN 11:1966 AND 11:1971 
AVLAG TADVANCE LIFESALE AVSALES RELEASE ORIGIN MULTI TCLASS NUMSALES 
AVLAG 1. 0000 0.0738 -0.1077 -0.1084 -0.1878 o. 2120 0.0850 -0.0077 -0.2294 
TADVANCE 0.0738 1. 0000 0.0382 0.0654 0.1935 -0.0401 0.0389 -0.1215 -0.2658 
LIFESALE -0.1077 0.0382 1.0000 0.9938 0. 0613 0.0455 -0.0744 0.1232 0. 2490 
AVSALES -0.1084 0.0654 0.9938 1.0000 0.1334 0.0259 -0.0617 0.1310 0.2327 
RELEASE -0.1878 0.1935 0. 0613 0.1334 1.0000 0.0039 -0.0547 0.0955 -0.0789 
ORIGIN 0.2120 -0.0401 0.0455 0.0259 0.0039 1.0000 -0.0392 -0.2479 -0.0955 
MULTI 0.0850 0.0389 -0.0744 -0.0617 -0.0547 -0.0392 1.0000 -0.1753 -0.0835 
TCLASS -0.0077 -0.1215 0.1232 0.1310 0.0955 -0.2479 -0.1753 1.0000 0.0395 
NUMSALES -0.2294 -0.2658 0.2490 0.2327 -0.0789 -0.0955 -0.0835 0.0395 1. 0000 
TABLE A. 1. 4 
CORRELATION COEFFICIENTS FOR NINE VARIABLES. DRUGS RELEASED BETWEEN 12:1971 and 12:1976 
AVLAG TADVANCE LIFESALE AVSALES RELEASE ORIGIN MULTI TCLASS NUMSALES 
AVLAG 1. 0000 0.3896 -0.2584 0.0462 -0.5424 0.0991 -0.0306 0.0550 0.2786 
TADVANCE 0.3896 1. 0000 -0.2508 0.1052 -0.2523 -0.1822 -0.0678 -0.1052 -0.1693 
LIFE SALE -0.2584 -0.2508 1. 0000 0.7403 0.4235 -0.1980 0.2242 -0.2708 0.2508 
AVSALES 0.0462 0.1052 0.7403 1.0000 -0.0629 -0.1633 o. 2624 -0.0349 0.4329 
RELEASE -0.5424 -0.2523 0.4235 -0.0629 1.0000 -0.4077 0.1359 -0.4257 -0.2415 
ORIGIN 0.0991 -0.1822 -0.1980 -0.1633 -0.4077 1.0000 0.1083 0.1655 0.0140 
MULTI -0.0306 -0.0678 0.2242 0.2624 0.1359 0.1083 1.0000 -0.0858 -0.1345 
TCLASS 0.0550 -0.1052 -0.2708 -0.0349 -0.4257 0.1655 -0.0858 1.0000 0.0046 
NUMSALES 0.2785 -0.1693 0.2508 0.4329 -0.2415 0.0140 -0.1345 0.0046 1. 0000 
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